KR20060079121A - Quinazoline derivatives for the treatment or prevention of diabetes and obesity - Google Patents
Quinazoline derivatives for the treatment or prevention of diabetes and obesity Download PDFInfo
- Publication number
- KR20060079121A KR20060079121A KR1020050134722A KR20050134722A KR20060079121A KR 20060079121 A KR20060079121 A KR 20060079121A KR 1020050134722 A KR1020050134722 A KR 1020050134722A KR 20050134722 A KR20050134722 A KR 20050134722A KR 20060079121 A KR20060079121 A KR 20060079121A
- Authority
- KR
- South Korea
- Prior art keywords
- quinazolin
- amine compound
- alkyl
- benzyl
- phenyl
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/93—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
본 발명은 혈당 강하, 체중 감소를 나타내는 신규의 퀴나졸린 유도체와, 이 화합물을 유효성분으로 함유하는 당뇨 및 비만 치료예방제에 관한 것이다.The present invention relates to a novel quinazoline derivative that exhibits blood sugar drop and weight loss, and a diabetes and obesity treatment preventive agent containing the compound as an active ingredient.
당뇨병 치료제, 비만 치료제, 퀴나졸린 Diabetes treatment, obesity treatment, quinazoline
Description
도 1은 본 발명에 따른 화합물을 세린79 잔기의 인산화 정도를 웨스턴 블롯(Western blot) 분석한 결과이다.1 is a result of Western blot analysis of phosphorylation degree of the serine 79 residue of the compound according to the present invention.
도 2a 내지 도 2g는 본 발명에 따른 화합물을 세린79잔기와 트레오닌172 잔기의 인산화 정도를 웨스턴 블롯(Western blot) 분석한 결과이다.2A to 2G show Western blot analysis of phosphorylation levels of 79 residues and
도 3a 및 도 3b는 본 발명에 따른 화합물을 db/db 마우스에 복강 투여함에 따른 혈당변화를 보여주는 그래프이다.Figure 3a and Figure 3b is a graph showing the change in blood glucose by intraperitoneal administration of the compound according to the invention to db / db mice.
도 4a 및 도 4b는 본 발명에 따른 화합물을 db/db 마우스에 복강 투여함에 따른 체중변화를 보여주는 그래프이다.Figures 4a and 4b is a graph showing the weight change by the abdominal administration of the compound according to the invention to db / db mice.
도 5a, 도 5b 및 도 5c는 본 발명에 따른 화합물을 db/db 마우스에 경구 투여함에 따른 혈당변화를 보여주는 그래프이다.Figures 5a, 5b and 5c is a graph showing the change in blood glucose by oral administration of the compound according to the invention to db / db mice.
도 6a, 도 6b 및 도 6c는 본 발명에 따른 화합물을 db/db 마우스에 경구 투여함에 따른 체중변화를 보여주는 그래프이다.6a, 6b and 6c is a graph showing the weight change by oral administration of the compound according to the invention to db / db mice.
도 7a 및 도 7b는 본 발명에 따른 화합물을 ob/ob 마우스에 복강 투여함에 따른 체중변화를 보여주는 그래프이다.Figures 7a and 7b is a graph showing the weight change following the intraperitoneal administration of the compound according to the invention to ob / ob mice.
도 8a 및 도 8b는 본 발명에 따른 화합물을 ob/ob 마우스에 복강 투여함에 따른 혈당변화를 보여주는 그래프이다.8A and 8B are graphs showing changes in blood glucose by intraperitoneal administration of a compound according to the present invention to ob / ob mice.
도 9는 본 발명에 따른 화합물을 ob/ob 마우스에 경구 투여함에 따른 체중변화를 보여주는 그래프이다.Figure 9 is a graph showing the weight change by oral administration of the compound according to the invention to ob / ob mice.
본 발명은 혈당 강하, 체중 감소를 나타내는 신규의 퀴나졸린 유도체와, 이 화합물을 유효성분으로 함유하는 당뇨 및 비만 치료예방제에 관한 것이다.The present invention relates to a novel quinazoline derivative that exhibits blood sugar drop and weight loss, and a diabetes and obesity treatment preventive agent containing the compound as an active ingredient.
오늘날 가장 흔한 문화병의 하나인 당뇨병은 우리 나라에서도 발생 빈도가 점차 증가되고 있으며 그 병태의 심각성과 후유증으로 말미암아 심각한 사회문제로 대두되고 있다. 경제 발전에 따른 생활 수준의 향상으로 인하여 생활 여건이 향상되면서 운동 부족 현상을 초래하고, 전반적인 식생활의 향상으로 섭취 열량이 크게 증가하여 심각한 비만이 발생됨으로써 제2형 당뇨병이 증가하고 있다. 당뇨병이 오래 지속되면 혈당의 증가 이외에도 혈중 지질 농도가 증가하여 동맥 경화, 관상 심장 질환 등의 심혈관 질환, 당뇨병성 신장 및 망막 질환 등의 합병증을 유발하므로 이의 치료제의 개발이 시급한 실정이다. Diabetes, one of the most common cultural illnesses today, is increasing in frequency in our country and is a serious social problem due to its seriousness and sequelae. As living conditions improve due to the improvement of living standards according to the economic development, the lack of exercise is caused, and the caloric intake is greatly increased due to the improvement of the overall diet, and
당뇨병은 크게 인슐린 의존형 당뇨병(Insulin dependent diabetes mellitus, 이하, "IDDM"라 함)과 인슐린 비의존형 당뇨병(Non insulin dependent diabetes mellitus, 이하, "NIDDM"라 함)으로 대별된다. 인슐린 의존형 당뇨병(IDDM) 즉, 제1형 당뇨병은 면역학적인 원인에 의하여 췌장의 베타세포가 파괴되어 인슐린 합성이 이루어지지 않는 질환이다. 반면에 인슐린 비의존형 당뇨병(NIDDM) 즉, 제2형 당뇨병은 인슐린 분비 장애와 인슐린 저항성의 복합 장애라는 두 가지 원인에 발생되는 질환으로, 당뇨병의 95% 이상을 차지한다. 인슐린 분비 장애란 혈당 농도에 따라 췌장의 베타세포에서 적절한 양의 인슐린이 분비되지 않는 상황을 일컬으며, 이는 인슐린을 분비하는 베타세포의 양적인 감소나 기능적인 분배장애를 모두 포함한다. 인슐린 저항성은 분비된 인슐린이 혈류를 타고 표적장기에 도달했으나 그 표적세포에서 인슐린의 작용이 저하된 상황을 의미하는데, 일반적으로 세포막 수용체 결합 후의 신호전달 장애로 생각하며, 그 원인으로는 유전적인 소인, 비만, 육체적 활동저하 및 고혈당 또는 이상지질혈증 등을 들 수 있다. 여기서 중요한 사실은 이 두 가지의 병인이 서로 맞물려 있다는 것이다. 즉, 인슐린 저항성이 있으면 저항성을 극복하기 위해 더 많은 양의 인슐린이 분비되어야 하고, 반대로 인슐린 분비가 충분하지 않아 생긴 고혈당 자체가 다시 인슐린 저항성을 악화시킬 수 있다는 것이다. 따라서 NIDDM의 병인을 이해하기 위해 국내외적으로 인슐린 신호전달체계, 글루코스 이송 및 대사과정에 관한 연구가 방대하게 이루어지고 있으나 NIDDM의 병인이 매우 복잡하고 다양하여 정확한 병리 기전이 밝혀지지 않고 있어 그에 따른 적절한 치료 방법의 개선이 이루어지지 않고 있다.Diabetes is roughly divided into insulin dependent diabetes mellitus (hereinafter referred to as "IDDM") and insulin independent diabetes mellitus (hereinafter referred to as "NIDDM"). Insulin-dependent diabetes mellitus (IDDM), that is,
한편, 제2형 당뇨병(NIDDM)이 비만과 관련되어 있음은 잘 알려져 있으나, 아직 정확한 상호 작용이나 연관성에 관한 기전이 정확히 밝혀지지 않았다. 하지 만 비만과 그에 따른 지방산 대사장애가 대사질환의 발병과 불가분의 관계가 있을 것이라는 전제를 두고, 최근 당뇨병 병인연구의 초점이 '포도당 대사'에서 '지방산 대사' 중심으로 옮겨지고 있다. 제2형 당뇨병 환자에서 고혈당 이외에 지질대사의 이상, 즉 혈중 지방산의 증가, 중성지방 증가, 고밀도 지단백 콜레스테롤 감소, 근육 내 지방의 축적, 복부 지방량 증가, 지방간의 발생 등을 흔히 발견할 수 있다. 물론 이런 지질 항상성의 장애가 당뇨병으로 인한 고혈당의 결과인지 아니면 당뇨병 발생의 원인으로 작용한 것인지는 아직 확실하지 않다. 그러나 인슐린 저항성 발생에 선행하여 인슐린 표적장기인 골격근, 심장 근육, 간조직 등에 중성지방의 비정상적인 축적이나 지방조직에서 지방산 유리 증가 등 지방산 대사장애가 선행하여 나타나고, 이런 현상이 지속될 때 인슐린 저항성이 악화되면서, 식후 또는 공복 시 고혈당이 나타나기 시작하고, 이는 다시 인슐린 저항성 및 지방산 대사장애를 더욱 악화시키게 되는 악순환을 거치게 되면서 결국 다른 대사질환들을 유발하게 된다. 이러한 병리현상은 생체밖 실험 또는 동물실험 뿐 아니라 사람을 대상으로 한 연구에서 비교적 일관되게 증명되고 있다. 하지만 무엇이 이런 지방대사 장애를 유발하는지 또는 어떤 기전에 의해서 인슐린 저항성이 초래되어 생리적 항상성을 파괴하는지에 대해서는 아직도 명확하지 않은 실정이다. It is well known that
이런 상황 속에서 현재 인슐린 저항성(insulin resistance)이 NIDDM의 가장 중요한 병리 기전으로 인식되고 있으며, 이는 체내인슐린이 충분하다 해도 당을 제대로 활용하지 못하는 현상을 의미하고 있으며, 이를 치료하기 위해 다양한 혈당 강하제가 사용되고 있다. 혈당 강하제는 치료기전 및 작용 약물의 작용점에 따 라 다음과 같이 분류된다 :In this situation, insulin resistance is currently recognized as the most important pathological mechanism of NIDDM, which means that even if the body's insulin is sufficient, it does not utilize sugar properly. It is used. Hypoglycemic agents are classified as follows according to the mechanism of action and the point of action of the acting drug:
1) 설포닐우레아계 약물은 주로 췌장의 베타세포 안에 있는 인슐린을 함유한 과립포의 이동을 촉진하여 간접적으로 인슐린을 분비시키는 약물로, 저혈당 유발 등의 심각한 부작용이 보고되고 있으나 최근에는 부작용을 최소화한 약물이 개발되기도 하였다.1) Sulfonylurea drugs are drugs that indirectly secrete insulin by promoting the movement of granules containing insulin in the beta cells of the pancreas, and serious side effects such as hypoglycemia have been reported. A drug has been developed.
2) 비구아나이드계 약물은 근육세포로 당을 이동시키고 간에서 당의 합성(gluconeogenesis)을 억제하는 약물로, 저혈당을 일으키지 않는 장점을 갖고 있으나 고령자와 심 혈관 질환 환자에게는 사용 시 주의가 요구되고 있다.2) Biguanide-based drugs transfer drugs to muscle cells and inhibit glucose synthesis (gluconeogenesis) in the liver. They have the advantage of not causing hypoglycemia, but they require caution when used in elderly and cardiovascular patients.
3) 알파 글루코시다아제 저해제는 소장에서 포도당을 만드는 효소 활동을 억제시켜 식후에 일시적으로 혈당이 급상승하는 것을 막아주고, 부작용이 심하지 않은 편이어서 경증 당뇨병 치료에 이용된다.3) Alpha glucosidase inhibitors inhibit the activity of glucose-producing enzymes in the small intestine to prevent blood glucose spikes temporarily after meals, and they are used for the treatment of mild diabetes because of their moderate side effects.
4) 티아졸리디온(TZD)계 약물은 최근에 개발된 것으로, 지방세포의 분화에 관계되는 피피에알 감마를 활성화하는 것으로 알려져 있다.4) Thiazolidion (TZD) -based drugs have recently been developed and are known to activate PPIE gamma, which is involved in the differentiation of adipocytes.
이러한 경구용 혈당 강하제 만으로는 혈당이 효과적으로 떨어지지 않고 이미 알려진 대부분의 약물에서 부작용이 나타나므로 보다 안전한 당뇨병 치료제 개발이 시급한 실정이다. 또한 제2형 당뇨병은 인슐린 신호 전달 체계 및 탄수화물과 지질대사 과정에서의 다양한 문제점으로 인해 발생하기 때문에 새로운 치료제 개발을 위해서는 이러한 신호전달 및 대사 과정을 전반적으로 조절하는 새로운 목표 단백질의 발굴이 절실한 실정이다.Since oral blood glucose lowering agents alone do not drop blood sugar effectively and most of the known side effects occur in the drug, it is urgent to develop a safer diabetes treatment. In addition, since
최근 5'AMP 활성화 단백질 인산화 효소(5'AMP-activated protein kinase, 이 하, "AMPK"라 함)가 탄수화물 및 지질대사 그리고 포도당 흡수를 조절하는 역할이 밝혀지면서 이의 활성물질이 제2형 당뇨병 치료제로서의 개발 가능성이 제시되고 있으며 이러한 근거는 다음과 같다.Recently, 5'AMP-activated protein kinase (hereinafter referred to as "AMPK") has been shown to regulate carbohydrate, lipid metabolism and glucose absorption, its active substance is a
1) 운동을 시킨 쥐의 근육세포에서 ATP 소모의 결과로 AMP의 양이 증가하고, 이로 인해 AMPK의 활성도가 증가하고, 그 결과 포도당 흡수가 증가하는 사실이 관찰되었다.1) It was observed that the amount of AMP increased as a result of ATP depletion in exercised rat muscle cells, which resulted in increased AMPK activity and increased glucose uptake.
2) AMPK에 의해 포도당 흡수가 증가되는 기전은 인슐린 신호 전달 체계와 독립적이며, 이 사실은 인슐린 신호 전달체계에 이상이 발견되는 대부분의 제2형 당뇨병 환자에서 새로운 치료 목표 물질이 될 수 있다는 사실을 의미한다.2) The mechanism by which AMPK increases glucose uptake is independent of the insulin signaling system, suggesting that it may be a new therapeutic target in most patients with
3) 실제로 제2형 당뇨 환자들의 대부분이 운동을 함으로써 혈당량을 감소할 수 있으며, 당뇨 모델 동물실험 결과 운동에 의해 AMPK가 활성화되며 동시에 혈당량이 감소되는 사실도 보고되고 있다.3) In fact, most of the patients with
4) 이 뿐 아니라 AMPK는 생체 내에서 다양할 역할을 수행하는데 췌장세포에서 인슐린의 분비를 조절할 뿐만 아니라 지방세포에서 아세틸 CoA 카르복시라제(ACC)와 HMG-CoA 환원효소의 활성을 저해하여 지방생성 및 콜레스테롤 합성을 억제하여 비만의 조절에도 중요한 역할을 한다.4) In addition, AMPK plays a variety of roles in vivo. It not only regulates insulin secretion in pancreatic cells but also inhibits the activity of acetyl CoA carboxylase (ACC) and HMG-CoA reductase in adipocytes. It inhibits cholesterol synthesis and plays an important role in the control of obesity.
결론적으로, AMPK는 그 이름에서 시사하는 바와 같이 근육수축이나 운동 후 세포내의 에너지 고갈의 결과로 축적된 AMP에 의해 활성화되어 에너지 항상성 조절과 탄수화물 및 지질 대사 조절의 중추적인 역할을 하고 있다. 또한 에너지 불균형으로 인하여 초래되는 당뇨 및 비만 등 대사성 질환 치료를 위한 새로운 목표 물질로 인식되고 있다. 운동에 의한 포도당 흡수 과정에서 AMPK의 중요성은 현재 널리 인식되고 있으며, 이 기전은 인슐린 신호 전달 체계와 독립적으로 일어나고 있으며, 이 사실은 인슐린 신호 전달 체계에 이상이 발견되는 대부분의 제2형 당뇨병 환자에서 새로운 치료 목표 물질이 될 수 있다는 사실을 의미한다. 실제로 제2형 당뇨 환자들의 대부분이 운동을 함으로써 혈당량을 감소할 수 있으며 당뇨 모델 동물에서 운동에 의해 AMPK가 활성화되며 동시에 혈당량이 감소되는 사실도 보고되고 있다. 또한 현재 당뇨 치료제로서 널리 사용되는 메트포민(Metformin) 혹은 티아졸리딘디온(TZD) 계열의 약물도 그 효과가 부분적으로 AMPK를 통해 혈당을 강하시킨다는 보고가 있다. 이러한 사실을 종합적으로 볼 때 AMPK를 활성화시킬 수 있는 약물 발굴은 운동으로 인한 다양한 대사성 질환 개선 효과를 모방할 수 있는 신 개념의 치료제 개발로 이어지리라 예상된다. In conclusion, AMPK, as its name suggests, is activated by AMP accumulated as a result of intracellular energy depletion after muscle contraction or exercise, and plays a pivotal role in regulating energy homeostasis and carbohydrate and lipid metabolism. It is also recognized as a new target for the treatment of metabolic diseases such as diabetes and obesity caused by energy imbalance. The importance of AMPK in the process of glucose uptake by exercise is now widely recognized, and this mechanism occurs independently of the insulin signaling system, which is found in most patients with
그러나 AMPK의 활성제로서 제2형 당뇨병과 비만증에 선택적으로 효과가 있으면서 당뇨병 실험동물에 대하여 현저히 혈당을 감소시키는 저해물질에 대해서는 보고가 미비하다.However, there are few reports on inhibitors that significantly reduce blood sugar levels in diabetic experimental animals, while being selectively active against
따라서, 본 발명은 AMPK 효소의 활성증가, 비만 및 당뇨 예방 및 치료 등에 뚜렷한 효과가 있는 신규 물질을 합성하여, 그 효과를 확인함으로써 완성하게 되었다.Accordingly, the present invention has been completed by synthesizing a novel substance having a marked effect on increasing the activity of the AMPK enzyme, preventing and treating obesity and diabetes, and confirming its effect.
본 발명자들은 상기한 여러 문제를 해결하기 위하여 퀴나졸린 골격을 가진 여러 화합물들을 합성하여 혈당 강하 활성과 체중 감소를 측정한 결과 탁월한 활성과 체중 감소를 나타내는 것을 확인하였다. The present inventors synthesized various compounds having a quinazoline skeleton in order to solve the above-described problems, and as a result of measuring the blood glucose lowering activity and weight loss, it was confirmed that it shows excellent activity and weight loss.
따라서 본 발명은 당뇨병 및 비만 치료에 필수적인 혈당 강하 효과와 체중 감소 효과가 우수한 신규의 퀴나졸린 화합물을 제공하는데 그 목적이 있다.Accordingly, an object of the present invention is to provide a novel quinazoline compound having excellent hypoglycemic effect and weight loss effect, which are essential for treating diabetes and obesity.
또한, 본 발명은 신규의 퀴나졸린 화합물, 약제학적으로 허용 가능한 이의 염, 또는 약제학적으로 허용 가능한 이의 프로드럭을 유효성분으로 함유하는, 독성 및 부작용이 없는 당뇨병 및 비만 치료제를 제공하는데 다른 목적이 있다.The present invention also provides a novel quinazoline compound, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable prodrug thereof as an active ingredient, wherein the present invention provides a therapeutic agent for diabetes and obesity without toxicity and side effects. have.
본 발명은 당뇨 및 비만 치료제로 유효한 다음 화학식 1로 표시되는 퀴나졸린 유도체, 약제학적으로 허용 가능한 이의 염, 또는 약제학적으로 허용 가능한 이의 프로드럭을 그 특징으로 한다.The present invention is characterized by a quinazoline derivative represented by the following formula (1), a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable prodrug thereof, which is effective as a therapeutic agent for diabetes and obesity.
상기 화학식 1에서, In
Ra은 수소, (C1-C18)알킬, (C2-C8)알케닐, (C2-C8)알키닐, 할로게노-(C1-C6)알킬, 히드록시-(C1-C6)알킬, (C1-C6)알콕시-(C1-C6)알킬, 시아노-(C1-C6)알킬, 아미노- (C1-C6)알킬, (C1-C6)알킬아미노-(C1-C6)알킬, 디-[(C1-C6)알킬]아미노-(C1-C6)알킬, (C1-C6)알킬티오-(C1-C6)알킬, (C1-C6)알킬설피닐-(C1-C6)알킬 또는 (C1-C6)알킬설포닐-(C1-C6)알킬에서 선택된 치환체이거나, 화학식 -X1-Q1 [여기서, X1는 직접 결합이거나, O, S, SO, SO2, N(R4), CO, CO2, CH(OR4), CON(R4), N(R4)CO, SO2N(R4), N(R4)SO2, C(R4)2O, C(R4)2S, N(R4)C(R4)2 , N(R4)CON(R4), N(R4)CSN(R4)]에서 선택되고, R4은 수소, (C1-C6)알킬, 아릴, 아릴-(C1-C6)알킬, (C3-C7)싸이클로알킬, (C3-C7)싸이클로알킬-(C1-C6)알킬, (C3-C7)싸이클로알케닐, (C3-C7)싸이클로알케닐-(C1-C6)알킬, 헤테로아릴, 헤테로아릴-(C1-C6)알킬, 헤테로싸이클릴 또는 헤테로싸이클릴-(C1-C6)알킬의 기이고, Q1은 R4 와 동일하거나 상이한 치환기에서 선택될 수 있으며, R a is hydrogen, (C 1 -C 18 ) alkyl, (C 2 -C 8 ) alkenyl, (C 2 -C 8 ) alkynyl, halogeno- (C 1 -C 6 ) alkyl, hydroxy- ( C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy- (C 1 -C 6 ) alkyl, cyano- (C 1 -C 6 ) alkyl, amino- (C 1 -C 6 ) alkyl, ( C 1 -C 6 ) alkylamino- (C 1 -C 6 ) alkyl, di-[(C 1 -C 6 ) alkyl] amino- (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkylthio At-(C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkylsulfinyl- (C 1 -C 6 ) alkyl or (C 1 -C 6 ) alkylsulfonyl- (C 1 -C 6 ) alkyl Is a selected substituent or is of the formula -X 1 -Q 1 wherein X 1 is a direct bond or is O, S, SO, SO 2 , N (R 4 ), CO, CO 2 , CH (OR 4 ), CON (R 4 ), N (R 4 ) CO, SO 2 N (R 4 ), N (R 4 ) SO 2 , C (R 4 ) 2 O, C (R 4 ) 2 S, N (R 4 ) C (R 4 ) 2 , N (R 4 ) CON (R 4 ), N (R 4 ) CSN (R 4 )], and R 4 is hydrogen, (C 1 -C 6 ) alkyl, aryl, aryl- (C 1 -C 6 ) alkyl, (C 3 -C 7 ) cycloalkyl, (C 3 -C 7 ) cycloalkyl- (C 1 -C 6 ) alkyl, (C 3 -C 7 ) cycloalkenyl, (C 3 -C 7 ) cycloalkenyl- (C 1 Is a group of -C 6 ) alkyl, heteroaryl, heteroaryl- (C 1 -C 6 ) alkyl, heterocyclyl or heterocyclyl- (C 1 -C 6 ) alkyl, Q 1 is R 4 and May be selected from the same or different substituents,
그리고, 여기서 Ra 기내에서의 (C2-C6)알킬렌 기에서 인접 탄소 원자는 O, S, SO, SO2 , N(R5), CO, CH(OR5), CON(R5), N(R5)CO, SO2N(R5), N(R5)SO2, C(R5)=C(R5) 및 C≡C에서 선택된 기의 삽입에 의해서 분리될 수 있고, 여기서 R5는 수소 또는 (C1-C6)알킬이고 And wherein adjacent carbon atoms in the (C 2 -C 6 ) alkylene group in the group R a are O, S, SO, SO 2 , N (R 5 ), CO, CH (OR 5 ), CON (R 5 ), N (R 5 ) CO, SO 2 N (R 5 ), N (R 5 ) SO 2 , C (R 5 ) = C (R 5 ) and C≡C can be separated by insertion of a group selected Wherein R 5 is hydrogen or (C 1 -C 6 ) alkyl
여기서 Ra 기내에서의 임의의 CH2=CH- 또는 HC≡C- 기는 말단 CH2= 또는 HC≡ 위치에서 할로게노, 카르복시, 카르바모일, (C1-C6)알콕시카르보닐, N-(C1-C6)알킬카르바모일, N,N-디-[(C1-C6)알킬]카르바모일, 아미노-(C1-C6)알킬, (C1-C6)알킬아미노-(C1-C6)알킬 및 디-[(C1-C6)알킬]아미노-(C1-C6)알킬에서 선택되거나 또는 화학식 Q2-X2-[여기서, X2는 직접 결합이거나, CO 및 N(R6)CO에서 선택되고, 여기서 R6는 수소 또는 (C1-C6)알킬이고, Q2는 아릴, 아릴-(C1-C6)알킬, 헤테로아릴, 헤테로아릴-(C1-C6)알킬, 헤테로싸이클릴 또는 헤테로싸이클릴-(C1-C6)알킬임]의 기에서 선택된 치환체를 포함할 수 있고,Wherein any CH 2 ═CH— or HC≡C— group in the R a group is halogeno, carboxy, carbamoyl, (C 1 -C 6 ) alkoxycarbonyl, N— at the terminal CH 2 = or HC≡ position (C 1 -C 6 ) alkylcarbamoyl, N, N- di-[(C 1 -C 6 ) alkyl] carbamoyl, amino- (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkylamino, - (C 1 -C 6) alkyl and di - [(C 1 -C 6) alkyl] amino - (C 1 -C 6) alkyl selected from or the formula Q 2 -X 2 - [wherein, X 2 Is a direct bond or is selected from CO and N (R 6 ) CO, wherein R 6 is hydrogen or (C 1 -C 6 ) alkyl, Q 2 is aryl, aryl- (C 1 -C 6 ) alkyl, hetero Aryl, heteroaryl- (C 1 -C 6 ) alkyl, heterocyclyl or heterocyclyl- (C 1 -C 6 ) alkyl], and
여기서 Ra 기내에서의 임의의 CH2 또는 CH3기는 각각의 CH2 또는 CH3기에서 1 이상의 할로게노, (C1-C6)알킬 치환체, 히드록시, 시아노, 아미노, 카르복시, 카르바모일, (C1-C6)알콕시, (C1-C6)알킬티오, (C1-C6)알킬설피닐, (C1-C6)알킬설포닐, (C1-C6)알킬아미노, 디-[(C1-C6)알킬]아미노, (C1-C6)알콕시카르보닐, N-(C1-C6)알킬카르바모일, N,N-디-[(C1-C6)알킬]카르바모일, (C2-C6)알카노일, (C2-C6)알카노일옥시, (C2-C6)알카노일아미노, N-(C1-C6)알킬-(C2-C6)알카노일아미노, N-(C1-C6)알킬설 파모일, N,N-디-[(C1-C6)알킬]설파모일, (C1-C6)알칸설포닐아미노 및 N-(C1-C6)알킬-(C1-C6)알칸설포닐아미노에서 선택된 치환체 또는, 화학식 -X3-Q3 [여기서, X3는 직접 결합이거나, O, S, SO, SO2, N(R7), CO, CH(OR7), CON(R7), N(R7)CO, SO2N(R7), N(R7)SO2, C(R7)2O, C(R7)2S, N(R7)C(R7)2, N(R7)CON(R7) 및 N(R7)CSN(R7)에서 선택되고, R7 은 수소, (C1-C6)알킬, 아릴, 아릴-(C1-C6)알킬, (C3-C7)싸이클로알킬, (C3-C7)싸이클로알킬-(C1-C6)알킬, (C3-C7)싸이클로알케닐, (C3-C7)싸이클로알케닐-(C1-C6)알킬, 헤테로아릴, 헤테로아릴-(C1-C6)알킬, 헤테로싸이클릴 또는 헤테로싸이클릴-(C1-C6)알킬의 기이고, Q3 은 R7 와 동일하거나 상이한 치환기에서 선택될 수 있으며Wherein any CH 2 or CH 3 group in the R a group is at least one halogeno, (C 1 -C 6 ) alkyl substituent, hydroxy, cyano, amino, carboxy, carba at each CH 2 or CH 3 group together, (C 1 -C 6) alkoxy, (C 1 -C 6) alkylthio, (C 1 -C 6) alkylsulfinyl, (C 1 -C 6) alkylsulfonyl, (C 1 -C 6) alkylamino, di - [(C 1 -C 6) alkyl] amino, (C 1 -C 6) alkoxycarbonyl, N- (C 1 -C 6) alkyl-carbamoyl, N, N- di - [( C 1 -C 6 ) alkyl] carbamoyl, (C 2 -C 6 ) alkanoyl, (C 2 -C 6 ) alkanoyloxy, (C 2 -C 6 ) alkanoylamino, N- (C 1- C 6 ) alkyl- (C 2 -C 6 ) alkanoylamino, N- (C 1 -C 6 ) alkylsulfamoyl, N, N- di-[(C 1 -C 6 ) alkyl] sulfamoyl, ( C 1 -C 6) alkane sulfonyl amino, N- (C 1 -C 6) alkyl, - (C 1 -C 6) alkane-sulfonyl-amino or a substituent selected from the formula -X 3 -Q 3 [wherein, X 3 Is a direct bond or O, S, SO, SO 2 , N (R 7 ), CO, CH (OR 7 ), CON (R 7 ), N (R 7 ) CO, SO 2 N (R 7 ), N ( R 7 ) SO 2 , C (R 7 ) 2 O, C (R 7 ) 2 S, N (R 7 ) C (R 7 ) 2 , N (R 7 ) CON (R 7 ) and N (R 7 ) CSN (R 7 ), R 7 is hydrogen, (C 1 -C 6 ) alkyl, aryl, aryl- (C 1 -C 6 ) Alkyl, (C 3 -C 7 ) cycloalkyl, (C 3 -C 7 ) cycloalkyl- (C 1 -C 6 ) alkyl, (C 3 -C 7 ) cycloalkenyl, (C 3 -C 7 ) cyclo Is a group of alkenyl- (C 1 -C 6 ) alkyl, heteroaryl, heteroaryl- (C 1 -C 6 ) alkyl, heterocyclyl or heterocyclyl- (C 1 -C 6 ) alkyl, Q 3 is With R 7 May be selected from the same or different substituents,
여기서, Ra 상의 치환체내에서의 임의의 아릴, 헤테로아릴 또는 헤테로싸이클릴기는 0 내지 3개의 치환체를 포함할 수 있고, 이 치환체는 동일하거나 상이할 수 있으며, 할로게노, 트리플루오로메틸, 시아노, 니트로, 히드록시, 아미노, 카르복시, 카르바모일, (C1-C6)알킬, (C2-C8)알케닐, (C2-C8)알키닐, (C1-C6)알콕시, (C2-C6)알케닐옥시, (C2-C6)알키닐옥시, (C1-C6)알킬티오, (C1-C6)알킬설피닐, (C1-C6)알킬설포닐, (C1-C6)알킬아미노, 디-[(C1-C6)알킬]아미노, (C1-C6)알콕시카르보닐, N-(C1- C6)알킬카르바모일, N,N-디-[(C1-C6)알킬]카르바모일, (C2-C6)알카노일, (C2-C6)알카노일옥시, (C2-C6)알카노일아미노, N-(C1-C6)알킬-(C2-C6)알카노일아미노, N-(C1-C6)알킬설파모일, N,N-디-[(C1-C6)알킬]설파모일, (C1-C6)알칸설포닐아미노 및 N-(C1-C6)알킬-(C1-C6)알칸설포닐아미노에서 선택되거나 또는, 화학식 -X4-R8 [여기서, X4는 직접 결합이거나, O 및 N(R9)에서 선택되고, 여기서 R9는 수소 또는 (C1-C6)알킬이고, R8은 할로게노-(C1-C6)알킬, 히드록시-(C1-C6)알킬, (C1-C6)알콕시-(C1-C6)알킬, 시아노-(C1-C6)알킬, 아미노-(C1-C6)알킬, (C1-C6)알킬아미노-(C1-C6)알킬, 디-[(C1-C6)알킬]아미노-(C1-C6)알킬, (C2-C6)알카노일아미노-(C1-C6)알킬 또는 (C1-C6)알콕시카르보닐아미노-(C1-C6)알킬 임]의 기에서 선택되거나, 또는 화학식-X5-Q4 [여기서, X5는 직접 결합이거나 O, CO 및 N(R10)에서 선택되고, 여기서 R10은 수소 또는 (C1-C6)알킬이고, Q4은 아릴, 아릴-(C1-C6)알킬, 헤테로아릴, 헤테로아릴-(C1-C6)알킬, 헤테로싸이클릴 또는 헤테로싸이클릴-(C1-C6)알킬이고, 이것은 1 또는 2개의 치환체를 포함할 수 있으며, 이 치환체는 동일하거나 상이할 수 있으며, 할로게노, (C1-C6)알킬 및 (C1-C6)알콕시에서 선택되는 것임]의 기에서 선택되고,Wherein any aryl, heteroaryl, or heterocyclyl group in the substituent on R a may comprise 0 to 3 substituents, which substituents may be the same or different and include halogeno, trifluoromethyl, cya Furnace, nitro, hydroxy, amino, carboxy, carbamoyl, (C 1 -C 6 ) alkyl, (C 2 -C 8 ) alkenyl, (C 2 -C 8 ) alkynyl, (C 1 -C 6 ) Alkoxy, (C 2 -C 6 ) alkenyloxy, (C 2 -C 6 ) alkynyloxy, (C 1 -C 6 ) alkylthio, (C 1 -C 6 ) alkylsulfinyl, (C 1- C 6 ) alkylsulfonyl, (C 1 -C 6 ) alkylamino, di-[(C 1 -C 6 ) alkyl] amino, (C 1 -C 6 ) alkoxycarbonyl, N- (C 1 -C 6 ) alkyl carbamoyl, N, N- di - [(C 1 -C 6) alkyl] carbamoyl, (C 2 -C 6) alkanoyl, (C 2 -C 6) alkanoyloxy, (C 2 -C 6 ) alkanoylamino, N- (C 1 -C 6 ) alkyl- (C 2 -C 6 ) alkanoylamino, N- (C 1 -C 6 ) alkylsulfamoyl, N, N- di- [ (C 1 -C 6) alkyl] sulfamoyl, (C 1 -C 6) alkane sulfonylamino N- (C 1 -C 6) alkyl, - (C 1 -C 6) alkane sulfonyl selected or in the amino, the formula -X 4 -R 8 [wherein, X 4 is either a direct bond, O or N (R 9 ), Where R 9 is hydrogen or (C 1 -C 6 ) alkyl, R 8 is halogeno- (C 1 -C 6 ) alkyl, hydroxy- (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy- (C 1 -C 6 ) alkyl, cyano- (C 1 -C 6 ) alkyl, amino- (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkylamino- ( C 1 -C 6 ) alkyl, di-[(C 1 -C 6 ) alkyl] amino- (C 1 -C 6 ) alkyl, (C 2 -C 6 ) alkanoylamino- (C 1 -C 6 ) alkyl Or (C 1 -C 6 ) alkoxycarbonylamino- (C 1 -C 6 ) alkyl], or a compound of formula-X 5 -Q 4 , wherein X 5 is a direct bond or O, CO and N (R 10 ), wherein R 10 is hydrogen or (C 1 -C 6 ) alkyl, Q 4 is aryl, aryl- (C 1 -C 6 ) alkyl, heteroaryl, heteroaryl- (C 1 -C 6 ) alkyl, heterocyclyl or heterocyclyl- (C 1 -C 6 ) alkyl , Which may comprise one or two substituents, which substituents may be the same or different and are selected from halogeno, (C 1 -C 6 ) alkyl and (C 1 -C 6 ) alkoxy] Is selected from,
그리고, 여기서 Ra 상의 치환체내에서 헤테로싸이클릴기는 1 또는 2개의 옥소 또는 티옥소 치환체를 포함할 수 있으며;And wherein the heterocyclyl group in the substituent on R a may comprise one or two oxo or thioxo substituents;
Rb은 수소, (C1-C18)알킬, (C2-C8)알케닐, (C2-C8)알키닐, 할로게노-(C1-C6)알킬, 히드록시-(C1-C6)알킬, (C1-C6)알콕시-(C1-C6)알킬, 시아노-(C1-C6)알킬, 아미노-(C1-C6)알킬, (C1-C6)알킬아미노-(C1-C6)알킬, 디-[(C1-C6)알킬]아미노-(C1-C6)알킬, (C1-C6)알킬티오-(C1-C6)알킬, (C1-C6)알킬설피닐-(C1-C6)알킬 또는 (C1-C6)알킬설포닐-(C1-C6)알킬에서 선택된 치환체이거나, 화학식 -X1-Q1 [여기서, X1는 직접 결합이거나, O, S, SO, SO2, N(R4), CO, CO2(R4), CH(OR4), CON(R4), N(R4)CO, SO2N(R4), N(R4)SO2, C(R4)2O, C(R4)2S, N(R4)C(R4)2 , N(R4)CON(R4), N(R4)CSN(R4)]에서 선택되고, R4은 수소, (C1-C6)알킬, 아릴, 아릴-(C1-C6)알킬, (C3-C7)싸이클로알킬, (C3-C7)싸이클로알킬-(C1-C6)알킬, (C3-C7)싸이클로알케닐, (C3-C7)싸이클로알케닐-(C1-C6)알킬, 헤테로아릴, 헤테로아릴-(C1-C6)알킬, 헤테로싸이클릴 또는 헤테로싸이클릴-(C1-C6)알킬의 기이고, Q1은 R4 와 동일하거나 상이한 치환기에서 선택될 수 있으며, R b is hydrogen, (C 1 -C 18 ) alkyl, (C 2 -C 8 ) alkenyl, (C 2 -C 8 ) alkynyl, halogeno- (C 1 -C 6 ) alkyl, hydroxy- ( C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy- (C 1 -C 6 ) alkyl, cyano- (C 1 -C 6 ) alkyl, amino- (C 1 -C 6 ) alkyl, ( C 1 -C 6 ) alkylamino- (C 1 -C 6 ) alkyl, di-[(C 1 -C 6 ) alkyl] amino- (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkylthio At-(C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkylsulfinyl- (C 1 -C 6 ) alkyl or (C 1 -C 6 ) alkylsulfonyl- (C 1 -C 6 ) alkyl Is a selected substituent or is of the formula -X 1 -Q 1 wherein X 1 is a direct bond or is O, S, SO, SO 2 , N (R 4 ), CO, CO 2 (R 4 ), CH (OR 4 ) , CON (R 4 ), N (R 4 ) CO, SO 2 N (R 4 ), N (R 4 ) SO 2 , C (R 4 ) 2 O, C (R 4 ) 2 S, N (R 4 ) C (R 4 ) 2 , N (R 4 ) CON (R 4 ), N (R 4 ) CSN (R 4 )], and R 4 is hydrogen, (C 1 -C 6 ) alkyl, aryl, Aryl- (C 1 -C 6 ) alkyl, (C 3 -C 7 ) cycloalkyl, (C 3 -C 7 ) cycloalkyl- (C 1 -C 6 ) alkyl, (C 3 -C 7 ) cycloalkenyl , (C 3 -C 7 ) cycloalkenyl - (C 1 -C 6) alkyl, heteroaryl, heteroaryl - (C 1 -C 6) alkyl, heteroaryl or heteroaryl cycle the cycle reel reel - a group of (C 1 -C 6) alkyl, Q 1 is R 4 Wow May be selected from the same or different substituents,
그리고, 여기서 Rb 기내에서의 (C2-C6)알킬렌 기에서 인접 탄소 원자는 O, S, SO, SO2 , N(R5), CO, CH(OR5), CON(R5), N(R5)CO, SO2N(R5), N(R5)SO2, CH=CH 및 C≡C에서 선택된 기의 삽입에 의해서 분리될 수 있고, 여기서 R5는 수소 또는 (C1-C6)알킬이고 And wherein adjacent carbon atoms in the (C 2 -C 6 ) alkylene group in the group R b are O, S, SO, SO 2 , N (R 5 ), CO, CH (OR 5 ), CON (R 5 ), N (R 5 ) CO, SO 2 N (R 5 ), N (R 5 ) SO 2 , CH═CH and C≡C can be separated by insertion of a group wherein R 5 is hydrogen or (C 1 -C 6 ) alkyl
여기서 Rb 기내에서의 임의의 CH2=CH- 또는 HC≡C- 기는 말단 CH2= 또는 HC≡위치에서 할로게노, 카르복시, 카르바모일, (C1-C6)알콕시카르보닐, N-(C1-C6)알킬카르바모일, N,N-디-[(C1-C6)알킬]카르바모일, 아미노-(C1-C6)알킬, (C1-C6)알킬아미노-(C1-C6)알킬 및 디-[(C1-C6)알킬]아미노-(C1-C6)알킬에서 선택되거나 또는 화학식 Q2-X2-[여기서, X2는 직접 결합이거나, CO 및 N(R6)CO에서 선택되고, 여기서 Rb 상의 치환체내에서의 임의의 아릴, 헤테로아릴 또는 헤테로싸이클릴기 R6는 수소 또는 (C1-C6)알킬이고, Q2는 아릴, 아릴-(C1-C6)알킬, 헤테로아릴, 헤테로아릴-(C1-C6)알킬, 헤테로싸이클릴 또는 헤테로싸이클릴-(C1-C6)알킬임]의 기에서 선택된 치환체를 포함할 수 있고,Wherein any CH 2 ═CH— or HC≡C— group in the R b group is halogeno, carboxy, carbamoyl, (C 1 -C 6 ) alkoxycarbonyl, N— at the terminal CH 2 = or HC≡ position (C 1 -C 6 ) alkylcarbamoyl, N, N- di-[(C 1 -C 6 ) alkyl] carbamoyl, amino- (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkylamino, - (C 1 -C 6) alkyl and di - [(C 1 -C 6) alkyl] amino - (C 1 -C 6) alkyl selected from or the formula Q 2 -X 2 - [wherein, X 2 Is a direct bond or is selected from CO and N (R 6 ) CO, wherein any aryl, heteroaryl or heterocyclyl group R 6 in the substituent on R b is hydrogen or (C 1 -C 6 ) alkyl, Q 2 is aryl, aryl- (C 1 -C 6 ) alkyl, heteroaryl, heteroaryl- (C 1 -C 6 ) alkyl, heterocyclyl or heterocyclyl- (C 1 -C 6 ) alkyl] May include a substituent selected from a group,
여기서 Rb 기내에서의 임의의 CH2 또는 CH3기는 각각의 CH2 또는 CH3기에서 1 이상의 할로게노 또는 (C1-C6)알킬 치환체, 또는 히드록시, 시아노, 아미노, 카르복 시, 카르바모일, (C1-C6)알콕시, (C1-C6)알킬티오, (C1-C6)알킬설피닐, (C1-C6)알킬설포닐, (C1-C6)알킬아미노, 디-[(C1-C6)알킬]아미노, (C1-C6)알콕시카르보닐, N-(C1-C6)알킬카르바모일, N,N-디-[(C1-C6)알킬]카르바모일, (C2-C6)알카노일, (C2-C6)알카노일옥시, (C2-C6)알카노일아미노, N-(C1-C6)알킬-(C2-C6)알카노일아미노, N-(C1-C6)알킬설파모일, N,N-디-[(C1-C6)알킬]설파모일, (C1-C6)알칸설포닐아미노 및 N-(C1-C6)알킬-(C1-C6)알칸설포닐아미노에서 선택된 치환체 또는, 화학식 -X3-Q3 [여기서, X3는 직접 결합이거나, O, S, SO, SO2, N(R7), CO, CH(OR7), CON(R7), N(R7)CO, SO2N(R7), N(R7)SO2, C(R7)2O, C(R7)2S, N(R7)C(R7)2, N(R7)CON(R7) 및 N(R7)CSN(R7)에서 선택되고, R7 은 수소, (C1-C6)알킬, 아릴, 아릴-(C1-C6)알킬, (C3-C7)싸이클로알킬, (C3-C7)싸이클로알킬-(C1-C6)알킬, (C3-C7)싸이클로알케닐, (C3-C7)싸이클로알케닐-(C1-C6)알킬, 헤테로아릴, 헤테로아릴-(C1-C6)알킬, 헤테로싸이클릴 또는 헤테로싸이클릴-(C1-C6)알킬의 기이고, Q3 은 R7 와 동일하거나 상이한 치환기에서 선택될 수 있으며Wherein any CH 2 or CH 3 group in the R b group is at least one halogeno or (C 1 -C 6 ) alkyl substituent at each CH 2 or CH 3 group, or hydroxy, cyano, amino, carboxy , Carbamoyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) alkylthio, (C 1 -C 6 ) alkylsulfinyl, (C 1 -C 6 ) alkylsulfonyl, (C 1- C 6 ) alkylamino, di-[(C 1 -C 6 ) alkyl] amino, (C 1 -C 6 ) alkoxycarbonyl, N- (C 1 -C 6 ) alkylcarbamoyl, N, N- di - [(C 1 -C 6) alkyl] carbamoyl, (C 2 -C 6) alkanoyl, (C 2 -C 6) alkanoyloxy, (C 2 -C 6) alkanoylamino, N- ( C 1 -C 6 ) alkyl- (C 2 -C 6 ) alkanoylamino, N- (C 1 -C 6 ) alkylsulfamoyl, N, N- di-[(C 1 -C 6 ) alkyl] sulfamoyl , (C 1 -C 6) alkane sulfonyl amino, N- (C 1 -C 6) alkyl, - (C 1 -C 6) alkane sulfonyl amino substituent selected from or the formula -X 3 -Q 3 [wherein, X 3 is a direct bond or O, S, SO, SO 2 , N (R 7 ), CO, CH (OR 7 ), CON (R 7 ), N (R 7 ) CO, SO 2 N (R 7 ), N (R 7 ) SO 2 , C (R 7 ) 2 O, C (R 7 ) 2 S, N (R 7 ) C (R 7 ) 2 , N (R 7 ) CON (R 7 ) and N (R 7 ) CSN (R 7 ), R 7 is hydrogen, (C 1 -C 6 ) alkyl, aryl, aryl- (C 1 -C 6 ) Alkyl, (C 3 -C 7 ) cycloalkyl, (C 3 -C 7 ) cycloalkyl- (C 1 -C 6 ) alkyl, (C 3 -C 7 ) cycloalkenyl, (C 3 -C 7 ) cyclo Is a group of alkenyl- (C 1 -C 6 ) alkyl, heteroaryl, heteroaryl- (C 1 -C 6 ) alkyl, heterocyclyl or heterocyclyl- (C 1 -C 6 ) alkyl, Q 3 is With R 7 May be selected from the same or different substituents,
Rb 기내에서의 임의의 아릴, 헤테로아릴 또는 헤테로싸이클릴기는 1, 2 또는 3개의 치환체를 포함할 수 있고, 이 치환체는 동일하거나 상이할 수 있으며, 수소, 할로게노, 트리플루오로메틸, 시아노, 니트로, 히드록시, 아미노, 카르복시, 카르바모일, (C1-C6)알킬, (C2-C8)알케닐, (C2-C8)알키닐, (C1-C6)알콕시, (C2-C6)알케닐옥시, (C2-C6)알키닐옥시, (C1-C6)알킬티오, (C1-C6)알킬설피닐, (C1-C6)알킬설포닐, (C1-C6)알킬아미노, 디-[(C1-C6)알킬]아미노, (C1-C6)알콕시카르보닐, N-(C1-C6)알킬카르바모일, N,N-디-[(C1-C6)알킬]카르바모일, (C2-C6)알카노일, (C2-C6)알카노일옥시, (C2-C6)알카노일아미노, N-(C1-C6)알킬-(C2-C6)알카노일아미노, (C3-C6)알케노일아미노, N-(C1-C6)알킬-(C3-C6)알케노일아미노, (C3-C6)알키노일아미노, N-(C1-C6)알킬-(C3-C6)알키노일아미노, N-(C1-C6)알킬설파모일, N,N-디-[(C1-C6)알킬]설파모일, (C1-C6)알칸설포닐아미노 및 N-(C1-C6)알킬-(C1-C6)알칸설포닐아미노에서 선택되거나 화학식 -X4-R8 [여기서, X4 은 직접 결합이거나, O 및 N(R9)에서 선택되고, 여기서 R9는 수소 또는 (C1-C6)알킬이고, R8 은 할로게노-(C1-C6)알킬, 히드록시-(C1-C6)알킬, (C1-C6)알콕시-(C1-C6)알킬, 시아노-(C1-C6)알킬, 아미노-(C1-C6)알킬, (C1-C6)알킬아미노-(C1-C6)알킬 또는 디-[(C1-C6)알킬]아미노-(C1-C6)알킬임]의 기에서 선택되거나 또는 화학식-X5-Q4 [여기서, X5는 직접 결합이거나 O, CO 및 N(R10)에서 선택되 고, 여기서 R10은 수소 또는 (C1-C6)알킬이고, Q4은 아릴, 아릴-(C1-C6)알킬, 헤테로아릴, 헤테로아릴-(C1-C6)알킬, 헤테로싸이클릴 또는 헤테로싸이클릴-(C1-C6)알킬이고, 이것은 1 또는 2개의 치환체를 포함할 수 있으며, 이 치환체는 동일하거나 상이할 수 있으며, 할로게노, (C1-C6)알킬 및 (C1-C6)알콕시에서 선택되는 것임]의 기에서 선택되고,Any aryl, heteroaryl, or heterocyclyl group in the group R b may contain 1, 2 or 3 substituents, which substituents may be the same or different and include hydrogen, halogeno, trifluoromethyl, cya Furnace, nitro, hydroxy, amino, carboxy, carbamoyl, (C 1 -C 6 ) alkyl, (C 2 -C 8 ) alkenyl, (C 2 -C 8 ) alkynyl, (C 1 -C 6 ) Alkoxy, (C 2 -C 6 ) alkenyloxy, (C 2 -C 6 ) alkynyloxy, (C 1 -C 6 ) alkylthio, (C 1 -C 6 ) alkylsulfinyl, (C 1- C 6 ) alkylsulfonyl, (C 1 -C 6 ) alkylamino, di-[(C 1 -C 6 ) alkyl] amino, (C 1 -C 6 ) alkoxycarbonyl, N- (C 1 -C 6 ) alkyl carbamoyl, N, N- di - [(C 1 -C 6) alkyl] carbamoyl, (C 2 -C 6) alkanoyl, (C 2 -C 6) alkanoyloxy, (C 2 -C 6 ) alkanoylamino, N- (C 1 -C 6 ) alkyl- (C 2 -C 6 ) alkanoylamino, (C 3 -C 6 ) alkenoylamino, N- (C 1 -C 6 ) Alkyl- (C 3 -C 6 ) alkenoylamino, (C 3 -C 6 ) alkynoylamino, N- ( C 1 -C 6 ) alkyl- (C 3 -C 6 ) alkynoylamino, N- (C 1 -C 6 ) alkylsulfamoyl, N, N- di-[(C 1 -C 6 ) alkyl] sulfa Moyl, (C 1 -C 6 ) alkanesulfonylamino and N- (C 1 -C 6 ) alkyl- (C 1 -C 6 ) alkanesulfonylamino, or a compound of formula -X 4 -R 8 [where X 4 is a direct bond or is selected from O and N (R 9 ) wherein R 9 is hydrogen or (C 1 -C 6 ) alkyl and R 8 is halogeno- (C 1 -C 6 ) alkyl, hydroxy - (C 1 -C 6) alkyl, (C 1 -C 6) alkoxy - (C 1 -C 6) alkyl, cyano, - (C 1 -C 6) alkyl, amino, - (C 1 -C 6) alkyl , (C 1 -C 6 ) alkylamino- (C 1 -C 6 ) alkyl or di-[(C 1 -C 6 ) alkyl] amino- (C 1 -C 6 ) alkyl]; or Formula -X 5 -Q 4 , wherein X 5 is a direct bond or is selected from O, CO and N (R 10 ), wherein R 10 is hydrogen or (C 1 -C 6 ) alkyl and Q 4 is aryl , Aryl- (C 1 -C 6 ) alkyl, heteroaryl, heteroaryl- (C 1 -C 6 ) alkyl, heterocyclyl or he Interrogating cycle reel - (C 1 -C 6) alkyl, which may include one or two substituents, the substituents may be the same or different, halogeno, (C 1 -C 6) alkyl and (C 1- C 6 ) alkoxy], and
여기서 Rb 상의 치환체내에서 헤테로싸이클릴기는 1 또는 2개의 옥소 또는 티옥소 치환체를 포함할 수 있으며,Wherein the heterocyclyl group in the substituent on R b may comprise one or two oxo or thioxo substituents,
그리고 Rb 기내에서의 임의의 아릴, 헤테로아릴 또는 헤테로싸이클릴기의 동일하거나 상이한 치환기는 서로 결합하여 화학식 CH=CH-CH=CH-, -N=CH-CH=CH-, -CH=N-CH=CH-, -CH=CH-N=CH-, CH=CH-CH=N-, -N=CH-N=CH-, -CH=N-CH=N-, -N=CH-CH=N-, -N=N-CH=CH-, -CH=CH-N=N-, -CH=CH-O-, -O-CH=CH-, -CH=CH-S-, -S-CH=CH-, -C(R11)2-C(R11)2-O-, -O-C(R11)2-C(R11)2-, -C(R11)2-C(R11)2-S-, -S-C(R11)2-C(R11)2-, -O-C(R11)2-O-, -O-C(R11)2-C(R11)2-O-, -S-C(R11)2-S-, -S-C(R11)2-C(R11)2-S-, -CH=CH-NH-, -NH-CH=CH-, -C(R11)2-C(R11)2-NH-, -NH-C(R11)2-C(R11)2-, -N=CH-NH-, -NH-CH=N-, -NH-C(R11)2-NH-, -O-CH=N-, -N=CH-O-, -S-CH=N-, -N=CH-S-, -O-C(R11)2-NH-, -NH- C(R11)2-O-, -S-C(R11)2-NH-, -NH-C(R11)2-S-, -O-N=CH-, -CH=N-O-, -S-N=CH-, -CH=N-S-, -O-NH-C(R11)2-, -C(R11)2-NH-O-, -S-NH-C(R11)2-, -C(R11)2-NH-S-, -NH-N=CH-, -CH=N-NH-, -NH-NH-C(R11)2-, -C(R11)2-NH-NH, -N=N-NH- 또는 -NH-N=N-의 기 [여기서, R11은 수소 또는 (C1-C6)알킬]를 형성할 수 있고, And the same or different substituents of any aryl, heteroaryl, or heterocyclyl group in the group R b are bonded to each other to formula CH = CH-CH = CH-, -N = CH-CH = CH-, -CH = N- CH = CH-, -CH = CH-N = CH-, CH = CH-CH = N-, -N = CH-N = CH-, -CH = N-CH = N-, -N = CH-CH = N-, -N = N-CH = CH-, -CH = CH-N = N-, -CH = CH-O-, -O-CH = CH-, -CH = CH-S-, -S -CH = CH-, -C (R 11 ) 2 -C (R 11 ) 2 -O-, -OC (R 11 ) 2 -C (R 11 ) 2- , -C (R 11 ) 2 -C ( R 11 ) 2 -S-, -SC (R 11 ) 2 -C (R 11 ) 2- , -OC (R 11 ) 2 -O-, -OC (R 11 ) 2 -C (R 11 ) 2- O-, -SC (R 11 ) 2 -S-, -SC (R 11 ) 2 -C (R 11 ) 2 -S-, -CH = CH-NH-, -NH-CH = CH-, -C (R 11 ) 2 -C (R 11 ) 2 -NH-, -NH-C (R 11 ) 2 -C (R 11 ) 2- , -N = CH-NH-, -NH-CH = N-, -NH-C (R 11 ) 2 -NH-, -O-CH = N-, -N = CH-O-, -S-CH = N-, -N = CH-S-, -OC (R 11 ) 2 -NH-, -NH-C (R 11 ) 2 -O-, -SC (R 11 ) 2 -NH-, -NH-C (R 11 ) 2 -S-, -ON = CH-,- CH = NO-, -SN = CH-, -CH = NS-, -O-NH-C (R 11 ) 2- , -C (R 11 ) 2 -NH-O-, -S-NH-C ( R 11 ) 2- , -C (R 11 ) 2 -NH-S-, -NH-N = CH-, -CH = N-NH-, -NH-NH-C (R 11 ) 2- , -C (R 11 ) 2 -NH-NH, -N = N-NH- or -NH A group of -N = N-, wherein R 11 can form hydrogen or (C 1 -C 6 ) alkyl;
상기 화학식에서, m은 0, 1, 2, 3 또는 4이고;Wherein m is 0, 1, 2, 3 or 4;
각각의 Rc 기는 동일하거나 상이할 수 있으며, 수소, 할로게노, 트리플루오로메틸, 시아노, 이소시아노, 니트로, 히드록시, 머캅토, 아미노, 포르밀, 카르복시, 카르바모일, (C1-C6)알킬, (C2-C8)알케닐, (C2-C8)알키닐, (C1-C6)알콕시, (C2-C6)알케닐옥시, (C2-C6)알키닐옥시, (C1-C6)알킬티오, (C1-C6)알킬설피닐, (C1-C6)알킬설포닐, (C1-C6)알킬아미노, 디-[(C1-C6)알킬]아미노, (C1-C6)알콕시카르보닐, N-(C1-C6)알킬카르바모일, N,N-디-[(C1-C6)알킬]카르바모일, (C2-C6)알카노일, (C2-C6)알카노일옥시, (C2-C6)알카노일아미노, N-(C1-C6)알킬-(C2-C6)알카노일아미노, (C3-C6)알케노일아미노, N-(C1-C6)알킬-(C3-C6)알케노일아미노, (C3-C6)알키노일아미노, N-(C1-C6)알킬-(C3-C6)알키노일아미노, N-(C1-C6)알킬설파모일, N,N-디-[(C1-C6)알킬]설파모일, (C1-C6)알칸설포닐아미노 및 N-(C1-C6)알킬-(C1-C6)알칸설포닐아미노, 아릴, 아릴 -(C1-C6)알킬, (C3-C7)싸이클로알킬, (C3-C7)싸이클로알킬-(C1-C6)알킬, (C3-C7)싸이클로알케닐, (C3-C7)싸이클로알케닐-(C1-C6)알킬, 헤테로아릴, 헤테로아릴-(C1-C6)알킬, 헤테로싸이클릴 또는 헤테로싸이클릴-(C1-C6)알킬임]의 기에서 선택된다.Each R c group can be the same or different and is hydrogen, halogeno, trifluoromethyl, cyano, isocyano, nitro, hydroxy, mercapto, amino, formyl, carboxy, carbamoyl, (C 1 -C 6 ) alkyl, (C 2 -C 8 ) alkenyl, (C 2 -C 8 ) alkynyl, (C 1 -C 6 ) alkoxy, (C 2 -C 6 ) alkenyloxy, (C 2 -C 6) alkynyloxy, (C 1 -C 6) alkylthio, (C 1 -C 6) alkylsulfinyl, (C 1 -C 6) alkylsulfonyl, (C 1 -C 6) alkylamino, di - [(C 1 -C 6) alkyl] amino, (C 1 -C 6) alkoxycarbonyl, N- (C 1 -C 6) alkyl-carbamoyl, N, N- di - [(C 1 - C 6 ) alkyl] carbamoyl, (C 2 -C 6 ) alkanoyl, (C 2 -C 6 ) alkanoyloxy, (C 2 -C 6 ) alkanoylamino, N- (C 1 -C 6 ) Alkyl- (C 2 -C 6 ) alkanoylamino, (C 3 -C 6 ) alkenoylamino, N- (C 1 -C 6 ) alkyl- (C 3 -C 6 ) alkenoylamino, (C 3- C 6 ) alkynoylamino, N- (C 1 -C 6 ) alkyl- (C 3 -C 6 ) alkynoylamino, N- (C 1 -C 6 ) alkylsulfamoyl, N, N- di- [(C 1- C 6 ) alkyl] sulfamoyl, (C 1 -C 6 ) alkanesulfonylamino and N- (C 1 -C 6 ) alkyl- (C 1 -C 6 ) alkanesulfonylamino, aryl, aryl-(C 1 -C 6 ) alkyl, (C 3 -C 7 ) cycloalkyl, (C 3 -C 7 ) cycloalkyl- (C 1 -C 6 ) alkyl, (C 3 -C 7 ) cycloalkenyl, (C 3- C 7 ) cycloalkenyl- (C 1 -C 6 ) alkyl, heteroaryl, heteroaryl- (C 1 -C 6 ) alkyl, heterocyclyl or heterocyclyl- (C 1 -C 6 ) alkyl] Is selected from the group.
여기서 Rc 치환체내에서의 임의의 (C2-C6)알킬렌 기에서 인접 탄소 원자는 O, S, SO, SO2 , N(R12), CO, CH(OR12), CON(R12), N(R12)CO, SO2N(R12), N(R12)SO2 , CH=CH 및 C≡C에서 선택된 기의 삽입에 의해서 분리될 수 있고, 여기서 R12는 수소 또는 (C1-C6)알킬이고, Wherein adjacent carbon atoms in any (C 2 -C 6 ) alkylene group in the R c substituent are O, S, SO, SO 2 , N (R 12 ), CO, CH (OR 12 ), CON (R 12 ), N (R 12 ) CO, SO 2 N (R 12 ), N (R 12 ) SO 2 , CH = CH and C≡C can be separated by insertion of a group, wherein R 12 is hydrogen Or (C 1 -C 6 ) alkyl,
여기서 Rc 치환체내에서의 임의의 CH2=CH- 또는 HC≡C- 기는 말단 CH2= 또는 HC≡위치에서 할로게노, 카르복시, 카르바모일, (C1-C6)알콕시카르보닐, N-(C1-C6)알킬카르바모일, N,N-디-[(C1-C6)알킬]카르바모일, 아미노-(C1-C6)알킬, (C1-C6)알킬아미노-(C1-C6)알킬 및 디-[(C1-C6)알킬]아미노-(C1-C6)알킬에서 선택되거나 또는 화학식 Q5-X6-[여기서, X6는 직접 결합이거나, CO 및 N(R13)CO에서 선택되고, 여기서 R13는 수소 또는 (C1-C6)알킬이고, Q5는 아릴, 아릴-(C1-C6)알킬, 헤테로아릴, 헤테로아릴-(C1-C6)알킬, 헤테로싸이클릴 또는 헤테로싸이클릴-(C1-C6)알킬임]의 기에서 선택 된 치환체를 포함할 수 있고,Wherein any CH 2 ═CH— or HC≡C— group in the R c substituent is halogeno, carboxy, carbamoyl, (C 1 -C 6 ) alkoxycarbonyl, N at the terminal CH 2 = or HC≡ position - (C 1 -C 6 ) alkylcarbamoyl, N, N- di-[(C 1 -C 6 ) alkyl] carbamoyl, amino- (C 1 -C 6 ) alkyl, (C 1 -C 6 ) Alkylamino- (C 1 -C 6 ) alkyl and di-[(C 1 -C 6 ) alkyl] amino- (C 1 -C 6 ) alkyl or is selected from the formula Q 5 -X 6- [where X 6 is a direct bond or is selected from CO and N (R 13 ) CO, wherein R 13 is hydrogen or (C 1 -C 6 ) alkyl, Q 5 is aryl, aryl- (C 1 -C 6 ) alkyl, Heteroaryl, heteroaryl- (C 1 -C 6 ) alkyl, heterocyclyl or heterocyclyl- (C 1 -C 6 ) alkyl], and
여기서 Rc 치환체내에서의 임의의 CH2 또는 CH3기는 각각의 CH2 또는 CH3기에서 1 이상의 할로게노 또는 (C1-C6)알킬 치환체, 또는 히드록시, 시아노, 아미노, 카르복시, 카르바모일, (C1-C6)알콕시, (C1-C6)알킬티오, (C1-C6)알킬설피닐, (C1-C6)알킬설포닐, (C1-C6)알킬아미노, 디-[(C1-C6)알킬]아미노, (C1-C6)알콕시카르보닐, N-(C1-C6)알킬카르바모일, N,N-디-[(C1-C6)알킬]카르바모일, (C2-C6)알카노일, (C2-C6)알카노일옥시, (C2-C6)알카노일아미노, N-(C1-C6)알킬-(C2-C6)알카노일아미노, N-(C1-C6)알킬설파모일, N,N-디-[(C1-C6)알킬]설파모일, (C1-C6)알칸설포닐아미노 및 N-(C1-C6)알킬-(C1-C6)알칸설포닐아미노에서 선택된 치환체 또는, 화학식 -X7-Q6 [여기서, X7는 직접 결합이거나, O, S, SO, SO2, N(R14), CO, CH(OR14), CON(R14), N(R14)CO, SO2N(R14), N(R14)SO2, C(R14)2O, C(R14)2S 및 N(R14)C(R14)2에서 선택되고, 여기서 R14은 수소 또는 (C1-C6)알킬이고, Q6는 아릴, 아릴-(C1-C6)알킬, (C3-C7)싸이클로알킬, (C3-C7)싸이클로알킬-(C1-C6)알킬, (C3-C7)싸이클로알케닐, (C3-C7)싸이클로알케닐-(C1-C6)알킬, 헤테로아릴, 헤테로아릴-(C1-C6)알킬, 헤테로싸이클릴 또는 헤테로싸이 클릴-(C1-C6)알킬임]의 기에서 선택되는 치환체를 포함할 수 있으며,Wherein any CH 2 or CH 3 group in the R c substituent is at least one halogeno or (C 1 -C 6 ) alkyl substituent at each CH 2 or CH 3 group, or hydroxy, cyano, amino, carboxy, Carbamoyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) alkylthio, (C 1 -C 6 ) alkylsulfinyl, (C 1 -C 6 ) alkylsulfonyl, (C 1 -C 6 ) alkylamino, di-[(C 1 -C 6 ) alkyl] amino, (C 1 -C 6 ) alkoxycarbonyl, N- (C 1 -C 6 ) alkylcarbamoyl, N, N- di- [(C 1 -C 6) alkyl] carbamoyl, (C 2 -C 6) alkanoyl, (C 2 -C 6) alkanoyloxy, (C 2 -C 6) alkanoylamino, N- (C 1- C 6 ) alkyl- (C 2 -C 6 ) alkanoylamino, N- (C 1 -C 6 ) alkylsulfamoyl, N, N- di-[(C 1 -C 6 ) alkyl] sulfamoyl, (C 1 -C 6) alkane sulfonylamino N- and (C 1 -C 6) alkyl, - (C 6 -C 1) alkane sulfonyl substituent selected from amino, or the formula -X 7 -Q 6 [where, X 7 is a direct bond or O, S, SO, SO 2 , N (R 14 ), CO, CH (OR 14 ), CON (R 14 ), N (R 14 ) CO, SO 2 N (R 14 ), N (R 14 ) SO 2 , C (R 14 ) 2 O, C (R 14 ) 2 S and N (R 14 ) C (R 14 ) 2 , Wherein R 14 is hydrogen or (C 1 -C 6 ) alkyl, Q 6 is aryl, aryl- (C 1 -C 6 ) alkyl, (C 3 -C 7 ) cycloalkyl, (C 3 -C 7 ) cyclo alkyl, - (C 1 -C 6) alkyl, (C 3 -C 7) cyclo-alkenyl, (C 3 -C 7) cyclo alkenyl, - (C 1 -C 6) alkyl, heteroaryl, heteroaryl - (C 1 -C 6 ) alkyl, heterocyclyl or heterocyclyl- (C 1 -C 6 ) alkyl], and
여기서, Rc 기내에서의 임의의 아릴, 헤테로아릴 또는 헤테로싸이클릴기는 1, 2 또는 3개의 치환체를 포함할 수 있고, 이 치환체는 동일하거나 상이할 수 있으며, 수소, 할로게노, 트리플루오로메틸, 시아노, 니트로, 히드록시, 아미노, 카르복시, 카르바모일, (C1-C6)알킬, (C2-C8)알케닐, (C2-C8)알키닐, (C1-C6)알콕시, (C2-C6)알케닐옥시, (C2-C6)알키닐옥시, (C1-C6)알킬티오, (C1-C6)알킬설피닐, (C1-C6)알킬설포닐, (C1-C6)알킬아미노, 디-[(C1-C6)알킬]아미노, (C1-C6)알콕시카르보닐, N-(C1-C6)알킬카르바모일, N,N-디-[(C1-C6)알킬]카르바모일, (C2-C6)알카노일, (C2-C6)알카노일옥시, (C2-C6)알카노일아미노, N-(C1-C6)알킬-(C2-C6)알카노일아미노, (C3-C6)알케노일아미노, N-(C1-C6)알킬-(C3-C6)알케노일아미노, (C3-C6)알키노일아미노, N-(C1-C6)알킬-(C3-C6)알키노일아미노, N-(C1-C6)알킬설파모일, N,N-디-[(C1-C6)알킬]설파모일, (C1-C6)알칸설포닐아미노 및 N-(C1-C6)알킬-(C1-C6)알칸설포닐아미노에서 선택되거나 화학식 -X8-R15 [여기서, X8은 직접 결합이거나, O 및 N(R16)에서 선택되고, 여기서 R16는 수소 또는 (C1-C6)알킬이고, R15은 할로게노-(C1-C6)알킬, 히드록시-(C1-C6)알킬, (C1-C6)알콕시-(C1-C6)알킬, 시아노-(C1-C6)알킬, 아미노-(C1-C6)알킬, (C1-C6)알킬아미노-(C1-C6)알킬 또는 디-[(C1-C6)알킬]아미노-(C1-C6)알킬 임]의 기에서 선택되거나 또는 화학식 -X9-Q7 [여기서, X9은 직접 결합이거나 O, CO 및 N(R17)에서 선택되고, R17은 수소 또는 (C1-C6)알킬이고, Q7은 1 또는 2개의 치환체를 지닐 수 있는, 아릴, 아릴-(C1-C6)알킬, 헤테로아릴, 헤테로아릴-(C1-C6)알킬, 헤테로싸이클릴 또는 헤테로싸이클릴-(C1-C6)알킬이고, 이 치환체는 동일하거나 상이할 수 있으며, 할로게노, (C1-C6)알킬 및 (C1-C6)알콕시에서 선택되고, Q7 내에서의 임의의 헤테로싸이클릴기는 1 또는 2개의 옥소 또는 티옥소 치환체를 포함할 수 있음]의 기에서 선택되고, Wherein any aryl, heteroaryl, or heterocyclyl group in the R c group may comprise 1, 2 or 3 substituents, which substituents may be the same or different and are hydrogen, halogeno, trifluoromethyl , Cyano, nitro, hydroxy, amino, carboxy, carbamoyl, (C 1 -C 6 ) alkyl, (C 2 -C 8 ) alkenyl, (C 2 -C 8 ) alkynyl, (C 1- C 6 ) alkoxy, (C 2 -C 6 ) alkenyloxy, (C 2 -C 6 ) alkynyloxy, (C 1 -C 6 ) alkylthio, (C 1 -C 6 ) alkylsulfinyl, (C 1- C 6 ) alkylsulfonyl, (C 1 -C 6 ) alkylamino, di-[(C 1 -C 6 ) alkyl] amino, (C 1 -C 6 ) alkoxycarbonyl, N- (C 1- C 6 ) alkylcarbamoyl, N, N- di-[(C 1 -C 6 ) alkyl] carbamoyl, (C 2 -C 6 ) alkanoyl, (C 2 -C 6 ) alkanoyloxy, ( C 2 -C 6 ) alkanoylamino, N- (C 1 -C 6 ) alkyl- (C 2 -C 6 ) alkanoylamino, (C 3 -C 6 ) alkenoylamino, N- (C 1 -C 6) alkyl, - (C 3 -C 6) alkenyl alkanoyl amino, (C 3 -C 6) Al Keno ilah No, N- (C 1 -C 6) alkyl, - (C 3 -C 6) Al Keno-ylamino, N- (C 1 -C 6) alkyl sulfamoyl, N, N- di - [(C 1 -C 6 ) alkyl] sulfamoyl, (C 1 -C 6 ) alkanesulfonylamino and N- (C 1 -C 6 ) alkyl- (C 1 -C 6 ) alkanesulfonylamino or is selected from the formula -X 8 -R 15 wherein X 8 is a direct bond or is selected from O and N (R 16 ), wherein R 16 is hydrogen or (C 1 -C 6 ) alkyl and R 15 is halogeno- (C 1 -C 6 ) Alkyl, hydroxy- (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy- (C 1 -C 6 ) alkyl, cyano- (C 1 -C 6 ) alkyl, amino- (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkylamino- (C 1 -C 6 ) alkyl or di-[(C 1 -C 6 ) alkyl] amino- (C 1 -C 6 ) alkyl] Is selected from the group or of the formula -X 9 -Q 7 wherein X 9 is a direct bond or is selected from O, CO and N (R 17 ), R 17 is hydrogen or (C 1 -C 6 ) alkyl, Q 7 is aryl, aryl- (C 1 -C 6 ) alkyl, heteroaryl, heteroa, which may bear 1 or 2 substituents Aryl- (C 1 -C 6 ) alkyl, heterocyclyl or heterocyclyl- (C 1 -C 6 ) alkyl, which substituents may be the same or different, halogeno, (C 1 -C 6 ) alkyl And (C 1 -C 6 ) alkoxy, and any heterocyclyl group in Q 7 may include 1 or 2 oxo or thioxo substituents, and
여기서 Rc 상의 치환체내에서 헤테로싸이클릴기는 1 또는 2개의 옥소 또는 티옥소 치환체를 포함할 수 있으며,Wherein the heterocyclyl group in the substituent on R c may comprise one or two oxo or thioxo substituents,
Rc 기내에서의 임의의 아릴, 헤테로아릴 또는 헤테로싸이클릴기의 동일하거나 상이한 치환기는 서로 결합하여 화학식 CH=CH-CH=CH-, -N=CH-CH=CH-, -CH=N-CH=CH-, -CH=CH-N=CH-, CH=CH-CH=N-, -N=CH-N=CH-, -CH=N-CH=N-, -N=CH-CH=N-, -N=N-CH=CH-, -CH=CH-N=N-, -CH=CH-O-, -O-CH=CH-, -CH=CH-S-, -S-CH=CH-, -C(R18)2-C(R18)2-O-, -O-C(R18)2-C(R18)2-, -C(R18)2-C(R18)2-S-, -S-C(R18)2-C(R18)2-, -O-C(R18)2-O-, -O-C(R18)2-C(R18)2-O-, -S-C(R18)2-S-, -S-C(R18)2-C(R18)2-S-, -CH=CH-NH-, -NH-CH=CH-, -C(R18)2-C(R18)2-NH-, -NH-C(R18)2-C(R18)2-, -N=CH-NH-, -NH-CH=N-, -NH-C(R18)2-NH-, -O-CH=N-, -N=CH-O-, -S-CH=N-, -N=CH-S-, -O-C(R18)2-NH-, -NH-C(R18)2-O-, -S-C(R18)2-NH-, -NH-C(R18)2-S-, -O-N=CH-, -CH=N-O-, -S-N=CH-, -CH=N-S-, -O-NH-C(R18)2-, -C(R18)2-NH-O-, -S-NH-C(R18)2-, -C(R18)2-NH-S-, -NH-N=CH-, -CH=N-NH-, -NH-NH-C(R18)2-, -C(R18)2-NH-NH, -N=N-NH- 또는 -NH-N=N-의 기 [여기서, R18은 수소 또는 (C1-C6)알킬]를 형성할 수 있다.The same or different substituents of any aryl, heteroaryl, or heterocyclyl group in the R c group are bonded to each other to form the formula CH = CH-CH = CH-, -N = CH-CH = CH-, -CH = N-CH = CH-, -CH = CH-N = CH-, CH = CH-CH = N-, -N = CH-N = CH-, -CH = N-CH = N-, -N = CH-CH = N-, -N = N-CH = CH-, -CH = CH-N = N-, -CH = CH-O-, -O-CH = CH-, -CH = CH-S-, -S- CH = CH-, -C (R 18 ) 2 -C (R 18 ) 2 -O-, -OC (R 18 ) 2 -C (R 18 ) 2- , -C (R 18 ) 2 -C (R 18 ) 2 -S-, -SC (R 18 ) 2 -C (R 18 ) 2- , -OC (R 18 ) 2 -O-, -OC (R 18 ) 2 -C (R 18 ) 2 -O -, -SC (R 18 ) 2 -S-, -SC (R 18 ) 2 -C (R 18 ) 2 -S-, -CH = CH-NH-, -NH-CH = CH-, -C ( R 18 ) 2 -C (R 18 ) 2 -NH-, -NH-C (R 18 ) 2 -C (R 18 ) 2- , -N = CH-NH-, -NH-CH = N-,- NH-C (R 18 ) 2 -NH-, -O-CH = N-, -N = CH-O-, -S-CH = N-, -N = CH-S-, -OC (R 18 ) 2 -NH-, -NH-C (R 18 ) 2 -O-, -SC (R 18 ) 2 -NH-, -NH-C (R 18 ) 2 -S-, -ON = CH-, -CH = NO-, -SN = CH-, -CH = NS-, -O-NH-C (R 18 ) 2- , -C (R 18 ) 2 -NH-O-, -S-NH-C (R 18 ) 2- , -C (R 18 ) 2 -NH-S-, -NH-N = CH-, -CH = N-NH-, -NH-NH-C (R 18 ) 2- , -C ( R 18) 2 -NH-NH, -N = N-NH- or -NH-N = N- of It may form a [where, R 18 is hydrogen or (C 1 -C 6) alkyl].
상기 화학식 1로 표시되는 퀴나졸린 화합물 중에서도 바람직하기로는 다음 화학식 1-1로 표시되는 화합물이다.Among the quinazoline compounds represented by
[화학식 1-1][Formula 1-1]
상기 화학식 1-1에서, In Chemical Formula 1-1,
X는 직접 결합이거나, O, S, SO, SO2 또는 NR5에서 선택되고, R5는 수소, (C1-C6)알킬, 아릴, 아릴-(C1-C6)알킬, (C3-C7)싸이클로알킬, (C3-C7)싸이클로알킬-(C1-C6)알킬, 헤테로아릴, 헤테로아릴-(C1-C6)알킬, 헤테로싸이클릴 또는 헤테로싸이클릴-(C1-C6)알킬의 기이며;X is a direct bond or is selected from O, S, SO, SO 2 or NR 5 , R 5 is hydrogen, (C 1 -C 6 ) alkyl, aryl, aryl- (C 1 -C 6 ) alkyl, (C 3 -C 7 ) cycloalkyl, (C 3 -C 7 ) cycloalkyl- (C 1 -C 6 ) alkyl, heteroaryl, heteroaryl- (C 1 -C 6 ) alkyl, heterocyclyl or heterocyclyl- A group of (C 1 -C 6 ) alkyl;
R1은 수소, (C1-C8)알킬, 할로게노-(C1-C6)알킬, 히드록시-(C1-C6)알킬, (C1-C6)알콕시-(C1-C6)알킬, 아미노-(C1-C6)알킬, (C1-C6)알킬아미노-(C1-C6)알킬, 디-[(C1-C6)알킬]아미노-(C1-C6)알킬 및 (C1-C6)알킬설피닐 중에서 선택된 치환체이거나, 또는 화학식 -X1-Q1 [여기서, X1는 직접 결합이거나, O, S 또는 NR5]에서 선택되고, Q1은 R5와 동일하거나 상이한 치환기에서 선택될 수 있으며,R 1 is hydrogen, (C 1 -C 8 ) alkyl, halogeno- (C 1 -C 6 ) alkyl, hydroxy- (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy- (C 1 -C 6 ) alkyl, amino- (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkylamino- (C 1 -C 6 ) alkyl, di-[(C 1 -C 6 ) alkyl] amino- (C 1 -C 6) alkyl and (C 1 -C 6), or a substituent selected from alkyl sulfinyl, or the formula -X 1 -Q 1 [wherein, X 1 is either a direct bond, O, S or NR 5] from Q 1 may be selected from the same or different substituents as R 5 ,
그리고, 여기서 R1 기내에서의 (C2-C6)알킬렌 기에서 인접 탄소 원자는 O, S 및 N(R5)에서 선택된 기의 삽입에 의해서 분리될 수 있고,And wherein adjacent carbon atoms in the (C 2 -C 6) alkylene group of R 1 in flight may be separated by insertion of a group selected from O, S and N (R 5),
여기서 R1 기내에서의 임의의 CH2 또는 CH3기는 각각의 CH2 또는 CH3기에서 1 이상의 할로게노, (C1-C6)알킬 치환체, 히드록시, 아미노, (C1-C6)알콕시 (C1-C6)알킬티오, (C1-C6)알킬설피닐, (C1-C6)알킬아미노 및 디-[(C1-C6)알킬]아미노에서 선택된 치환체를 포함할 수 있고,Wherein any CH 2 or CH 3 group in the R 1 group is at least one halogeno, (C 1 -C 6 ) alkyl substituent, hydroxy, amino, (C 1 -C 6 ) at each CH 2 or CH 3 group Substituents selected from alkoxy (C 1 -C 6 ) alkylthio, (C 1 -C 6 ) alkylsulfinyl, (C 1 -C 6 ) alkylamino and di-[(C 1 -C 6 ) alkyl] amino Can do it,
여기서 R1상의 치환체내에서의 임의의 아릴, 헤테로아릴 또는 헤테로싸이클릴기는 0 내지 3개의 치환체를 포함할 수 있고, 이 치환체는 동일하거나 상이할 수 있으며, 할로게노, 히드록시, 아미노, (C1-C6)알킬, 아릴, 아릴-(C1-C6)알킬, 헤테로아릴, 헤테로아릴-(C1-C6)알킬, 헤테로싸이클릴 또는 헤테로싸이클릴-(C1-C6)알킬, (C1-C6)알콕시, (C1-C6)알킬티오 및 (C1-C6)알킬설피닐 중에서 선택된 치환체를 포함할 수 있고,Wherein any aryl, heteroaryl or heterocyclyl group in the substituent on R 1 may comprise 0 to 3 substituents, which substituents may be the same or different and include halogeno, hydroxy, amino, (C 1 -C 6 ) alkyl, aryl, aryl- (C 1 -C 6 ) alkyl, heteroaryl, heteroaryl- (C 1 -C 6 ) alkyl, heterocyclyl or heterocyclyl- (C 1 -C 6 ) May include a substituent selected from alkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) alkylthio and (C 1 -C 6 ) alkylsulfinyl,
그리고, 여기서 R1 상의 치환체내에서 헤테로싸이클릴기는 1 또는 2개의 옥소 또는 티옥소 치환체를 포함할 수 있으며;And wherein the heterocyclyl group in the substituent on R 1 may comprise one or two oxo or thioxo substituents;
R2은 수소, (C1-C18)알킬, (C2-C8)알케닐, 할로게노-(C1-C8)알킬, 히드록시-(C1-C8)알킬, (C1-C8)알콕시-(C1-C8)알킬, 아미노-(C1-C8)알킬, (C1-C8)알킬아미노-(C1-C8)알킬, 디-[(C1-C8)알킬]아미노-(C1-C8)알킬, (C1-C8)알킬설피닐, 아릴, 아릴-(C1-C8)알킬, (C3-C7)싸이클로알킬, (C3-C7)싸이클로알킬-(C1-C8)알킬, 헤테로아릴, 헤테로아릴-(C1-C8)알킬, 헤테로싸이클릴 및 헤테로싸이클릴-(C1-C8)알킬 중의 치환기에서 선택될 수 있으며,R 2 is hydrogen, (C 1 -C 18 ) alkyl, (C 2 -C 8 ) alkenyl, halogeno- (C 1 -C 8 ) alkyl, hydroxy- (C 1 -C 8 ) alkyl, (C 1 -C 8 ) alkoxy- (C 1 -C 8 ) alkyl, amino- (C 1 -C 8 ) alkyl, (C 1 -C 8 ) alkylamino- (C 1 -C 8 ) alkyl, di-[( C 1 -C 8 ) alkyl] amino- (C 1 -C 8 ) alkyl, (C 1 -C 8 ) alkylsulfinyl, aryl, aryl- (C 1 -C 8 ) alkyl, (C 3 -C 7 ) Cycloalkyl, (C 3 -C 7 ) cycloalkyl- (C 1 -C 8 ) alkyl, heteroaryl, heteroaryl- (C 1 -C 8 ) alkyl, heterocyclyl and heterocyclyl- (C 1 -C 8 ) may be selected from substituents in alkyl,
그리고, 여기서 R2 기내에서의 (C2-C6)알킬렌 기에서 인접 탄소 원자는 O, S, N(R5), CO, CH(OR5), CON(R5), N(R5)CO, SO2N(R5), N(R5)SO2 및 CH=CH에서 선택된 기 의 삽입에 의해서 분리될 수 있고,And wherein adjacent carbon atoms in the (C 2 -C 6 ) alkylene group in the R 2 group are O, S, N (R 5 ), CO, CH (OR 5 ), CON (R 5 ), N (R 5 ) can be separated by insertion of a group selected from CO, SO 2 N (R 5 ), N (R 5 ) SO 2 and CH = CH,
여기서 R2 기내에서의 임의의 CH2 또는 CH3기는 각각의 CH2 또는 CH3기에서 1 이상의 할로게노, (C1-C6)알킬 치환체, 히드록시, 시아노, 아미노, 카르복시, 카르바모일, (C1-C6)알콕시 (C1-C6)알킬티오 및 (C1-C6)알킬설피닐, (C1-C6)알킬아미노, 디-[(C1-C6)알킬]아미노, (C1-C6)알콕시카르보닐, N-(C1-C6)알킬카르바모일, N,N-디-[(C1-C6)알킬]카르바모일, 아릴, 아릴-(C1-C6)알킬, (C3-C7)싸이클로 알킬, (C3-C7)싸이클로알킬-(C1-C6)알킬, 헤테로아릴, 헤테로아릴-(C1-C6)알킬, 헤테로싸이클릴 및 헤테로싸이클릴-(C1-C6)알킬기 중에서 선택된 치환체를 포함할 수 있고,Wherein any CH 2 or CH 3 group in the R 2 group is at least one halogeno, (C 1 -C 6 ) alkyl substituent, hydroxy, cyano, amino, carboxy, carba at each CH 2 or CH 3 group Moyl, (C 1 -C 6 ) alkoxy (C 1 -C 6 ) alkylthio and (C 1 -C 6 ) alkylsulfinyl, (C 1 -C 6 ) alkylamino, di-[(C 1 -C 6 ) Alkyl] amino, (C 1 -C 6 ) alkoxycarbonyl, N- (C 1 -C 6 ) alkylcarbamoyl, N, N -di-[(C 1 -C 6 ) alkyl] carbamoyl, Aryl, aryl- (C 1 -C 6 ) alkyl, (C 3 -C 7 ) cycloalkyl, (C 3 -C 7 ) cycloalkyl- (C 1 -C 6 ) alkyl, heteroaryl, heteroaryl- (C It may include a substituent selected from 1 -C 6 ) alkyl, heterocyclyl and heterocyclyl- (C 1 -C 6 ) alkyl group,
여기서 R2상의 치환체내에서의 임의의 아릴, 헤테로아릴 또는 헤테로싸이클릴기는 0 내지 3개의 치환체를 포함할 수 있고, 이 치환체는 동일하거나 상이할 수 있으며, 할로게노, 트리플루오로메틸, 시아노, 니트로, 히드록시, 아미노, 카르복시, 카르바모일, (C1-C6)알킬, 아릴, 아릴-(C1-C6)알킬, 헤테로아릴, 헤테로아릴-(C1-C6)알킬, 헤테로싸이클릴 또는 헤테로싸이클릴-(C1-C6)알킬, (C2-C8)알케닐, (C2-C8)알키닐, (C1-C6)알콕시, (C1-C6)알킬티오, (C1-C6)알킬설피닐, (C1-C6)알킬아미노, 디-[(C1-C6)알킬]아미노, (C1-C6)알콕시카르보닐, N-(C1-C6)알킬카르바모일 및 N,N-디-[(C1-C6)알킬]카르바모일에서 선택된 치환체를 포함할 수 있고,Wherein any aryl, heteroaryl, or heterocyclyl group in a substituent on R 2 may comprise 0 to 3 substituents, which substituents may be the same or different and include halogeno, trifluoromethyl, cyano , Nitro, hydroxy, amino, carboxy, carbamoyl, (C 1 -C 6 ) alkyl, aryl, aryl- (C 1 -C 6 ) alkyl, heteroaryl, heteroaryl- (C 1 -C 6 ) alkyl , Heterocyclyl or heterocyclyl- (C 1 -C 6 ) alkyl, (C 2 -C 8 ) alkenyl, (C 2 -C 8 ) alkynyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) alkylthio, (C 1 -C 6 ) alkylsulfinyl, (C 1 -C 6 ) alkylamino, di-[(C 1 -C 6 ) alkyl] amino, (C 1 -C 6 ) alkoxy Carbonyl, N- (C 1 -C 6 ) alkylcarbamoyl and N, N -di-[(C 1 -C 6 ) alkyl] carbamoyl;
그리고, 여기서 R2 상의 치환체내에서 헤테로싸이클릴기는 1 또는 2개의 옥소 또는 티옥소 치환체를 포함할 수 있으며,And wherein the heterocyclyl group in the substituent on R 2 may comprise one or two oxo or thioxo substituents,
그리고 R2기내에서의 임의의 아릴, 헤테로아릴 또는 헤테로싸이클릴기의 동일하거나 상이한 치환기는 서로 결합하여 화학식 CH=CH-CH=CH-, -N=CH-CH=CH-, -CH=N-CH=CH-, -CH=CH-N=CH-, CH=CH-CH=N-, -N=CH-N=CH-, -CH=N-CH=N-, -N=CH-CH=N-, -CH=CH-O-, -O-CH=CH-, -CH=CH-S-, -S-CH=CH-, -C(R6)2-C(R6)2-O-, -O-C(R6)2-C(R6)2-, -C(R6)2-C(R6)2-S-, -S-C(R6)2-C(R6)2-, -O-C(R6)2-O-, -O-C(R6)2-C(R6)2-O-, -S-C(R6)2-S-, -S-C(R6)2-C(R6)2-S-, -CH=CH-NH-, -NH-CH=CH-, -C(R6)2-C(R6)2-NH-, -NH-C(R6)2-C(R6)2-, -N=CH-NH-, -NH-CH=N-, -NH-C(R6)2-NH-, -O-CH=N-, -N=CH-O-, -S-CH=N-, -N=CH-S-, -O-C(R6)2-NH-, -NH-C(R6)2-O-, -S-C(R6)2-NH-, -NH-C(R6)2-S-, -N=N-NH- 또는 -NH-N=N-의 기 [여기서, R6는 수소 또는 (C1-C3)알킬기]를 형성할 수 있고; And the same or different substituents of any aryl, heteroaryl, or heterocyclyl group in the R 2 group are bonded to each other to form the formula CH = CH-CH = CH-, -N = CH-CH = CH-, -CH = N- CH = CH-, -CH = CH-N = CH-, CH = CH-CH = N-, -N = CH-N = CH-, -CH = N-CH = N-, -N = CH-CH = N-, -CH = CH-O-, -O-CH = CH-, -CH = CH-S-, -S-CH = CH-, -C (R 6 ) 2 -C (R 6 ) 2 -O-, -OC (R 6 ) 2 -C (R 6 ) 2- , -C (R 6 ) 2 -C (R 6 ) 2 -S-, -SC (R 6 ) 2 -C (R 6 ) 2- , -OC (R 6 ) 2 -O-, -OC (R 6 ) 2 -C (R 6 ) 2 -O-, -SC (R 6 ) 2 -S-, -SC (R 6 ) 2 -C (R 6 ) 2 -S-, -CH = CH-NH-, -NH-CH = CH-, -C (R 6 ) 2 -C (R 6 ) 2 -NH-, -NH-C (R 6 ) 2 -C (R 6 ) 2- , -N = CH-NH-, -NH-CH = N-, -NH-C (R 6 ) 2 -NH-, -O-CH = N- , -N = CH-O-, -S-CH = N-, -N = CH-S-, -OC (R 6 ) 2 -NH-, -NH-C (R 6 ) 2 -O-,- Group of SC (R 6 ) 2 -NH-, -NH-C (R 6 ) 2 -S-, -N = N-NH- or -NH-N = N-, wherein R 6 is hydrogen or (C 1 -C 3 ) alkyl group];
R3 및 R4는 각각 동일하거나 상이할 수 있으며, 수소, 할로게노, 트리플루오로메틸, 시아노, 니트로, 히드록시, 머캅토, 아미노, 포르밀, 카르복시, 카르바모일,(C1-C6)알킬, (C2-C8)알케닐, (C2-C6)알콕시, (C1-C6)알킬티오, (C1-C6)알킬설피닐, (C1-C6)알킬아미노, 디-[(C1-C6)알킬]아미노, (C1-C6)알콕시카르보닐, N-(C1-C6)알킬카르바모일, N,N-디-[(C1-C6)알킬]카르바모일, 아릴, 아릴-(C1-C6)알킬, (C3-C7)싸이클로알킬, (C3-C7)싸이클로알킬-(C1-C6)알킬, 헤테로아릴, 헤테로아릴-(C1-C6)알킬, 헤테로싸이클릴 또는 헤테로싸이클릴-(C1-C6)알킬기에서 선택될 수 있고, R 3 and R 4 may be the same or different, respectively, hydrogen, halogeno, trifluoromethyl, cyano, nitro, hydroxy, mercapto, amino, formyl, carboxy, carbamoyl, (C 1- C 6 ) alkyl, (C 2 -C 8 ) alkenyl, (C 2 -C 6 ) alkoxy, (C 1 -C 6 ) alkylthio, (C 1 -C 6 ) alkylsulfinyl, (C 1 -C 6 ) alkylamino, di-[(C 1 -C 6 ) alkyl] amino, (C 1 -C 6 ) alkoxycarbonyl, N- (C 1 -C 6 ) alkylcarbamoyl, N, N -di- [(C 1 -C 6) alkyl] carbamoyl, aryl, - (C 1 -C 6) alkyl, (C 3 -C 7) cyclo-alkyl, (C 3 -C 7) cyclo-alkyl - (C 1 May be selected from a -C 6 ) alkyl, heteroaryl, heteroaryl- (C 1 -C 6 ) alkyl, heterocyclyl or heterocyclyl- (C 1 -C 6 ) alkyl group,
여기서 R3 및 R4 치환체 내에서의 임의의 CH2 또는 CH3기는 각각의 CH2 또는 CH3기에서 1 이상의 할로게노, 히드록시, 아미노, 카르복시, 카르바모일, (C1-C6)알콕시, (C1-C6)알킬티오, (C1-C6)알킬설피닐, (C1-C6)알킬아미노, 디-[(C1-C6)알킬]아미노, (C1-C6)알콕시카르보닐, N-(C1-C6)알킬카르바모일, N,N-디-[(C1-C6)알킬]카르바모일, 아릴, 아릴-(C1-C6)알킬, (C3-C7)싸이클로알킬, (C3-C7)싸이클로알킬-(C1-C6)알킬, 헤테로아릴, 헤테로아릴-(C1-C6)알킬, 헤테로싸이클릴 및 헤테로싸이클릴-(C1-C6)알킬기 중에서 선택되는 치환체를 포함할 수 있으며,Wherein any CH 2 or CH 3 group in the R 3 and R 4 substituents is at least one halogeno, hydroxy, amino, carboxy, carbamoyl, (C 1 -C 6 ) group at each CH 2 or CH 3 group Alkoxy, (C 1 -C 6 ) alkylthio, (C 1 -C 6 ) alkylsulfinyl, (C 1 -C 6 ) alkylamino, di-[(C 1 -C 6 ) alkyl] amino, (C 1 -C 6 ) alkoxycarbonyl, N- (C 1 -C 6 ) alkylcarbamoyl, N, N -di-[(C 1 -C 6 ) alkyl] carbamoyl, aryl, aryl- (C 1- C 6 ) alkyl, (C 3 -C 7 ) cycloalkyl, (C 3 -C 7 ) cycloalkyl- (C 1 -C 6 ) alkyl, heteroaryl, heteroaryl- (C 1 -C 6 ) alkyl, hetero May include a substituent selected from a cyclyl and a heterocyclyl- (C 1 -C 6 ) alkyl group,
여기서 R3 및 R4 기내에서의 임의의 아릴, 헤테로아릴 또는 헤테로싸이클릴기는 1, 2 또는 3개의 치환체를 포함할 수 있고, 이 치환체는 동일하거나 상이할 수 있으며 할로게노, 트리플루오로메텔, 니트로, 히드록시, 아미노, (C1-C6)알콕시, (C1-C6)알킬티오, (C1-C6)알킬아미노, 디-[(C1-C6)알킬]아미노, (C1-C6)알콕시카르보닐, N-(C1-C6)알킬카르바모일 및 N,N-디-[(C1-C6)알킬]카르바모일기에서 선택되는 치 환체를 포함할 수 있으며,Wherein any aryl, heteroaryl or heterocyclyl group in the R 3 and R 4 groups may comprise 1, 2 or 3 substituents, which substituents may be the same or different and may be halogeno, trifluoromethel, Nitro, hydroxy, amino, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) alkylthio, (C 1 -C 6 ) alkylamino, di-[(C 1 -C 6 ) alkyl] amino, A substituent selected from (C 1 -C 6 ) alkoxycarbonyl, N- (C 1 -C 6 ) alkylcarbamoyl and N, N -di-[(C 1 -C 6 ) alkyl] carbamoyl groups Can include,
여기서 R3 및 R4 상의 치환체내에서 헤테로싸이클릴기는 1 또는 2개의 옥소 또는 티옥소 치환체를 포함할 수 있다.Wherein the heterocyclyl group in the substituents on R 3 and R 4 may comprise one or two oxo or thioxo substituents.
상기 화학식 1-1로 표시되는 퀴나졸린 화합물에 있어, 보다 바람직하게는 다음과 같다 :In the quinazoline compound represented by Formula 1-1, more preferably:
상기 X는 O, S 또는 NR5이고; R1은 수소원자, C1-C6알킬기, C1-C4할로알킬기, C1-C6알킬하이드록시기, C1-C6알킬설파닐기, 페닐기, 페닐 C1-C8알킬기, 피리딘기, 퓨란기, 티오펜기, C3-C7싸이클로알킬기, 피롤리딘기, 피페리딘기, 몰포린기, 또는 N-(C1-C6)알킬 피페라진기이고; R2는 C1-C18알킬기, C2-C8할로알킬기, C3-C7싸이클로알킬기, (C3-C7)싸이클로알킬 C1-C8알킬기, C2-C8알케닐기, (C3-C7)싸이클로알케닐 C1-C8알킬기, (C1-C8)알킬 C1-C8알콕시알킬기, C1-C8의 하이드록시알킬기, 하이드록시-(C1-C8)알킬-(C1-C8)알콕시알킬기, 페닐기, 페닐 C1-C8알킬기, 디-페닐 C1-C8알킬기, 페닐 C1-C8알킬하이드록시기, 페닐 C1-C8알케닐기, 피페리딘 C1-C8알킬기, N-[페닐-(C1-C6)알킬] 피페리딘기, N-(C1-C6)알킬 피페리딘 C1-C8알킬기, 피롤리딘온 N-(C1-C8)알킬기, 나프탈렌 C1-C8알킬기, 몰포린 C1-C8알킬기, 피페라진 C1-C8알킬기, N-(C1-C6)알 킬피페라진 C1-C8알킬기, 피리딘 C1-C8알킬기, 피롤리딘 C1-C8알킬기, N-(C1-C6)알킬피롤리딘 C1-C8알킬기, 티오펜 C1-C8알킬기 또는 벤조디옥솔 C1-C8알킬기; R3, 및 R4는 각각 수소원자, 니트로기, 또는 C1-C8알콕시기이고; R5는 수소원자, C1-C4알킬기 또는 C1-C8의 하이드록시알킬기이고; 그리고, 상기 C3-C7싸이클로알킬, 페닐, 피페리딘, 나프탈렌, 몰포린, 피리딘, 피롤리딘, 피롤리딘온, 피페라진, 티오펜, 및 벤조디옥솔 중에서 선택된 치환체는 C1-C8알킬기, 할로겐원자, 하이드록시, C1-C8알콕시기, 니트로기, 및 트리플루오로메틸기 중에서 선택된 치환기가 1 내지 3개 치환된 화합물의 경우이다.X is O, S or NR 5 ; R 1 is a hydrogen atom, a C 1 -C 6 alkyl group, a C 1 -C 4 haloalkyl group, a C 1 -C 6 alkylhydroxy group, a C 1 -C 6 alkylsulfanyl group, a phenyl group, a phenyl C 1 -C 8 alkyl group, A pyridine group, a furan group, a thiophene group, a C 3 -C 7 cycloalkyl group, a pyrrolidine group, a piperidine group, a morpholine group, or an N- (C 1 -C 6 ) alkyl piperazine group; R 2 is a C 1 -C 18 alkyl group, a C 2 -C 8 haloalkyl group, a C 3 -C 7 cycloalkyl group, a (C 3 -C 7 ) cycloalkyl C 1 -C 8 alkyl group, a C 2 -C 8 alkenyl group, (C 3 -C 7 ) cycloalkenyl C 1 -C 8 alkyl group, (C 1 -C 8 ) alkyl C 1 -C 8 alkoxyalkyl group, C 1 -C 8 hydroxyalkyl group, hydroxy- (C 1- C 8 ) alkyl- (C 1 -C 8 ) alkoxyalkyl group, phenyl group, phenyl C 1 -C 8 alkyl group, di-phenyl C 1 -C 8 alkyl group, phenyl C 1 -C 8 alkylhydroxy group, phenyl C 1- C 8 alkenyl group, piperidine C 1 -C 8 alkyl group, N- [phenyl- (C 1 -C 6 ) alkyl] piperidine group, N- (C 1 -C 6 ) alkyl piperidine C 1 -C 8 alkyl group, pyrrolidinone N- (C 1 -C 8 ) alkyl group, naphthalene C 1 -C 8 alkyl group, morpholine C 1 -C 8 alkyl group, piperazine C 1 -C 8 alkyl group, N- (C 1 -C 6 ) Al-Kilpiperazine C 1 -C 8 alkyl group, pyridine C 1 -C 8 alkyl group, pyrrolidine C 1 -C 8 alkyl group, N- (C 1 -C 6 ) alkylpyrrolidine C 1 -C 8 alkyl group , Thiophene C 1 -C 8 alkyl group or benzodioxol C 1- C 8 alkyl group; R 3 , and R 4 are each a hydrogen atom, a nitro group, or a C 1 -C 8 alkoxy group; R 5 is a hydrogen atom, a C 1 -C 4 alkyl group or a C 1 -C 8 hydroxyalkyl group; And the substituent selected from C 3 -C 7 cycloalkyl, phenyl, piperidine, naphthalene, morpholine, pyridine, pyrrolidine, pyrrolidinone, piperazine, thiophene, and benzodioxol is C 1 -C 8 is a compound in which 1 to 3 substituents are selected from an alkyl group, a halogen atom, hydroxy, a C 1 -C 8 alkoxy group, a nitro group, and a trifluoromethyl group.
상기 화학식 1-1로 표시되는 화합물을 구체적으로 예시하면 다음 표 1과 같다:Specific examples of the compound represented by Formula 1-1 are shown in Table 1 below:
본 발명에 따른 상기 화학식 1로 표시되는 화합물은 약제학적으로 허용가능한 염을 형성할 수도 있는 바, 예를 들면 염산염, 황산염, 인산염, 이인산염, 브롬화수소염 및 질산염과 같은 무기산과의 염, 또는 말레이트, 말레에이트, 푸마레이트, 타르트레이트, 숙시네이트, 시트레이트, 아세테이트, 락테이트, 메탄술포네이트, p-톨루엔술포네이트, 팔미테이트, 살리실레이트 및 스테아레이트와 같은 유기산과의 염을 포함한다.The compound represented by
본 발명의 화합물의 일부는 수성 및 유기 용매와 같은 용매로부터 결정화되거나 또는 재결정화될 수 있다. 그러한 경우, 용매화물이 형성될 수 있다. 동결건조와 같은 방법으로 제조 가능한 다양한 양의 물 함유 화합물 이외에 수화물을 비롯한 화학 양론적 용매화물도 본 발명의 범위에 속한다.Some of the compounds of the present invention may be crystallized or recrystallized from solvents such as aqueous and organic solvents. In such cases, solvates may be formed. In addition to various amounts of water-containing compounds that can be prepared by methods such as lyophilization, stoichiometric solvates, including hydrates, are also within the scope of the present invention.
상기 화학식 1로 표시되는 화합물은 거울상 이성질체, 입체 이성질체 또는 토토머일 수도 있다. 상이한 이성질체는 통상의 방법에 의해 분리되거나 또는 분해될 수 있거나, 또는 임의의 소정 이성질체는 통상의 합성법에 의해 또는 입체특이적 또는 비대칭적 합성에 의해 수득할 수 있다.The compound represented by
또한, 본 발명은 상기 화학식 1로 표시되는 화합물의 방사성 유도체를 포함하며, 이들 방사성 화합물은 생체연구 분야에 유용하다.In addition, the present invention includes a radioactive derivative of the compound represented by the formula (1), these radioactive compounds are useful in the field of biological research.
한편, 본 발명은 상기 화학식 1로 표시되는 퀴나졸린 유도체와 약제학적으로 허용 가능한 이들의 염의 제조과정을 포함한다.On the other hand, the present invention includes a process for preparing a quinazoline derivative represented by the formula (1) and pharmaceutically acceptable salts thereof.
또한, 본 발명은 상기 화학식 1-1로 표시되는 화합물의 제조방법을 포함하는 바, 다음 반응식 1에 나타낸 바와 같이 다음 화학식 2로 표시되는 4-클로로-2-치환-퀴나졸린 유도체와 다음 화학식 3으로 표시되는 화합물과의 치환 반응하여 합성할 수 있다.In addition, the present invention includes a method for preparing a compound represented by Chemical Formula 1-1, as shown in the following
상기 반응식 1에서, R1, R2, R3, R4 및 X는 각각 상기 화학식 1에서 정의한 바와 같다.In
상기 반응식 1에 따른 치환반응은 염기와 유기극성용매를 사용하는 조건에서 수행한다. 이때, 염기는 피리딘 또는 알킬아민류를 포함하는 유기염기, 또는 알칼리금속 및 토금속염을 포함하는 무기염기를 사용할 수 있다.The substitution reaction according to
본 발명에 따른 상기 화학식 1-1로 표시되는 화합물의 다른 제조방법으로는, 다음 반응식 2에 나타낸 바와 같이 다음 화학식 4로 표시되는 2-클로로-4-치환-퀴나졸린 유도체와 다음 화학식 5로 표시되는 화합물과의 치환 반응하여 합성할 수 있다.As another method for preparing the compound represented by Chemical Formula 1-1 according to the present invention, a 2-chloro-4-substituted-quinazolin derivative represented by the following
상기 반응식 2에서, R1, R2, R3, R4 및 X는 각각 상기 화학식 1에서 정의한 바와 같다.In
상기 반응식 2에 따른 치환반응은 염기와 유기극성용매를 사용하는 조건에서 수행한다. 염기는 피리딘 또는 알킬아민류를 포함하는 유기염기, 또는 알칼리금속 및 토금속염을 포함하는 무기염기를 사용할 수 있다.The substitution reaction according to
본 발명에 따른 상기 화학식 1-1로 표시되는 화합물의 또 다른 제조방법으로는, 다음 반응식 3에 나타낸 바와 같이 다음 화학식 6으로 표시되는 2-메틸-3H-퀴나졸린-4-온의 4번 위치가 X로 치환된 유도체와 다음 화학식 7로 표시되는 화합물과의 치환 반응하여 합성할 수 있다.As another method for preparing a compound represented by Chemical Formula 1-1 according to the present invention, No. 4 of 2-methyl- 3H -quinazolin-4-one represented by
상기 반응식 3에서, R1, R2, R3, R4 및 X는 각각 상기 화학식 1에서 정의한 바와 같고, Y는 Cl, Br, I, OMs 및 OTs 중에서 선택된 이탈기이다.In
상기 반응식 3에 따른 치환반응은 염기와 유기극성용매를 사용하는 조건에서 수행한다. 염기는 피리딘 또는 알킬아민류를 포함하는 유기염기, 또는 알칼리금속 및 토금속염을 포함하는 무기염기를 사용할 수 있다.The substitution reaction according to
한편, 상기 반응식 1에 따른 치환반응에서 사용된 원료물질로서 상기 화학식 2 및 3으로 표시되는 화합물은 각각 공지화합물로서, 유기합성 분야에서는 잘 알려진 공지합성법에 의거하여 제조 사용할 수 있다. On the other hand, the compounds represented by the formula (2) and 3 as the raw material used in the substitution reaction according to
상기 화학식 2로 표시되는 화합물에 있어, R1=에틸설파닐기인 퀴나졸린 유도체는 다음 반응식 4에 따른 제조방법에 의해 합성할 수 있다.In the compound represented by
상기 반응식 4에서, R3, 및 R4는 각각 상기 화학식 1에서 정의한 바와 같다.In
상기 반응식 4에 의하면, 먼저 2-머캅토-3H-퀴나졸린-4-온을 소듐에톡사이드(NaOEt) 및 에틸아이오다이드(EtI)와 함께 실온 내지 용매의 환류온도 범위에서 교반 반응하여, C-2 위치에 에틸설파닐기를 도입한다. 그런 다음, 상기에서 제조한 2-에틸설파닐-3H-퀴나졸린-4-온은 -20 내지 10 ℃ 온도에서 티오닐 클로라이드(SOCl2)를 가한 후, N,N-디메틸포름아마이드 촉매 존재 하에서 환류반응시켜, C-4 위치의 케톤기를 클로로(Cl)로 전환한다.According to
또한, 상기 화학식 2로 표시되는 화합물에 있어, R1=수소, 알킬 또는 아릴 유도체는 다음 반응식 5에 따른 제조방법에 의해 합성할 수 있다.In addition, in the compound represented by
상기 반응식 5에서, R3, 및 R4는 각각 상기 화학식 1에서 정의한 바와 같다.In
상기 반응식 5에 의하면, 먼저 이미데이트 화합물을 안트라닐릭 엑시드 및 소듐메톡사이드(NaOMe)와 함께 실온 내지 용매의 환류온도 범위에서 교반 반응하 여, 원하는 치환체 R1을 포함하는 3H-퀴나졸린-4-온을 제조한다. 그런 다음, 포스포러스 옥시클로라이드와 디에틸아닐린을 첨가하고 실온 내지 용매의 환류온도 범위에서 교반 반응하여, C-4 위치의 케톤기를 클로로(Cl)로 전환한다.According to
또한, 상기 화학식 2로 표시되는 화합물에 있어, R1=수소, 알킬 또는 아릴 유도체는 상기 반응식 4와 함께 다음 반응식 6에 따른 제조방법에 의해 합성할 수 있다.In addition, in the compound represented by
상기 반응식 6에서, R1, R3, 및 R4는 각각 상기 화학식 1에서 정의한 바와 같다.In
상기 반응식 6에 의하면, 먼저 아실 할라이드를 안트라닐 아미드와 반응시킨 후 NaOH 존재 하에서 환류 반응하여, 원하는 치환체 R1을 포함하는 3H-퀴나졸린-4-온을 제조한다. 그런 다음, 포스포러스 옥시클로라이드와 디에틸아닐린을 첨가하고 실온 내지 용매의 환류온도 범위에서 교반 반응하여, C-4 위치의 케톤기를 클로로(Cl)로 전환한다.According to
또한, 상기 반응식 2에 따른 치환반응에서 원료 물질로 사용된 상기 화학식 4 및 5로 표시되는 화합물은 각각 공지화합물로서, 유기합성 분야에서는 잘 알려진 공지합성법에 의거하여 제조 사용할 수 있다. 예컨대 상기 화학식 4로 표시되 는 화합물은 다음 반응식 7에 따른 제조방법에 의해 합성할 수 있다.In addition, the compounds represented by
상기 반응식 7에서, R2, R3, R4, 및 X는 각각 상기 화학식 1에서 정의한 바와 같다.In
상기 반응식 7에 따른 치환반응은 상기 화학식 3의 화합물을 유기용매겸 반응물질로서 과량 사용하거나 반응물로서 화학양론적으로 사용하고 별도의 유기용매를 사용할 수 있으며, 필요에 따라 염기를 사용하는 조건에서 반응을 수행할 수도 있다. 이때, 염기는 피리딘 또는 알킬아민류를 포함하는 유기염기, 또는 알칼리금속 및 토금속염을 포함하는 무기염기를 사용할 수 있다.Substitution reaction according to
이상의 제조방법으로부터 합성한 중간체 화합물 및 최종 목적 화합물은 크로마토그래피와 재결정화와 같은 통상적인 방법에 의하여 분리 및 정제될 수 있다.Intermediate compounds and final target compounds synthesized from the above preparation methods can be separated and purified by conventional methods such as chromatography and recrystallization.
본 발명에 따른 화합물들은 적당한 방법, 예를 들면 경구, 구강내, 혀밑, 직장내, 질내, 비강내, 국소 또는 비경구(정맥내, 해면체내, 근육내, 피하 및 관내를 포함)의 방법으로 투여될 수 있다.The compounds according to the invention can be prepared by any suitable method, for example, by oral, oral, sublingual, rectal, vaginal, intranasal, topical or parenteral (including intravenous, cavernous, intramuscular, subcutaneous and intraluminal) methods. May be administered.
상술한 바 있는 당뇨 및 비만의 치료 또는 예방을 목적으로 상기 화학식 1로 표시되는 화합물을 경구, 구강내 또는 혀밑 투여하는 경우, 투여량은 평균 몸무게가 70 ㎏인 성인환자를 기준으로할 때 일반적으로 0.1 ∼ 400 ㎎/일이다. 따라서, 일반 성인환자의 경우 약제학적으로 허용 가능한 부형제 또는 담체를 사용하여 유효 화합물이 0.05 ∼ 200 ㎎ 함유되도록 정제 또는 캡슐로 제형화하여 하루에 한 번 또는 여러 회에 걸쳐서, 1회의 투여량 또는 여러 번의 투여량으로 복용된다.In the case of oral, oral or sublingual administration of the compound represented by
비경구 투여를 위한 제형에 있어서는, 유효 화합물은 0.01 ∼ 100 ㎎의 양으로 투여되는데, 실제적으로 의사는 각각의 환자에 대하여 환자의 나이, 몸무게 및 환자의 특성에 따라 가장 적당한 투여량을 결정한다. 상기한 투여량은 평균적인 경우를 예시한 것으로서 개인적인 차이에 따라 그 투여량이 높거나 낮을 수 있으며, 이러한 것은 본 발명의 범주에 속하는 것이다.In formulations for parenteral administration, the effective compound is administered in an amount of 0.01 to 100 mg, in practice the physician determines the most appropriate dosage for each patient depending on the age, weight and characteristics of the patient. The above dosages exemplify the average case and may be high or low depending on individual differences, which is within the scope of the present invention.
사람에게 적용함에 있어서, 상기 화학식 1로 표시되는 화합물은 단독으로 투여될 수 있으나, 일반적으로 투여방식과 표준 약제학적 관행(standard phamaceutical practice)을 고려하여 선택된 약제학적 담체와 혼합되어 투여될 수 있다. 예를 들면, 상기 화합물은 전분 또는 락토오즈를 함유하는 정제 형태로, 또는 단독 또는 부형제를 함유하는 캡슐 또는 포낭(ovules) 형태로, 또는 맛을 내거나 색을 띄게 하는 화학 약품을 함유하는 엘릭시르 또는 현탁제 형태로 경구, 구강내 또는 혀밑 투여될 수 있다.In human application, the compound represented by
이러한 액체 제제는 현탁제(예를 들면, 메틸셀룰로오즈, 위텝솔(witepsol)과 같은 반합성 글리세라이드 또는 행인유(apricot kernel oil)와 PEG-6 에스테르의 혼합물 또는 PEG-8과 카프릴릭/카프릭 글리세라이드의 혼합물과 같은 글리세라이드 혼합물)와 같은 약제학적으로 허용 가능한 첨가제와 함께 제조된다. 또한, 비경구적으로 예를 들면, 정맥내, 해면체내, 근육내, 피하 및 관내를 통하여 주사될 수 있다. 또한, 비경구 투여를 위해서는 상기 화합물을 무균의 수용액 형태로 서 사용하는 것이 가장 바람직하며, 이때 상기 용액은 혈액과의 등장성을 갖기 위하여 다른 물질들(예를 들면 염(salt) 또는 만니톨, 글루코오스와 같은 단당류)를 함유할 수도 있다.Such liquid preparations may be suspending agents (e.g., semisynthetic glycerides such as methylcellulose, witepsol or mixtures of apricot kernel oil and PEG-6 esters or PEG-8 and caprylic / capric Pharmaceutically acceptable additives such as glyceride mixtures such as mixtures of glycerides). It can also be injected parenterally, for example, intravenously, intracavernosally, intramuscularly, subcutaneously and intratracheally. In addition, for parenteral administration, it is most preferable to use the compound in the form of a sterile aqueous solution, in which the solution has other substances (e.g. salt or mannitol, glucose) to have isotonicity with blood. Monosaccharides).
따라서, 본 발명은 상기 화학식 1로 표시되는 화합물 또는 약제학적으로 허용 가능한 이들의 염을 유효성분으로 하고, 여기에 약제학적으로 허용 가능한 희석제 또는 부형제가 함유되어 있는 약제학적 조성물을 포함한다. Therefore, the present invention includes a pharmaceutical composition containing a compound represented by the formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient, and containing a pharmaceutically acceptable diluent or excipient.
본 발명은 의약품의 용도로서 상기 화학식 1로 표시되는 화합물 또는 약제학적으로 허용 가능한 이들의 염 또는 약제학적으로 허용 가능한 이들의 프로드럭을 유효성분으로 함유하는 약제학적 조성물을 제공한다.The present invention provides a pharmaceutical composition containing a compound represented by the formula (1) or a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable prodrug thereof as an active ingredient as a use of a pharmaceutical.
이와 같은 본 발명은 다음의 실시예 및 시험예를 통하여 보다 구체적으로 설명하겠는 바, 본 발명이 이에 한정되는 것은 아니다.Such the present invention will be described in more detail through the following examples and test examples, but the present invention is not limited thereto.
다음의 실시예 1 내지 3은 X=NH 및 R1=에틸설파닐기인 화합물 합성을 위한 일구현예이다. Examples 1 to 3 below are one embodiment for synthesizing compounds wherein X = NH and R 1 = ethylsulfanyl group.
실시예 1. 2-에틸설파닐-3H-퀴나졸린-4-온 (화학식 B)의 합성Example 1 Synthesis of 2-ethylsulfanyl-3H-quinazolin-4-one (Formula B)
2-머캅토-3H-퀴나졸린-4-온(화학식 A; 3 g, 16.83 mmol)을 에탄올 100 mL에 녹인 후 NaOEt(1.5 eq, 9.4 mL, 25.25 mmol)와 EtI(1.5 eq, 2.02 mL, 25.25 mmol)를 실온에서 첨가하였다. 첨가된 혼합물을 3시간 환류하여 출발물질이 사라지면 감압 증류하여 에탄올을 제거하였다. 혼합물에 에틸 아세테이트를 첨가하고 물로 씻어준 후 무수 황산마그네슘으로 수분을 제거하였다. 유기용매를 감압 증류 한 후 혼합물을 관 크로마토그래피(실리카겔; 230∼400 mesh)를 이용하여 수율 80%의 목적 화합물(2.78 g)을 얻었다. 2-mercapto-3H-quinazolin-4-one (Formula A; 3 g, 16.83 mmol) was dissolved in 100 mL of ethanol, followed by NaOEt (1.5 eq, 9.4 mL, 25.25 mmol) and EtI (1.5 eq, 2.02 mL, 25.25 mmol) was added at room temperature. The mixture was refluxed for 3 hours to remove starting material and distilled under reduced pressure to remove ethanol. Ethyl acetate was added to the mixture, and the mixture was washed with water and then dried with anhydrous magnesium sulfate. After distillation of the organic solvent under reduced pressure, the mixture was subjected to column chromatography (silica gel; 230 to 400 mesh) to obtain a target compound (2.78 g) having a yield of 80%.
1H NMR (CDCl3, 300 MHz) δ 8.27 (d, J=7.8 Hz, 1H), 7.73 (t, J=7.5 Hz, 1H), 7.71 (d, J=7.8 Hz, 1H), 7.41 (t, J=7.5, 1H), 3.34 (q, J=14.4 Hz, 2H), 1.49 (t, J=7.35 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.27 (d, J = 7.8 Hz, 1H), 7.73 (t, J = 7.5 Hz, 1H), 7.71 (d, J = 7.8 Hz, 1H), 7.41 (t , J = 7.5, 1H), 3.34 (q, J = 14.4 Hz, 2H), 1.49 (t, J = 7.35 Hz, 3H)
실시예 2. 4-클로로-2-에틸설파닐-퀴나졸린 (화학식 2a)의 합성Example 2. Synthesis of 4-chloro-2-ethylsulfanyl-quinazolin (Formula 2a)
2-에틸설파닐-3H-퀴나졸린-4-온(화학식 B; 1.5 g, 7.27 mmol)에 티오닐 클로라이드 50 mL를 0 ℃에서 천천히 가하였다. N,N-디메틸포름아마이드를 2∼3방울 넣고 3∼4시간 환류하여 출발물질이 사라지면 감압 증류하여 티오닐 클로라이드를 제거하였다. 잔여 티오닐 클로라이드는 탄산나트륨 포화수용액을 이용하여 씻어 주었다. 혼합물을 에틸 아세테이트로 추출하고 유기층을 소금물으로 씻어준 후 무수 황산마그네슘으로 수분을 제거하였다. 유기용매를 감압 증류한 후 혼합물을 관 크로마토그래피(실리카겔; 230∼400 mesh)를 이용하여 수율 79%의 목적 화합물(1.29 g)을 얻었다.50 mL of thionyl chloride was slowly added to 2-ethylsulfanyl-3H-quinazolin-4-one (Formula B; 1.5 g, 7.27 mmol) at 0 ° C. 2-3 drops of N, N- dimethylformamide was added to the mixture, and the mixture was refluxed for 3 to 4 hours. When the starting material disappeared, distillation under reduced pressure was carried out to remove thionyl chloride. The remaining thionyl chloride was washed with a saturated aqueous sodium carbonate solution. The mixture was extracted with ethyl acetate, and the organic layer was washed with brine, and then dried over anhydrous magnesium sulfate. After distilling the organic solvent under reduced pressure, the mixture was subjected to column chromatography (silica gel; 230 to 400 mesh) to obtain a target compound (1.29 g) having a yield of 79%.
1H NMR (CDCl3, 300 MHz) δ 8.02 (d, J=7.8 Hz, 1H), 7.85 (m, 2H), 7.56 (t, J=7.5 Hz, 1H), 3.29 (q, J=14.4 Hz, 2H), 1.49 (t, J=7.35 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.02 (d, J = 7.8 Hz, 1H), 7.85 (m, 2H), 7.56 (t, J = 7.5 Hz, 1H), 3.29 (q, J = 14.4 Hz , 2H), 1.49 (t, J = 7.35 Hz, 3H)
실시예 3. 4-치환된아민-2-에틸설파닐-퀴나졸린 (화학식 1a)의 합성Example 3. Synthesis of 4-substituted Amine-2-ethylsulfanyl-quinazolin (Formula 1a)
THF 40 mL에 4-클로로-2-에틸설파닐-퀴나졸린(1.0 g, 4.45 mmol)을 녹인 후 트리에틸아민(TEA; 3 eq, 1.86 mL, 13.35 mmol)과 아민 화합물(1.5 eq)을 넣고 실온에서 밤새 교반 하였다. 출발물질이 사라지면 감압 증류하여 THF를 제거하였다. 감압 증류한 혼합물을 관 크로마토그래피(실리카겔; 230∼400 mesh)를 이용하여 수율 90%의 목적 화합물을 얻었다. Dissolve 4-chloro-2-ethylsulfanyl-quinazolin (1.0 g, 4.45 mmol) in 40 mL of THF, add triethylamine (TEA; 3 eq, 1.86 mL, 13.35 mmol) and amine compound (1.5 eq). Stir overnight at room temperature. When the starting material disappeared, the mixture was distilled under reduced pressure to remove THF. The target compound of 90% yield was obtained using the column distillation under reduced pressure using the column chromatography (silica gel; 230-400 mesh).
다음의 실시예 4는 X=NH 및 R1=페닐기인 화합물 합성을 위한 일구현예이다. Example 4 below is an embodiment for synthesizing compounds wherein X = NH and R 1 = phenyl.
실시예 4. 4-치환된아민-2-페닐-퀴나졸린 (화학식 1b)의 합성Example 4. Synthesis of 4-Substituted Amine-2-phenyl-Quinazoline (Formula 1b)
THF 30 mL에 4-클로로-2-페닐-퀴나졸린(화학식 2b; 0.5 g, 2.08 mmol)을 녹인 후 TEA(5 eq, 1.45 mL, 10.38 mmol)와 아민(1.5 eq)를 넣고 실온에서 밤새 교반하였다. 출발물질이 사라지면 감압 증류하여 THF를 제거하였다. 감압 증류한 혼합물을 관 크로마토그래피(실리카겔; 230∼400 mesh)를 이용하여 수율 90%의 목적 화합물을 얻었다. Dissolve 4-chloro-2-phenyl-quinazoline (Formula 2b; 0.5 g, 2.08 mmol) in 30 mL of THF, add TEA (5 eq, 1.45 mL, 10.38 mmol) and amine (1.5 eq) and stir overnight at room temperature It was. When the starting material disappeared, the mixture was distilled under reduced pressure to remove THF. The target compound of 90% yield was obtained using the column distillation under reduced pressure using the column chromatography (silica gel; 230-400 mesh).
다음의 실시예 5 내지 7은 X=NH 및 R1=수소, 알킬 또는 아릴기인 화합물 합성을 위한 일구현예이다.Examples 5-7 which follow are one embodiment for the synthesis of compounds wherein X = NH and R 1 = hydrogen, alkyl or aryl groups.
실시예 5. 2-치환된-3H-퀴나졸린-4-온 (화학식 E)의 합성Example 5. Synthesis of 2-substituted-3 H -quinazolin-4-one (Formula E)
R1을 포함하는 이미데이트 화합물(화학식 C; 50 mmol)의 염산염을 메탄올 100 mL에 녹인 후 NaOMe(1.2 eq, 60 mmol)와 안트라닐릭 엑시드(화학식 D, 1.0 eq, 50 mmol)를 0 ℃에서 천천히 가하였다. 첨가된 혼합물을 환류 온도까지 천천히 온도를 올린 후 밤새 환류하였다. TLC로 출발물질이 완전히 사라지는 것을 확인한 후 온도를 0 ℃로 냉각하였다. 혼합물에 물(100 mL)를 가한 후 생성된 결정을 여과 후 건조하여 수율 70%의 목적 화합물(35 mmol)을 얻었다.Hydrochloride of an imidate compound containing R 1 (Formula C; 50 mmol) was dissolved in 100 mL of methanol, followed by NaOMe (1.2 eq, 60 mmol) and anthranilic acid (Formula D, 1.0 eq, 50 mmol) at 0 ° C. Slowly added. The added mixture was slowly raised to reflux and then refluxed overnight. After confirming that the starting material disappeared completely by TLC, the temperature was cooled to 0 ° C. Water (100 mL) was added to the mixture, and the resulting crystals were filtered and dried to afford the desired compound (35 mmol) with a yield of 70%.
실시예 6. 4-클로로-2-치환된-퀴나졸린 (화학식 2c)의 합성Example 6. Synthesis of 4-chloro-2-substituted-quinazolin (Formula 2c)
2-치환된-3H-퀴나졸린-4-온(화학식 E; 35 mmol)을 톨루엔 100 mL에 녹인 후 N,N-디에틸아닐린(1.5 eq, 52.5 mmol)과 포스포러스 옥시클로라이드(1.0 eq, 35 mmol)를 첨가하였다. 혼합물을 80 ℃에서 3시간 교반하여 출발물질이 사라지면 0 ℃로 냉각하였다. 혼합물을 1N-NaOH과 1N-HCl로 씻어준 후 무수 황산나트륨으로 수분을 제거하였다. 유기용매를 감압 증류한 후 혼합물을 관 크로마토그래피(실리카겔; 230∼400 mesh)를 이용하여 수율 98%의 목적 화합물 (34 mmol)을 얻었다.2-substituted-3 H -quinazolin-4-one (Formula E; 35 mmol) was dissolved in 100 mL of toluene , followed by N, N -diethylaniline (1.5 eq, 52.5 mmol) and phosphorus oxychloride (1.0 eq). , 35 mmol) was added. The mixture was stirred at 80 ° C. for 3 hours and cooled to 0 ° C. when the starting material disappeared. The mixture was washed with 1 N -NaOH and 1 N -HCl was dried over anhydrous sodium sulfate. After distilling off the organic solvent under reduced pressure, the mixture was purified by column chromatography (silica gel; 230 to 400 mesh) to obtain a target compound (34 mmol) having a yield of 98%.
실시예 7. R2-(2-(R1-치환된)-퀴나졸린-4-일)-아민 (화학식 1c)의 합성Example 7. R 2 - synthesis of the amine (Formula 1c) - (2- (1 R-substituted) - quinazolin-4-yl)
4-클로로-2-치환된-퀴나졸린(화학식 2c; 10 mmol)을 THF 30mL에 녹인 후 트리에틸아민 (2 eq, 20 mmol)과 아민 화합물(1.5 eq, 15 mmol)을 넣고 실온에서 밤새 교반하였다. 출발물질이 사라지면 감압 증류하여 THF를 제거하였다. 클로로포름을 첨가한 후 탄산나트륨 포화수용액, 소금물로 씻어준 후 무수 황산나트륨으로 수분을 제거하였다. 유기용매를 감압 증류로 제거한 후 혼합물을 관 크로마토그래피(실리카겔; 230∼400 mesh)를 이용하여 수율 95%의 목적 화합물(9.5 mmol)을 얻었다.Dissolve 4-chloro-2-substituted-quinazoline (Formula 2c; 10 mmol) in 30 mL of THF, add triethylamine (2 eq, 20 mmol) and amine compound (1.5 eq, 15 mmol) and stir overnight at room temperature It was. When the starting material disappeared, the mixture was distilled under reduced pressure to remove THF. After adding chloroform, washed with saturated aqueous sodium carbonate solution and brine, and then water was removed with anhydrous sodium sulfate. After distilling off the organic solvent under reduced pressure, the mixture was purified by column chromatography (silica gel; 230 to 400 mesh) to obtain a target compound (9.5 mmol) with a yield of 95%.
다음의 실시예 8 내지 9는 R1=H, 알킬 또는 아릴기인 화합물 합성을 위한 일구현예이다.Examples 8 to 9 below are one embodiment for synthesizing compounds wherein R 1 = H, alkyl or aryl groups.
실시예 8. 2-(치환된-카르보닐-아미노)-벤즈아미드 (화학식 H)의 합성Example 8. Synthesis of 2- (substituted-carbonyl-amino) -benzamide (Formula H)
R1을 포함하는 아실 클로라이드(화학식 F; 50 mmol), 안트라닐아미드(1.0 eq, 화학식 G, 50 mmol)과 트리에틸아민(1.5 eq, 75 mmol)을 THF에 녹인 후 실온에서 밤새 교반하였다. 출발물질이 사라지면 감압 증류하여 THF를 제거하였다. 클로로포름을 첨가한 후 1N-NaOH와 소금물로 씻어준 후 황산나트륨으로 수분을 제거하였다. 유기용매를 감압증류한 후 디에틸에테르로 결정화하여 수율 95%의 목적화합물(48 mmol)을 얻었다.Acyl chloride containing R 1 (Formula F; 50 mmol), anthranylamide (1.0 eq, Formula G, 50 mmol), and triethylamine (1.5 eq, 75 mmol) were dissolved in THF, followed by stirring at room temperature overnight. When the starting material disappeared, the mixture was distilled under reduced pressure to remove THF. After adding chloroform and washed with 1N-NaOH and brine, water was removed with sodium sulfate. The organic solvent was distilled under reduced pressure and crystallized with diethyl ether to obtain the title compound (48 mmol) with a yield of 95%.
실시예 9. 2-치환된-3H-퀴나졸린-4-온 (화학식 E)의 합성Example 9. Synthesis of 2-substituted-3 H -quinazolin-4-one (Formula E)
2-(치환된-카르보닐-아미노)-벤즈아미드(화학식 H; 45 mmol)를 2.5N-NaOH 60 mL에 녹인후 1시간 환류하였다. 출발물질이 사라지면 0 ℃로 냉각한 후 3N-HCl로 중화하였다. 생성된 결정을 여과를 통하여 취한 후 건조하여 수율 95%의 목적 화합물(43 mmol)을 얻었다. 얻은 목적화합물(화학식 E)은 상기 실시예 6과 7의 방법을 통하여 X=NH 및 R1=H, 알킬 또는 아릴기인 화합물 합성에 이용할 수 있다.2- (substituted-carbonyl-amino) -benzamide (Formula H; 45 mmol) was dissolved in 60 mL of 2.5 N- NaOH and refluxed for 1 hour. When the starting material disappeared, it was cooled to 0 ℃ and neutralized with 3 N -HCl. The resulting crystals were collected through filtration and dried to give the title compound (43 mmol) with a yield of 95%. The obtained target compound (Formula E) can be used for the synthesis of compounds in which X = NH and R 1 = H, alkyl or aryl groups through the methods of Examples 6 and 7.
다음의 실시예 10 내지 11은 X=NH 및 R1=아민인 화합물 합성을 위한 일구현예이다.Examples 10 to 11 which follow are one embodiment for the synthesis of compounds wherein X = NH and R 1 = amine.
실시예 10. (2-클로로-퀴나졸린-4-일)-치환된-아민 (화학식 4a)의 합성Example 10. Synthesis of (2-chloro-quinazolin-4-yl) -substituted-amine (Formula 4a)
THF 30 mL에 2,4-디클로로-퀴나졸린(화학식 J; 10 mmol)을 녹인 후 트리에틸아민(1.2 eq, 12 mmol)과 R2로 치환된 아민화합물(화학식 I, 1.05 eq, 10.5 mmol)을 넣고 실온에서 3시간 교반하였다. 출발물질이 사라지면 감압 증류하여 유기용매를 제거하였다. 에틸아세테이트를 첨가한 후 탄산나트륨 포화수용액, 소금물로 씻어준 후 무수황산나트륨으로 수분을 제거하였다. 유기용매는 감압 증류하여 제거한 후 혼합물을 디에틸 에테르로 결정화하여 수율 100%의 목적화합물(10 mmol)을 얻었다.Amine compound substituted with triethylamine (1.2 eq, 12 mmol) and R 2 after dissolving 2,4-dichloro-quinazolin (Formula J; 10 mmol) in 30 mL of THF (Formula I, 1.05 eq, 10.5 mmol) Was added and stirred at room temperature for 3 hours. When the starting material disappeared, the organic solvent was removed by distillation under reduced pressure. Ethyl acetate was added, washed with saturated aqueous sodium carbonate solution and brine, and then dried with anhydrous sodium sulfate. The organic solvent was distilled off under reduced pressure, and the mixture was crystallized with diethyl ether to obtain a target compound (10 mmol) with a yield of 100%.
실시예 11. (2-(R5-치환된 아민)-퀴나졸린-4-일)-R1-치환된-아민 (1d)의 합성Example 11.Synthesis of (2- (R 5 -substituted amine) -quinazolin-4-yl) -R 1 -substituted-amine (1d)
(2-클로로-퀴나졸린-4-일)-치환된-아민(화학식 4a; 1.5 mmol)과 R5로 치환된 아민(3 eq, 4.5 mmol)을 에탄올 15 mL에 녹인 후 밤새 환류교반 하였다. TLC로 출발물질이 완전히 사라진 것을 확인한 후 유기용매를 감압 증류로 제거하였다. 혼합물에 에틸 아세테이트를 첨가한 후 탄산나트륨 포화수용액과 소금물로 씻어준 후 무수 황산나트륨으로 수분을 제거하였다. 유기용매를 감압 증류로 제거한 후 혼합물을 관 크로마토그래피(실리카겔; 230∼400 mesh)를 이용하여 수율 95%의 목적 화합물(1.4 mmol)을 얻었다.(2-Chloro-quinazolin-4-yl) -substituted-amine (Formula 4a; 1.5 mmol) and R 5 substituted amine (3 eq, 4.5 mmol) were dissolved in 15 mL of ethanol and stirred under reflux overnight. After confirming that the starting material disappeared completely by TLC, the organic solvent was removed by distillation under reduced pressure. Ethyl acetate was added to the mixture, followed by washing with saturated aqueous sodium carbonate solution and brine, followed by anhydrous sodium sulfate. After distilling off the organic solvent under reduced pressure, the mixture was purified by column chromatography (silica gel; 230 to 400 mesh) to obtain a target compound (1.4 mmol) having a yield of 95%.
다음의 실시예 12는 X=NH 및 R1=알콕시인 화합물 합성을 위한 일구현예이다.Example 12 below is an embodiment for the synthesis of compounds wherein X = NH and R 1 = alkoxy.
실시예 12. (2-(R5-치환된 알콕시)-퀴나졸린-4-일)-R1-치환된-아민 (1d)의 합성Example 12.Synthesis of (2- (R 5 -substituted alkoxy) -quinazolin-4-yl) -R 1 -substituted-amine (1d)
(2-클로로-퀴나졸린-4-일)-치환된-아민(화학식 4a; 1.5 mmol)을 에탄올 15 mL에 녹인 후 NaOEt(2 eq, 3.0mmol)을 0 ℃에서 첨가하였다. 첨가된 혼합물을 실온에서 3시간 교반하여 출발물질이 사라지면 감압증류하여 에탄올을 제거하였다. 혼합물에 에틸 아세테이트를 첨가하고 물로 씻어준 후 황산나트륨으로 수분을 제거하였다. 유기용매를 감압 증류한 후 혼합물을 관 크로마토그래피(실리카겔; 230∼400 mesh)를 이용하여 수율 85%의 목적 화합물(1.3 mmol)을 얻었다.(2-Chloro-quinazolin-4-yl) -substituted-amine (Formula 4a; 1.5 mmol) was dissolved in 15 mL of ethanol, and NaOEt (2 eq, 3.0 mmol) was added at 0 ° C. The added mixture was stirred at room temperature for 3 hours, after which the starting material disappeared and distilled under reduced pressure to remove ethanol. Ethyl acetate was added to the mixture, washed with water, and water was removed with sodium sulfate. After distilling the organic solvent under reduced pressure, the mixture was purified by column chromatography (silica gel; 230 to 400 mesh) to obtain a target compound (1.3 mmol) having a yield of 85%.
다음의 실시예 13 내지 14는 X=S인 화합물 합성을 위한 일구현예이다.Examples 13-14 below are one embodiment for synthesizing compounds where X = S.
실시예 13. 2-치환된-3H-퀴나졸린-4-티온 (화학식 6a)의 합성Example 13. Synthesis of 2-substituted-3 H -quinazolin-4-thione (Formula 6a)
톨루엔 9 mL에 2-치환된-3H-퀴나졸린-4-온(화학식 E; 3 mmol)과 Lawesson's 시약(0.5 eq, 1.5 mmol)을 녹인 후 1시간 환류교반 하였다. 출발물질이 사라지면 유기용매를 감압 증류한 후 혼합물을 관 크로마토그래피(실리카겔; 230∼400 mesh)를 이용하여 수율 95%의 목적 화합물(2.9 mmol)을 얻었다.2-substituted- 3H -quinazolin-4-one (Formula E; 3 mmol) and Lawesson's reagent (0.5 eq, 1.5 mmol) were dissolved in 9 mL of toluene and stirred under reflux for 1 hour. When the starting material disappeared, the organic solvent was distilled off under reduced pressure, and the mixture was subjected to column chromatography (silica gel; 230 to 400 mesh) to give a yield of 95% of the title compound (2.9 mmol).
실시예 14. 2-(R1-치환된)-4-(R2-설파닐)-퀴나졸린 (화학식 1f)의 합성Example 14 Synthesis of 2- (R 1 -Substituted) -4- (R 2 -sulfanyl) -quinazolin (Formula 1f)
2-치환된-3H-퀴나졸린-4-티온(화학식 6a, 2 mmol)과 탄산칼륨(1.5 eq, 3 mmol)을 N,N-디메틸포름아마이드 8 mL에 녹인 후 R2-치환된 브롬화합물(1.2 eq, 2.4 mmol)을 실온에서 첨가하였다. 1시간 교반하여 출발물질이 사라지면 혼합물을 에틸 아세테이트로 묽힌 후 물과 소금물로 씻어준 후 무수 황산나트륨으로 수분을 제거하였다. 유기용매를 감압 증류한 후 혼합물을 관 크로마토그래피(실리카겔; 230∼400 mesh)를 이용하여 수율 95%의 목적 화합물(1.9 mmol)을 얻었다.2-substituted- 3H -quinazolin-4-thione (
다음의 실시예 15는 X=O인 화합물 합성을 위한 일구현예이다.Example 15 below is an embodiment for the synthesis of compounds wherein X═O.
실시예 15. 2-(R1-치환된)-4-(R2-치환된-옥시)-퀴나졸린 (화학식 1g)의 합성.Example 15. Synthesis of 2- (R 1 -substituted) -4- (R 2 -substituted-oxy) -quinazolin (Formula 1 g).
2-치환된-3H-퀴나졸린-4-온(화학식 E; 3 mmol)과 탄산칼륨(1.0 eq, 3 mmol)을 N,N-디메틸포름아마이드 9 mL에 녹인 후 R2-치환된 브롬화합물(1.5 eq, 4.5 mmol)을 실온에서 첨가하였다. 밤새 실온에서 교반하여 출발물질이 사라지면 혼합물을 에틸 아세테이트로 묽힌 후 물과 소금물로 씻어준 후 무수 황산나트륨으로 수분을 제거하였다. 유기용매를 감압 증류한 후 혼합물을 관 크로마토그래피(실리카겔; 230∼400 mesh)를 이용하여 수율 45%의 목적 화합물(1.4 mmol)을 얻었다.Dissolved 2- H -quinazolin-4-one (Formula E; 3 mmol) and potassium carbonate (1.0 eq, 3 mmol) in 9 mL of N, N -dimethylformamide followed by R 2 -substituted bromine Compound (1.5 eq, 4.5 mmol) was added at room temperature. After stirring at room temperature overnight, the starting material disappeared, the mixture was diluted with ethyl acetate, washed with water and brine, and then dried with anhydrous sodium sulfate. After distilling the organic solvent under reduced pressure, the mixture was purified by column chromatography (silica gel; 230 to 400 mesh) to obtain a target compound (1.4 mmol) having a yield of 45%.
다음의 실시예 16은 X=O인 화합물 합성을 위한 일구현예이다.Example 16 below is an embodiment for the synthesis of compounds wherein X═O.
실시예 16. 2-(R1-치환된)-4-(R2-치환된-옥시)-퀴나졸린 (화학식 1g)의 합성.Example 16 Synthesis of 2- (R 1 -substituted) -4- (R 2 -substituted-oxy) -quinazolin (Formula 1 g).
R2-치환된 알콜 화합물(1.2 eq, 24 mmol)과 소듐 히드리드(1.2 eq, 24 mmol)의 N,N-디메틸포름아마이드 60 mL 용액을 0 ℃에서 만든 후 4-클로로-2-치환된-퀴나졸린(화학식 2c; 20 mmol)을 첨가하였다. 밤새 실온에서 교반한 후 혼합물을 에틸 아세테이트로 묽힌 후 물과 소금물로 씻어준 후 무수 황산나트륨으로 수분을 제거하였다. 유기용매를 감압 증류한 후 혼합물을 관 크로마토그래피(실리카겔; 230∼400 mesh)를 이용하여 수율 46%의 목적 화합물(9.2 mmol)을 얻었다.A 60 mL solution of N, N -dimethylformamide of R 2 -substituted alcohol compound (1.2 eq, 24 mmol) and sodium hydride (1.2 eq, 24 mmol) was made at 0 ° C. and then 4-chloro-2-substituted. -Quinazoline (Formula 2c; 20 mmol) was added. After stirring overnight at room temperature, the mixture was diluted with ethyl acetate, washed with water and brine, and then dried with anhydrous sodium sulfate. After distilling off the organic solvent under reduced pressure, the mixture was purified by column chromatography (silica gel; 230 to 400 mesh) to obtain a target compound (9.2 mmol) having a yield of 46%.
당 분야에서 종사해온 전문가라면 상기 실시예 1 내지 4에 예시된 제조방법에 의거하여 본 발명에 따른 상기 화학식 1로 표시되는 화합물을 쉽게 합성할 수 있다. 본 발명에서 합성한 몇몇 화합물을 예시하면 다음과 같다.Those skilled in the art can easily synthesize the compound represented by
화합물번호 1. 2-[2-(2-페닐-퀴나졸린-4-일아미노)-에톡시]-에탄올Compound No. 1. 2- [2- (2-phenyl-quinazolin-4-ylamino) -ethoxy] -ethanol
1H NMR(CDCl3, 300 MHz) δ 8.56(m, 2H), 7.91(d, J=8.1 Hz, 1H), 7.70(m, 2H), 7.50(m, 3H), 7.37(t, J=7.5 Hz, 1H), 6.40(m, 1H), 4.00(m, 2H), 3.82(m, 4H), 3.64(m, 2H), 2.83(br s, 1H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.56 (m, 2H), 7.91 (d, J = 8.1 Hz, 1H), 7.70 (m, 2H), 7.50 (m, 3H), 7.37 (t, J = 7.5 Hz, 1H), 6.40 (m, 1H), 4.00 (m, 2H), 3.82 (m, 4H), 3.64 (m, 2H), 2.83 (br s, 1H)
화합물번호 2. 이소프로필-(2-트리클로로메틸-퀴나졸린-4-일)-아민Compound No. 2. Isopropyl- (2-trichloromethyl-quinazolin-4-yl) -amine
화합물번호 3. 싸이클로프로필-(2-트리클로로메틸-퀴나졸린-4-일)-아민Compound No. 3. Cyclopropyl- (2-trichloromethyl-quinazolin-4-yl) -amine
화합물번호 4. (2-피페리딘-1-일-에틸)-(2-트리클로로메틸-퀴나졸린-4-일)-아민Compound No. 4. (2-Piperidin-1-yl-ethyl)-(2-trichloromethyl-quinazolin-4-yl) -amine
화합물번호 5. (1-페닐-에틸)-(2-트리클로로메틸-퀴나졸린-4-일)-아민Compound No. 5. (1-phenyl-ethyl)-(2-trichloromethyl-quinazolin-4-yl) -amine
화합물번호 6. (4-페닐-부틸)-(2-트리클로로메틸-퀴나졸린-4-일)-아민Compound No. 6. (4-phenyl-butyl)-(2-trichloromethyl-quinazolin-4-yl) -amine
화합물번호 7. 프로필-(2-트리클로로메틸-퀴나졸린-4-일)-아민Compound No. 7. Propyl- (2-trichloromethyl-quinazolin-4-yl) -amine
화합물번호 8. (2-에틸설파닐-퀴나졸린-4-일)-이소프로필-아민Compound No. 8. (2-Ethylsulfanyl-quinazolin-4-yl) -isopropyl-amine
화합물번호 9. (2-에틸설파닐-퀴나졸린-4-일)-(3-플루오로-벤질)-아민Compound No. 9. (2-ethylsulfanyl-quinazolin-4-yl)-(3-fluoro-benzyl) -amine
1H NMR(CDCl3, 300 MHz) δ 7.68(m, 3H), 7.30(m, 2H), 7.15(d, J=7.5 Hz, 1H), 7.05(d, J=7.5 Hz, 1H), 6.95(t, J=7.5 Hz, 1H), 6.24(s, 1H), 4.85(d, J=5.4 Hz, 2H), 3.15(q, J=14.4 Hz, 2H), 1.37(t, J=7.35 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.68 (m, 3H), 7.30 (m, 2H), 7.15 (d, J = 7.5 Hz, 1H), 7.05 (d, J = 7.5 Hz, 1H), 6.95 (t, J = 7.5 Hz, 1H), 6.24 (s, 1H), 4.85 (d, J = 5.4 Hz, 2H), 3.15 (q, J = 14.4 Hz, 2H), 1.37 (t, J = 7.35 Hz , 3H)
화합물번호 10. (2-에틸설파닐-퀴나졸린-4-일)-[2-(3-플루오로-페닐)-에틸]-아민Compound No. 10. (2-ethylsulfanyl-quinazolin-4-yl)-[2- (3-fluoro-phenyl) -ethyl] -amine
화합물번호 11. (2-에틸설파닐-퀴나졸린-4-일)-(2-몰포린-4-일-에틸)-아민Compound No. 11. (2-Ethylsulfanyl-quinazolin-4-yl)-(2-morpholin-4-yl-ethyl) -amine
화합물번호 12. (2-에틸설파닐-퀴나졸린-4-일)-[2-(3-트리플루오로메틸-페닐)에틸]-아민Compound No. 12. (2-ethylsulfanyl-quinazolin-4-yl)-[2- (3-trifluoromethyl-phenyl) ethyl] -amine
화합물번호 13. (6-니트로-퀴나졸린-4-일)-페닐-아민Compound No. 13. (6-Nitro-quinazolin-4-yl) -phenyl-amine
화합물번호 14. (6,7-디에톡시-퀴나졸린-4-일)-나프탈렌-1-일메틸-아민Compound No. 14. (6,7-Diethoxy-quinazolin-4-yl) -naphthalen-1-ylmethyl-amine
화합물번호 15. (6,7-디에톡시-퀴나졸린-4-일)-(3-몰포린-4-일-프로필)-아민Compound No. 15. (6,7-Diethoxy-quinazolin-4-yl)-(3-morpholin-4-yl-propyl) -amine
화합물번호 16. 알릴-(6,7-디에톡시-퀴나졸린-4-일)-아민Compound No. 16. Allyl- (6,7-diethoxy-quinazolin-4-yl) -amine
화합물번호 17. (6,7-디에톡시-퀴나졸린-4-일)-(2-피리딘-2-일-에틸)-아민Compound No. 17. (6,7-Diethoxy-quinazolin-4-yl)-(2-pyridin-2-yl-ethyl) -amine
화합물번호 18. (4-클로로-벤질)-(6,7-디에톡시-퀴나졸린-4-일)-아민Compound No. 18. (4-Chloro-benzyl)-(6,7-diethoxy-quinazolin-4-yl) -amine
화합물번호 19. 부틸-(2-에틸설파닐-퀴나졸린-4-일)-아민Compound No. 19. Butyl- (2-ethylsulfanyl-quinazolin-4-yl) -amine
화합물번호 20. sec-부틸-(2-에틸설파닐-퀴나졸린-4-일)-아민Compound No. 20. sec- Butyl- (2-ethylsulfanyl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 7.86(d, J=7.5 Hz, 1H), 7.61(m, 2H), 7.30(d, J=7.5 Hz, 1H), 6.57(s, 1H), 4.42(m, 1H), 3.23(q, J=14.4 Hz, 2H), 1.74(m, 2H), 1.47-1.22(m, 6H), 1.00(t, J=7.35 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.86 (d, J = 7.5 Hz, 1H), 7.61 (m, 2H), 7.30 (d, J = 7.5 Hz, 1H), 6.57 (s, 1H), 4.42 (m, 1H), 3.23 (q, J = 14.4 Hz, 2H), 1.74 (m, 2H), 1.47-1.22 (m, 6H), 1.00 (t, J = 7.35 Hz, 3H)
화합물번호 21. (2-에틸설파닐-퀴나졸린-4-일)-이소부틸-아민Compound No. 21. (2-Ethylsulfanyl-quinazolin-4-yl) -isobutyl-amine
화합물번호 22. 벤질-(2-에틸설파닐-퀴나졸린-4-일)-아민Compound No. 22. Benzyl- (2-ethylsulfanyl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 7.65(m, 3H), 7.34(m, 6H), 6.01(s, 1H), 4.86(d, J=5.4 Hz, 2H), 3.65(q, J=14.4 Hz, 2H), 1.40(t, J=7.35 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.65 (m, 3H), 7.34 (m, 6H), 6.01 (s, 1H), 4.86 (d, J = 5.4 Hz, 2H), 3.65 (q, J = 14.4 Hz, 2H), 1.40 (t, J = 7.35 Hz, 3H)
화합물번호 23. (2-에틸설파닐-퀴나졸린-4-일)-(1-페닐-에틸)-아민Compound No. 23. (2-Ethylsulfanyl-quinazolin-4-yl)-(1-phenyl-ethyl) -amine
화합물번호 24. (2-에틸설파닐-퀴나졸린-4-일)-(3-메톡시-벤질)-아민Compound No. 24. (2-Ethylsulfanyl-quinazolin-4-yl)-(3-methoxy-benzyl) -amine
1H NMR(CDCl3, 300 MHz) δ 7.66(m, 3H), 7.29(m, 2H), 6.95(m, 2H), 6.88(m, 1H), 6.02(s, 1H), 4.82(d, J=5.5 Hz, 2H), 3.80(s, 3H), 3.20(q, J=14.4 Hz, 2H), 1.40(t, J=7.35 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.66 (m, 3H), 7.29 (m, 2H), 6.95 (m, 2H), 6.88 (m, 1H), 6.02 (s, 1H), 4.82 (d, J = 5.5 Hz, 2H), 3.80 (s, 3H), 3.20 (q, J = 14.4 Hz, 2H), 1.40 (t, J = 7.35 Hz, 3H)
화합물번호 25. (2-에틸설파닐-퀴나졸린-4-일)-(4-메톡시-벤질)-아민Compound No. 25. (2-Ethylsulfanyl-quinazolin-4-yl)-(4-methoxy-benzyl) -amine
1H NMR(CDCl3, 300 MHz) δ 7.62(m, 3H), 7.33(m, 3H), 6.90(d, J=8.4 Hz, 2H), 4,78(d, J=5.7 Hz, 2H), 3.81(s, 3H), 3.23(q, J=14.4 Hz, 2H), 1.43(t, J=7.36 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.62 (m, 3H), 7.33 (m, 3H), 6.90 (d, J = 8.4 Hz, 2H), 4,78 (d, J = 5.7 Hz, 2H) , 3.81 (s, 3H), 3.23 (q, J = 14.4 Hz, 2H), 1.43 (t, J = 7.36 Hz, 3H)
화합물번호 26. (2-에틸설파닐-퀴나졸린-4-일)-(3-트리플루오로메틸-벤질)-아민Compound No. 26. (2-Ethylsulfanyl-quinazolin-4-yl)-(3-trifluoromethyl-benzyl) -amine
1H NMR(CDCl3, 300 MHz) δ 7.92(d, J=8.3 Hz, 1H), 7.63(m, 4H), 7.55(m, 2H), 7.46(m, 2H), 7.33(m, 1H), 4.94(d, J=5.4 Hz, 2H), 3.12(q, J=14.4 Hz, 2H), 1.30(t, J=7.35 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.92 (d, J = 8.3 Hz, 1H), 7.63 (m, 4H), 7.55 (m, 2H), 7.46 (m, 2H), 7.33 (m, 1H) , 4.94 (d, J = 5.4 Hz, 2H), 3.12 (q, J = 14.4 Hz, 2H), 1.30 (t, J = 7.35 Hz, 3H)
화합물번호 27. 싸이클로헥실-(2-에틸설파닐-퀴나졸린-4-일)-아민Compound No. 27. Cyclohexyl- (2-ethylsulfanyl-quinazolin-4-yl) -amine
화합물번호 28. 싸이클로펜틸-(2-에틸설파닐-퀴나졸린-4-일)-아민Compound No. 28. Cyclopentyl- (2-ethylsulfanyl-quinazolin-4-yl) -amine
화합물번호 29. (2-에틸설파닐-퀴나졸린-4-일)-펜에틸-아민Compound No. 29. (2-Ethylsulfanyl-quinazolin-4-yl) -phenethyl-amine
1H NMR(CDCl3, 300 MHz) δ 7.66(m, 2H), 7.45(d, J=8.2 Hz, 1H), 7.33(m, 6H), 5.84(br s, 1H), 3.91(q, J=12.6 Hz, 2H), 3.26(q, J=14.4 Hz, 2H), 3.03(t, J=6.9 Hz, 2H), 1.47(t, J=7.36 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.66 (m, 2H), 7.45 (d, J = 8.2 Hz, 1H), 7.33 (m, 6H), 5.84 (br s, 1H), 3.91 (q, J = 12.6 Hz, 2H), 3.26 (q, J = 14.4 Hz, 2H), 3.03 (t, J = 6.9 Hz, 2H), 1.47 (t, J = 7.36 Hz, 3H)
화합물번호 30. (2-에틸설파닐-퀴나졸린-4-일)-(4-페닐-부틸)-아민Compound No. 30. (2-Ethylsulfanyl-quinazolin-4-yl)-(4-phenyl-butyl) -amine
1H NMR(CDCl3, 300 MHz) δ 7.61(m, 3H), 7.30(m, 3H), 7.20(m, 3H), 5.74(br s, 1H), 3.68(m, 2H), 3.23(q, J=14.4 Hz, 2H), 2.69(m, 2H), 1.76(m, 4H), 1.44(t, J=7.36 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.61 (m, 3H), 7.30 (m, 3H), 7.20 (m, 3H), 5.74 (br s, 1H), 3.68 (m, 2H), 3.23 (q , J = 14.4 Hz, 2H), 2.69 (m, 2H), 1.76 (m, 4H), 1.44 (t, J = 7.36 Hz, 3H)
화합물번호 31. (2-에틸설파닐-퀴나졸린-4-일)-프로필-아민Compound number 31. (2-ethylsulfanyl-quinazolin-4-yl) -propyl-amine
화합물번호 32. (2-에틸설파닐-퀴나졸린4-일)-(3-페닐-프로필)-아민
화합물번호 33. (2-에틸설파닐-퀴나졸린-4-일)-(3-이소프로폭시프로필)-아민Compound 33. (2-Ethylsulfanyl-quinazolin-4-yl)-(3-isopropoxypropyl) -amine
화합물번호 34. (2-에틸설파닐-퀴나졸린-4-일)-(2-메톡시-에틸)-아민
화합물번호 35. (2-에틸설파닐-퀴나졸린-4-일)-나프탈렌-1-일메틸-아민Compound No. 35. (2-Ethylsulfanyl-quinazolin-4-yl) -naphthalen-1-ylmethyl-amine
1H NMR(CDCl3, 300 MHz) δ 8.11(m, 1H), 7.90(m, 2H), 7.65(m, 2H), 7.53(m, 5H), 7.24(m, 1H), 5.92(br s, 1H), 5.27(d, J=4.5 Hz, 2H), 3.26(q, J=14.4 Hz, 2H), 1.22(t, J=7.4 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.11 (m, 1H), 7.90 (m, 2H), 7.65 (m, 2H), 7.53 (m, 5H), 7.24 (m, 1H), 5.92 (br s , 1H), 5.27 (d, J = 4.5 Hz, 2H), 3.26 (q, J = 14.4 Hz, 2H), 1.22 (t, J = 7.4 Hz, 3H)
화합물번호 36. (2-에틸설파닐-퀴나졸린-4-일)-(3-몰포린-4-일-프로필)-아민Compound No. 36. (2-Ethylsulfanyl-quinazolin-4-yl)-(3-morpholin-4-yl-propyl) -amine
1H NMR(CDCl3, 300 MHz) δ 7.93(m, 1H), 7.70(m, 3H), 7.31(m, 1H), 3.78(m, 6H), 3.22(q, J=14.4 Hz, 2H), 2.59(m, 6H), 1.87(m, 2H), 1.43(t, J=7.41 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.93 (m, 1H), 7.70 (m, 3H), 7.31 (m, 1H), 3.78 (m, 6H), 3.22 (q, J = 14.4 Hz, 2H) , 2.59 (m, 6H), 1.87 (m, 2H), 1.43 (t, J = 7.41 Hz, 3H)
화합물번호 37. 벤조[1,3]디옥솔-5-일메틸-(2-에틸설파닐-퀴나졸린-4-일)-아민Compound No. 37.Benzo [1,3] dioxol-5-ylmethyl- (2-ethylsulfanyl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 7.66(m, 3H), 7.31(m, 1H), 6.80(m, 3H), 5.97(s, 2H), 5.90(br s, 1H), 4.76(d, J=5.1 Hz, 2H), 3.23(q, J=14.4 Hz, 2H), 1.44(t, J=7.36 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.66 (m, 3H), 7.31 (m, 1H), 6.80 (m, 3H), 5.97 (s, 2H), 5.90 (br s, 1H), 4.76 (d , J = 5.1 Hz, 2H), 3.23 (q, J = 14.4 Hz, 2H), 1.44 (t, J = 7.36 Hz, 3H)
화합물번호 38. (3,5-디메톡시-벤질)-(2-에틸설파닐-퀴나졸린-4-일)-아민Compound No. 38. (3,5-Dimethoxy-benzyl)-(2-ethylsulfanyl-quinazolin-4-yl) -amine
화합물번호 39. (2-에틸설파닐-퀴나졸린-4-일)-(2-플루오로-벤질)-아민Compound No. 39. (2-Ethylsulfanyl-quinazolin-4-yl)-(2-fluoro-benzyl) -amine
화합물번호 40. (2-에틸설파닐-퀴나졸린-4-일)-(1-메톡시메틸-프로필)-아민Compound No. 40. (2-Ethylsulfanyl-quinazolin-4-yl)-(1-methoxymethyl-propyl) -amine
1H NMR(CDCl3, 300 MHz) δ 7.65(m, 3H), 7.32(m, 1H), 5.96(d, J=7.5 Hz, 1H), 4.48(d, J=3.6 Hz, 1H), 3.60(m, 2H), 3.41(s, 3H), 3.20(q, J=14.4 Hz, 2H), 1.75(m, 2H), 1.44(t, J=7.4 Hz, 3H), 1.01(t, J=7.35 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.65 (m, 3H), 7.32 (m, 1H), 5.96 (d, J = 7.5 Hz, 1H), 4.48 (d, J = 3.6 Hz, 1H), 3.60 (m, 2H), 3.41 (s, 3H), 3.20 (q, J = 14.4 Hz, 2H), 1.75 (m, 2H), 1.44 (t, J = 7.4 Hz, 3H), 1.01 (t, J = 7.35 Hz, 3H)
화합물번호 41. (1-벤질-피페리딘-4-일)-(2-에틸설파닐-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 7.60(m, 3H), 7.34(m, 6H), 5.54(d, J=6.9 Hz, 1H), 4.26(m, 1H), 3.50(m, 2H), 3.22(q, J=14.4 Hz, 2H), 2.90(m, 2H), 2.17(m, 4H), 1.65(m, 2H), 1.22(t, J=7.35 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.60 (m, 3H), 7.34 (m, 6H), 5.54 (d, J = 6.9 Hz, 1H), 4.26 (m, 1H), 3.50 (m, 2H) , 3.22 (q, J = 14.4 Hz, 2H), 2.90 (m, 2H), 2.17 (m, 4H), 1.65 (m, 2H), 1.22 (t, J = 7.35 Hz, 3H)
화합물번호 42. 알릴-(2-에틸설파닐-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 7.66(m, 3H), 7.33(m ,1H), 6.03(m, 1H), 5.79(br s ,1H), 5.29(m, 2H), 4.31(t, J=5.55 Hz, 2H), 3.23(q, J=14.5 Hz, 2H), 1.44(t, J=7.35 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.66 (m, 3H), 7.33 (m, 1H), 6.03 (m, 1H), 5.79 (br s, 1H), 5.29 (m, 2H), 4.31 (t , J = 5.55 Hz, 2H), 3.23 (q, J = 14.5 Hz, 2H), 1.44 (t, J = 7.35 Hz, 3H)
화합물번호 43. (2-에틸설파닐-퀴나졸린-4-일)-헥사데실-아민
화합물번호 44. (2-에틸설파닐-퀴나졸린-4-일)-(2-피페리딘-1-일-에틸)-아민Compound No. 44. (2-Ethylsulfanyl-quinazolin-4-yl)-(2-piperidin-1-yl-ethyl) -amine
화합물번호 45. (2-에틸설파닐-퀴나졸린-4-일)-(2-피롤리딘-1-일-에틸)-아민Compound No. 45. (2-ethylsulfanyl-quinazolin-4-yl)-(2-pyrrolidin-1-yl-ethyl) -amine
화합물번호 46. (2-에틸설파닐-퀴나졸린-4-일)-(2-피리딘-2-일-에틸)-아민Compound No. 46. (2-Ethylsulfanyl-quinazolin-4-yl)-(2-pyridin-2-yl-ethyl) -amine
화합물번호 47. 2-(2-에틸설파닐-퀴나졸린-4-일아미노)-에탄올Compound No. 47. 2- (2-Ethylsulfanyl-quinazolin-4-ylamino) -ethanol
1H NMR(DMSO-d6, 300 MHz) δ 8.33(m, 1H), 8.14(d, J=8.2 Hz, 1H), 7.67(t, J=7.5 Hz, 1H), 7.48(d, J=8.1 Hz, 1H), 7.36(t, J=7.6 Hz, 1H), 4.81(br s, 1H), 3.60(m, 4H), 3.13(q, J=14.4 Hz, 2H), 1.32(t, J=7.35 Hz, 3H) 1 H NMR (DMSO-d 6 , 300 MHz) δ 8.33 (m, 1H), 8.14 (d, J = 8.2 Hz, 1H), 7.67 (t, J = 7.5 Hz, 1H), 7.48 (d, J = 8.1 Hz, 1H), 7.36 (t, J = 7.6 Hz, 1H), 4.81 (br s, 1H), 3.60 (m, 4H), 3.13 (q, J = 14.4 Hz, 2H), 1.32 (t, J = 7.35 Hz, 3H)
화합물번호 48. (2-에틸설파닐-퀴나졸린-4-일)-[3-(2-메틸-피페리딘-1-일)-프로필]-아민Compound No. 48. (2-Ethylsulfanyl-quinazolin-4-yl)-[3- (2-methyl-piperidin-1-yl) -propyl] -amine
화합물번호 49. (2-클로로-6-플루오로-벤질)-(2-에틸설파닐-퀴나졸린-4-일)-아민Compound No. 49. (2-Chloro-6-fluoro-benzyl)-(2-ethylsulfanyl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 7.64(m, 3H), 7.25(m, 3H), 7.05(m, 1H), 6.00(br s, 1H), 5.06(d, J=5.6 Hz, 2H), 3.28(q, J=14.4 Hz, 2H), 1.46(t, J=7.35 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.64 (m, 3H), 7.25 (m, 3H), 7.05 (m, 1H), 6.00 (br s, 1H), 5.06 (d, J = 5.6 Hz, 2H ), 3.28 (q, J = 14.4 Hz, 2H), 1.46 (t, J = 7.35 Hz, 3H)
화합물번호 50. 2-[2-(2-에틸설파닐-퀴나졸린-4-일아미노)-에톡시]-에탄올
1H NMR(CDCl3, 300 MHz) δ 7.60(m, 3H), 7.27(m, 1H), 6.50(br s, 1H), 3.85(m, 4H), 3.78(m, 2H), 3.65(m, 2H), 3.20(q, J=14.4 Hz, 2H), 1.42(t, J=7.35 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.60 (m, 3H), 7.27 (m, 1H), 6.50 (br s, 1H), 3.85 (m, 4H), 3.78 (m, 2H), 3.65 (m , 2H), 3.20 (q, J = 14.4 Hz, 2H), 1.42 (t, J = 7.35 Hz, 3H)
화합물번호 51. 싸이클로헥실-(2-페닐-퀴나졸린-4-일)-아민Compound No. 51. Cyclohexyl- (2-phenyl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 8.58(m, 4H), 7.93(m, 1H), 7.72(m, 2H), 7.50(m, 4H), 5.58(d, J=7.2 Hz, 1H), 4.43(m, 1H), 2.27(m, 2H), 1.85(m, 3H), 1.54(m, 2H), 1.34(m, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.58 (m, 4H), 7.93 (m, 1H), 7.72 (m, 2H), 7.50 (m, 4H), 5.58 (d, J = 7.2 Hz, 1H) , 4.43 (m, 1H), 2.27 (m, 2H), 1.85 (m, 3H), 1.54 (m, 2H), 1.34 (m, 3H)
화합물번호 52. (4-페닐-부틸)-(2-페닐-퀴나졸린-4-일)-아민Compound 52. (4-phenyl-butyl)-(2-phenyl-quinazolin-4-yl) -amine
화합물번호 53. (5-페닐-펜틸)-(2-페닐-퀴나졸린-4-일)-아민Compound 53. (5-phenyl-pentyl)-(2-phenyl-quinazolin-4-yl) -amine
화합물번호 54. (4-메틸-벤질)-(2-페닐-퀴나졸린-4-일)-아민Compound number 54. (4-Methyl-benzyl)-(2-phenyl-quinazolin-4-yl) -amine
화합물번호 55. 이소부틸-(2-페닐-퀴나졸린-4-일)-아민
화합물번호 56. 부틸-(2-페닐-퀴나졸린-4-일)-아민Compound No. 56. Butyl- (2-phenyl-quinazolin-4-yl) -amine
화합물번호 57. 나프탈렌-1-일메틸-(2-페닐-퀴나졸린-4-일)-아민Compound No. 57. Naphthalen-1-ylmethyl- (2-phenyl-quinazolin-4-yl) -amine
화합물번호 58. (2-페닐-퀴나졸린-4-일)-피리딘-2-일메틸-아민Compound 58. (2-phenyl-quinazolin-4-yl) -pyridin-2-ylmethyl-amine
1H NMR(CDCl3, 300 MHz) δ 8.61(m, 3H), 7.91(t, J=8.2 Hz, 1H), 7.72(t, J=8.2 Hz, 1H), 7.52(m, 6H), 7.28(m, 1H), 5.07(d, J=4.5 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.61 (m, 3H), 7.91 (t, J = 8.2 Hz, 1H), 7.72 (t, J = 8.2 Hz, 1H), 7.52 (m, 6H), 7.28 (m, 1H), 5.07 (d, J = 4.5 Hz, 2H)
화합물번호 59. (1-페닐-퀴나졸린-4-일)-티오펜-2-일메틸-아민Compound 59. (1-phenyl-quinazolin-4-yl) -thiophen-2-ylmethyl-amine
1H NMR(CDCl3, 300 MHz) δ 8.66(m, 2H), 7.96(d, J=8.1 Hz, 1H), 7.69(m, 2H), 7.53(m, 3H), 7.41(m, 1H), 7.24(t, J=7.4 Hz, 1H), 7.13(t, J=7.4 Hz, 1H), 7.00(t, J=7.36 Hz, 1H), 6.09(d, J=5.1 Hz, 1H), 5.17(d, J=5.4 Hz, 2H), 1 H NMR (CDCl 3 , 300 MHz) δ 8.66 (m, 2H), 7.96 (d, J = 8.1 Hz, 1H), 7.69 (m, 2H), 7.53 (m, 3H), 7.41 (m, 1H) , 7.24 (t, J = 7.4 Hz, 1H), 7.13 (t, J = 7.4 Hz, 1H), 7.00 (t, J = 7.36 Hz, 1H), 6.09 (d, J = 5.1 Hz, 1H), 5.17 (d, J = 5.4 Hz, 2H),
화합물번호 60. 이소프로필-(2-페닐-퀴나졸린-4-일)-아민Compound No. 60. Isopropyl- (2-phenyl-quinazolin-4-yl) -amine
화합물번호 61. (2-페닐-퀴나졸린-4-일)-프로필-아민Compound No. 61. (2-phenyl-quinazolin-4-yl) -propyl-amine
1H NMR(CDCl3, 300 MHz) δ 8.60(m, 1H), 7.94(d, J=8.2 Hz, 1H), 7.70(m, 2H), 7.41(m, 4H), 5.78(t, J=5.4 Hz, 1H), 3.76(q, J=13.2 Hz, 2H), 1.80(q, J=14.4 Hz, 2H), 1.08(t, J=8.4 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.60 (m, 1H), 7.94 (d, J = 8.2 Hz, 1H), 7.70 (m, 2H), 7.41 (m, 4H), 5.78 (t, J = 5.4 Hz, 1H), 3.76 (q, J = 13.2 Hz, 2H), 1.80 (q, J = 14.4 Hz, 2H), 1.08 (t, J = 8.4 Hz, 3H)
화합물번호 62. (3-이소프로폭시프로필)-(2-페닐-퀴나졸린-4-일)-아민Compound No. 62. (3-Isopropoxypropyl)-(2-phenyl-quinazolin-4-yl) -amine
화합물번호 63. (3-플루오로-벤질)-(2-페닐-퀴나졸린-4-일)-아민Compound No. 63. (3-Fluoro-benzyl)-(2-phenyl-quinazolin-4-yl) -amine
화합물번호 64. (2-페닐-퀴나졸린-4-일)-[2-(3-트리플루오로메틸-페닐)-에틸]-아민Compound No. 64. (2-phenyl-quinazolin-4-yl)-[2- (3-trifluoromethyl-phenyl) -ethyl] -amine
1H NMR(CDCl3, 300 MHz) δ 8.64(m, 2H), 7.95(d, J=8.3 Hz, 1H), 7.74(t, J=7.4 Hz, 1H), 7.50(m, 4H), 7.40(t, J=6.6 Hz, 1H), 7.30(m, 1H), 7.03(m, 3H), 5.85(t, J=5.4 Hz, 1H), 4.03(q, J=13.2 Hz, 2H), 3.10(t, J=7.9 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.64 (m, 2H), 7.95 (d, J = 8.3 Hz, 1H), 7.74 (t, J = 7.4 Hz, 1H), 7.50 (m, 4H), 7.40 (t, J = 6.6 Hz, 1H), 7.30 (m, 1H), 7.03 (m, 3H), 5.85 (t, J = 5.4 Hz, 1H), 4.03 (q, J = 13.2 Hz, 2H), 3.10 (t, J = 7.9 Hz, 2H)
화합물번호 65. 벤조[1,3]디옥솔-5-일메틸-(2-페닐-퀴나졸린-4-일)-아민Compound number 65. Benzo [1,3] dioxol-5-ylmethyl- (2-phenyl-quinazolin-4-yl) -amine
화합물번호 66. (2-페닐-퀴나졸린-4-일)-(3-트리플루오로메틸-벤질)-아민Compound No. 66. (2-phenyl-quinazolin-4-yl)-(3-trifluoromethyl-benzyl) -amine
화합물번호 67. (2-메톡시-에틸)-(2-페닐-퀴나졸린-4-일)-아민Compound number 67. (2-methoxy-ethyl)-(2-phenyl-quinazolin-4-yl) -amine
화합물번호 68. 펜에틸-(2-페닐-퀴나졸린-4-일)-아민Compound number 68. Phenethyl- (2-phenyl-quinazolin-4-yl) -amine
화합물번호 69. 페닐-(2-페닐-퀴나졸린-4-일)-아민Compound number 69. Phenyl- (2-phenyl-quinazolin-4-yl) -amine
1H NMR(DMSO, 300 MHz) δ 11.56(br s, 1H), 8.92(d, J=8.2 Hz, 1H), 8.35(m, 3H), 8.09(t, J=7.4 Hz, 1H), 7.83(m, 3H), 7.60(m, 5H), 7.38(d, J=8.4 Hz, 1H) 1 H NMR (DMSO, 300 MHz) δ 11.56 (br s, 1H), 8.92 (d, J = 8.2 Hz, 1H), 8.35 (m, 3H), 8.09 (t, J = 7.4 Hz, 1H), 7.83 (m, 3H), 7.60 (m, 5H), 7.38 (d, J = 8.4 Hz, 1H)
화합물번호 70. (4-메톡시-페닐)-(2-페닐-퀴나졸린-4-일)-아민Compound No. 70. (4-methoxy-phenyl)-(2-phenyl-quinazolin-4-yl) -amine
화합물번호 71. (2-페닐-퀴나졸린-4-일)-o-톨릴-아민Compound number 71. (2-phenyl-quinazolin-4-yl) -o- tolyl-amine
화합물번호 72. (4-이소프로필-페닐)-(2-페닐-퀴나졸린-4-일)-아민Compound number 72. (4-Isopropyl-phenyl)-(2-phenyl-quinazolin-4-yl) -amine
1H NMR(DMSO, 300 MHz) δ 11.45(br s, 1H), 8.90(d, J=8.2 Hz, 1H), 8.35(m, 3H), 8.08(t, J=7.4 Hz, 1H), 7.80(m, 3H), 7.68(m, 3H), 7.41(d, J=8.4 Hz, 1H) 1 H NMR (DMSO, 300 MHz) δ 11.45 (br s, 1H), 8.90 (d, J = 8.2 Hz, 1H), 8.35 (m, 3H), 8.08 (t, J = 7.4 Hz, 1H), 7.80 (m, 3H), 7.68 (m, 3H), 7.41 (d, J = 8.4 Hz, 1H)
화합물번호 73. (2,4-디메틸-페닐)-(2-페닐-퀴나졸린-4-일)-아민Compound No. 73. (2,4-Dimethyl-phenyl)-(2-phenyl-quinazolin-4-yl) -amine
1H NMR(DMSO, 300 MHz) δ 11.41(br s, 1H), 8.82(d, J=8.2 Hz, 1H), 8.33(d, J=8.2 Hz, 1H), 8.18(m, 3H), 7.83(t, J=7.4 Hz, 1H), 7.65(m, 3H), 7.38(d, J=8.1 Hz, 1H), 7.19(m, 3H), 2.37(s, 3H), 2.27(s, 3H) 1 H NMR (DMSO, 300 MHz) δ 11.41 (br s, 1H), 8.82 (d, J = 8.2 Hz, 1H), 8.33 (d, J = 8.2 Hz, 1H), 8.18 (m, 3H), 7.83 (t, J = 7.4 Hz, 1H), 7.65 (m, 3H), 7.38 (d, J = 8.1 Hz, 1H), 7.19 (m, 3H), 2.37 (s, 3H), 2.27 (s, 3H)
화합물번호 74. (2-페닐-퀴나졸린-4-일)-(4-운데실-페닐)-아민Compound number 74. (2-phenyl-quinazolin-4-yl)-(4-undecyl-phenyl) -amine
화합물번호 75. (4-에틸-페닐)-(2-페닐-퀴나졸린-4-일)-아민Compound number 75. (4-Ethyl-phenyl)-(2-phenyl-quinazolin-4-yl) -amine
화합물번호 76. (4-플루오로-페닐)-(2-페닐-퀴나졸린-4-일)-아민Compound number 76. (4-Fluoro-phenyl)-(2-phenyl-quinazolin-4-yl) -amine
1H NMR(DMSO, 300 MHz) δ 11.42(br s, 1H), 8.90(d, J=8.2 Hz, 1H), 8.34(m, 3H), 8.09(t, J=7.4 Hz, 1H), 7.86(m, 3H), 7.68(m, 3H), 7.40(m, 2H) 1 H NMR (DMSO, 300 MHz) δ 11.42 (br s, 1H), 8.90 (d, J = 8.2 Hz, 1H), 8.34 (m, 3H), 8.09 (t, J = 7.4 Hz, 1H), 7.86 (m, 3H), 7.68 (m, 3H), 7.40 (m, 2H)
화합물번호 77. (2-메톡시-페닐)-(2-페닐-퀴나졸린-4-일)-아민Compound No. 77. (2-Methoxy-phenyl)-(2-phenyl-quinazolin-4-yl) -amine
화합물번호 78. (2-페닐-퀴나졸린-4-일)-(2,4,6-트리메틸-페닐)-아민Compound number 78. (2-phenyl-quinazolin-4-yl)-(2,4,6-trimethyl-phenyl) -amine
1H NMR(DMSO, 300 MHz) δ 11.39(br s, 1H), 8.83(d, J=8.2 Hz, 1H), 8.27(t, J=7.4 Hz, 1H), 8.11(m, 3H), 7.85(t, J=7.5 Hz, 1H), 7.67(t, J=7.5 Hz, 1H), 7.60(m, 2H), 7.07(s, 2H), 2.33(s, 3H), 2.18(s, 6H) 1 H NMR (DMSO, 300 MHz) δ 11.39 (br s, 1H), 8.83 (d, J = 8.2 Hz, 1H), 8.27 (t, J = 7.4 Hz, 1H), 8.11 (m, 3H), 7.85 (t, J = 7.5 Hz, 1H), 7.67 (t, J = 7.5 Hz, 1H), 7.60 (m, 2H), 7.07 (s, 2H), 2.33 (s, 3H), 2.18 (s, 6H)
화합물번호 79. (4-부틸-페닐)-(2-페닐-퀴나졸린-4-일)-아민Compound number 79. (4-butyl-phenyl)-(2-phenyl-quinazolin-4-yl) -amine
화합물번호 80. (2-페녹시-페닐)-(2-페닐-퀴나졸린-4-일)-아민Compound No. 80. (2-Phenoxy-phenyl)-(2-phenyl-quinazolin-4-yl) -amine
1H NMR(DMSO, 300 MHz) δ 11.62(br s, 1H), 8.69(d, J=8.2 Hz, 1H), 8.28(m, 3H), 8.09(t, J=7.5 Hz, 1H), 7.79(t, J=7.5 Hz, 1H), 7.68(m, 3H), 7.34(d, J=7.8 Hz, 1H), 7.16(d, J=7.8 Hz, 1H), 7.12(m, 3H), 6.90(m, 3H) 1 H NMR (DMSO, 300 MHz) δ 11.62 (br s, 1H), 8.69 (d, J = 8.2 Hz, 1H), 8.28 (m, 3H), 8.09 (t, J = 7.5 Hz, 1H), 7.79 (t, J = 7.5 Hz, 1H), 7.68 (m, 3H), 7.34 (d, J = 7.8 Hz, 1H), 7.16 (d, J = 7.8 Hz, 1H), 7.12 (m, 3H), 6.90 (m, 3 H)
화합물번호 81. (3-페녹시-페닐)-(2-페닐-퀴나졸린-4-일)-아민Compound No. 81. (3-phenoxy-phenyl)-(2-phenyl-quinazolin-4-yl) -amine
화합물번호 82. (4-페녹시-페닐)-(2-페닐-퀴나졸린-4-일)-아민Compound number 82. (4-Penoxy-phenyl)-(2-phenyl-quinazolin-4-yl) -amine
화합물번호 83. (3-브로모-페닐)-(2-페닐-퀴나졸린-4-일)-아민Compound number 83. (3-Bromo-phenyl)-(2-phenyl-quinazolin-4-yl) -amine
화합물번호 84. 2-메톡시-5-(2-페닐-퀴나졸린-4-일아미노)페놀Compound number 84. 2-methoxy-5- (2-phenyl-quinazolin-4-ylamino) phenol
1H NMR(DMSO, 300 MHz) δ 11.29(br s, 1H), 9.45(br s, 1H), 8.82(d, J=8.2 Hz, 1H), 8.36(m, 2H), 8.25(d, J=8.1 Hz, 1H), 8.06(t, J=7.4 Hz, 1H), 7.79(t, J=7.4 Hz, 1H), 7.64(m, 3H), 7.33(s, 1H), 7.25(d, J=8.7 Hz, 1H), 7.05(d, J=8.7 Hz, 1H), 3.83(s, 3H) 1 H NMR (DMSO, 300 MHz) δ 11.29 (br s, 1H), 9.45 (br s, 1H), 8.82 (d, J = 8.2 Hz, 1H), 8.36 (m, 2H), 8.25 (d, J = 8.1 Hz, 1H), 8.06 (t, J = 7.4 Hz, 1H), 7.79 (t, J = 7.4 Hz, 1H), 7.64 (m, 3H), 7.33 (s, 1H), 7.25 (d, J = 8.7 Hz, 1H), 7.05 (d, J = 8.7 Hz, 1H), 3.83 (s, 3H)
화합물번호 85. 5-(2-페닐-퀴나졸린-4-일아미노)-펜탄-1-올Compound number 85. 5- (2-phenyl-quinazolin-4-ylamino) -pentan-1-ol
화합물번호 86. 벤질-(2-페닐-퀴나졸린-4-일)-아민Compound number 86. Benzyl- (2-phenyl-quinazolin-4-yl) -amine
화합물번호 87. (1-페닐-에틸)-(2-페닐-퀴나졸린-4-일)-아민Compound number 87. (1-phenyl-ethyl)-(2-phenyl-quinazolin-4-yl) -amine
화합물번호 88. (4-클로로-벤질)-(2-페닐-퀴나졸린-4-일)-아민Compound No. 88. (4-Chloro-benzyl)-(2-phenyl-quinazolin-4-yl) -amine
화합물번호 89. (3,4-디클로로-벤질)-(2-페닐-퀴나졸린-4-일)-아민Compound number 89. (3,4-Dichloro-benzyl)-(2-phenyl-quinazolin-4-yl) -amine
화합물번호 90. (3-메톡시-벤질)-(2-페닐-퀴나졸린-4-일)-아민Compound 90. (3-methoxy-benzyl)-(2-phenyl-quinazolin-4-yl) -amine
화합물번호 91. (2-메톡시-벤질)-(2-페닐-퀴나졸린-4-일)-아민Compound number 91. (2-methoxy-benzyl)-(2-phenyl-quinazolin-4-yl) -amine
화합물번호 92. (3,5-디메톡시-벤질)-(2-페닐-퀴나졸린-4-일)-아민Compound 92. (3,5-Dimethoxy-benzyl)-(2-phenyl-quinazolin-4-yl) -amine
화합물번호 93. (2,3-디메톡시-벤질)-(2-페닐-퀴나졸린-4-일)-아민Compound 93. (2,3-Dimethoxy-benzyl)-(2-phenyl-quinazolin-4-yl) -amine
화합물번호 94. (2-플루오로-벤질)-(2-페닐-퀴나졸린-4-일)-아민Compound 94. (2-Fluoro-benzyl)-(2-phenyl-quinazolin-4-yl) -amine
화합물번호 95. 싸이클로펜틸-(2-페닐-퀴나졸린-4-일)-아민Compound number 95. Cyclopentyl- (2-phenyl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 8.61(m, 2H), 7.93(d, J=8.1 Hz, 1H), 7.72(m, 2H), 7.50(m, 4H), 5.67(d, J=6.3 Hz, 1H), 4.80(q, J=13.5 Hz, 1H), 2.31(m, 2H), 1.80(m, 4H), 1.65(m, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.61 (m, 2H), 7.93 (d, J = 8.1 Hz, 1H), 7.72 (m, 2H), 7.50 (m, 4H), 5.67 (d, J = 6.3 Hz, 1H), 4.80 (q, J = 13.5 Hz, 1H), 2.31 (m, 2H), 1.80 (m, 4H), 1.65 (m, 2H)
화합물번호 96. sec-부틸-(2-페닐-퀴나졸린-4-일)-아민Compound No. 96. sec- butyl- (2-phenyl-quinazolin-4-yl) -amine
화합물번호 97. 알릴-(2-페닐-퀴나졸린-4-일)-아민Compound number 97. Allyl- (2-phenyl-quinazolin-4-yl) -amine
화합물번호 98. (2-페닐-퀴나졸린-4-일)-(2-트리플루오로메틸-벤질)-아민Compound 98. (2-phenyl-quinazolin-4-yl)-(2-trifluoromethyl-benzyl) -amine
화합물번호 99. 헥사데실-(2-페닐-퀴나졸린-4-일)-아민Compound No. 99. Hexadecyl- (2-phenyl-quinazolin-4-yl) -amine
화합물번호 100. (2-페닐-퀴나졸린-4-일)-(2-피롤리딘-1-일-에틸)-아민Compound No. 100. (2-phenyl-quinazolin-4-yl)-(2-pyrrolidin-1-yl-ethyl) -amine
화합물번호 101. (2-페닐-퀴나졸린-4-일)-(2-피페리딘-1-일-에틸)-아민
화합물번호 102. (2-페닐-퀴나졸린-4-일)-(2-피리딘-2-일-에틸)-아민Compound number 102. (2-phenyl-quinazolin-4-yl)-(2-pyridin-2-yl-ethyl) -amine
화합물번호 103. [2-(3-플루오로-페닐)-에틸]-(2-페닐-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 8.59(dd, J 1 =7.8 Hz, J 2 =1.8 Hz, 2H), 7.93(d, J=8.1 Hz, 1H), 7.72(t, J=7.5 Hz, 1H), 7.47(m, 7H), 6.99(m, 3H), 5.76(br s, 1H), 4.06(m, 2H), 3.12(t, J=7.2 Hz, 2H) 1 H NMR (
화합물번호 104. (1-메톡시메틸-프로필)-(2-페닐-퀴나졸린-4-일)-아민Compound number 104. (1-methoxymethyl-propyl)-(2-phenyl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 8.56(t, J=3.8 Hz, 2H), 7.96(d J=8.3 Hz, 1H), 7.72(m, 2H), 7.49-7.39(m, 5H), 6.06(d J=7.2 Hz, 1H), 4.72(t J=3.8 Hz, 1H), 3.65(m, 2H), 3.43(s, 1H), 1.84(m, 2H), 1.06(t, J=7.4 Hz, 3H) 1 H NMR (
화합물번호 105. (1-벤질-피페리딘-4-일)-(2-페닐-퀴나졸린-4-일)-아민Compound number 105. (1-benzyl-piperidin-4-yl)-(2-phenyl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 8.54(t J=6.7 Hz, 2H), 7.92(d, J=8.3 Hz, 1H), 7.69(m, 2H), 7.50-2.27(m, 8H), 5.59(d J=7.1 Hz, 1H), 4.46(m, 1H), 3.61(s, 2H), 2.95(m, 2H), 2.68(s, 1H), 2.30(m, 4H), 1.70(m, 2H) 1 H NMR (
화합물번호 106.(2-몰포린-4-일-에틸)-(2-페닐-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 8.56(t J=6.2 Hz, 2H), 7.92(d, J=8.5 Hz, 2H), 7.71(m, 2H), 7.49-7.26(m, 4H), 6.56 (s, 1H), 3.86-3.74(m. 6H), 2.73(t, J=5.9 Hz 2H), 3.76(m, 4H) 1 H NMR (
화합물번호 107. [2-(3,4-디메톡시-페닐)-에틸]-(2-페닐-퀴나졸린-4-일)-아민Compound number 107. [2- (3,4-Dimethoxy-phenyl) -ethyl]-(2-phenyl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 8.60(t J=5.2 Hz, 2H), 7.93(d J=8.3 Hz, 1H), 7.69(t J=7.5 Hz, 1H), 7.57(t J=8.1 Hz, 1H), 7.50(m, 3H), 7.36(t J=3.6 Hz, 1H), 6.84(m, 3H), 5.96(s, 1H), 4.12(m, 2H), 3.87(s, 3H), 3.81(s, 3H), 3.03(t, J=6.7 Hz, 2H) 1 H NMR (
화합물번호 108. (2,4-디클로로-벤질)-(2-페닐-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 8.53(m, 2H), 7.93(d, J=8.1 Hz, 1H), 7.74(t, J=7.7Hz, 2H), 7.47(m, 6H), 7.17(dd, J 1 =8.4 Hz, J 2 =2.0Hz, 1H), 6.17(br, 1H), 5.06(d, J=6.0 Hz, 2H) 1 H NMR (
화합물번호 109. (2-클로로-벤질)-(2-페닐-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 8.56(t, J=3.3 Hz, 2H), 7.95(d J=8.6 Hz, 1H), 7.71(m, 2H), 7.55-7.37(m, 6H), 7.21(t, J=3.6 Hz, 2H), 6.31(s, 1H), 5.09(d, J=5.8 Hz, 2H) 1 H NMR (
화합물번호 110. 싸이클로프로필-(2-페닐-퀴나졸린-4-일)-아민Compound No. 110. Cyclopropyl- (2-phenyl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 8.63(d, J=7.3 Hz, 2H), 7.93(d, J=8.3 Hz, 2H), 7.70(m, 2H), 7.49(m, 3H), 7.37(t, J=7.5 Hz, 1H), 6.03(s, 1H), 3.17(m, 1H), 0.97(m, 2H), 0.73(m, 2H) 1 H NMR (
화합물번호 111. (2-페닐-퀴나졸린-4-일)-피리딘-3-일메틸-아민
1H NMR(CDCl3, 300 MHz) δ 8.73(m, 1H), 8.51(m, 3H), 8.04(d J=8.2 Hz, 1H,), 7.94(d, J=8.2 Hz, 1H), 7.85(d, J=7.1 Hz, 1H), 7.67(t, J=7.7 Hz, 1H), 7.47(m, 3H), 7.37(m, 1H), 7.26(m, 2H), 5.03(d, J=5.1 Hz, 2H) 1 H NMR (
화합물번호 112. 2-(2-페닐-퀴나졸린-4-일아미노)-프로판-1-올
1H NMR(CDCl3, 300 MHz) δ 8.49(m, 2H), 7.93(t, J=7.8 Hz, 2H), 7.58(m, 5H), 7.34(t, J=7.6 Hz, 1H), 7.71(t, J=7.7 Hz, 1H), 3.91(m, 2H), 1.45(m, 4H) 1 H NMR (
화합물번호 113. 2-메톡시-4-[(2-페닐-퀴나졸린-4-일아미노)-메틸]-페놀
1H NMR(MeOD, 300 MHz) δ 8.35(d, J=2.2 Hz, 2H), 8.02(m, 1H), 7.80(m,2H), 7.45(m, 4H), 7.07(s, 1H), 6.89(t, J=8.0 Hz, 1H), 6.75(t, J=8.0 Hz, 1H), 4.85(s, 2H), 3.72(s, 3H) 1 H NMR (
화합물번호 114. (2-플루오로-에틸)-(2-페닐-퀴나졸린-4-일)-아민Compound number 114. (2-Fluoro-ethyl)-(2-phenyl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 8.53(m, 2H), 7.93(d, J=8.4 Hz, 1H), 7.74(t, J=7.5Hz, 2H), 7.50(m, 4H), 6.03(br s, 1H), 4.86(t, J=4.8Hz, 1H), 4.70(t, J=5.1Hz, 1H), 4.20(q, J=5.1Hz, 1H), 4.10(q, J=5.1Hz, 1H) 1 H NMR (
화합물번호 115. (2,3-디클로로-벤질)-(2-페닐-퀴나졸린-4-일)-아민Compound number 115. (2,3-Dichloro-benzyl)-(2-phenyl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 8.52(t, J=3.7 Hz, 2H), 7.92(d, J=8.5 Hz, 1H), 7.72(t, J=6.6 Hz, 2H), 7.42(m, 6H), 7.08(t, J=7.8 Hz, 1H), 6.24(s, 1H), 5.09(d, J=5.9 Hz, 2H) 1 H NMR (
화합물번호 116. (3-니트로-벤질)-(2-페닐-퀴나졸린-4-일)-아민Compound No. 116. (3-Nitro-benzyl)-(2-phenyl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 8.46(m, 2H), 8.19(m, 1H), 8.03(d, J=7.5 Hz, 1H), 7.91(d, J=7.9 Hz, 1H), 7.82(d, J=7.7 Hz, 1H), 7.70(d, J=6.0 Hz, 1H), 7.42(m, 5H), 6.54(s, 1H), 4.96(d, J=4.4 Hz, 2H) 1 H NMR (
화합물번호 117. (1-에틸-피롤리딘-2-일메틸)-(2-페닐-퀴나졸린-4-일)-아민Compound 117. (1-Ethyl-pyrrolidin-2-ylmethyl)-(2-phenyl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 8.47(d, J=5.6 Hz, 2H), 8.10(d, J=8.1 Hz, 1H), 7.94(s, 1H), 7.84(d, J=8.3 Hz, 1H), 7.68(t, J=7.6 Hz, 1H), 7.42(m, 4H), 5.97(s, 1H), 4.08(m, 2H), 3.58(m, 2H), 3.01(t, J=4.7 Hz, 1H), 2.67(m, 2H), 2.09-1.91(m, 4H), 1.19(m, 3H) 1 H NMR (
화합물번호 118. (3,4-디메톡시-벤질)-(2-페닐-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 8.59(t, J=3.8 Hz, 2H), 7.93(d, J=8.1 Hz, 1H), 7.71(m, 2H), 7.45(m, 3H), 7.36(t, J=7.6 Hz, 1H), 7.04(s, 1H), 6.97(d, J=8.4 Hz, 1H), 6.80(t, J=4.1 Hz, 1H), 6.21(s, 1H), 4.90(d, J=5.2 Hz, 2H), 3.87(s, 3H), 3.78(s, 3H) 1 H NMR (
화합물번호 119. (2-페닐-퀴나졸린-4-일)-(2-p-톨릴-에틸)-아민
1H NMR(CDCl3, 300 MHz) δ 8.59(t, J=3.3 Hz, 2H), 7.93(d, J=8.4 Hz, 1H), 7.69(t, J=7.6 Hz, 1H), 7.55(m, 4H), 7.36(t, J=7.5 Hz, 1H), 7.16(m, 4H), 5.91(s, 1H), 4.01(m, 2H), 3.05(t, J=6.9 Hz, 2H), 2.43(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.59 (t, J = 3.3 Hz, 2H), 7.93 (d, J = 8.4 Hz, 1H), 7.69 (t, J = 7.6 Hz, 1H), 7.55 (m , 4H), 7.36 (t, J = 7.5 Hz, 1H), 7.16 (m, 4H), 5.91 (s, 1H), 4.01 (m, 2H), 3.05 (t, J = 6.9 Hz, 2H), 2.43 (s, 3H)
화합물번호 120. [2-(3-메톡시-페닐)-에틸]-(2-페닐-퀴나졸린-4-일)-아민Compound number 120. [2- (3-Methoxy-phenyl) -ethyl]-(2-phenyl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 8.61(t, J=3.8 Hz, 2H), 7.93(d, J=8.3 H, 1Hz), 7.70(m, 1H), 7.49(m, 4H), 7.30(m, 2H), 6.85(m, 3H), 5.90(s, 1H), 4.02(m, 2H), 3.76(s, 3H), 3.05(t, J=6.9 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.61 (t, J = 3.8 Hz, 2H), 7.93 (d, J = 8.3 H, 1 Hz), 7.70 (m, 1H), 7.49 (m, 4H), 7.30 (m, 2H), 6.85 (m, 3H), 5.90 (s, 1H), 4.02 (m, 2H), 3.76 (s, 3H), 3.05 (t, J = 6.9 Hz, 2H)
화합물번호 121. (1-에틸-프로필)-(2-페닐-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 8.55(t, J=3.5 Hz, 2H), 7.95(d, J=8.2 Hz, 1H), 7.69(m, 2H), 7.46(m, 4H), 5.59(s, 1H), 4.53(d, J=6.7 Hz, 1H), 1.85-1.62(m, 4H), 1.00(m, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.55 (t, J = 3.5 Hz, 2H), 7.95 (d, J = 8.2 Hz, 1H), 7.69 (m, 2H), 7.46 (m, 4H), 5.59 (s, 1H), 4.53 (d, J = 6.7 Hz, 1H), 1.85-1.62 (m, 4H), 1.00 (m, 6H)
화합물번호 122. [2-(2,5-디메톡시-페닐)-에틸]-(2-페닐-퀴나졸린-4-일)-아민Compound No. 122. [2- (2,5-Dimethoxy-phenyl) -ethyl]-(2-phenyl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 8.59(t, J=3.2 Hz, 2H), 7.91(d, J=8.4 Hz, 1H), 7.67(t, J=7.6 Hz, 1H), 7.59(d, J=8.1 Hz, 1H), 7.47(m, 3H), 7.36(t, J=7.5 Hz, 1H), 6.80(m, 3H), 6.39(s, 1H), 3.98(m, 2H), 3.86(s, 3H), 3.71(s, 3H), 3.08(t, J=6.5 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.59 (t, J = 3.2 Hz, 2H), 7.91 (d, J = 8.4 Hz, 1H), 7.67 (t, J = 7.6 Hz, 1H), 7.59 (d , J = 8.1 Hz, 1H), 7.47 (m, 3H), 7.36 (t, J = 7.5 Hz, 1H), 6.80 (m, 3H), 6.39 (s, 1H), 3.98 (m, 2H), 3.86 (s, 3H), 3.71 (s, 3H), 3.08 (t, J = 6.5 Hz, 2H)
화합물번호 123. [2-(4-클로로-페닐)-에틸]-(2-페닐-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 8.57(t, J=3.6 Hz, 2H), 7.91(m, 1H), 7.69(m, 1H), 7.53(m, 4H), 7.38(d, J=6.9 Hz, 1H), 7.25(m, 2H), 7.18(m, 2H), 5.76(s, 1H), 4.00(m, 2H), 3.05(m, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.57 (t, J = 3.6 Hz, 2H), 7.91 (m, 1H), 7.69 (m, 1H), 7.53 (m, 4H), 7.38 (d, J = 6.9 Hz, 1H), 7.25 (m, 2H), 7.18 (m, 2H), 5.76 (s, 1H), 4.00 (m, 2H), 3.05 (m, 2H)
화합물번호 124. [2-(4-메톡시-페닐)-에틸]-(2-페닐-퀴나졸린-4-일)-아민Compound 124. [2- (4-methoxy-phenyl) -ethyl]-(2-phenyl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 8.60(t, J=3.2 Hz, 2H), 7.93(d, J=8.3 Hz, 1H), 7.69(t, J=7.6 Hz, 1H), 7.50(m, 4H), 7.35(t, J=7.5 Hz, 1H), 7.20(d, J=8.3 Hz, 2H), 6.87(d, J=8.3 Hz, 2H), 5.85(s, 1H), 4.00(m, 2H), 3.79(s, 3H), 3.02(t, J=6.9 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.60 (t, J = 3.2 Hz, 2H), 7.93 (d, J = 8.3 Hz, 1H), 7.69 (t, J = 7.6 Hz, 1H), 7.50 (m , 4H), 7.35 (t, J = 7.5 Hz, 1H), 7.20 (d, J = 8.3 Hz, 2H), 6.87 (d, J = 8.3 Hz, 2H), 5.85 (s, 1H), 4.00 (m , 2H), 3.79 (s, 3H), 3.02 (t, J = 6.9 Hz, 2H)
화합물번호 125. (1,3-디메틸-부틸)-(2-페닐-퀴나졸린-4-일)-아민Compound No. 125. (1,3-Dimethyl-butyl)-(2-phenyl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 8.58(t, J=3.8 Hz, 2H), 7.93(d, J=8.5 Hz, 1H), 7.69(m, 2H), 7.48-7.24(m, 4H), 5.52(d, J=6.9 Hz, 1H), 4.80(t, J=6.86 Hz, 1H), 1.78-1.63(m, 2H), 1.46(t, J=6.7 Hz, 1H), 1.39(m, 3H), 0.97(m, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.58 (t, J = 3.8 Hz, 2H), 7.93 (d, J = 8.5 Hz, 1H), 7.69 (m, 2H), 7.48-7.24 (m, 4H) , 5.52 (d, J = 6.9 Hz, 1H), 4.80 (t, J = 6.86 Hz, 1H), 1.78-1.63 (m, 2H), 1.46 (t, J = 6.7 Hz, 1H), 1.39 (m, 3H), 0.97 (m, 6H)
화합물번호 126. [2-(3-클로로-페닐)-에틸]-(2-페닐-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 8.59(t, J=3.3 Hz, 2H), 7.93(d, J=8.3 Hz, 1H), 7.69(m, 1H), 7.58(m, 1H), 7.49(m, 3H), 7.38(m, 1H), 7.24(m, 1H), 7.12(m, 2H), 7.11(m, 1H), 5.92(s, 1H), 3.95(m, 2H), 3.02(t, J= 7.1 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.59 (t, J = 3.3 Hz, 2H), 7.93 (d, J = 8.3 Hz, 1H), 7.69 (m, 1H), 7.58 (m, 1H), 7.49 (m, 3H), 7.38 (m, 1H), 7.24 (m, 1H), 7.12 (m, 2H), 7.11 (m, 1H), 5.92 (s, 1H), 3.95 (m, 2H), 3.02 ( t, J = 7.1 Hz, 2H)
화합물번호 127. [2-(2,4-디클로로-페닐)-에틸]-(2-페닐-퀴나졸린-4-일)-아민Compound 127. [2- (2,4-Dichloro-phenyl) -ethyl]-(2-phenyl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 8.57(t, J=3.6 Hz, 2H), 7.92(d, J=8.2 Hz, 1H), 7.70(m, 1H), 7.59(d, J=8.1 Hz, 1H), 7.47(m, 2H), 7.37(m, 2H), 7.18(m, 2H), 5.81(s, 1H), 4.04(m, 2H), 3.23(, J=6.8 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.57 (t, J = 3.6 Hz, 2H), 7.92 (d, J = 8.2 Hz, 1H), 7.70 (m, 1H), 7.59 (d, J = 8.1 Hz , 1H), 7.47 (m, 2H), 7.37 (m, 2H), 7.18 (m, 2H), 5.81 (s, 1H), 4.04 (m, 2H), 3.23 (, J = 6.8 Hz, 2H)
화합물번호 128. [2-(3,4-디플루오로-페닐)-에틸]-(2-페닐-퀴나졸린-4-일)-아민Compound No. 128. [2- (3,4-Difluoro-phenyl) -ethyl]-(2-phenyl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 8.50(t, J=4.0 Hz, 2H), 7.93(d, J=8.6 Hz, 1H), 7.72(m, 2H), 7.41(m, 4H), 7.22(t, J=8.8 Hz, 1H), 7.07(m, 2H), 6.11(s, 1H), 4.91(d, J=5.5 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.50 (t, J = 4.0 Hz, 2H), 7.93 (d, J = 8.6 Hz, 1H), 7.72 (m, 2H), 7.41 (m, 4H), 7.22 (t, J = 8.8 Hz, 1H), 7.07 (m, 2H), 6.11 (s, 1H), 4.91 (d, J = 5.5 Hz, 2H)
화합물번호 129. (2-페닐-퀴나졸린-4-일)-(3,4,5-트리메톡시-벤질)-아민Compound number 129. (2-phenyl-quinazolin-4-yl)-(3,4,5-trimethoxy-benzyl) -amine
1H NMR(CDCl3, 300 MHz) δ 8.58(t, J=3.5 Hz, 2H), 7.96(d, J=8.4 Hz, 2H), 7.78(d, J=8.3 Hz, 1H), 7.67(t, J=7.6 Hz, 1H), 7.47(m, 3H), 7.36(t, J=7.6 Hz, 1H), 6.73(s, 2H), 6.43(s, 1H), 4.91(d, J=5.2 Hz, 2H), 3.86(d, J=6.6 Hz, 2H), 3.82(m, 9H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.58 (t, J = 3.5 Hz, 2H), 7.96 (d, J = 8.4 Hz, 2H), 7.78 (d, J = 8.3 Hz, 1H), 7.67 (t , J = 7.6 Hz, 1H), 7.47 (m, 3H), 7.36 (t, J = 7.6 Hz, 1H), 6.73 (s, 2H), 6.43 (s, 1H), 4.91 (d, J = 5.2 Hz , 2H), 3.86 (d, J = 6.6 Hz, 2H), 3.82 (m, 9H)
화합물번호 130. (3-메틸-부틸)-(2-페닐-퀴나졸린-4-일)-아민Compound No. 130. (3-Methyl-butyl)-(2-phenyl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 8.57(t, J=3.4 Hz, 2H), 7.92(d, J=8.3 Hz, 1H), 7.68(m, 2H), 7.46(m, 3H), 7.37(t, J=7.5 Hz, 1H), 5.76(s, 1H), 3.80(m, 2H), 1.76(m, 1H), 1.65(m, 2H), 0.99(m, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.57 (t, J = 3.4 Hz, 2H), 7.92 (d, J = 8.3 Hz, 1H), 7.68 (m, 2H), 7.46 (m, 3H), 7.37 (t, J = 7.5 Hz, 1H), 5.76 (s, 1H), 3.80 (m, 2H), 1.76 (m, 1H), 1.65 (m, 2H), 0.99 (m, 6H)
화합물번호 131. (2-싸이클로hex-1-enyl-에틸)-(2-페닐-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 8.57(t, J=3.4 Hz, 2H), 7.92(d, J=8.3 Hz, 1H), 7.69(t, J=7.7 Hz, 1H), 7.61(d, J=8.1 Hz, 1H), 7.49(m, 3H), 7.38(t, J=7.4 Hz, 1H), 5.82(s, 1H), 5.61(1H), 3.83(m, 2H), 2.39(t, J=6.6 Hz, 2H), 2.03(m, 4H), 1.62(m, 4H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.57 (t, J = 3.4 Hz, 2H), 7.92 (d, J = 8.3 Hz, 1H), 7.69 (t, J = 7.7 Hz, 1H), 7.61 (d , J = 8.1 Hz, 1H), 7.49 (m, 3H), 7.38 (t, J = 7.4 Hz, 1H), 5.82 (s, 1H), 5.61 (1H), 3.83 (m, 2H), 2.39 (t , J = 6.6 Hz, 2H), 2.03 (m, 4H), 1.62 (m, 4H)
화합물번호 132. 싸이클로헥실메틸-(2-페닐-퀴나졸린-4-일)-아민Compound No. 132. Cyclohexylmethyl- (2-phenyl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 8.56(t, J=3.1 Hz, 2H), 7.92(d, J=8.7 Hz, 1H), 7.69(t, J=6.1 Hz, 2H), 7.49(m, 4H), 5.85(s, 1H), 3.64(t, J=6.1 Hz, 2H), 1.88-1.70(m, 6H), 1.29-1.05(m, 5H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.56 (t, J = 3.1 Hz, 2H), 7.92 (d, J = 8.7 Hz, 1H), 7.69 (t, J = 6.1 Hz, 2H), 7.49 (m , 4H), 5.85 (s, 1H), 3.64 (t, J = 6.1 Hz, 2H), 1.88-1.70 (m, 6H), 1.29-1.05 (m, 5H)
화합물번호 133. (2,2-디페닐-에틸)-(2-페닐-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 8.63(t, J=3.8 Hz, 2H), 7.93(d, J=8.4 Hz, 1H), 7.67(t, J=7.5 Hz, 1H), 7.51(m, 3H), 7.29(m, 12H), 5.73(s, 1H), 4.56(t, J=7.7 Hz, 1H), 4.42(t, J=6.5 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.63 (t, J = 3.8 Hz, 2H), 7.93 (d, J = 8.4 Hz, 1H), 7.67 (t, J = 7.5 Hz, 1H), 7.51 (m , 3H), 7.29 (m, 12H), 5.73 (s, 1H), 4.56 (t, J = 7.7 Hz, 1H), 4.42 (t, J = 6.5 Hz, 2H)
화합물번호 134. (2,4-디플루오로-벤질)-(2-페닐-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 8.55(t, J=3.9 Hz, 2H), 7.93(d, J=8.4 Hz, 1H), 7.71(m, 2H), 7.49(m, 5H), 6.80(m, 2H), 6.24(s, 1H), 5.00(d, J=5.6 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.55 (t, J = 3.9 Hz, 2H), 7.93 (d, J = 8.4 Hz, 1H), 7.71 (m, 2H), 7.49 (m, 5H), 6.80 (m, 2H), 6.24 (s, 1H), 5.00 (d, J = 5.6 Hz, 2H)
화합물번호 135. (2,5-디플루오로-벤질)-(2-페닐-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 8.52(t, J=3.6 Hz, 2H), 7.93(d, J=8.4 Hz, 1H), 7.72(t, J=7.9 Hz, 2H), 7.41(m, 4H), 7.18(m, 1H), 7.00(m, 1H), 6.92(t, J=3.9 Hz, 1H), 6.20(s, 1H), 5.00(d, J=5.6 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.52 (t, J = 3.6 Hz, 2H), 7.93 (d, J = 8.4 Hz, 1H), 7.72 (t, J = 7.9 Hz, 2H), 7.41 (m , 4H), 7.18 (m, 1H), 7.00 (m, 1H), 6.92 (t, J = 3.9 Hz, 1H), 6.20 (s, 1H), 5.00 (d, J = 5.6 Hz, 2H)
화합물번호 136. (3,3-디페닐-프로필)-(2-페닐-퀴나졸린-4-일)-아민Compound 136. (3,3-Diphenyl-propyl)-(2-phenyl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 8.51(m, 2H), 7.92(d, J=8.4 Hz, 1H), 7.67(m, 1H), 7.43(m, 3H), 7.34-7.20(m, 12H), 5.73(s, 1H), 4.09(t, J=7.7 Hz, 1H), 2.53(m, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.51 (m, 2H), 7.92 (d, J = 8.4 Hz, 1H), 7.67 (m, 1H), 7.43 (m, 3H), 7.34-7.20 (m, 12H), 5.73 (s, 1H), 4.09 (t, J = 7.7 Hz, 1H), 2.53 (m, 2H)
화합물번호 137. [2-(4-브로모-페닐)-에틸]-(2-페닐-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 8.57(t, 2.8 Hz, 2H), 7.92(d, J=8.4 Hz, 1H), 7.71(m, 1H), 7.50(m, 7H), 7.20(m, 2H), 5.75(s, 1H), 3.98(m, 2H), 3.04(t, J=6.7 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.57 (t, 2.8 Hz, 2H), 7.92 (d, J = 8.4 Hz, 1H), 7.71 (m, 1H), 7.50 (m, 7H), 7.20 (m , 2H), 5.75 (s, 1H), 3.98 (m, 2H), 3.04 (t, J = 6.7 Hz, 2H)
화합물번호 138. 부틸-메틸-(2-페닐-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 8.55(dd, J 1 =7.5 Hz, J 2 =1.5 Hz, 2H), 7.99-7.91(m, 2H), 7.67(m, 1H), 7.46(m, 3H), 7.34(m, 1H), 3.80(t, J=7.8 Hz, 2H), 3.41(s, 3H), 1.86(m, 2H), 1.43(m, 2H), 1.00(t, 3H, J=7.5 Hz) 1 H NMR (CDCl 3 , 300 MHz) δ 8.55 (dd, J 1 = 7.5 Hz, J 2 = 1.5 Hz, 2H), 7.99-7.91 (m, 2H), 7.67 (m, 1H), 7.46 (m, 3H), 7.34 (m, 1H), 3.80 (t, J = 7.8 Hz, 2H), 3.41 (s, 3H), 1.86 (m, 2H), 1.43 (m, 2H), 1.00 (t, 3H, J) = 7.5 Hz)
화합물번호 139. (2-페닐-퀴나졸린-4-일)-(4-트리플루오로메틸-벤질)-아민
1H NMR(CDCl3, 300 MHz) δ 8.50(m, 2H), 7.96(d, J=8.1 Hz, 1H), 7.75(m, 2H), 7.59(m, 4H), 7.46(m, 4H), 6.06(br, 1H), 5.07(d, J=6.0 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.50 (m, 2H), 7.96 (d, J = 8.1 Hz, 1H), 7.75 (m, 2H), 7.59 (m, 4H), 7.46 (m, 4H) , 6.06 (br, 1 H), 5.07 (d, J = 6.0 Hz, 2 H)
화합물번호 140. [2-(2-플루오로-페닐)-에틸]-(2-페닐-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 8.60(t, J=3.5 Hz, 2H), 7.93(d, J=8.3 Hz, 1H), 7.69(, J=7.6 Hzt, 1H), 7.60(d, J=8.1 Hz, 1H), 7.49(m, 3H), 7.36(t, J=7.5 Hz, 1H), 7.24(t, J=7.2 Hz, 2H), 7.06(t, J=9.0 Hz, 2H), 4.00(m, 2H), 3.14(t, J=6.7 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.60 (t, J = 3.5 Hz, 2H), 7.93 (d, J = 8.3 Hz, 1H), 7.69 (, J = 7.6 Hzt, 1H), 7.60 (d, J = 8.1 Hz, 1H), 7.49 (m, 3H), 7.36 (t, J = 7.5 Hz, 1H), 7.24 (t, J = 7.2 Hz, 2H), 7.06 (t, J = 9.0 Hz, 2H) , 4.00 (m, 2H), 3.14 (t, J = 6.7 Hz, 2H)
화합물번호 141. (2-페닐-퀴나졸린-4-일)-피리딘-4-일메틸-아민Compound number 141. (2-phenyl-quinazolin-4-yl) -pyridin-4-ylmethyl-amine
1H NMR(CDCl3, 300 MHz) δ 8.51(m, 2H), 8.42(t, J=3.4 Hz, 2H), 8.00(d, J=8.4 Hz, 1H), 7.89(d, J=8.1 Hz, 1H), 7.71(t, J=7.6 Hz, 1H), 7.43(m, 4H), 7.31(m, 2H), 4.99(d, J=5.5 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.51 (m, 2H), 8.42 (t, J = 3.4 Hz, 2H), 8.00 (d, J = 8.4 Hz, 1H), 7.89 (d, J = 8.1 Hz , 1H), 7.71 (t, J = 7.6 Hz, 1H), 7.43 (m, 4H), 7.31 (m, 2H), 4.99 (d, J = 5.5 Hz, 2H)
화합물번호 142. (2-페닐-퀴나졸린-4-일)-피리딘-2-일메틸-아민
1H NMR(CDCl3, 300 MHz) δ 8.60(m, 2H), 7.91(m, 2H), 7.69(m, 3H), 7.43(m, 5H), 7.25(m, 1H), 5.00(d, J=4.3 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.60 (m, 2H), 7.91 (m, 2H), 7.69 (m, 3H), 7.43 (m, 5H), 7.25 (m, 1H), 5.00 (d, J = 4.3 Hz, 2H)
화합물번호 143. (2,3-디메틸-싸이클로헥실)-(2-페닐-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 8.53(t, J=3.5 Hz, 2H), 7.92 (d, J=8.3 Hz, 1H), 7.69(m, 2H), 7.41(m, 4H), 5.76(m, 1H), 4.56(m, 1H), 1.94-1.46(m, 7H), 1.00(m, 5H), 0.86(d, J=7.1 Hz, 1H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.53 (t, J = 3.5 Hz, 2H), 7.92 (d, J = 8.3 Hz, 1H), 7.69 (m, 2H), 7.41 (m, 4H), 5.76 (m, 1H), 4.56 (m, 1H), 1.94-1.46 (m, 7H), 1.00 (m, 5H), 0.86 (d, J = 7.1 Hz, 1H)
화합물번호 144. (2,4-디메톡시-벤질)-(2-페닐-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 8.60(m, 2H), 7.90(d, J=8.4 Hz, 1H), 7.72-7.63(m, 2H), 7.48(m, 3H), 7.38(m, 2H), 6.51(d, 1H, J=2.1 Hz), 6.45(dd, J 1 =8.1 Hz, J 2 =2.4 Hz, 1H), 6.16(br, 1H), 4.94(d, J=5.4 Hz, 2H), 3.90(s, 3H), 3.79(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.60 (m, 2H), 7.90 (d, J = 8.4 Hz, 1H), 7.72-7.63 (m, 2H), 7.48 (m, 3H), 7.38 (m, 2H), 6.51 (d, 1H, J = 2.1 Hz), 6.45 (dd, J 1 = 8.1 Hz, J 2 = 2.4 Hz, 1H), 6.16 (br, 1H), 4.94 (d, J = 5.4 Hz, 2H), 3.90 (s, 3H), 3.79 (s, 3H)
화합물번호 145. (3-클로로-벤질)-(2-페닐-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 8.51(m, 2H), 7.92(d, J=8.8 Hz, 1H), 7.71(m, 2H), 7.45(m, 5H), 7.27(m, 3H), 5.13(s, 1H), 4.92(d, J=5.5 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.51 (m, 2H), 7.92 (d, J = 8.8 Hz, 1H), 7.71 (m, 2H), 7.45 (m, 5H), 7.27 (m, 3H) , 5.13 (s, 1 H), 4.92 (d, J = 5.5 Hz, 2 H)
화합물번호 146. 1-페닐-2-(2-페닐-퀴나졸린-4-일아미노)-에탄올Compound No. 146. 1-phenyl-2- (2-phenyl-quinazolin-4-ylamino) -ethanol
1H NMR(DMSO-d6, 300 MHz) δ 8.49(m, 2H), 8.25(dH, J=8.3 Hz, 1), 7.74(m, 2H), 7.50-7.31(m, 7H), 7.23(t, J=7.1 Hz, 1H), 5.62(d, J=4.3 Hz, 1H), 5.05(m, 1H), 4.01-3.90(m, 2H), 3.57(m, 1H), 3.28(m, 2H) 1 H NMR (DMSO-d 6 , 300 MHz) δ 8.49 (m, 2H), 8.25 (dH, J = 8.3 Hz, 1), 7.74 (m, 2H), 7.50-7.31 (m, 7H), 7.23 ( t, J = 7.1 Hz, 1H), 5.62 (d, J = 4.3 Hz, 1H), 5.05 (m, 1H), 4.01-3.90 (m, 2H), 3.57 (m, 1H), 3.28 (m, 2H )
화합물번호 147. (2,5-디메톡시-벤질)-(2-페닐-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 8.60(dd, J 1 =8.1 Hz, J 2 =2.1 Hz, 2H), 7.91(d, J=8.4 Hz, 1H), 7.67(m, 2H), 7.52-7.36(m, 4H), 7.10(d, J=3.0 Hz, 1H), 6.85(d, J=9.0 Hz, 1H), 6.78(dd, J 1 =9.0 Hz, J 2 =3.0 Hz, 1H), 6.272(br, 1H), 4.99(d, J=6.0 Hz, 2H), 3.89(s, 3H), 3.71(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.60 (dd, J 1 = 8.1 Hz, J 2 = 2.1 Hz, 2H), 7.91 (d, J = 8.4 Hz, 1H), 7.67 (m, 2H), 7.52 -7.36 (m, 4H), 7.10 (d, J = 3.0 Hz, 1H), 6.85 (d, J = 9.0 Hz, 1H), 6.78 (dd, J 1 = 9.0 Hz, J 2 = 3.0 Hz, 1H) , 6.272 (br, 1H), 4.99 (d, J = 6.0 Hz, 2H), 3.89 (s, 3H), 3.71 (s, 3H)
화합물번호 148. (4-브로모-벤질)-(2-페닐-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 8.54(t, J=3.6 Hz, 2H), 7.92(d, J=8.3 Hz, 1H), 7.71(t, J=6.6 Hz, 1H), 7.44(m, 6H), 7.26(t, J=7.0 Hz, 2H), 6.09(s, 1H), 4.91(d, J=5.5 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.54 (t, J = 3.6 Hz, 2H), 7.92 (d, J = 8.3 Hz, 1H), 7.71 (t, J = 6.6 Hz, 1H), 7.44 (m , 6H), 7.26 (t, J = 7.0 Hz, 2H), 6.09 (s, 1H), 4.91 (d, J = 5.5 Hz, 2H)
화합물번호 149. [2-(3,4-디클로로-페닐)-에틸]-(2-페닐-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 8.57(m, 2H), 7.94(d, J=8.4 Hz, 1H), 7.74(m, 1H), 7.59(d, J=7.8 Hz, 1H), 7.55-7.37(m, 6H), 7.10(dd, J 1 =8.4 Hz, J 2 =1.8 Hz, 1H), 5.75(br, 1H), 4.03(q, J=7.2 Hz, 2H), 3.08(t, J=7.2 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.57 (m, 2H), 7.94 (d, J = 8.4 Hz, 1H), 7.74 (m, 1H), 7.59 (d, J = 7.8 Hz, 1H), 7.55 -7.37 (m, 6H), 7.10 (dd, J 1 = 8.4 Hz, J 2 = 1.8 Hz, 1H), 5.75 (br, 1H), 4.03 (q, J = 7.2 Hz, 2H), 3.08 (t, J = 7.2 Hz, 2H)
화합물번호 150. 1-[3-(2-페닐-퀴나졸린-4-일아미노)-프로필]-피롤리딘-2-온
1H NMR(CDCl3, 300 MHz) δ 8.55(m, 2H), 8.00(d, J=8.1 Hz, 1H), 7.89(d, J=8.6 Hz, 1H), 7.69(d, J=7.3 Hz, 1H), 7.59(s, 1H), 7.44(m, 4H), 3.76(m, 2H), 3.41(m, 4H), 2.45(t, J=8.1 Hz, 2H), 2.06(m, 2H), 1.87(m, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.55 (m, 2H), 8.00 (d, J = 8.1 Hz, 1H), 7.89 (d, J = 8.6 Hz, 1H), 7.69 (d, J = 7.3 Hz , 1H), 7.59 (s, 1H), 7.44 (m, 4H), 3.76 (m, 2H), 3.41 (m, 4H), 2.45 (t, J = 8.1 Hz, 2H), 2.06 (m, 2H) , 1.87 (m, 2 H)
화합물번호 151. [2-(2-클로로-페닐)-에틸]-(2-페닐-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 8.59(m, 2H), 7.92(d, J=8.4 Hz, 1H), 7.71(d, J=7.3 Hz, 1H), 7.63(d, J=8.1 Hz, 1H), 7.48(m, 3H), 7.37(t, J=7.2 Hz, 2H), 7.25(t, J=3.5 Hz, 1H), 7.17(t, J=4.5 Hz, 2H), 5.99(s, 1H), 4.05(m, 2H), 3.24(t, J=6.9 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.59 (m, 2H), 7.92 (d, J = 8.4 Hz, 1H), 7.71 (d, J = 7.3 Hz, 1H), 7.63 (d, J = 8.1 Hz , 1H), 7.48 (m, 3H), 7.37 (t, J = 7.2 Hz, 2H), 7.25 (t, J = 3.5 Hz, 1H), 7.17 (t, J = 4.5 Hz, 2H), 5.99 (s , 1H), 4.05 (m, 2H), 3.24 (t, J = 6.9 Hz, 2H)
화합물번호 152. 2-[2-(2-페닐-퀴나졸린-4-일아미노)-에틸]-페놀Compound 152. 2- [2- (2-phenyl-quinazolin-4-ylamino) -ethyl] -phenol
1H NMR(DMSO-d6, 300 MHz) δ 9.18(s, 1H), 8.46(m, 3H), 8.19(d, J=8.1 Hz, 1H), 7.73(m, 2H),7.47(m, 4H), 7.07(d, J=8.2 Hz, 2H), 6.66(d, J=8.2 Hz, 2H), 4.12(s, 1H), 3.77(m, 2H), 2,91(t, J=7.4 Hz, 2H) 1 H NMR (DMSO-d 6 , 300 MHz) δ 9.18 (s, 1H), 8.46 (m, 3H), 8.19 (d, J = 8.1 Hz, 1H), 7.73 (m, 2H), 7.47 (m, 4H), 7.07 (d, J = 8.2 Hz, 2H), 6.66 (d, J = 8.2 Hz, 2H), 4.12 (s, 1H), 3.77 (m, 2H), 2,91 (t, J = 7.4 Hz, 2H)
화합물번호 153. (3-브로모-벤질)-(2-페닐-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 8.52(m, 2H), 7.92(d, J=8.5 Hz, 1H), 7.71(t, J=3.1 Hz, 2H), 7.56(s, 1H), 7.45(m, 6H), 7.14(m, 1H), 6.13(s, 1H), 4.91(d, J=5.3 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.52 (m, 2H), 7.92 (d, J = 8.5 Hz, 1H), 7.71 (t, J = 3.1 Hz, 2H), 7.56 (s, 1H), 7.45 (m, 6H), 7.14 (m, 1H), 6.13 (s, 1H), 4.91 (d, J = 5.3 Hz, 2H)
화합물번호 154. (2,6-디메톡시-벤질)-(2-페닐-퀴나졸린-4-일)-아민Compound 154. (2,6-Dimethoxy-benzyl)-(2-phenyl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 8.70(m, 2H), 7.92(d, J=8.4 Hz, 1H), 7.84(m, 2H), 7.51(m, 3H), 7.46(m, 1H), 7.23(m, 1H), 6.58(d, J=8.4 Hz, 2H), 6.38(s, 1H), 5.13(d, J=5.3 Hz, 2H), 3.88(s, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.70 (m, 2H), 7.92 (d, J = 8.4 Hz, 1H), 7.84 (m, 2H), 7.51 (m, 3H), 7.46 (m, 1H) , 7.23 (m, 1H), 6.58 (d, J = 8.4 Hz, 2H), 6.38 (s, 1H), 5.13 (d, J = 5.3 Hz, 2H), 3.88 (s, 6H)
화합물번호 155. (2-브로모-벤질)-(2-페닐-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 8.56(t, J=3.8 Hz, 2H), 7.92(d, J=8.4 Hz, 1H), 7.72(m, 2H), 7.50(m, 5H), 7.46(m, 1H), 7.24(m, 1H), 6.34(s, 1H), 5.06(d, J=5.8 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.56 (t, J = 3.8 Hz, 2H), 7.92 (d, J = 8.4 Hz, 1H), 7.72 (m, 2H), 7.50 (m, 5H), 7.46 (m, 1H), 7.24 (m, 1H), 6.34 (s, 1H), 5.06 (d, J = 5.8 Hz, 2H)
화합물번호 156. (3-몰포린-4-일-프로필)-(2-페닐-퀴나졸린-4-일)-아민Compound 156. (3-Morpholin-4-yl-propyl)-(2-phenyl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 8.55(m, 2H), 7.89(d, J=8.3 Hz, 1H), 7.78(d, J=8.1 Hz, 1H), 7.68(m, 3H), 7.45(m, 3H), 3.81(m, 6H), 2.57(m, 7H), 1.89(m, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.55 (m, 2H), 7.89 (d, J = 8.3 Hz, 1H), 7.78 (d, J = 8.1 Hz, 1H), 7.68 (m, 3H), 7.45 (m, 3H), 3.81 (m, 6H), 2.57 (m, 7H), 1.89 (m, 2H)
화합물번호 157. 2-[부틸-(2-페닐-퀴나졸린-4-일)-아미노]-에탄올Compound 157. 2- [butyl- (2-phenyl-quinazolin-4-yl) -amino] -ethanol
1H NMR(CDCl3, 300 MHz) δ 8.53(m, 2H), 8.18-7.91(m,2H), 7.69(m, 1H), 7.45(m, 4H), 4.85(t, J=5.2 Hz, 1H), 4.01(s, 2H), 3.67(t, J=8.0 Hz, 1H), 3.21(t, J=5.2 Hz, 1H), 2.74(t, J=7.3 Hz, 1H), 1.95(m, 1H), 1.60(m, 1H), 1.03-0.87(m, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.53 (m, 2H), 8.18-7.91 (m, 2H), 7.69 (m, 1H), 7.45 (m, 4H), 4.85 (t, J = 5.2 Hz, 1H), 4.01 (s, 2H), 3.67 (t, J = 8.0 Hz, 1H), 3.21 (t, J = 5.2 Hz, 1H), 2.74 (t, J = 7.3 Hz, 1H), 1.95 (m, 1H), 1.60 (m, 1H), 1.03-0.87 (m, 3H)
화합물번호 158. [2-(4-메틸-피페라진-1-일)-에틸]-(2-페닐-퀴나졸린-4-일)-아민Compound 158. [2- (4-Methyl-piperazin-1-yl) -ethyl]-(2-phenyl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 8.51(t, J=3.9 Hz, 2H), 8.03(s, 1H), 7.92(d, J=8.3 Hz, 1H), 7.84(d, J=8.8 Hz, 1H), 7.65(t, J=7.6 Hz, 1H), 7.39(m, 4H), 5.84(br s, 1H), 3.83(m, 2H), 2.98(m, 4H), 2.66(m, 10H), 2.33(s, 3H), 1.05(m, 2H), 1.29(m, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.51 (t, J = 3.9 Hz, 2H), 8.03 (s, 1H), 7.92 (d, J = 8.3 Hz, 1H), 7.84 (d, J = 8.8 Hz , 1H), 7.65 (t, J = 7.6 Hz, 1H), 7.39 (m, 4H), 5.84 (br s, 1H), 3.83 (m, 2H), 2.98 (m, 4H), 2.66 (m, 10H ), 2.33 (s, 3H), 1.05 (m, 2H), 1.29 (m, 6H)
화합물번호 159. 싸이클로펜틸-메틸-(2-페닐-퀴나졸린-4-일)-아민Compound 159. Cyclopentyl-methyl- (2-phenyl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 8.84(m, 2H), 7.98(t, J=8.1 Hz, 2H), 7.68(t, J=7.7 Hz, 1H), 7.47(m, 3H), 7.35(t, J=7.6 Hz, 1H), 4.99(t, J=7.7 Hz, 1H), 3.26(s, 3H), 2.08(m, 2H), 1.71(m, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.84 (m, 2H), 7.98 (t, J = 8.1 Hz, 2H), 7.68 (t, J = 7.7 Hz, 1H), 7.47 (m, 3H), 7.35 (t, J = 7.6 Hz, 1H), 4.99 (t, J = 7.7 Hz, 1H), 3.26 (s, 3H), 2.08 (m, 2H), 1.71 (m, 6H)
화합물번호 160. (2-페닐-퀴나졸린-4-일)-(2-피페라진-1-일-에틸)-아민Compound No. 160. (2-phenyl-quinazolin-4-yl)-(2-piperazin-1-yl-ethyl) -amine
1H NMR(CDCl3, 300 MHz) δ 8.54(m, 2H), 7.97(m, 2H), 7.74(m, 1H), 7.46(m, 4H), 4.08(m, 4H), 3.06(m, 4H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.54 (m, 2H), 7.97 (m, 2H), 7.74 (m, 1H), 7.46 (m, 4H), 4.08 (m, 4H), 3.06 (m, 4H)
화합물번호 161. O-(4-니트로-벤질)-N-(2-페닐-퀴나졸린-4-일)-히드록실아민Compound No. 161. O - (4- nitro-benzyl) -N- (2- phenyl-quinazolin-4-yl) hydroxylamine
1H NMR(CDCl3, 300 MHz) δ 8.21(m, 3H), 7.97(m, 2H), 7.88(d, J=7.9 Hz, 1H), 7.57(m, 8H), 7.28(m, 1H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.21 (m, 3H), 7.97 (m, 2H), 7.88 (d, J = 7.9 Hz, 1H), 7.57 (m, 8H), 7.28 (m, 1H)
화합물번호 162. (4-클로로-페닐)-(2-페닐-퀴나졸린-4-일)-아민Compound 162. (4-Chloro-phenyl)-(2-phenyl-quinazolin-4-yl) -amine
1H NMR(DMSO-d6, 300 MHz) δ 9.92(s, 1H), 8.53(d, J=8.3 Hz, 1H), 8.41(t, J=3.9 Hz, 2H), 7.98(d, J=8.8 Hz, 2H), 7.85(d, J=3.8 Hz, 2H), 7.62-7.48(m, 6H) 1 H NMR (DMSO-d 6 , 300 MHz) δ 9.92 (s, 1H), 8.53 (d, J = 8.3 Hz, 1H), 8.41 (t, J = 3.9 Hz, 2H), 7.98 (d, J = 8.8 Hz, 2H), 7.85 (d, J = 3.8 Hz, 2H), 7.62-7.48 (m, 6H)
화합물번호 163. 벤질-(2-메틸-퀴나졸린-4-일)-아민
1H NMR(DMSO-d6, 300 MHz) δ 9.69(s, 1H), 8.47(d, J=8.1 Hz, 1H), 8.20(t, J=7.2 Hz, 2H), 7.81(d, J=3.6 Hz, 2H), 7.55(t, J= 4.1 Hz, 1H), 7.46-7.23(m, 7H), 2.22(s, 3H) 1 H NMR (DMSO-d 6 , 300 MHz) δ 9.69 (s, 1H), 8.47 (d, J = 8.1 Hz, 1H), 8.20 (t, J = 7.2 Hz, 2H), 7.81 (d, J = 3.6 Hz, 2H), 7.55 (t, J = 4.1 Hz, 1H), 7.46-7.23 (m, 7H), 2.22 (s, 3H)
화합물번호 164. (3-메톡시-벤질)-(2-메틸-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 7.77-7.63(m, 3H), 7.35(t, J=7.6 Hz, 1H), 7.24(t, J=6.3 Hz, 1H), 6.96(m, 2H), 6.82(m, 1H), 6.32(s, 1H), 4.84(m, 2H), 3.74(s, 3H), 2.62(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.77-7.63 (m, 3H), 7.35 (t, J = 7.6 Hz, 1H), 7.24 (t, J = 6.3 Hz, 1H), 6.96 (m, 2H) , 6.82 (m, 1H), 6.32 (s, 1H), 4.84 (m, 2H), 3.74 (s, 3H), 2.62 (s, 3H)
화합물번호 165. (4-메톡시-벤질)-(2-메틸-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 7.74(d, J=8.2 Hz, 1H), 7.67(m, 2H), 7.35(m, 3H), 6.86(d, J=8.6 Hz, 2H), 6.12(s, 1H), 4.77(d, J=4.0 Hz, 2H), 3.78(s, 3H), 2.64(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.74 (d, J = 8.2 Hz, 1H), 7.67 (m, 2H), 7.35 (m, 3H), 6.86 (d, J = 8.6 Hz, 2H), 6.12 (s, 1H), 4.77 (d, J = 4.0 Hz, 2H), 3.78 (s, 3H), 2.64 (s, 3H)
화합물번호 166. (2-메틸-퀴나졸린-4-일)-(3-트리플루오로메틸-벤질)-아민
1H NMR(CDCl3, 300 MHz) δ 7.82(m, 2H), 7.64(m, 2H), 7.52(m, 1H), 7.35(m, 2H), 6.73(s, 1H), 4.93(s, 2H), 2.63(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.82 (m, 2H), 7.64 (m, 2H), 7.52 (m, 1H), 7.35 (m, 2H), 6.73 (s, 1H), 4.93 (s, 2H), 2.63 (s, 3H)
화합물번호 167. (2-메틸-퀴나졸린-4-일)-펜에틸-아민
1H NMR(CDCl3, 300 MHz) δ 7.77(d, J=8.3 Hz, 1H), 7.60(m, 2H), 7.33(m, 3H), 7.24(m, 3H), 6.12(br, 1H), 3.94(m, 2H), 3.01(t, J=6.9 Hz, 2H), 2.65(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.77 (d, J = 8.3 Hz, 1H), 7.60 (m, 2H), 7.33 (m, 3H), 7.24 (m, 3H), 6.12 (br, 1H) , 3.94 (m, 2H), 3.01 (t, J = 6.9 Hz, 2H), 2.65 (s, 3H)
화합물번호 168. (2-메틸-퀴나졸린-4-일)-(4-페닐-부틸)-아민
1H NMR(CDCl3, 300 MHz) δ 7.70(m, 3H), 7.36(t, J=7.5 Hz, 1H), 7.26(m, 2H), 7,17(m, 3H), 6.12(br, 1H), 3.69(d, J=5.3 Hz, 2H), 2.68(t, J=6.8 Hz, 2H), 2.62(s, 3H), 1.75(t, J=3.4 Hz, 4H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.70 (m, 3H), 7.36 (t, J = 7.5 Hz, 1H), 7.26 (m, 2H), 7,17 (m, 3H), 6.12 (br, 1H), 3.69 (d, J = 5.3 Hz, 2H), 2.68 (t, J = 6.8 Hz, 2H), 2.62 (s, 3H), 1.75 (t, J = 3.4 Hz, 4H)
화합물번호 169. (2-메틸-퀴나졸린-4-일)-나프탈렌-1-일메틸-아민
1H NMR(CDCl3, 300 MHz) δ 8.07(m, 1H), 7.86(m, 3H), 7.64(t, J=7.4 Hz, 2H), 7.55-7.42(m, 4H), 7.24(m, 2H), 6.22(br s, 1H), 5.27(s, 2H), 2.70(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.07 (m, 1H), 7.86 (m, 3H), 7.64 (t, J = 7.4 Hz, 2H), 7.55-7.42 (m, 4H), 7.24 (m, 2H), 6.22 (br s, 1H), 5.27 (s, 2H), 2.70 (s, 3H)
화합물번호 170. 벤조[1,3]디옥솔-5-일메틸-(2-메틸-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 7.74(m, 3H), 7.35(t, J=7.5 Hz, 1H), 6.84(t, J=6.5 Hz, 2H), 6.74(d, J=7.8 Hz, 1H), 6.24(br, 1H), 5.92(s, 2H), 4.76(d, J=4.1 Hz, 2H), 2.65(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.74 (m, 3H), 7.35 (t, J = 7.5 Hz, 1H), 6.84 (t, J = 6.5 Hz, 2H), 6.74 (d, J = 7.8 Hz , 1H), 6.24 (br, 1H), 5.92 (s, 2H), 4.76 (d, J = 4.1 Hz, 2H), 2.65 (s, 3H)
화합물번호 171. (3-플루오로-벤질)-(2-메틸-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 7.79(m, 2H), 7.66(t, J=7.7 Hz, 1H), 7.37(t, J=7.5 Hz, 1H), 7.26(t, J=3.9 Hz, 1H), 7.14(m, 2H), 6.96 (m, 1H), 6.51(s, 1H), 4.87(d, J=3.3 Hz, 2H), 2.63(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.79 (m, 2H), 7.66 (t, J = 7.7 Hz, 1H), 7.37 (t, J = 7.5 Hz, 1H), 7.26 (t, J = 3.9 Hz , 1H), 7.14 (m, 2H), 6.96 (m, 1H), 6.51 (s, 1H), 4.87 (d, J = 3.3 Hz, 2H), 2.63 (s, 3H)
화합물번호 172. [2-(3-플루오로-페닐)-에틸]-(2-메틸-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 7.78(d, J=8.5 Hz, 1H), 7.65(t, J=7.3 Hz, 2H), 7.35(t, J=7.8 Hz, 1H), 7.27(m, 1H), 6.94(m, 3H), 6.24(br, 1H), 3.93(m, 2H), 3.02(t, J=6.99 Hz, 2H), 2.65 (s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.78 (d, J = 8.5 Hz, 1H), 7.65 (t, J = 7.3 Hz, 2H), 7.35 (t, J = 7.8 Hz, 1H), 7.27 (m , 1H), 6.94 (m, 3H), 6.24 (br, 1H), 3.93 (m, 2H), 3.02 (t, J = 6.99 Hz, 2H), 2.65 (s, 3H)
화합물번호 173. 2-[2-(2-메틸-퀴나졸린-4-일아미노)-에톡시]-에탄올Compound 173. 2- [2- (2-Methyl-quinazolin-4-ylamino) -ethoxy] -ethanol
1H NMR(CDCl3, 300 MHz) δ 7.83(d, J=8.1 Hz, 1H), 7.72(d, J=10.7 Hz, 1H), 7.61(t, J=7.1 Hz, 1H), 7.30(t, J=6.5 Hz, 1H), 6.96(br, 1H), 3.82(m, 6H), 3.68(m, 2H), 2.60(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.83 (d, J = 8.1 Hz, 1H), 7.72 (d, J = 10.7 Hz, 1H), 7.61 (t, J = 7.1 Hz, 1H), 7.30 (t , J = 6.5 Hz, 1H), 6.96 (br, 1H), 3.82 (m, 6H), 3.68 (m, 2H), 2.60 (s, 3H)
화합물번호 174. 2-(2-메틸-퀴나졸린-4-일아미노)-에탄올Compound No. 174. 2- (2-Methyl-quinazolin-4-ylamino) -ethanol
1H NMR(CDCl3, 300 MHz) δ 8.27(d, J=8.2 Hz, 1H), 7.88(t, J=7.2 Hz, 1H), 7.79(t, J=7.5 Hz, 1H), 7.51(m, 1H), 3.93(m, 4H), 2.70(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.27 (d, J = 8.2 Hz, 1H), 7.88 (t, J = 7.2 Hz, 1H), 7.79 (t, J = 7.5 Hz, 1H), 7.51 (m , 1H), 3.93 (m, 4H), 2.70 (s, 3H)
화합물번호 175. 벤질-(2-이소프로필-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 7.82(d, J=7.8 Hz, 1H), 7.71-7.63(m, 2H), 7.45-7.26(m, 6H), 5.88(br, 1H), 4.90(d, J=5.4 Hz, 2H), 3.12(m, 1H), 1.37(d, J=6.6 Hz, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.82 (d, J = 7.8 Hz, 1H), 7.71-7.63 (m, 2H), 7.45-7.26 (m, 6H), 5.88 (br, 1H), 4.90 ( d, J = 5.4 Hz, 2H), 3.12 (m, 1H), 1.37 (d, J = 6.6 Hz, 6H)
화합물번호 176. (2-이소프로필-퀴나졸린-4-일)-(3-메톡시-벤질)-아민
1H NMR(CDCl3, 300 MHz) δ 7.82(d, J=8.4 Hz, 1H), 7.75(m, 1H), 7.66(m, 1H), 7.38(t, J=7.9 Hz, 1H), 7.25(t, J=7.7 Hz, 1H), 7.00(m, 2H), 6.80(m, 1H), 4.88(d, J=5.0 Hz, 2H), 3.77(s, 3H), 3.13(m, 1H), 1.37(d, J=6.8 Hz, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.82 (d, J = 8.4 Hz, 1H), 7.75 (m, 1H), 7.66 (m, 1H), 7.38 (t, J = 7.9 Hz, 1H), 7.25 (t, J = 7.7 Hz, 1H), 7.00 (m, 2H), 6.80 (m, 1H), 4.88 (d, J = 5.0 Hz, 2H), 3.77 (s, 3H), 3.13 (m, 1H) , 1.37 (d, J = 6.8 Hz, 6H)
화합물번호 177. (2-이소프로필-퀴나졸린-4-일)-(4-메톡시-벤질)-아민
1H NMR(CDCl3, 300 MHz) δ 7.82(d, J=8.1 Hz, 1H), 7.70-7.61(m, 2H), 7.35(m, 3H), 6.89(d, J=8.7 Hz, 2H), 5.86(br, 1H), 4.83(d, J=5.4 Hz, 2H), 3.81(s, 3H), 3.14(m, 1H), 1.38(d, J=6.6 Hz, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.82 (d, J = 8.1 Hz, 1H), 7.70-7.61 (m, 2H), 7.35 (m, 3H), 6.89 (d, J = 8.7 Hz, 2H) , 5.86 (br, 1H), 4.83 (d, J = 5.4 Hz, 2H), 3.81 (s, 3H), 3.14 (m, 1H), 1.38 (d, J = 6.6 Hz, 6H)
화합물번호 178. (2-이소프로필-퀴나졸린-4-일)-(3-트리플루오로메틸-벤질)-아민
1H NMR(CDCl3, 300 MHz) δ 7.87(m, 2H), 7.66(m, 3H), 7.51(d, J=7.8 Hz, 1H), 7.39(m, 2H), 4.96(d, J=5.0 Hz, 2H), 3.17 (m, 1H), 1.33(d, J=6.8 Hz, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.87 (m, 2H), 7.66 (m, 3H), 7.51 (d, J = 7.8 Hz, 1H), 7.39 (m, 2H), 4.96 (d, J = 5.0 Hz, 2H), 3.17 (m, 1H), 1.33 (d, J = 6.8 Hz, 6H)
화합물번호 179. (2-이소프로필-퀴나졸린-4-일)-펜에틸-아민
1H NMR(CDCl3, 300 MHz) δ 7.82(d, J=8.1 Hz, 1H), 7.67(m, 1H), 7.55(d, J=7.8 Hz, 1H), 7.38-7.21(m, 6H), 5.84(br, 1H), 3.95(q, J=6.9 Hz, 2H), 3.16(m, 1H), 3.05(t, J=6.9 Hz, 2H), 1.40(d, J=6.9 Hz, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.82 (d, J = 8.1 Hz, 1H), 7.67 (m, 1H), 7.55 (d, J = 7.8 Hz, 1H), 7.38-7.21 (m, 6H) , 5.84 (br, 1H), 3.95 (q, J = 6.9 Hz, 2H), 3.16 (m, 1H), 3.05 (t, J = 6.9 Hz, 2H), 1.40 (d, J = 6.9 Hz, 6H)
화합물번호 180. (2-이소프로필-퀴나졸린-4-일)-(4-페닐-부틸)-아민
1H NMR(CDCl3, 300 MHz) δ 7.83(d, J=7.9 Hz, 1H), 7.75(d, J=7.7 Hz, 1H), 7.65(t, J=7.6 Hz, 1H), 7.35(t, J=7.6 Hz, 1H), 7.25(m, 6H), 3.73(d, J=5.5 Hz, 2H), 3.14(m, 1H), 2.68(d, J=6.5 Hz, 2H), 1.77(m, 4H), 1.36(d, J=6.8 Hz, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.83 (d, J = 7.9 Hz, 1H), 7.75 (d, J = 7.7 Hz, 1H), 7.65 (t, J = 7.6 Hz, 1H), 7.35 (t , J = 7.6 Hz, 1H), 7.25 (m, 6H), 3.73 (d, J = 5.5 Hz, 2H), 3.14 (m, 1H), 2.68 (d, J = 6.5 Hz, 2H), 1.77 (m , 4H), 1.36 (d, J = 6.8 Hz, 6H)
화합물번호 181. (2-이소프로필-퀴나졸린-4-일)-나프탈렌-1-일메틸-아민
1H NMR(CDCl3, 300 MHz) δ 8.18(m, 1H), 7.93-7.81(m, 3H), 7.68-7.43(m, 6H), 7.30(m, 1H), 5.85(br, 1H), 5.35(d, J=5.1 Hz, 2H), 3.20(m, 1H), 1.44(d, J=6.6 Hz, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.18 (m, 1H), 7.93-7.81 (m, 3H), 7.68-7.43 (m, 6H), 7.30 (m, 1H), 5.85 (br, 1H), 5.35 (d, J = 5.1 Hz, 2H), 3.20 (m, 1H), 1.44 (d, J = 6.6 Hz, 6H)
화합물번호 182. 벤조[1,3]디옥솔-5-일메틸-(2-이소프로필-퀴나졸린-4-일)-아민Compound No. 182. Benzo [1,3] dioxol-5-ylmethyl- (2-isopropyl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 7.81(d, J=7.8 Hz, 1H), 7.70-7.63(m, 2H), 7.66(m, 1H), 6.94-6.87(m, 2H), 6.78(d, 1H, J=7.8 Hz), 5.94(s, 2H), 5.90(br, 1H), 4.80(d, J=5.4 Hz, 2H), 3.13(m, 1H), 1.38(d, J=6.6 Hz, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.81 (d, J = 7.8 Hz, 1H), 7.70-7.63 (m, 2H), 7.66 (m, 1H), 6.94-6.87 (m, 2H), 6.78 ( d, 1H, J = 7.8 Hz, 5.94 (s, 2H), 5.90 (br, 1H), 4.80 (d, J = 5.4 Hz, 2H), 3.13 (m, 1H), 1.38 (d, J = 6.6 Hz, 6H)
화합물번호 183. (3-플루오로-벤질)-(2-이소프로필-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 7.82(t, J=5.6 Hz, 1H), 7.67(t, J=7.7 Hz, 1H), 7.37(t, J=7.5 Hz, 1H), 7.28-7.12(m, 3H), 6.95(t, J=7.3 Hz, 1H), 6.34(br, 1H), 4.89(d, J=3.5 Hz, 2H), 3.14(m, 1H), 1.33(d, J=6.8 Hz, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.82 (t, J = 5.6 Hz, 1H), 7.67 (t, J = 7.7 Hz, 1H), 7.37 (t, J = 7.5 Hz, 1H), 7.28-7.12 (m, 3H), 6.95 (t, J = 7.3 Hz, 1H), 6.34 (br, 1H), 4.89 (d, J = 3.5 Hz, 2H), 3.14 (m, 1H), 1.33 (d, J = 6.8 Hz, 6H)
화합물번호 184. [2-(3-플루오로-페닐)-에틸]-(2-이소프로필-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 7.83(d, J=8.7 Hz, 1H), 7.66(t, J=7.2 Hz, 2H), 7.38-7.23(m, 2H), 6.89(m, 3H), 6.32(br, 1H), 3.94(m, 1H), 3.17(t, J=6.8 Hz, 1H), 3.06(m, 1H), 1.39(d, J=6.8 Hz, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.83 (d, J = 8.7 Hz, 1H), 7.66 (t, J = 7.2 Hz, 2H), 7.38-7.23 (m, 2H), 6.89 (m, 3H) , 6.32 (br, 1H), 3.94 (m, 1H), 3.17 (t, J = 6.8 Hz, 1H), 3.06 (m, 1H), 1.39 (d, J = 6.8 Hz, 6H)
화합물번호 185. 2-[2-(2-이소프로필-퀴나졸린-4-일아미노)-에톡시]-에탄올Compound 185. 2- [2- (2-isopropyl-quinazolin-4-ylamino) -ethoxy] -ethanol
1H NMR(MeOD, 300 MHz) δ 7.78(t, J=8.1 Hz, 2H), 7.61(t, J=7.6 Hz, 1H), 7.29(m, 1H), 6.78(br, 1H), 3.89(d, J=4.4 Hz, 2H), 3.80(m, 4H), 3.66(t, J=4.4 Hz, 2H), 3.11(m, 1H), 1.33(d, J=6.8 Hz, 6H) 1 H NMR (MeOD, 300 MHz) δ 7.78 (t, J = 8.1 Hz, 2H), 7.61 (t, J = 7.6 Hz, 1H), 7.29 (m, 1H), 6.78 (br, 1H), 3.89 ( d, J = 4.4 Hz, 2H), 3.80 (m, 4H), 3.66 (t, J = 4.4 Hz, 2H), 3.11 (m, 1H), 1.33 (d, J = 6.8 Hz, 6H)
화합물번호 186. 2-(2-이소프로필-퀴나졸린-4-일아미노)-에탄올Compound No.186. 2- (2-Isopropyl-quinazolin-4-ylamino) -ethanol
1H NMR(CDCl3+MeOD, 300 MHz) δ 7.85(d, J=8.2 Hz, 1H), 7.64(m, 2H), 7.31(m, 1H), 3.78(m, 4H), 3.02(m, 1H), 1.27(d, J=6.8 Hz, 6H) 1 H NMR (CDCl 3 + MeOD, 300 MHz) δ 7.85 (d, J = 8.2 Hz, 1H), 7.64 (m, 2H), 7.31 (m, 1H), 3.78 (m, 4H), 3.02 (m, 1H), 1.27 (d, J = 6.8 Hz, 6H)
화합물번호 187. 벤질-(2-tert-부틸-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 7.90(d, J=8.2 Hz, 1H), 7.12(d, J=5.3 Hz, 1H), 7.53(t, J=7.6 Hz, 1H), 7.36-7.25(m, 6H), 6.22(br, 1H), 4.90(d, J=5.3 Hz, 2H), 1.44(s, 9H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.90 (d, J = 8.2 Hz, 1H), 7.12 (d, J = 5.3 Hz, 1H), 7.53 (t, J = 7.6 Hz, 1H), 7.36-7.25 (m, 6H), 6.22 (br, 1H), 4.90 (d, J = 5.3 Hz, 2H), 1.44 (s, 9H)
화합물번호 188. (2-tert-부틸-퀴나졸린-4-일)-(3-메톡시-벤질)-아민Compound 188. (2- tert -Butyl-quinazolin-4-yl)-(3-methoxy-benzyl) -amine
1H NMR(CDCl3, 300 MHz) δ 7.88(d, J=8.1 Hz, 1H), 7.66(m, 2H), 7.44-7.23(m, 3H, 6.99(d, J=8.0 Hz, 2H), 6.84(t, J=4.2 Hz, 1H), 6.16(br, 1H), 4.87(d, J=5.3 Hz, 2H), 3.78(s, 3H), 1.44(s, 9H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.88 (d, J = 8.1 Hz, 1H), 7.66 (m, 2H), 7.44-7.23 (m, 3H, 6.99 (d, J = 8.0 Hz, 2H), 6.84 (t, J = 4.2 Hz, 1H), 6.16 (br, 1H), 4.87 (d, J = 5.3 Hz, 2H), 3.78 (s, 3H), 1.44 (s, 9H)
화합물번호 189. (2-tert-부틸-퀴나졸린-4-일)-(4-메톡시-벤질)-아민Compound number 189. (2- tert -Butyl-quinazolin-4-yl)-(4-methoxy-benzyl) -amine
1H NMR(CDCl3, 300 MHz) δ 7.86(m, 1H), 7.64(m, 2H), 7.32(m, 3H), 6.99(d, J=8.7 Hz, 1H), 6.86(d, J=5.6 Hz, 2H), 6.19(br, 1H), 4.82 (d, J=5.4 Hz, 2H), 3.80(s, 3H), 1.44(s, 9H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.86 (m, 1H), 7.64 (m, 2H), 7.32 (m, 3H), 6.99 (d, J = 8.7 Hz, 1H), 6.86 (d, J = 5.6 Hz, 2H), 6.19 (br, 1H), 4.82 (d, J = 5.4 Hz, 2H), 3.80 (s, 3H), 1.44 (s, 9H)
화합물번호 190. (2-tert-부틸-퀴나졸린-4-일)-(3-트리플루오로메틸-벤질)-아민Compound No. 190. (2- tert -Butyl-quinazolin-4-yl)-(3-trifluoromethyl-benzyl) -amine
1H NMR(CDCl3, 300 MHz) δ 7.91(d, J=8.3 Hz, 1H), 7.79-7.61(m, 4H), 7.53(d, J=7.9 Hz, 1H), 7.46-7.34(m, 2H), 6.21(br, 1H), 4.95(d, J=5.3 Hz, 2H), 1.45(s, 9H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.91 (d, J = 8.3 Hz, 1H), 7.79-7.61 (m, 4H), 7.53 (d, J = 7.9 Hz, 1H), 7.46-7.34 (m, 2H), 6.21 (br, 1H), 4.95 (d, J = 5.3 Hz, 2H), 1.45 (s, 9H)
화합물번호 191. (2-tert-부틸-퀴나졸린-4-일)-펜에틸-아민
1H NMR(CDCl3, 300 MHz) δ 7.85(d, J=8.4 Hz, 1H), 7.66(t, J=7.5 Hz, 1H), 7.53(d, J=7.8 Hz, 1H), 7.31(m, 6H), 5.72(br s, 1H), 3.93(q, J=6.9 Hz, 2H), 3.05(t, J=7.2 Hz, 2H), 1.48(s, 9H) 1 H NMR (
화합물번호 192. (2-tert-부틸-퀴나졸린-4-일)-(4-페닐-부틸)-아민
1H NMR(CDCl3, 300 MHz) δ 7.87(d, J=8.3 Hz, 1H), 7.65(m, 2H), 7.37-7.25(m, 3H), 7.19(m, 3H), 5.98(br, 1H), 3.71(d, J=5.66 Hz, 2H), 2.68(d, J=6.5 Hz, 2H), 1.44(m, 4H), 1.44(s, 9H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.87 (d, J = 8.3 Hz, 1H), 7.65 (m, 2H), 7.37-7.25 (m, 3H), 7.19 (m, 3H), 5.98 (br, 1H), 3.71 (d, J = 5.66 Hz, 2H), 2.68 (d, J = 6.5 Hz, 2H), 1.44 (m, 4H), 1.44 (s, 9H)
화합물번호 193. (2-tert-부틸-퀴나졸린-4-일)-나프탈렌-1-일메틸-아민Compound number 193. (2- tert -butyl-quinazolin-4-yl) -naphthalen-1-ylmethyl-amine
1H NMR(CDCl3, 300 MHz) δ 8.20(d, J=9.4 Hz, 1H), 7.89(m, 3H), 7.61(m, 3H), 7.50(m, 3H), 6.10(br, 1H), 5.35(d, J=5.1 Hz, 2H), 1.52(s, 9H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.20 (d, J = 9.4 Hz, 1H), 7.89 (m, 3H), 7.61 (m, 3H), 7.50 (m, 3H), 6.10 (br, 1H) , 5.35 (d, J = 5.1 Hz, 2H), 1.52 (s, 9H)
화합물번호 194. 벤조[1,3]디옥솔-5-일메틸-(2-tert-부틸-퀴나졸린-4-일)-아민Compound 194.Benzo [1,3] dioxol-5-ylmethyl- (2- tert -butyl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 7.89(d, J=8.3Hz, 1H), 7.66(m, 2H), 7.34(t, J=7.5 Hz, 1H), 6.91(m, 2H), 6.76(d, J=7.9 Hz, 1H), 6.21(br, 1H), 5.93(s, 2H), 4.80(d, J=6.2 Hz, 2H), 1.44(s, 9H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.89 (d, J = 8.3 Hz, 1H), 7.66 (m, 2H), 7.34 (t, J = 7.5 Hz, 1H), 6.91 (m, 2H), 6.76 (d, J = 7.9 Hz, 1H), 6.21 (br, 1H), 5.93 (s, 2H), 4.80 (d, J = 6.2 Hz, 2H), 1.44 (s, 9H)
화합물번호 195. (2-tert-부틸-퀴나졸린-4-일)-(3-플루오로-벤질)-아민Compound 195. (2- tert -Butyl-quinazolin-4-yl)-(3-fluoro-benzyl) -amine
1H NMR(CDCl3, 300 MHz) δ 7.89(d, J=8.3 Hz, 1H), 7.69(m, 2H), 7.35(m, 1H), 7.28(m, 1H), 7.14(m, 2H), 6.94(d, J=5.4 Hz, 1H), 6.24(br, 1H), 4.99(d, J=6.2Hz, 2H), 1.45(s, 9H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.89 (d, J = 8.3 Hz, 1H), 7.69 (m, 2H), 7.35 (m, 1H), 7.28 (m, 1H), 7.14 (m, 2H) , 6.94 (d, J = 5.4 Hz, 1H), 6.24 (br, 1H), 4.99 (d, J = 6.2 Hz, 2H), 1.45 (s, 9H)
화합물번호 196. (2-tert-부틸-퀴나졸린-4-일)-[2-(3-플루오로-페닐)-에틸]-아민
1H NMR(CDCl3, 300 MHz) δ 7.89(d, J=8.3 Hz, 1H), 7.68(m, 2H), 7.33(m, 1H), 7.25(m, 1H), 6.98(m, 2H), 6.01(br, 1H), 3.93(m, 2H), 3.06(t, J=2.6 Hz, 2H), 1.45(s, 9H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.89 (d, J = 8.3 Hz, 1H), 7.68 (m, 2H), 7.33 (m, 1H), 7.25 (m, 1H), 6.98 (m, 2H) , 6.01 (br, 1H), 3.93 (m, 2H), 3.06 (t, J = 2.6 Hz, 2H), 1.45 (s, 9H)
화합물번호 197. 2-[2-(2-tert-부틸-퀴나졸린-4-일아미노)-에톡시]-에탄올Compound 197. 2- [2- (2- tert -butyl-quinazolin-4-ylamino) -ethoxy] -ethanol
1H NMR(CDCl3, 300 MHz) δ 7.85(d, J=8.3 Hz, 1H), 7.71(d, J=8.2 Hz, 1H), 7.63(t, J=7.8 Hz, 1H), 7.33(t, J=7.5 Hz, 1H), 6.33(br, 1H), 3.90(d, J=4.1 Hz, 2H), 3.80(t, J=4.6 Hz, 4H), 3.65(t, J=4.6 Hz, 2H), 1.44(s, 9H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.85 (d, J = 8.3 Hz, 1H), 7.71 (d, J = 8.2 Hz, 1H), 7.63 (t, J = 7.8 Hz, 1H), 7.33 (t , J = 7.5 Hz, 1H), 6.33 (br, 1H), 3.90 (d, J = 4.1 Hz, 2H), 3.80 (t, J = 4.6 Hz, 4H), 3.65 (t, J = 4.6 Hz, 2H ), 1.44 (s, 9 H)
화합물번호 198. 2-(2-tert-부틸-퀴나졸린-4-일아미노)-에탄올Compound 198. 2- (2- tert -butyl-quinazolin-4-ylamino) -ethanol
1H NMR(CDCl3, 300 MHz) δ 7.83(d, J=8.0 Hz, 1H), 7.69(t, J=7.6 Hz, 2H), 7.38(t, J=7.6 Hz, 1H), 6.14(br, 1H), 4.59(s, 1H), 3.93-3.83(m, 4H), 1.44(s, 9H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.83 (d, J = 8.0 Hz, 1H), 7.69 (t, J = 7.6 Hz, 2H), 7.38 (t, J = 7.6 Hz, 1H), 6.14 (br) , 1H), 4.59 (s, 1H), 3.93-3.83 (m, 4H), 1.44 (s, 9H)
화합물번호 199. 벤질-(2-싸이클로헥실-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 7.83(d, J=8.0 Hz, 1H), 7.68(m, 2H), 7.43(d, J=7.5 Hz, 2H), 7.31(m, 4H), 6.26(br, 1H), 4.90((d, J=5.2 Hz, 2H), 2.82(t, J=11.5 Hz, 1H), 1.97 (m, 2H), 1.73(m, 5H), 1.33(m, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.83 (d, J = 8.0 Hz, 1H), 7.68 (m, 2H), 7.43 (d, J = 7.5 Hz, 2H), 7.31 (m, 4H), 6.26 (br, 1H), 4.90 ((d, J = 5.2 Hz, 2H), 2.82 (t, J = 11.5 Hz, 1H), 1.97 (m, 2H), 1.73 (m, 5H), 1.33 (m, 3H )
화합물번호 200. (2-싸이클로헥실-퀴나졸린-4-일)-(3-메톡시-벤질)-아민Compound No. 200. (2-Cyclohexyl-quinazolin-4-yl)-(3-methoxy-benzyl) -amine
1H NMR(CDCl3, 300 MHz) δ 7.84(d, J=8.3 Hz, 1H), 7.73(d, J=8.2 Hz, 1H), 7.65(t, J=7.3 Hz, 1H), 7.34(t, J=7.6 Hz, 1H), 7.26(t, J=7.8 Hz, 1H), 7.01(d, J=7.3 Hz, 2H), 6.84(t, J=4.5 Hz, 1H), 6.43(br, 1H), 4.88(d, J=6.8 Hz, 2H), 3.78(s, 3H), 2.84(m, 1H), 2.02(m, 2H), 1.85-1.66(m, 5H), 1.48-1.28(m, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.84 (d, J = 8.3 Hz, 1H), 7.73 (d, J = 8.2 Hz, 1H), 7.65 (t, J = 7.3 Hz, 1H), 7.34 (t , J = 7.6 Hz, 1H), 7.26 (t, J = 7.8 Hz, 1H), 7.01 (d, J = 7.3 Hz, 2H), 6.84 (t, J = 4.5 Hz, 1H), 6.43 (br, 1H ), 4.88 (d, J = 6.8 Hz, 2H), 3.78 (s, 3H), 2.84 (m, 1H), 2.02 (m, 2H), 1.85-1.66 (m, 5H), 1.48-1.28 (m, 3H)
화합물번호 201. (2-싸이클로헥실-퀴나졸린-4-일)-(4-메톡시-벤질)-아민Compound No. 201. (2-Cyclohexyl-quinazolin-4-yl)-(4-methoxy-benzyl) -amine
1H NMR(CDCl3, 300 MHz) δ 7.84(d, J=8.3 Hz, 1H), 7.73(d, J=8.2 Hz, 1H), 7.64(t, J=7.4 Hz, 1H), 7.36(m, 3H), 6.87(d, J=8.5 Hz, 2H), 6.48n (br, 1H), 4.83(d, J=6.8 Hz, 2H), 3.80(s, 3H), 2.85(m, 1H), 2.02(m, 2H), 2.04-1.69(m, 5H), 1.49-1.25(m, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.84 (d, J = 8.3 Hz, 1H), 7.73 (d, J = 8.2 Hz, 1H), 7.64 (t, J = 7.4 Hz, 1H), 7.36 (m , 3H), 6.87 (d, J = 8.5 Hz, 2H), 6.48 n (br, 1H), 4.83 (d, J = 6.8 Hz, 2H), 3.80 (s, 3H), 2.85 (m, 1H), 2.02 (m, 2H), 2.04-1.69 (m, 5H), 1.49-1.25 (m, 3H)
화합물번호 202. (2-싸이클로헥실-퀴나졸린-4-일)-(3-트리플루오로메틸-벤질)-아민Compound 202. (2-Cyclohexyl-quinazolin-4-yl)-(3-trifluoromethyl-benzyl) -amine
1H NMR(CDCl3, 300 MHz) δ 7.83(m, 2H), 7.78(m, 1H), 7.64(m, 2H), 7.53(m, 1H), 7.40(m, 2H), 6.67(br, 1H), 4.93(d, J=5.0 Hz, 2H), 2.80 (m, 1H), 1.90(m, 2H), 1.84-1.60(m, 5H), 1.45-1.25(m, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.83 (m, 2H), 7.78 (m, 1H), 7.64 (m, 2H), 7.53 (m, 1H), 7.40 (m, 2H), 6.67 (br, 1H), 4.93 (d, J = 5.0 Hz, 2H), 2.80 (m, 1H), 1.90 (m, 2H), 1.84-1.60 (m, 5H), 1.45-1.25 (m, 3H)
화합물번호 203. (2-싸이클로헥실-퀴나졸린-4-일)-펜에틸-아민
1H NMR(CDCl3, 300 MHz) δ 7.83(d, J=8.3 Hz, 1H), 7.65(m, 2H), 7.28(m, 6H), 6.06(br, 1H), 3.95(m, 2H), 3.05(t, J=7.0 Hz, 2H), 2.83(m, 1H), 2.04(m, 2H), 1.88-1.71(m, 5H), 1.50-1.35(m, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.83 (d, J = 8.3 Hz, 1H), 7.65 (m, 2H), 7.28 (m, 6H), 6.06 (br, 1H), 3.95 (m, 2H) , 3.05 (t, J = 7.0 Hz, 2H), 2.83 (m, 1H), 2.04 (m, 2H), 1.88-1.71 (m, 5H), 1.50-1.35 (m, 3H)
화합물번호 204. (2-싸이클로헥실-퀴나졸린-4-일)-(4-페닐-부틸)-아민Compound 204. (2-Cyclohexyl-quinazolin-4-yl)-(4-phenyl-butyl) -amine
1H NMR(CDCl3, 300 MHz) δ 7.83(d, J=8.3 Hz, 1H), 7.69(m, 2H), 7.37-7.17(m, 7H), 6.12(br, 1H), 3.72(d, J=5.6 Hz, 2H), 2.78(t, J= 11.1 Hz, 1H), 2.70(t, J=6.7 Hz, 2H), 2.00(m, 2H), 1.86-1.68(m, 9H), 1.44-1.28(m, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.83 (d, J = 8.3 Hz, 1H), 7.69 (m, 2H), 7.37-7.17 (m, 7H), 6.12 (br, 1H), 3.72 (d, J = 5.6 Hz, 2H), 2.78 (t, J = 11.1 Hz, 1H), 2.70 (t, J = 6.7 Hz, 2H), 2.00 (m, 2H), 1.86-1.68 (m, 9H), 1.44- 1.28 (m, 3H)
화합물번호 205. (2-싸이클로헥실-퀴나졸린-4-일)-나프탈렌-1-일메틸-아민Compound 205. (2-Cyclohexyl-quinazolin-4-yl) -naphthalen-1-ylmethyl-amine
1H NMR(CDCl3, 300 MHz) δ 8.20 (d, J=9.4 Hz, 1H), 7.87(m, 3H), 7.62(m, 3H), 7.50(m, 3H), 7.30(m, 1H), 6.34(br, 1H), 5.35(d, J=4.9 Hz, 2H), 2.92(m, 1H), 2.08(m, 2H), 1.86-1.73(m, 5H), 1.47-1.25(m, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.20 (d, J = 9.4 Hz, 1H), 7.87 (m, 3H), 7.62 (m, 3H), 7.50 (m, 3H), 7.30 (m, 1H) , 6.34 (br, 1H), 5.35 (d, J = 4.9 Hz, 2H), 2.92 (m, 1H), 2.08 (m, 2H), 1.86-1.73 (m, 5H), 1.47-1.25 (m, 3H )
화합물번호 206. 벤조[1,3]디옥솔-5-일메틸-(2-싸이클로헥실-퀴나졸린-4-일)-아민Compound 206. Benzo [1,3] dioxol-5-ylmethyl- (2-cyclohexyl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 7.83(d, J=8.4 Hz, 1H), 7.73(d, J=8.2 Hz, 1H), 7.65(t, J=7.5 Hz, 2H), 6.91 (m, 2H), 6.76(d, J=7.9 Hz, 1H), 6.34(br, 1H), 5.93(s, 2H), 4.80(d, J=5.2 Hz, 2H), 2.84(m, 1H), 2.00(m, 2H), 1.86-1.68(m, 5H), 1.48-1.25(m, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.83 (d, J = 8.4 Hz, 1H), 7.73 (d, J = 8.2 Hz, 1H), 7.65 (t, J = 7.5 Hz, 2H), 6.91 (m , 2H), 6.76 (d, J = 7.9 Hz, 1H), 6.34 (br, 1H), 5.93 (s, 2H), 4.80 (d, J = 5.2 Hz, 2H), 2.84 (m, 1H), 2.00 (m, 2H), 1.86-1.68 (m, 5H), 1.48-1.25 (m, 3H)
화합물번호 207. (2-싸이클로헥실-퀴나졸린-4-일)-(3-플루오로-벤질)-아민
1H NMR(CDCl3, 300 MHz) δ 7.80(m, 1H), 7.66(t, J=7.6 Hz, 1H), 7.35(m, 1H), 7.27(m, 2H), 7.16(m, 2H), 6.95(d, J=8.4 Hz, 1H), 6.47(br, 1H), 4.90(d, J=5.2 Hz, 2H), 2.83(m, 1H), 1.99(m, 2H), 1.84-1.63(m, 5H), 1.46-1.25(m, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.80 (m, 1H), 7.66 (t, J = 7.6 Hz, 1H), 7.35 (m, 1H), 7.27 (m, 2H), 7.16 (m, 2H) , 6.95 (d, J = 8.4 Hz, 1H), 6.47 (br, 1H), 4.90 (d, J = 5.2 Hz, 2H), 2.83 (m, 1H), 1.99 (m, 2H), 1.84-1.63 ( m, 5H), 1.46-1.25 (m, 3H)
화합물번호 208. (2-싸이클로헥실-퀴나졸린-4-일)-[2-(3-플루오로-페닐)-에틸]-아민
1H NMR(CDCl3, 300 MHz) δ 7.83(d, J=8.3 Hz, 1H), 7.65(t, J=7.7 Hz, 2H), 7.30(m, 2H), 6.99(m, 3H), 6.15(br, 1H), 3.94(m, 2H), 3.05(t, J=7.1 Hz, 2H), 2.83(m, 1H), 2.00(m, 2H), 1.88-1.69(m, 5H), 1.46-1.25(m, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.83 (d, J = 8.3 Hz, 1H), 7.65 (t, J = 7.7 Hz, 2H), 7.30 (m, 2H), 6.99 (m, 3H), 6.15 (br, 1H), 3.94 (m, 2H), 3.05 (t, J = 7.1 Hz, 2H), 2.83 (m, 1H), 2.00 (m, 2H), 1.88-1.69 (m, 5H), 1.46- 1.25 (m, 3H)
화합물번호 209. 2-[2-(2-싸이클로헥실-퀴나졸린-4-일아미노)-에톡시]-에탄올Compound 209. 2- [2- (2-cyclohexyl-quinazolin-4-ylamino) -ethoxy] -ethanol
1H NMR(CDCl3, 300 MHz) δ 7.75(m, 2H), 7.62(t, J=7.6 Hz, 1H), 7.31(t, J=7.5 Hz, 1H), 6.48(br, 1H), 3.90(m, 2H), 3.80(m, 4H), 3.36(m, 2H), 2.78(m, 1H), 1.90(m, 2H), 1.85-1.62(m, 5H), 1.47-1.27(m, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.75 (m, 2H), 7.62 (t, J = 7.6 Hz, 1H), 7.31 (t, J = 7.5 Hz, 1H), 6.48 (br, 1H), 3.90 (m, 2H), 3.80 (m, 4H), 3.36 (m, 2H), 2.78 (m, 1H), 1.90 (m, 2H), 1.85-1.62 (m, 5H), 1.47-1.27 (m, 3H )
화합물번호 210. 2-(2-싸이클로헥실-퀴나졸린-4-일아미노)-에탄올Compound No. 210. 2- (2-Cyclohexyl-quinazolin-4-ylamino) -ethanol
1H NMR(CDCl3, 300 MHz) δ 7.80(d, J=8.4 Hz, 1H), 7.69(m, 2H), 7.40(t, J=7.0 Hz, 1H), 6.20(br, 1H), 5.08(br, 1H), 3.93(m, 2H), 3.85(m, 2H), 2.77(m, 1H), 1.97(m, 2H), 1.86-1.66(m, 5H), 1.47-1.25(m, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.80 (d, J = 8.4 Hz, 1H), 7.69 (m, 2H), 7.40 (t, J = 7.0 Hz, 1H), 6.20 (br, 1H), 5.08 (br, 1H), 3.93 (m, 2H), 3.85 (m, 2H), 2.77 (m, 1H), 1.97 (m, 2H), 1.86-1.66 (m, 5H), 1.47-1.25 (m, 3H )
화합물번호 211. 벤질-(2-벤질-퀴나졸린-4-일)-아민Compound number 211. Benzyl- (2-benzyl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 7.82(d, J=8.4 Hz, 1H), 7.71(m, 2H), 7.47(m, 2H), 7.29(m, 9H), 5.94(br, 1H), 4.82(d, J=5.5 Hz, 2H), 4.19(s, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.82 (d, J = 8.4 Hz, 1H), 7.71 (m, 2H), 7.47 (m, 2H), 7.29 (m, 9H), 5.94 (br, 1H) , 4.82 (d, J = 5.5 Hz, 2H), 4.19 (s, 2H)
화합물번호 212. (2-벤질-퀴나졸린-4-일)-(3-메톡시-벤질)-아민
1H NMR(CDCl3, 300 MHz) δ 7.82(d, J=8.1 Hz, 1H), 7.69(t, J=6.9 Hz, 1H), 7.60(d, J=8.1 Hz, 1H), 7.45(d, J=7.2 Hz, 2H), 7.37(t, J=7.2 Hz, 1H), 7.25(m, 4H), 6.85(m, 3H), 5.87(br, 1H), 4.80(d, J=5.4 Hz, 2H), 4.19(s, 2H), 3.76(s, 3H) 1 H NMR (
화합물번호 213. (2-벤질-퀴나졸린-4-일)-(4-메톡시-벤질)-아민Compound 213. (2-benzyl-quinazolin-4-yl)-(4-methoxy-benzyl) -amine
1H NMR(CDCl3, 300 MHz) δ 7.81(d, J=8.4 Hz, 1H), 7.67(t, J=7.7 Hz, 1H), 7.59(d, J=8.1 Hz, 1H), 7.46(d, J=7.3 Hz, 2H), 7.35(t, J=7.6 Hz, 1H), 7.23(m, 5H), 6.83(d, J=8.5 Hz, 2H), 5.87(br, 1H), 4.74(d, J=5.3 Hz, 2H), 4.20(s, 2H), 3.80(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.81 (d, J = 8.4 Hz, 1H), 7.67 (t, J = 7.7 Hz, 1H), 7.59 (d, J = 8.1 Hz, 1H), 7.46 (d , J = 7.3 Hz, 2H), 7.35 (t, J = 7.6 Hz, 1H), 7.23 (m, 5H), 6.83 (d, J = 8.5 Hz, 2H), 5.87 (br, 1H), 4.74 (d , J = 5.3 Hz, 2H), 4.20 (s, 2H), 3.80 (s, 3H)
화합물번호 214. (2-벤질-퀴나졸린-4-일)-(3-트리플루오로메틸-벤질)-아민
1H NMR(CDCl3, 300 MHz) δ 7.80(m, 2H), 7.66(m, 2H), 7.49(m, 2H), 7.37(m, 4H), 7.20(m, 2H), 6.56(br, 1H), 4.86(d, J=6.3 Hz, 2H), 4.18(s, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.80 (m, 2H), 7.66 (m, 2H), 7.49 (m, 2H), 7.37 (m, 4H), 7.20 (m, 2H), 6.56 (br, 1H), 4.86 (d, J = 6.3 Hz, 2H), 4.18 (s, 2H)
화합물번호 215. (2-벤질-퀴나졸린-4-일)-펜에틸-아민
1H NMR(CDCl3, 300 MHz) δ 7.82(d, J=8.3 Hz, 1H), 7.61(m, 4H), 7.34-7.17(m, 6H), 6.12(br, 1H), 4.21(s, 2H), 3.88(m, 2H), 2.94(t, J=7.2 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.82 (d, J = 8.3 Hz, 1H), 7.61 (m, 4H), 7.34-7.17 (m, 6H), 6.12 (br, 1H), 4.21 (s, 2H), 3.88 (m, 2H), 2.94 (t, J = 7.2 Hz, 2H)
화합물번호 216. (2-벤질-퀴나졸린-4-일)-(4-페닐-부틸)-아민
1H NMR(CDCl3, 300 MHz) δ 7.81(d, J = 8.3 Hz, 1H), 7.63(t, J = 7.8 Hz, 2H), 7.46(d, J = 7.3 Hz, 2H), 7.33(m, 5H), 7.24(m, 4H), 5.98(br, 1H), 4.18(s, 2H), 3.62(d, J = 5.7 Hz, 2H), 2.64(t, J = 5.1 Hz, 2H), 1.69(m, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.81 (d, J = 8.3 Hz, 1H), 7.63 (t, J = 7.8 Hz, 2H), 7.46 (d, J = 7.3 Hz, 2H), 7.33 (m , 5H), 7.24 (m, 4H), 5.98 (br, 1H), 4.18 (s, 2H), 3.62 (d, J = 5.7 Hz, 2H), 2.64 (t, J = 5.1 Hz, 2H), 1.69 (m, 2H)
화합물번호 217. (2-벤질-퀴나졸린-4-일)-나프탈렌-1-일메틸-아민Compound number 217. (2-benzyl-quinazolin-4-yl) -naphthalen-1-ylmethyl-amine
1H NMR(CDCl3, 300 MHz) δ 8.01(d, J=8.3 Hz, 1H), 7.85(m, 3H), 7.54(m, 2H), 7.52-7.39(m, 6H), 7.25(m, 4H), 6.32(br, 1H), 5.28(d, J=5.0 Hz, 2H), 4.25(s, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.01 (d, J = 8.3 Hz, 1H), 7.85 (m, 3H), 7.54 (m, 2H), 7.52-7.39 (m, 6H), 7.25 (m, 4H), 6.32 (br, 1H), 5.28 (d, J = 5.0 Hz, 2H), 4.25 (s, 2H)
화합물번호 218. 벤조[1,3]디옥솔-5-일메틸-(2-벤질-퀴나졸린-4-일)-아민Compound 218.Benzo [1,3] dioxol-5-ylmethyl- (2-benzyl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 7.82(d, J=8.4 Hz, 1H), 7.68(m, 1H), 7.61(d, J=8.1 Hz, 1H), 7.46(d, J=7.2 Hz, 2H), 7.36(m, 1H), 7.25(m, 2H), 7.18(m, 1H), 6.81-6.71(m, 3H), 5.94(s, 2H), 5.89(br, 1H), 4.71(d, J=5.7 Hz, 2H), 4.20(s, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.82 (d, J = 8.4 Hz, 1H), 7.68 (m, 1H), 7.61 (d, J = 8.1 Hz, 1H), 7.46 (d, J = 7.2 Hz , 2H), 7.36 (m, 1H), 7.25 (m, 2H), 7.18 (m, 1H), 6.81-6.71 (m, 3H), 5.94 (s, 2H), 5.89 (br, 1H), 4.71 ( d, J = 5.7 Hz, 2H), 4.20 (s, 2H)
화합물번호 219. (2-벤질-퀴나졸린-4-일)-(3-플루오로-벤질)-아민
1H NMR(CDCl3, 300 MHz) δ 7.83(d, J=8.0 Hz, 1H), 7.69(t, J=7.3 Hz, 2H), 7.40(m, 3H), 7.23(m, 4H), 7.03(m, 3H), 6.15(br, 1H), 4.81(d, J=5.7 Hz, 2H), 4.18(s, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.83 (d, J = 8.0 Hz, 1H), 7.69 (t, J = 7.3 Hz, 2H), 7.40 (m, 3H), 7.23 (m, 4H), 7.03 (m, 3H), 6.15 (br, 1H), 4.81 (d, J = 5.7 Hz, 2H), 4.18 (s, 2H)
화합물번호 220. (2-벤질-퀴나졸린-4-일)-[2-(3-플루오로-페닐)-에틸]-아민
1H NMR(CDCl3, 300 MHz) δ 7.82(d, J=8.4 Hz, 1H), 7.68(d, J=7.5 Hz, 1H), 7.49(m, 3H), 7.34(m, 5H), 6.92(m, 3H), 5.69(br, 1H), 4.21(s, 2H), 3.84(q, J=6.6 Hz, 2H), 2.92(t, J=7.2 Hz, 2H) 1 H NMR (
화합물번호 221. 2-[2-(2-벤질-퀴나졸린-4-일아미노)-에톡시]-에탄올
1H NMR(CDCl3, 300 MHz) δ 7.80(d, J=8.4 Hz, 1H), 7.66(d, J=8.4 Hz, 2H), 7.45(d, J=7.2 Hz, 2H), 7.36(d, J=7.7 Hz, 1H), 7.28(m, 3H), 6.12(br, 1H), 4.17(s, 2H), 3.78(m, 6H), 3.59(t, J=4.5 Hz, 2H), 2.13(br s, 1H), 1 H NMR (
화합물번호 222. 2-(2-벤질-퀴나졸린-4-일아미노)-에탄올Compound 222. 2- (2-benzyl-quinazolin-4-ylamino) -ethanol
1H NMR(CDCl3, 300 MHz) δ 7.80(d, J=8.3 Hz, 1H), 7.67(m, 2H), 7.40(m, 3H), 7.23(m, 4H), 6.22(br, 1H), 4.15(s, 2H), 3.83(t, J=4.5 Hz, 2H), 3.76(m, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.80 (d, J = 8.3 Hz, 1H), 7.67 (m, 2H), 7.40 (m, 3H), 7.23 (m, 4H), 6.22 (br, 1H) , 4.15 (s, 2H), 3.83 (t, J = 4.5 Hz, 2H), 3.76 (m, 2H)
화합물번호 223. 벤질-(2-피리딘-2-일-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 8.80(d, J=3.9 Hz, 1H), 8.55(d, J=7.9 Hz, 1H), 8.08(d, J=8.4 Hz, 1H), 7.84(m, 2H), 7.71(t, J=7.7 Hz, 1H), 7.42(m, 3H), 7.34(m, 4H), 6.65(br, 1H), 4.99(s, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.80 (d, J = 3.9 Hz, 1H), 8.55 (d, J = 7.9 Hz, 1H), 8.08 (d, J = 8.4 Hz, 1H), 7.84 (m) , 2H), 7.71 (t, J = 7.7 Hz, 1H), 7.42 (m, 3H), 7.34 (m, 4H), 6.65 (br, 1H), 4.99 (s, 2H)
화합물번호 224. (3-메톡시-벤질)-(2-피리딘-2-일-퀴나졸린-4-일)-아민Compound number 224. (3-Methoxy-benzyl)-(2-pyridin-2-yl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 8.81(d, J=4.2 Hz, 1H), 8.56(d, J=7.8 Hz, 1H), 8.08(d, J=8.4 Hz, 1H), 7.92-7.72(m, 3H), 7.44(t, J=7.6 Hz, 1H), 7.36(t, J=6.1 Hz, 1H), 7.24(m, 2H), 7.02(m, 1H), 6.83(m,1H), 6.80(br, 1H), 4.97(s, 2H), 3.75(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.81 (d, J = 4.2 Hz, 1H), 8.56 (d, J = 7.8 Hz, 1H), 8.08 (d, J = 8.4 Hz, 1H), 7.92-7.72 (m, 3H), 7.44 (t, J = 7.6 Hz, 1H), 7.36 (t, J = 6.1 Hz, 1H), 7.24 (m, 2H), 7.02 (m, 1H), 6.83 (m, 1H) , 6.80 (br, 1 H), 4.97 (s, 2 H), 3.75 (s, 3 H)
화합물번호 225. (4-메톡시-벤질)-(2-피리딘-2-일-퀴나졸린-4-일)-아민Compound 225. (4-Methoxy-benzyl)-(2-pyridin-2-yl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 8.82(d, J=4.2 Hz, 1H), 8.59(d, J=7.9 Hz, 1H), 8.08(d, J=8.3 Hz, 1H), 7.84(m, 2H), 7.71(t, J=7.3 Hz, 1H), 7.43(m, 4H), 6.86(d, J=8.6 Hz, 2H), 6.61(br, 1H), 4.93(s, 2H), 3.78(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.82 (d, J = 4.2 Hz, 1H), 8.59 (d, J = 7.9 Hz, 1H), 8.08 (d, J = 8.3 Hz, 1H), 7.84 (m , 2H), 7.71 (t, J = 7.3 Hz, 1H), 7.43 (m, 4H), 6.86 (d, J = 8.6 Hz, 2H), 6.61 (br, 1H), 4.93 (s, 2H), 3.78 (s, 3H)
화합물번호 226. (2-피리딘-2-일-퀴나졸린-4-일)-(3-트리플루오로메틸-벤질)-아민
1H NMR(CDCl3, 300 MHz) δ 8.78(d, J=4.4 Hz, 1H), 8.44(d, J=7.9 Hz, 1H), 8.04(m, 2H), 7.74(m, 1H), 7.65(m, 2H), 7.48(m, 1H), 7.44-7.34(m, 4H), 6.12(br, 1H), 5.03(s, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.78 (d, J = 4.4 Hz, 1H), 8.44 (d, J = 7.9 Hz, 1H), 8.04 (m, 2H), 7.74 (m, 1H), 7.65 (m, 2H), 7.48 (m, 1H), 7.44-7.34 (m, 4H), 6.12 (br, 1H), 5.03 (s, 2H)
화합물번호 227. 펜에틸-(2-피리딘-2-일-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 8.84(d, J=4.0 Hz, 1H), 8.62(d, J=7.9 Hz, 1H), 8.08(d, J=8.3 Hz, 1H), 7.86(t, J=3.8 Hz, 1H), 7.73(m, 2H), 7.45-7.24(m, 7H), 6.54(br, 1H), 4.07(t, J=6.7 Hz, 2H), 3.10(t, J=7.1 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.84 (d, J = 4.0 Hz, 1H), 8.62 (d, J = 7.9 Hz, 1H), 8.08 (d, J = 8.3 Hz, 1H), 7.86 (t , J = 3.8 Hz, 1H), 7.73 (m, 2H), 7.45-7.24 (m, 7H), 6.54 (br, 1H), 4.07 (t, J = 6.7 Hz, 2H), 3.10 (t, J = 7.1 Hz, 2H)
화합물번호 228. (4-페닐-부틸)-(2-피리딘-2-일-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 8.83(d, J=4.2 Hz, 1H), 8.55(d, J=7.9 Hz, 1H), 8.06(d, J=8.3 H, 1Hz), 7.84(m, 2H), 7.71(t, J=7.5 Hz, 1H), 7.44(t, J=7.5 Hz, 1H), 7.37(t, J=6.0 Hz, 1H), 7.28-7.16(m, 5H), 6.44(br, 1H), 3.83(m, 2H), 2.70(t, J=6.3 Hz, 2H), 1.81(m, 4H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.83 (d, J = 4.2 Hz, 1H), 8.55 (d, J = 7.9 Hz, 1H), 8.06 (d, J = 8.3 H, 1 Hz), 7.84 (m , 2H), 7.71 (t, J = 7.5 Hz, 1H), 7.44 (t, J = 7.5 Hz, 1H), 7.37 (t, J = 6.0 Hz, 1H), 7.28-7.16 (m, 5H), 6.44 (br, 1H), 3.83 (m, 2H), 2.70 (t, J = 6.3 Hz, 2H), 1.81 (m, 4H)
화합물번호 229. 나프탈렌-1-일메틸-(2-피리딘-2-일-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 8.83(d, J=4.0 Hz, 1H), 8.60(d, J=7.9 Hz, 1H), 8.10(d, J=8.3 Hz, 1H), 8.05(m, 1H), 7.83(m, 4H), 7,71(m, 1H), 7.63(m, 1H), 7.50-7.36(m, 5H), 6.78(br, 1H), 5.43(s, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.83 (d, J = 4.0 Hz, 1H), 8.60 (d, J = 7.9 Hz, 1H), 8.10 (d, J = 8.3 Hz, 1H), 8.05 (m , 1H), 7.83 (m, 4H), 7,71 (m, 1H), 7.63 (m, 1H), 7.50-7.36 (m, 5H), 6.78 (br, 1H), 5.43 (s, 2H)
화합물번호 230. 벤조[1,3]디옥솔-5-일메틸-(2-피리딘-2-일-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 8.83(d, J=4.1 Hz, 1H), 8.58(d, J=8.0 Hz, 1H), 8.08(d, J=8.3 Hz, 1H), 7.84(m, 2H), 7.73(d, J=7.2 Hz, 1H), 7.45(m, 1H), 7.36(m, 1H), 6.90(m, 2H), 6.76(d, J=7.8 Hz, 1H), 6.61(br, 1H), 5.92(s, 2H), 4.90(s, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.83 (d, J = 4.1 Hz, 1H), 8.58 (d, J = 8.0 Hz, 1H), 8.08 (d, J = 8.3 Hz, 1H), 7.84 (m , 2H), 7.73 (d, J = 7.2 Hz, 1H), 7.45 (m, 1H), 7.36 (m, 1H), 6.90 (m, 2H), 6.76 (d, J = 7.8 Hz, 1H), 6.61 (br, 1H), 5.92 (s, 2H), 4.90 (s, 2H)
화합물번호 231. (3-플루오로-벤질)-(2-피리딘-2-일-퀴나졸린-4-일)-아민Compound number 231. (3-Fluoro-benzyl)-(2-pyridin-2-yl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 8.80(d, J=4.1 Hz, 1H), 8.49(d, J=8.1 Hz, 1H), 8.05(m, 2H), 7.83(m, 1H), 7.73(t, J=7.7 Hz, 1H), 7.47(m, 1H), 7.37(m, 1H), 7.28(m, 2H), 7.18(m, 1H), 6.94(m, 1H), 6.43(br, 1H), 5.00(s, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.80 (d, J = 4.1 Hz, 1H), 8.49 (d, J = 8.1 Hz, 1H), 8.05 (m, 2H), 7.83 (m, 1H), 7.73 (t, J = 7.7 Hz, 1H), 7.47 (m, 1H), 7.37 (m, 1H), 7.28 (m, 2H), 7.18 (m, 1H), 6.94 (m, 1H), 6.43 (br, 1H), 5.00 (s, 2H)
화합물번호 232. [2-(3-플루오로-페닐)-에틸]-(2-피리딘-2-일-퀴나졸린-4-일)-아민Compound number 232. [2- (3-Fluoro-phenyl) -ethyl]-(2-pyridin-2-yl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 8.83(d, J=4.1 Hz, 1H), 8.59(d, J=8.2 Hz, 1H), 8.07(d, J=8.3 Hz, 1H), 7.86(t, J=7.7 Hz, 1H), 7.73(m, 2H), 7.39(m, 2H), 7.25(m, 1H), 7.00(m, 3H), 6.45(br, 1H), 4.03(m, 2H), 3.08(t, J=6.6 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.83 (d, J = 4.1 Hz, 1H), 8.59 (d, J = 8.2 Hz, 1H), 8.07 (d, J = 8.3 Hz, 1H), 7.86 (t , J = 7.7 Hz, 1H), 7.73 (m, 2H), 7.39 (m, 2H), 7.25 (m, 1H), 7.00 (m, 3H), 6.45 (br, 1H), 4.03 (m, 2H) , 3.08 (t, J = 6.6 Hz, 2H)
화합물번호 233. 2-[2-(2-피리딘-2-일-퀴나졸린-4-일아미노)-에톡시]-에탄올Compound 233. 2- [2- (2-pyridin-2-yl-quinazolin-4-ylamino) -ethoxy] -ethanol
1H NMR(CDCl3, 300 MHz) δ 8.89(t, J=6.8 Hz, 2H), 8.46(d, J=8.0 Hz, 1H), 8.00(m, 2H), 7.58(d, J=7.5 Hz, 2H), 7.41(, J=7.2 Hzt, 1H), 6.63(br, 1H), 4.08(m, 4H), 8.83(m, 4H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.89 (t, J = 6.8 Hz, 2H), 8.46 (d, J = 8.0 Hz, 1H), 8.00 (m, 2H), 7.58 (d, J = 7.5 Hz , 2H), 7.41 (, J = 7.2 Hzt, 1H), 6.63 (br, 1H), 4.08 (m, 4H), 8.83 (m, 4H)
화합물번호 234. 2-(2-피리딘-2-일-퀴나졸린-4-일아미노)-에탄올Compound 234. 2- (2-Pyridin-2-yl-quinazolin-4-ylamino) -ethanol
1H NMR(CDCl3, 300 MHz) δ 8.80(d, J=4.6 Hz, 1H), 8.56(d, J=8.1 Hz, 1H), 8.01(d, J=8.3 Hz, 1H), 7.84(m, 2H), 7.74(t, J=7.7 Hz, 1H), 7.40(m, 1H), 7.36(m, 1H), 6.81(br, 1H), 3.97(m, 4H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.80 (d, J = 4.6 Hz, 1H), 8.56 (d, J = 8.1 Hz, 1H), 8.01 (d, J = 8.3 Hz, 1H), 7.84 (m , 2H), 7.74 (t, J = 7.7 Hz, 1H), 7.40 (m, 1H), 7.36 (m, 1H), 6.81 (br, 1H), 3.97 (m, 4H)
화합물번호 235. 벤질-(2-피리딘-3-일-퀴나졸린-4-일)-아민Compound number 235. Benzyl- (2-pyridin-3-yl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 9.72(s, 1H), 8.67(d, J=4.5 Hz, 1H), 8.54(m, 1H), 7.96(d, J=8.3 Hz, 1H), 7.79(m, 2H), 7.46-7.29(m, 6H), 6.52(br, 1H), 4.99(d, J=5.4 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 9.72 (s, 1H), 8.67 (d, J = 4.5 Hz, 1H), 8.54 (m, 1H), 7.96 (d, J = 8.3 Hz, 1H), 7.79 (m, 2H), 7.46-7.29 (m, 6H), 6.52 (br, 1H), 4.99 (d, J = 5.4 Hz, 2H)
화합물번호 236. (3-메톡시-벤질)-(2-피리딘-3-일-퀴나졸린-4-일)-아민Compound 236. (3-Methoxy-benzyl)-(2-pyridin-3-yl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 9.72(s, 1H), 8.86(d, J = 7.9 Hz, 1H), 8.68(d, J=3.8 Hz, 1H), 8.01(d, J=8.3 Hz, 1H), 7.85(d, J=8.1 Hz, 1H), 7.83(m, 1H), 7.43(m, 2H), 7.26(m, 1H), 7.01(t, J=5.9 Hz, 2H), 6.84(t, J=4.13 Hz, 1H), 6.68(br, 1H), 4.97(d, J=5.4 Hz, 2H), 3.77(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 9.72 (s, 1H), 8.86 (d, J = 7.9 Hz, 1H), 8.68 (d, J = 3.8 Hz, 1H), 8.01 (d, J = 8.3 Hz , 1H), 7.85 (d, J = 8.1 Hz, 1H), 7.83 (m, 1H), 7.43 (m, 2H), 7.26 (m, 1H), 7.01 (t, J = 5.9 Hz, 2H), 6.84 (t, J = 4.13 Hz, 1H), 6.68 (br, 1H), 4.97 (d, J = 5.4 Hz, 2H), 3.77 (s, 3H)
화합물번호 237. (4-메톡시-벤질)-(2-피리딘-3-일-퀴나졸린-4-일)-아민Compound 237. (4-Methoxy-benzyl)-(2-pyridin-3-yl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 9.74(s, 1H), 8.83(d, J=7.9 Hz, 1H), 8.66(d, J=3.6 Hz, 1H), 7.95(d, J=8.3 Hz, 1H), 7.75(m, 2H), 7.38(m, 4H), 6.87(d, J=8.8 Hz, 2H), 6.38(br, 1H), 4.90(d, J=5.4 Hz, 2H), 3.78(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 9.74 (s, 1H), 8.83 (d, J = 7.9 Hz, 1H), 8.66 (d, J = 3.6 Hz, 1H), 7.95 (d, J = 8.3 Hz , 1H), 7.75 (m, 2H), 7.38 (m, 4H), 6.87 (d, J = 8.8 Hz, 2H), 6.38 (br, 1H), 4.90 (d, J = 5.4 Hz, 2H), 3.78 (s, 3H)
화합물번호 238. (2-피리딘-3-일-퀴나졸린-4-일)-(3-트리플루오로메틸-벤질)-아민Compound 238. (2-Pyridin-3-yl-quinazolin-4-yl)-(3-trifluoromethyl-benzyl) -amine
1H NMR(CDCl3, 300 MHz) δ 9.89(s, 1H), 8.74(m, 2H), 7.96(d, J=8.3 Hz, 1H), 7.78(m, 4H), 7.47(m, 4H), 6.39(br, 1H), 5.05(d, J=5.4 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 9.89 (s, 1H), 8.74 (m, 2H), 7.96 (d, J = 8.3 Hz, 1H), 7.78 (m, 4H), 7.47 (m, 4H) , 6.39 (br, 1 H), 5.05 (d, J = 5.4 Hz, 2 H)
화합물번호 239. 펜에틸-(2-피리딘-3-일-퀴나졸린-4-일)-아민Compound number 239. Phenethyl- (2-pyridin-3-yl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 9.77(s, 1H), 8.85(s, J=8.0 Hz, 1H), 7.95(d, J=8.5 Hz, 1H), 7.73(m, 1H), 7.41(m, 7H), 6.17(br, 1H), 4.05(m, 2H), 3.10(t, J=6.9 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 9.77 (s, 1H), 8.85 (s, J = 8.0 Hz, 1H), 7.95 (d, J = 8.5 Hz, 1H), 7.73 (m, 1H), 7.41 (m, 7H), 6.17 (br, 1H), 4.05 (m, 2H), 3.10 (t, J = 6.9 Hz, 2H)
화합물번호 240. (4-페닐-부틸)-(2-피리딘-3-일-퀴나졸린-4-일)-아민Compound number 240. (4-phenyl-butyl)-(2-pyridin-3-yl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 9.74(s, 1H), 8.82(d, J=8.0 Hz, 1H), 8.68(d, J=3.9 Hz, 1H), 7.95(d, J=8.1 Hz, 1H), 7.72(t, J=7.6 Hz, 2H), 7.41(m, 2H), 7.24(m, 5H), 6.12(br, 1H), 3.80(t, J=5.9 Hz, 2H), 2.71(t, J=6.7 Hz, 2H), 1.81(t, J=3.4 Hz, 4H) 1 H NMR (CDCl 3 , 300 MHz) δ 9.74 (s, 1H), 8.82 (d, J = 8.0 Hz, 1H), 8.68 (d, J = 3.9 Hz, 1H), 7.95 (d, J = 8.1 Hz , 1H), 7.72 (t, J = 7.6 Hz, 2H), 7.41 (m, 2H), 7.24 (m, 5H), 6.12 (br, 1H), 3.80 (t, J = 5.9 Hz, 2H), 2.71 (t, J = 6.7 Hz, 2H), 1.81 (t, J = 3.4 Hz, 4H)
화합물번호 241. 나프탈렌-1-일메틸-(2-피리딘-3-일-퀴나졸린-4-일)-아민Compound number 241. Naphthalen-1-ylmethyl- (2-pyridin-3-yl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz)) δ 9.82(s, 1H), 8.88(d, J=7.9 Hz, 1H), 8.69(m, 1H), 8.12(m, 1H), 7.92(m, 3H), 7.80(m, 1H), 7.61(m, 2H), 7.50(m, 5H), 6.05(br, 1H), 5.43(d, J=4.8 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 9.82 (s, 1H), 8.88 (d, J = 7.9 Hz, 1H), 8.69 (m, 1H), 8.12 (m, 1H), 7.92 (m, 3H ), 7.80 (m, 1H), 7.61 (m, 2H), 7.50 (m, 5H), 6.05 (br, 1H), 5.43 (d, J = 4.8 Hz, 2H)
화합물번호 242. 벤조[1,3]디옥솔-5-일메틸-(2-피리딘-3-일-퀴나졸린-4-일)-아민Compound 242. Benzo [1,3] dioxol-5-ylmethyl- (2-pyridin-3-yl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 9.72(s, 1H), 8.89(d, J=8.0 Hz, 1H), 8.69(d, J=4.5 Hz, 1H), 8.03(d, J=8.5 Hz, 1H), 7.86(d, J=8.1 Hz, 1H), 7.73(t, J=7.3 Hz, 1H), 7.43(t, J=6.5 Hz, 2H), 6.92(d, J=7.8 Hz, 2H), 7.77(d, J=7.7 Hz, 2H), 5.92(s, 2H), 4.90(d, J = 5.4 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 9.72 (s, 1H), 8.89 (d, J = 8.0 Hz, 1H), 8.69 (d, J = 4.5 Hz, 1H), 8.03 (d, J = 8.5 Hz , 1H), 7.86 (d, J = 8.1 Hz, 1H), 7.73 (t, J = 7.3 Hz, 1H), 7.43 (t, J = 6.5 Hz, 2H), 6.92 (d, J = 7.8 Hz, 2H ), 7.77 (d, J = 7.7 Hz, 2H), 5.92 (s, 2H), 4.90 (d, J = 5.4 Hz, 2H)
화합물번호 243. (3-플루오로-벤질)-(2-피리딘-3-일-퀴나졸린-4-일)-아민Compound number 243. (3-Fluoro-benzyl)-(2-pyridin-3-yl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 9.69(s, 1H), 8.81(d, J=8.0 Hz, 1H), 8.68(d, J=3.8 Hz, 1H), 8.00(d, J=8.3 Hz, 1H), 7.87(d, J=8.1 Hz, 1H), 7.75(m, 1H), 7.44(m, 2H), 7.29(m, 2H), 7.14(m, 1H), 6.96(m, 1H), 6.72(br, 1H), 5.00(d, J=5.6 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 9.69 (s, 1H), 8.81 (d, J = 8.0 Hz, 1H), 8.68 (d, J = 3.8 Hz, 1H), 8.00 (d, J = 8.3 Hz , 1H), 7.87 (d, J = 8.1 Hz, 1H), 7.75 (m, 1H), 7.44 (m, 2H), 7.29 (m, 2H), 7.14 (m, 1H), 6.96 (m, 1H) , 6.72 (br, 1 H), 5.00 (d, J = 5.6 Hz, 2H)
화합물번호 244. [2-(3-플루오로-페닐)-에틸]-(2-피리딘-3-일-퀴나졸린-4-일)-아민Compound 244. [2- (3-Fluoro-phenyl) -ethyl]-(2-pyridin-3-yl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 9.75(s, 1H), 8.86(d, J=8.0 Hz, 1H), 8.69(d, J=4. Hz, 1H), 7.97(d, J=8.4 Hz, 1H), 7.70(m, 2H), 7.43(m, 2H), 7.27(m, 2H), 6.99(m, 3H), 6.28(br, 1H), 4.05(m, 2H), 3.11(t, J=6.9 H, 2Hz) 1 H NMR (CDCl 3 , 300 MHz) δ 9.75 (s, 1H), 8.86 (d, J = 8.0 Hz, 1H), 8.69 (d, J = 4. Hz, 1H), 7.97 (d, J = 8.4 Hz, 1H), 7.70 (m, 2H), 7.43 (m, 2H), 7.27 (m, 2H), 6.99 (m, 3H), 6.28 (br, 1H), 4.05 (m, 2H), 3.11 (t , J = 6.9 H, 2 Hz)
화합물번호 245. 2-[2-(2-피리딘-3-일-퀴나졸린-4-일아미노)-에톡시]-에탄올Compound 245. 2- [2- (2-pyridin-3-yl-quinazolin-4-ylamino) -ethoxy] -ethanol
1H NMR(CDCl3, 300 MHz) δ 9.66(s, 1H), 8.73(d, J=7.2 Hz, 1H), 8.63(d, J=2.8 Hz, 1H), 7.86(d, J=8.3 H, 1Hz), 7.79(d, J=8.2 Hz, 1H), 7.65(m, 1H), 7.35(m, 2H), 6.81(br, 1H), 3.97(m, 2H), 3.83(m, 4H), 3.67(m, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 9.66 (s, 1H), 8.73 (d, J = 7.2 Hz, 1H), 8.63 (d, J = 2.8 Hz, 1H), 7.86 (d, J = 8.3 H , 1 Hz), 7.79 (d, J = 8.2 Hz, 1H), 7.65 (m, 1H), 7.35 (m, 2H), 6.81 (br, 1H), 3.97 (m, 2H), 3.83 (m, 4H) , 3.67 (m, 2 H)
화합물번호 246. 2-(2-피리딘-3-일-퀴나졸린-4-일아미노)-에탄올Compound 246. 2- (2-Pyridin-3-yl-quinazolin-4-ylamino) -ethanol
1H NMR(CDCl3, 300 MHz) δ 9.67(s, 1H), 8.76(d, J=8.03 Hz, 1H), 8.66(d, J=3.4 Hz, 1H), 7.94(t, J=7.7 Hz, 2H), 7.72(t, J=7.6 Hz, 1H), 7.42(m, 2H), 6.94(br, 1H), 4.00(m, 4H) 1 H NMR (CDCl 3 , 300 MHz) δ 9.67 (s, 1H), 8.76 (d, J = 8.03 Hz, 1H), 8.66 (d, J = 3.4 Hz, 1H), 7.94 (t, J = 7.7 Hz , 2H), 7.72 (t, J = 7.6 Hz, 1H), 7.42 (m, 2H), 6.94 (br, 1H), 4.00 (m, 4H)
화합물번호 247. 벤질-(2-피리딘-4-일-퀴나졸린-4-일)-아민Compound number 247. Benzyl- (2-pyridin-4-yl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 8.74(m, 2H),8.43(d, J=5.5 Hz, 2H), 7.98(d, J=8.3 Hz, 1H), 7.75(t, J=4.4 Hz, 2H), 7.48(m, 3H), 7.36(m, 3H), 6.21(br, 1H), 5.01(d, J=5.4 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.74 (m, 2H), 8.43 (d, J = 5.5 Hz, 2H), 7.98 (d, J = 8.3 Hz, 1H), 7.75 (t, J = 4.4 Hz , 2H), 7.48 (m, 3H), 7.36 (m, 3H), 6.21 (br, 1H), 5.01 (d, J = 5.4 Hz, 2H)
화합물번호 248. (3-메톡시-벤질)-(2-피리딘-4-일-퀴나졸린-4-일)-아민Compound 248. (3-Methoxy-benzyl)-(2-pyridin-4-yl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 8.73(d, J=5.0 Hz, 2H), 8.43(d, J=5.5 Hz, 2H), 9.98(d, J=8.2 Hz, 1H), 7.77(t, J=7.7 Hz, 2H), 7.49(d, J=7.2 Hz, 1H), 7.26(m, 2H), 6.84(m, 1H), 6.35(br, 1H), 4.98(d, J=5.3 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.73 (d, J = 5.0 Hz, 2H), 8.43 (d, J = 5.5 Hz, 2H), 9.98 (d, J = 8.2 Hz, 1H), 7.77 (t , J = 7.7 Hz, 2H), 7.49 (d, J = 7.2 Hz, 1H), 7.26 (m, 2H), 6.84 (m, 1H), 6.35 (br, 1H), 4.98 (d, J = 5.3 Hz , 2H)
화합물번호 249. (4-메톡시-벤질)-(2-피리딘-4-일-퀴나졸린-4-일)-아민Compound number 249. (4-Methoxy-benzyl)-(2-pyridin-4-yl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 8.74(d, J=5.5 Hz, 2H), 8.46(d, J=5.5 Hz, 2H), 7.98(d, J=8.2 Hz, 1H), 7.76(t, J=7.6 Hz, 2H), 7.47(t, J=7.6 Hz, 1H), 7.38(d, J=8.5 Hz, 2H), 6.90(d, J=8.5 Hz, 2H), 6.29(br, 1H), 4.93(d, J=5.4 Hz, 2H), 3.80(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.74 (d, J = 5.5 Hz, 2H), 8.46 (d, J = 5.5 Hz, 2H), 7.98 (d, J = 8.2 Hz, 1H), 7.76 (t , J = 7.6 Hz, 2H), 7.47 (t, J = 7.6 Hz, 1H), 7.38 (d, J = 8.5 Hz, 2H), 6.90 (d, J = 8.5 Hz, 2H), 6.29 (br, 1H) ), 4.93 (d, J = 5.4 Hz, 2H), 3.80 (s, 3H)
화합물번호 250. (2-피리딘-4-일-퀴나졸린-4-일)-(3-트리플루오로메틸-벤질)-아민
1H NMR(CDCl3, 300 MHz) δ 8.72(m, 2H), 8.40(d, J=4.71 Hz, 2H), 8.02(d, J=8.3 Hz, 1H), 7.84(m, 2H), 7.75(m, 1H), 7.65(m, 1H), 7.52(m, 3H), 6.57(br, 1H), 5.02(d, J=5.3 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.72 (m, 2H), 8.40 (d, J = 4.71 Hz, 2H), 8.02 (d, J = 8.3 Hz, 1H), 7.84 (m, 2H), 7.75 (m, 1H), 7.65 (m, 1H), 7.52 (m, 3H), 6.57 (br, 1H), 5.02 (d, J = 5.3 Hz, 2H)
화합물번호 251. 펜에틸-(2-피리딘-4-일-퀴나졸린-4-일)-아민Compound 251.Phenethyl- (2-pyridin-4-yl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 8.74(d, J=5.5 Hz, 2H), 8.45(d, J=5.5 Hz, 2H), 7.96(d, J=8.3 Hz, 1H), 7.76(t, J=7.4 Hz, 1H), 7.67(dH, J=8.2 Hz, 1), 7.46(d, J=7.2 Hz, 1H), 7.33(m, 5H), 6.09(br, 1H), 4.06(m, 2H), 3.11(t, J=6.9 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.74 (d, J = 5.5 Hz, 2H), 8.45 (d, J = 5.5 Hz, 2H), 7.96 (d, J = 8.3 Hz, 1H), 7.76 (t , J = 7.4 Hz, 1H), 7.67 (dH, J = 8.2 Hz, 1), 7.46 (d, J = 7.2 Hz, 1H), 7.33 (m, 5H), 6.09 (br, 1H), 4.06 (m , 2H), 3.11 (t, J = 6.9 Hz, 2H)
화합물번호 252. (4-페닐-부틸)-(2-피리딘-4-일-퀴나졸린-4-일)-아민Compound 252. (4-phenyl-butyl)-(2-pyridin-4-yl-quinazolin-4-yl) -amine
1H NMR(300MHz, CDCl3, 300 MHz) δ 8.76(d, J=5.4 Hz, 2H), 8.42(d, J=5.5 Hz, 2H), 7.97(d, J=8.3 Hz, 1H), 7.75(t, J=7.5 Hz, 2H), 7.47(t, J=7.5 Hz, 1H), 7.25(m, 6H), 6.10(br, 1H), 3.82(d, J=5.6 Hz, 2H), 2.73(t, J=6.6 Hz, 2H), 1.84(m, 4H) 1 H NMR (300 MHz,
화합물번호 253. 나프탈렌-1-일메틸-(2-피리딘-4-일-퀴나졸린-4-일)-아민Compound number 253. Naphthalen-1-ylmethyl- (2-pyridin-4-yl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 8.76(d, J=5.4 Hz, 2H), 8.46(d, J=5.3 Hz, 2H), 8.12(d, J=8.4 Hz, 1H), 7.95(m, 3H), 7.77(m, 1H), 7.62(t, J=5.8 Hz, 2H), 7.50(m, 4H), 5.99(br, 1H), 5.44(d, J=4.9 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.76 (d, J = 5.4 Hz, 2H), 8.46 (d, J = 5.3 Hz, 2H), 8.12 (d, J = 8.4 Hz, 1H), 7.95 (m) , 3H), 7.77 (m, 1H), 7.62 (t, J = 5.8 Hz, 2H), 7.50 (m, 4H), 5.99 (br, 1H), 5.44 (d, J = 4.9 Hz, 2H)
화합물번호 254. 벤조[1,3]디옥솔-5-일메틸-(2-피리딘-4-일-퀴나졸린-4-일)-아민Compound 254. Benzo [1,3] dioxol-5-ylmethyl- (2-pyridin-4-yl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 8.74(d, J=5.4 Hz, 2H), 8.40(d, J=6.06 Hz, 2H), 7.96(d, J=8.4 Hz, 1H), 7.76(m, 2H), 7.48(t, J=7.6 Hz, 1H), 6.92(d, J=7.97 Hz, 2H), 6.80(d, J=7.7 Hz, 1H), 6.07(br, 1H), 5.96(s, 2H), 4.91(d, J=5.3 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.74 (d, J = 5.4 Hz, 2H), 8.40 (d, J = 6.06 Hz, 2H), 7.96 (d, J = 8.4 Hz, 1H), 7.76 (m , 2H), 7.48 (t, J = 7.6 Hz, 1H), 6.92 (d, J = 7.97 Hz, 2H), 6.80 (d, J = 7.7 Hz, 1H), 6.07 (br, 1H), 5.96 (s , 2H), 4.91 (d, J = 5.3 Hz, 2H)
화합물번호 255. (3-플루오로-벤질)-(2-피리딘-4-일-퀴나졸린-4-일)-아민Compound 255. (3-Fluoro-benzyl)-(2-pyridin-4-yl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 8.74(d, J=5.4 Hz, 2H), 8.38(d, J=5.1 Hz, 2H), 7.98(d, J=8.4 H, 1Hz), 7.79(t, J=7.8 Hz, 2H), 7.51(t, J=3.9 Hz, 1H), 7.35(t, J=3.9 Hz, 1H), 7.25(m, 1H), 7.17(m, 1H), 7.01(m, 1H), 6.24(br, 1H), 5.01(d, J=5.5 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.74 (d, J = 5.4 Hz, 2H), 8.38 (d, J = 5.1 Hz, 2H), 7.98 (d, J = 8.4 H, 1 Hz), 7.79 (t , J = 7.8 Hz, 2H), 7.51 (t, J = 3.9 Hz, 1H), 7.35 (t, J = 3.9 Hz, 1H), 7.25 (m, 1H), 7.17 (m, 1H), 7.01 (m , 1H), 6.24 (br, 1H), 5.01 (d, J = 5.5 Hz, 2H)
화합물번호 256. [2-(3-플루오로-페닐)-에틸]-(2-피리딘-4-일-퀴나졸린-4-일)-아민Compound No. 256. [2- (3-Fluoro-phenyl) -ethyl]-(2-pyridin-4-yl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 8.76(d, J=5.5 Hz, 2H), 8.44(d, J=5.3 Hz, 2H), 7.98(d, J=8.4 Hz, 1H), 7.67(d, J=8.0 Hz, 1H), 7.48(d, J=7.3 Hz, 1H), 7.28(m, 1H), 7.03(m, 3H), 6.14(br, 1H), 4.05(m, 2H), 3.11(t, J=6.9 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.76 (d, J = 5.5 Hz, 2H), 8.44 (d, J = 5.3 Hz, 2H), 7.98 (d, J = 8.4 Hz, 1H), 7.67 (d , J = 8.0 Hz, 1H), 7.48 (d, J = 7.3 Hz, 1H), 7.28 (m, 1H), 7.03 (m, 3H), 6.14 (br, 1H), 4.05 (m, 2H), 3.11 (t, J = 6.9 Hz, 2H)
화합물번호 257. 2-[2-(2-피리딘-4-일-퀴나졸린-4-일아미노)-에톡시]-에탄올Compound number 257. 2- [2- (2-pyridin-4-yl-quinazolin-4-ylamino) -ethoxy] -ethanol
1H NMR(CDCl3, 300 MHz) δ 8.72(d, J=4.8 Hz, 2H), 8.36(d, J=5.8 Hz, 2H), 7.92(d, J=8.3 Hz, 1H), 7.83(d, J=8.2 Hz, 1H), 7.73(t, J=7.6 Hz, 1H), 7.45(t, J=7.6 Hz, 1H), 6.64(br, 1H), 4.02(m, 2H), 3.81(m, 4H), 3.69(m, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.72 (d, J = 4.8 Hz, 2H), 8.36 (d, J = 5.8 Hz, 2H), 7.92 (d, J = 8.3 Hz, 1H), 7.83 (d , J = 8.2 Hz, 1H), 7.73 (t, J = 7.6 Hz, 1H), 7.45 (t, J = 7.6 Hz, 1H), 6.64 (br, 1H), 4.02 (m, 2H), 3.81 (m) , 4H), 3.69 (m, 2H)
화합물번호 258. 2-(2-피리딘-4-일-퀴나졸린-4-일아미노)-에탄올Compound number 258. 2- (2-Pyridin-4-yl-quinazolin-4-ylamino) -ethanol
1H NMR(CDCl3, 300 MHz) δ 8.71(d, J=4.8 Hz, 2H), 8.35(d, J=5.5 Hz, 2H), 8.13(d, J=8.4 Hz, 1H), 7.90(d, J=8.2 Hz, 1H), 7.73(t, J=8.3 Hz, 1H), 7.47(t, J=7.6 Hz, 1H), 7.18(br, 1H), 3.99(m, 4H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.71 (d, J = 4.8 Hz, 2H), 8.35 (d, J = 5.5 Hz, 2H), 8.13 (d, J = 8.4 Hz, 1H), 7.90 (d , J = 8.2 Hz, 1H), 7.73 (t, J = 8.3 Hz, 1H), 7.47 (t, J = 7.6 Hz, 1H), 7.18 (br, 1H), 3.99 (m, 4H)
화합물번호 259. 벤질-[2-(4-클로로-페닐)-퀴나졸린-4-일]-아민Compound number 259. Benzyl- [2- (4-chloro-phenyl) -quinazolin-4-yl] -amine
1H NMR(CDCl3, 300 MHz) δ 8.52(d, J=8.6 Hz, 2H), 7.92(d, J=8.2 Hz, 1H), 7.71(m, 2H), 7.40(m, 8H), 5.97(br, 1H), 5.00(d, J=5.5 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.52 (d, J = 8.6 Hz, 2H), 7.92 (d, J = 8.2 Hz, 1H), 7.71 (m, 2H), 7.40 (m, 8H), 5.97 (br, 1H), 5.00 (d, J = 5.5 Hz, 2H)
화합물번호 260. [2-(4-클로로-페닐)-퀴나졸린-4-일]-(3-메톡시-벤질)-아민Compound 260. [2- (4-Chloro-phenyl) -quinazolin-4-yl]-(3-methoxy-benzyl) -amine
1H NMR(CDCl3, 300 MHz) δ 8.52(d, J=8.5 Hz, 2H), 7.92(d, J=8.3 Hz, 1H), 7.72(m, 2H), 7.42(m, 3H), 7.28(m, 1H), 7.03(d, J=8.0 Hz, 2H), 6.87(t, J=4.2 Hz, 1H), 5.98(br, 1H), 4.98(d, J=5.5 Hz, 2H), 3.78(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.52 (d, J = 8.5 Hz, 2H), 7.92 (d, J = 8.3 Hz, 1H), 7.72 (m, 2H), 7.42 (m, 3H), 7.28 (m, 1H), 7.03 (d, J = 8.0 Hz, 2H), 6.87 (t, J = 4.2 Hz, 1H), 5.98 (br, 1H), 4.98 (d, J = 5.5 Hz, 2H), 3.78 (s, 3H)
화합물번호 261. [2-(4-클로로-페닐)-퀴나졸린-4-일]-(4-메톡시-벤질)-아민Compound number 261. [2- (4-Chloro-phenyl) -quinazolin-4-yl]-(4-methoxy-benzyl) -amine
1H NMR(CDCl3, 300 MHz) δ 8.53(d, J=8.5 Hz, 2H), 7.96(d, J=8.55 Hz, 1H), 7.72(m, 2H), 7.38(m, 5H), 6.90(d, J=8.6 Hz, 2H), 4.92(d, J=5.3 Hz, 2H), 3.80(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.53 (d, J = 8.5 Hz, 2H), 7.96 (d, J = 8.55 Hz, 1H), 7.72 (m, 2H), 7.38 (m, 5H), 6.90 (d, J = 8.6 Hz, 2H), 4.92 (d, J = 5.3 Hz, 2H), 3.80 (s, 3H)
화합물번호 262. [2-(4-클로로-페닐)-퀴나졸린-4-일]-(3-트리플루오로메틸-벤질)-아민Compound 262. [2- (4-Chloro-phenyl) -quinazolin-4-yl]-(3-trifluoromethyl-benzyl) -amine
1H NMR(CDCl3, 300 MHz) δ 8.45(d, J=8.6 Hz, 2H), 7.95(d,, J=8.5 Hz 1H), 7.75(m, 3H), 7.65(d, J=7.7 Hz, 1H), 7.56(d, J=7.7 Hz, 1H), 7.45(m, 4H), 6.12(br, 1H), 5.05(d, J=5.5 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.45 (d, J = 8.6 Hz, 2H), 7.95 (d, J = 8.5 Hz 1H), 7.75 (m, 3H), 7.65 (d, J = 7.7 Hz , 1H), 7.56 (d, J = 7.7 Hz, 1H), 7.45 (m, 4H), 6.12 (br, 1H), 5.05 (d, J = 5.5 Hz, 2H)
화합물번호 263. [2-(4-클로로-페닐)-퀴나졸린-4-일]-펜에틸-아민Compound 263. [2- (4-Chloro-phenyl) -quinazolin-4-yl] -phenethyl-amine
1H NMR(CDCl3, 300 MHz) δ 8.54(d, J=8.4 Hz, 2H), 7.94(d, J=8.5 Hz, 1H), 7.70(t, J=7.5 Hz, 1H), 7.60(d, J=8.1 Hz, 1H), 7.46(d, J=8.6 Hz, 2H), 7.35(m, 6H), 6.04(br, 1H), 4.05(m, 2H), 3.10(t, J=7.0 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.54 (d, J = 8.4 Hz, 2H), 7.94 (d, J = 8.5 Hz, 1H), 7.70 (t, J = 7.5 Hz, 1H), 7.60 (d , J = 8.1 Hz, 1H), 7.46 (d, J = 8.6 Hz, 2H), 7.35 (m, 6H), 6.04 (br, 1H), 4.05 (m, 2H), 3.10 (t, J = 7.0 Hz , 2H)
화합물번호 264. [2-(4-클로로-페닐)-퀴나졸린-4-일]-(4-페닐-부틸)-아민Compound number 264. [2- (4-Chloro-phenyl) -quinazolin-4-yl]-(4-phenyl-butyl) -amine
1H NMR(CDCl3, 300 MHz) δ 8.50(d, J=8.5 Hz, 2H), 7.93(d, J=8.6 Hz, 1H), 7.70(m, 2H), 7.41(m, 3H), 7.25(m, 5H), 6.09(br, 1H), 3.80(d, J=5.5 Hz, 2H), 2.72(m, 2H), 1.82(m, 4H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.50 (d, J = 8.5 Hz, 2H), 7.93 (d, J = 8.6 Hz, 1H), 7.70 (m, 2H), 7.41 (m, 3H), 7.25 (m, 5H), 6.09 (br, 1H), 3.80 (d, J = 5.5 Hz, 2H), 2.72 (m, 2H), 1.82 (m, 4H)
화합물번호 265. [2-(4-클로로-페닐)-퀴나졸린-4-일]-나프탈렌-1-일메틸-아민Compound 265. [2- (4-Chloro-phenyl) -quinazolin-4-yl] -naphthalen-1-ylmethyl-amine
1H NMR(CDCl3, 300 MHz) δ 8.58(d, J=8.5 Hz, 2H), 8.17(m, 1H), 7.91(m, 3H), 7.63(m, 1H), 7.51(m, 7H), 7.36(m, 1H), 5.87(br, 1H), 5.42(d, J=4.8 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.58 (d, J = 8.5 Hz, 2H), 8.17 (m, 1H), 7.91 (m, 3H), 7.63 (m, 1H), 7.51 (m, 7H) , 7.36 (m, 1H), 5.87 (br, 1H), 5.42 (d, J = 4.8 Hz, 2H)
화합물번호 266. 벤조[1,3]디옥솔-5-일메틸-[2-(4-클로로-페닐)-퀴나졸린-4-일]-아민Compound No. 266. Benzo [1,3] dioxol-5-ylmethyl- [2- (4-chloro-phenyl) -quinazolin-4-yl] -amine
1H NMR(CDCl3, 300 MHz) δ 8.52(d, J=8.6 Hz, 2H), 7.92(d, J=8.3 Hz, 1H), 7.71(m, 2H), 7.43(m, 3H), 6.93(d, J=11.4 Hz, 2H), 6.80(d, J=10.2 Hz, 1H), 5.95(s, 2H), 5.94(br, 1H), 4.89(d, J=4.9 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.52 (d, J = 8.6 Hz, 2H), 7.92 (d, J = 8.3 Hz, 1H), 7.71 (m, 2H), 7.43 (m, 3H), 6.93 (d, J = 11.4 Hz, 2H), 6.80 (d, J = 10.2 Hz, 1H), 5.95 (s, 2H), 5.94 (br, 1H), 4.89 (d, J = 4.9 Hz, 2H)
화합물번호 267. [2-(4-클로로-페닐)-퀴나졸린-4-일]-(3-플루오로-벤질)-아민Compound number 267. [2- (4-Chloro-phenyl) -quinazolin-4-yl]-(3-fluoro-benzyl) -amine
1H NMR(CDCl3, 300 MHz) δ 8.48(d, J=8.5 Hz, 2H), 7.92(d, J=8.5 Hz, 1H), 7.74(m, 2H, 7.77(m, 3H), 7.23(m, 3H), 7.00(m, 1H), 6.07(br, 1H), 4.98(d, J=5.5 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.48 (d, J = 8.5 Hz, 2H), 7.92 (d, J = 8.5 Hz, 1H), 7.74 (m, 2H, 7.77 (m, 3H), 7.23 ( m, 3H), 7.00 (m, 1H), 6.07 (br, 1H), 4.98 (d, J = 5.5 Hz, 2H)
화합물번호 268. [2-(4-클로로-페닐)-퀴나졸린-4-일]-[2-(3-플루오로-페닐)-에틸]-아민Compound 268. [2- (4-Chloro-phenyl) -quinazolin-4-yl]-[2- (3-fluoro-phenyl) -ethyl] -amine
1H NMR(CDCl3, 300 MHz) δ 8.52(d, J=8.6 Hz, 2H), 7.94(d, J=8.6 Hz, 1H), 7.72(d, J=7.2 Hz, 1H), 7.63(d, J=8.1 Hz, 1H), 7.43(m, 3H), 7.28(m, 1H), 7.02(m, 3H), 6.08(br, 1H), 4.03(m, 2H), 3.10(t, J=7.0 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.52 (d, J = 8.6 Hz, 2H), 7.94 (d, J = 8.6 Hz, 1H), 7.72 (d, J = 7.2 Hz, 1H), 7.63 (d , J = 8.1 Hz, 1H), 7.43 (m, 3H), 7.28 (m, 1H), 7.02 (m, 3H), 6.08 (br, 1H), 4.03 (m, 2H), 3.10 (t, J = 7.0 Hz, 2H)
화합물번호 269. 2-{2-[2-(4-클로로-페닐)-퀴나졸린-4-일아미노]-에톡시}-에탄올Compound number 269. 2- {2- [2- (4-Chloro-phenyl) -quinazolin-4-ylamino] -ethoxy} -ethanol
1H NMR(CDCl3, 300 MHz) δ 8.47(d, J=8.4 Hz, 2H), 7.90(d, J=8.3 Hz, 1H), 7.72(m, 2H), 7.41(m, 3H), 6.52(br, 1H), 4.00(m, 2H), 3.81(m, 4H), 3.67(m, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.47 (d, J = 8.4 Hz, 2H), 7.90 (d, J = 8.3 Hz, 1H), 7.72 (m, 2H), 7.41 (m, 3H), 6.52 (br, 1H), 4.00 (m, 2H), 3.81 (m, 4H), 3.67 (m, 2H)
화합물번호 270. 2-[2-(4-클로로-페닐)-퀴나졸린-4-일아미노]-에탄올Compound 270. 2- [2- (4-Chloro-phenyl) -quinazolin-4-ylamino] -ethanol
1H NMR(CDCl3, 300 MHz) δ 8.46(d, J=8.5 Hz, 2H), 7.90(d, J=8.4 Hz, 1H), 7.75(m, 2H), 7.46(m, 3H), 6.21(br, 1H), 3.00(m, 4H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.46 (d, J = 8.5 Hz, 2H), 7.90 (d, J = 8.4 Hz, 1H), 7.75 (m, 2H), 7.46 (m, 3H), 6.21 (br, 1H), 3.00 (m, 4H)
화합물번호 271. (2,4-디메톡시-벤질)-(2-이소프로필-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 7.83(d, J=8.1 Hz, 1H), 7.68-7.60(m, 2H), 7.38-7.33(m, 2H), 6.50-6.42(m, 2H), 6.24(br, 1H), 4.83(d, J=5.7 Hz, 2H), 3.88(s, 3H), 3.80(s, 3H), 3.17(m, 1H), 1.40(d, J=6.9 Hz, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.83 (d, J = 8.1 Hz, 1H), 7.68-7.60 (m, 2H), 7.38-7.33 (m, 2H), 6.50-6.42 (m, 2H), 6.24 (br, 1H), 4.83 (d, J = 5.7 Hz, 2H), 3.88 (s, 3H), 3.80 (s, 3H), 3.17 (m, 1H), 1.40 (d, J = 6.9 Hz, 6H )
화합물번호 272. (2-벤질-퀴나졸린-4-일)-(2,4-디메톡시-벤질)-아민
1H NMR(CDCl3, 300 MHz) δ 7.77(d, J=8.4 Hz, 1H), 7.64(t, J=7.7Hz, 1H), 7.56(d, J=8.1 Hz, 1H), 7.48(d, J=6.9 Hz, 2H), 7.30(m, 4H), 7.09(d, J=8.4 Hz, 1H), 6.45(d, J=2.4Hz, 1H), 6.32(dd, J 1 =8.4 Hz, J 2 =2.4Hz, 1H), 6.17(br, 1H), 4.73(d, J=6.0 Hz, 2H), 4.20(s, 2H), 3.85(s, 3H), 3.78(s, 3H) 1 H NMR (
화합물번호 273. 4-(2,4-디메톡시-벤질옥시)-2-페닐-퀴나졸린
1H NMR(CDCl3, 300 MHz) δ 8.63(m, 2H), 8.17(d, 1H, J=7.8 Hz), 7.98(d, J=8.1 Hz, 1H), 7.79(m, 1H), 7.53(m, 5H), 6.53(m, 2H), 5.75(s, 2H), 3.87(s, 3H), 3.83(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.63 (m, 2H), 8.17 (d, 1H, J = 7.8 Hz), 7.98 (d, J = 8.1 Hz, 1H), 7.79 (m, 1H), 7.53 (m, 5H), 6.53 (m, 2H), 5.75 (s, 2H), 3.87 (s, 3H), 3.83 (s, 3H)
화합물번호 274. 4-(2,4-디메톡시-벤질설파닐)-2-페닐-퀴나졸린
1H NMR(CDCl3, 300 MHz) δ 8.68(dd, J 1 =7.5 Hz, J 2 =2.1Hz, 2H), 8.05(d, J=8.4Hz, 1H), 7.98(d, J=8.4 Hz, 1H), 7.80(t, J=7.5 Hz, 1H), 7.45(m, 5H), 6.50(d, J=2.4 Hz, 1H), 6.41(dd, J 1 =8.4 Hz, J 2 =2.3Hz, 1H), 4.80(s, 2H), 3.88(s, 3H), 3.78(s, 3H) 1 H NMR (
화합물번호 275. (2-메톡시-벤질)-(2-피롤리딘-1-일-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 7.48-7.38(m, 4H), 7.26(m, 1H), 6.99(m, 1H), 6.92(m, 2H), 6.02(br, 1H), 4.82(d, J=5.7 Hz, 2H), 3.91(s, 3H), 3.70(t, J=6.6 Hz, 4H), 1.98(m, 4H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.48-7.38 (m, 4H), 7.26 (m, 1H), 6.99 (m, 1H), 6.92 (m, 2H), 6.02 (br, 1H), 4.82 ( d, J = 5.7 Hz, 2H), 3.91 (s, 3H), 3.70 (t, J = 6.6 Hz, 4H), 1.98 (m, 4H)
화합물번호 276. (2-메톡시-벤질)-(2-피페리딘-1-일-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 7.50-7.46(m, 4H), 7.30-7.26(m, 1H), 7.00(t, J=7.5 Hz, 1H), 6.92(m, 2H), 5.96(br, 1H), 4.80(d, J=5.4 Hz, 2H), 3.91(s, 7H), 1.62(m, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.50-7.46 (m, 4H), 7.30-7.26 (m, 1H), 7.00 (t, J = 7.5 Hz, 1H), 6.92 (m, 2H), 5.96 ( br, 1H), 4.80 (d, J = 5.4 Hz, 2H), 3.91 (s, 7H), 1.62 (m, 6H)
화합물번호 277. (2-메톡시-벤질)-(2-몰포린-4-일-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 7.53-7.44(m, 3H), 7.36-7.26(m, 2H), 7.06(td, J 1 =6.6 Hz, J 2 =1.5 Hz, 1H), 6.93(m, 2H), 6.04(br, 1H), 4.80(d, J=5.7 Hz, 2H), 3.90(m, 7H), 3.79(m, 4H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.53-7.44 (m, 3H), 7.36-7.26 (m, 2H), 7.06 (td, J 1 = 6.6 Hz, J 2 = 1.5 Hz, 1H), 6.93 ( m, 2H), 6.04 (br, 1H), 4.80 (d, J = 5.7 Hz, 2H), 3.90 (m, 7H), 3.79 (m, 4H)
화합물번호 278. (2-메톡시-벤질)-[2-(4-메틸-피페라진-1-일)-퀴나졸린-4-일]-아민
1H NMR(CDCl3, 300 MHz) δ 7.52-7.43(m, 3H), 7.36(d, J=7.5 Hz, 1H), 7.28(m, 1H), 7.04(t, J=8.1 Hz, 1H), 6.93(m, 2H), 6.01(br, 1H), 4.80(d, J=5.4 Hz, 2H), 3.97(t, J=4.8 Hz, 4H), 3.91(s, 3H), 2.50(t, J=4.8 Hz, 4H), 2.35(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.52-7.43 (m, 3H), 7.36 (d, J = 7.5 Hz, 1H), 7.28 (m, 1H), 7.04 (t, J = 8.1 Hz, 1H) , 6.93 (m, 2H), 6.01 (br, 1H), 4.80 (d, J = 5.4 Hz, 2H), 3.97 (t, J = 4.8 Hz, 4H), 3.91 (s, 3H), 2.50 (t, J = 4.8 Hz, 4H), 2.35 (s, 3H)
화합물번호 279. (3-메톡시-벤질)-(2-피롤리딘-1-일-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 7.50-7.44(m, 3H), 7.27(m, 1H), 7.03-6.96(m, 3H), 6.83(dd, J 1 =8.4 Hz, J 2 =2.4 Hz, 1H), 5.73(br, 1H), 4.80(d, J=5.1 Hz, 2H), 3.80(s, 3H), 3.67(t, J=6.6 Hz, 4H), 1.96(m, 4H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.50-7.44 (m, 3H), 7.27 (m, 1H), 7.03-6.96 (m, 3H), 6.83 (dd, J 1 = 8.4 Hz, J 2 = 2.4 Hz, 1H), 5.73 (br, 1H), 4.80 (d, J = 5.1 Hz, 2H), 3.80 (s, 3H), 3.67 (t, J = 6.6 Hz, 4H), 1.96 (m, 4H)
화합물번호 280. (3-메톡시-벤질)-(2-피페리딘-1-일-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 7.52-7.43(m, 3H), 7.27(m, 1H), 7.04-6.96(m, 1H), 6.84(dd, J 1 =8.1 Hz, J 2 =2.1 Hz, 1H), 5.69(br, 1H), 4.77(d, J=5.4 Hz, 2H), 3.87(m, 4H), 3.80(s, 3H), 1.62(m, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.52-7.43 (m, 3H), 7.27 (m, 1H), 7.04-6.96 (m, 1H), 6.84 (dd, J 1 = 8.1 Hz, J 2 = 2.1 Hz, 1H), 5.69 (br, 1H), 4.77 (d, J = 5.4 Hz, 2H), 3.87 (m, 4H), 3.80 (s, 3H), 1.62 (m, 6H)
화합물번호 281. (3-메톡시-벤질)-(2-몰포린-4-일-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 7.57-7.47(m, 3H), 7.28(m, 1H), 7.08(t, J=7.8 Hz, 1H), 7.00-6.94(m, 2H), 6.85(dd, J 1 =8.4 Hz, J 2 =2.4 Hz, 1H), 5.76(br, 1H), 4.77(d, J=5.4 Hz, 2H), 3.89(m, 4H), 3.80-3.75(m, 7H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.57-7.47 (m, 3H), 7.28 (m, 1H), 7.08 (t, J = 7.8 Hz, 1H), 7.00-6.94 (m, 2H), 6.85 ( dd, J 1 = 8.4 Hz, J 2 = 2.4 Hz, 1H), 5.76 (br, 1H), 4.77 (d, J = 5.4 Hz, 2H), 3.89 (m, 4H), 3.80-3.75 (m, 7H )
화합물번호 282. (3-메톡시-벤질)-[2-(4-메틸-피페라진-1-일)-퀴나졸린-4-일]-아민
1H NMR(CDCl3, 300 MHz) δ 7.54-7.45(m, 3H), 7.27(m, 1H), 7.05(m, 1H), 6.97(m, 2H), 6.84(dd, J 1 =8.4 Hz, J 2 =2.1 Hz, 1H), 5.74(br, 1H), 4.77(d, J=5.4 Hz, 2H), 3.93(t, J=4.8 Hz, 4H), 3.80(s, 3H), 2.47(t, J=4.8 Hz, 4H), 2.34(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.54-7.45 (m, 3H), 7.27 (m, 1H), 7.05 (m, 1H), 6.97 (m, 2H), 6.84 (dd, J 1 = 8.4 Hz , J 2 = 2.1 Hz, 1H), 5.74 (br, 1H), 4.77 (d, J = 5.4 Hz, 2H), 3.93 (t, J = 4.8 Hz, 4H), 3.80 (s, 3H), 2.47 ( t, J = 4.8 Hz, 4H), 2.34 (s, 3H)
화합물번호 283. (4-메톡시-벤질)-(2-피롤리딘-1-일-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 7.49(d, J=3.6 Hz, 2H), 7.44(d, J=8.1 Hz, 1H), 7.33(d, J=8.7 Hz, 2H), 6.99(m, 1H), 6.88(d, J=8.7 Hz, 2H), 5.68(br, 1H), 4.75(d, J=5.4 Hz, 2H), 3.81(s, 3H), 3.68(t, J=6.9 Hz, 4H), 1.96(m, 4H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.49 (d, J = 3.6 Hz, 2H), 7.44 (d, J = 8.1 Hz, 1H), 7.33 (d, J = 8.7 Hz, 2H), 6.99 (m , 1H), 6.88 (d, J = 8.7 Hz, 2H), 5.68 (br, 1H), 4.75 (d, J = 5.4 Hz, 2H), 3.81 (s, 3H), 3.68 (t, J = 6.9 Hz , 4H), 1.96 (m, 4H)
화합물번호 284. (4-메톡시-벤질)-(2-피페리딘-1-일-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 7.51-7.41(m, 3H), 7.33(d, J=8.7 Hz, 2H), 7.00(m, 1H), 6.89(d, J=8.4 Hz, 2H), 5.62(br, 1H), 4.73(d, J=5.4 Hz, 2H), 3.88(m, 4H), 3.81(s, 3H), 1.27(m, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.51-7.41 (m, 3H), 7.33 (d, J = 8.7 Hz, 2H), 7.00 (m, 1H), 6.89 (d, J = 8.4 Hz, 2H) , 5.62 (br, 1H), 4.73 (d, J = 5.4 Hz, 2H), 3.88 (m, 4H), 3.81 (s, 3H), 1.27 (m, 6H)
화합물번호 285. (4-메톡시-벤질)-(2-몰포린-4-일-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 7.53-7.44(m, 3H), 7.32(d, J=8.7 Hz, 2H), 7.06(m, 1H), 6.89(d, J=8.7 Hz, 2H), 5.69(br, 1H), 4.72(d, J=5.1 Hz, 2H), 3.88(m, 4H), 3.81(s, 3H), 3.77(m, 4H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.53-7.44 (m, 3H), 7.32 (d, J = 8.7 Hz, 2H), 7.06 (m, 1H), 6.89 (d, J = 8.7 Hz, 2H) , 5.69 (br, 1H), 4.72 (d, J = 5.1 Hz, 2H), 3.88 (m, 4H), 3.81 (s, 3H), 3.77 (m, 4H)
화합물번호 286. (4-메톡시-벤질)-[2-(4-메틸-피페라진-1-일)-퀴나졸린-4-일]-아민Compound No. 286. (4-methoxy-benzyl)-[2- (4-methyl-piperazin-1-yl) -quinazolin-4-yl] -amine
1H NMR(CDCl3, 300 MHz) δ 7.54-7.42(m, 3H), 7.33(d, J=8.7 Hz, 2H), 7.03(m, 1H), 6.89(d, J=8.7 Hz, 2H), 5.65(br, 1H), 4.73(d, J=5.4 Hz, 2H), 3.95(t, J=4.8 Hz, 4H), 3.81(s, 3H), 2.48(t, J=4.8 Hz, 4H), 2.34(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.54-7.42 (m, 3H), 7.33 (d, J = 8.7 Hz, 2H), 7.03 (m, 1H), 6.89 (d, J = 8.7 Hz, 2H) , 5.65 (br, 1H), 4.73 (d, J = 5.4 Hz, 2H), 3.95 (t, J = 4.8 Hz, 4H), 3.81 (s, 3H), 2.48 (t, J = 4.8 Hz, 4H) , 2.34 (s, 3H)
화합물번호 287. (2,3-디메톡시-벤질)-(2-피롤리딘-1-일-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 7.47(m, 3H), 7.00(m, 3H), 6.88(dd, J 1 =5.4 Hz, J 2 =3.6 Hz, 1H), 6.01(br, 1H), 4.84(d, J=6.0 Hz, 2H), 3.92(s, 3H), 3.88(s, 3H), 3.69(t, 4H), 1.97(m, 4H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.47 (m, 3H), 7.00 (m, 3H), 6.88 (dd, J 1 = 5.4 Hz, J 2 = 3.6 Hz, 1H), 6.01 (br, 1H) , 4.84 (d, J = 6.0 Hz, 2H), 3.92 (s, 3H), 3.88 (s, 3H), 3.69 (t, 4H), 1.97 (m, 4H)
화합물번호 288. (2,3-디메톡시-벤질)-(2-피페리딘-1-일-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 7.50-7.41(m, 3H), 7.00(m, 3H), 6.88(dd, J 1 =7.2 Hz, J 2 =2.7 Hz, 1H), 5.97(br, 1H), 4.82(d, J=5.7 Hz, 2H), 3.92(s, 3H), 3.88(s, 7H), 1.65(m, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.50-7.41 (m, 3H), 7.00 (m, 3H), 6.88 (dd, J 1 = 7.2 Hz, J 2 = 2.7 Hz, 1H), 5.97 (br, 1H), 4.82 (d, J = 5.7 Hz, 2H), 3.92 (s, 3H), 3.88 (s, 7H), 1.65 (m, 6H)
화합물번호 289. (2,3-디메톡시-벤질)-(2-몰포린-4-일-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 7.51-7.44(m, 3H), 7.08-6.94(m, 3H), 6.89(dd, J 1 =8.1 Hz, J 2 =1.5 Hz, 1H), 6.05(br, 1H), 4.81(d, J=5.7 Hz, 2H), 3.93-3.89(m, 10H), 3.79(t, J=4.8 Hz, 4H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.51-7.44 (m, 3H), 7.08-6.94 (m, 3H), 6.89 (dd, J 1 = 8.1 Hz, J 2 = 1.5 Hz, 1H), 6.05 ( br, 1H), 4.81 (d, J = 5.7 Hz, 2H), 3.93-3.89 (m, 10H), 3.79 (t, J = 4.8 Hz, 4H)
화합물번호 290. (2,3-디메톡시-벤질)-[2-(4-메틸-피페라진-1-일)-퀴나졸린-4-일]-아민
1H NMR(CDCl3, 300 MHz) δ 7.49-7.44(m, 3H), 7.05-6.96(m, 3H), 6.89(dd, J 1 =7.5 Hz, J 2 =1.5 Hz, 1H), 6.00(br, 1H), 4.82(d, J=5.7 Hz, 2H), 3.96(t, J=4.8 Hz, 4H), 3.92(s, 3H), 3.89(s, 3H), 2.50(t, J=4.8 Hz, 4H), 2.35(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.49-7.44 (m, 3H), 7.05-6.96 (m, 3H), 6.89 (dd, J 1 = 7.5 Hz, J 2 = 1.5 Hz, 1H), 6.00 ( br, 1H), 4.82 (d, J = 5.7 Hz, 2H), 3.96 (t, J = 4.8 Hz, 4H), 3.92 (s, 3H), 3.89 (s, 3H), 2.50 (t, J = 4.8 Hz, 4H), 2.35 (s, 3H)
화합물번호 291. (2,4-디메톡시-벤질)-(2-피롤리딘-1-일-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 7.46(d, J=3.9 Hz, 2H), 7.42(d, J=8.1 Hz, 1H), 7.31(d, J=8.4 Hz, 1H), 6.98(s, 1H), 6.49(d, J=2.4 Hz, 1H), 6.44(dd, J 1 =8.1 Hz, J 2 =2.4 Hz, 1H), 5.94(br, 1H), 4.74(d, J=6.0 Hz, 2H), 3.87(s, 3H), 3.80(s, 3H), 3.71(t, J=6.6 Hz, 4H), 1.98(m, 4H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.46 (d, J = 3.9 Hz, 2H), 7.42 (d, J = 8.1 Hz, 1H), 7.31 (d, J = 8.4 Hz, 1H), 6.98 (s , 1H), 6.49 (d, J = 2.4 Hz, 1H), 6.44 (dd, J 1 = 8.1 Hz, J 2 = 2.4 Hz, 1H), 5.94 (br, 1H), 4.74 (d, J = 6.0 Hz , 2H), 3.87 (s, 3H), 3.80 (s, 3H), 3.71 (t, J = 6.6 Hz, 4H), 1.98 (m, 4H)
화합물번호 292. (2,4-디메톡시-벤질)-(2-피페리딘-1-일-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 7.49-7.39(m, 3H), 7.27(m, 1H), 6.99(t, J=6.6 Hz, 1H), 6.49(d, J=2.4 Hz, 1H), 6.44(dd, J 1 =8.1 Hz, J 2 =2.1 Hz, 1H), 5.88(br, 1H), 4.72(d, J=5.4 Hz, 2H), 3.97(m, 4H), 3.87(s, 3H), 3.80(s, 3H), 1.66(m, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.49-7.39 (m, 3H), 7.27 (m, 1H), 6.99 (t, J = 6.6 Hz, 1H), 6.49 (d, J = 2.4 Hz, 1H) , 6.44 (dd, J 1 = 8.1 Hz, J 2 = 2.1 Hz, 1H), 5.88 (br, 1H), 4.72 (d, J = 5.4 Hz, 2H), 3.97 (m, 4H), 3.87 (s, 3H), 3.80 (s, 3H), 1.66 (m, 6H)
화합물번호 293. (2,4-디메톡시-벤질)-(2-몰포린-4-일-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 7.53-7.43(m, 3H), 7.26(m, 2H), 7.05(m, 1H), 6.50(d, J=2.1 Hz, 1H), 6.45(dd, J 1 =8.1 Hz, J 2 =2.1 Hz, 1H), 5.94(br, 1H), 4.72(d, J=5.7 Hz, 2H), 3.94-3.78(m, 14H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.53-7.43 (m, 3H), 7.26 (m, 2H), 7.05 (m, 1H), 6.50 (d, J = 2.1 Hz, 1H), 6.45 (dd, J 1 = 8.1 Hz, J 2 = 2.1 Hz, 1H), 5.94 (br, 1H), 4.72 (d, J = 5.7 Hz, 2H), 3.94-3.78 (m, 14H)
화합물번호 294. (2,4-디메톡시-벤질)-[2-(4-메틸-피페라진-1-일)-퀴나졸린-4-일]-아민
1H NMR(CDCl3, 300 MHz) δ 7.50(m, 2H), 7.43(d, 1H, J=8.1 Hz), 7.26(m, 1H), 7.06(m, 1H), 6.50(d, J=2.1 Hz, 1H), 6.45(dd, J 1 =8.1 Hz, J 2 =2.1 Hz, 1H), 6.00(br, 1H), 4.72(d, J=5.4 Hz, 2H), 4.01(m, 4H), 3.87(s, 3H), 3.81(s, 3H), 2.54(t, J=4.8 Hz, 4H), 2.37(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.50 (m, 2H), 7.43 (d, 1H, J = 8.1 Hz), 7.26 (m, 1H), 7.06 (m, 1H), 6.50 (d, J = 2.1 Hz, 1H), 6.45 (dd, J 1 = 8.1 Hz, J 2 = 2.1 Hz, 1H), 6.00 (br, 1H), 4.72 (d, J = 5.4 Hz, 2H), 4.01 (m, 4H) , 3.87 (s, 3H), 3.81 (s, 3H), 2.54 (t, J = 4.8 Hz, 4H), 2.37 (s, 3H)
화합물번호 295. (2,5-디메톡시-벤질)-(2-피롤리딘-1-일-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 7.45(m, 3H), 6.99(m, 2H), 6.79(m, 2H), 6.02(br s, 1H), 4.79(d, J=5.7Hz, 2H), 3.86(s, 3H), 3.75(s, 3H), 3.71(br t, J=6.8Hz, 4H), 1.97(br t, J=6.8Hz, 4H) 1 H NMR (
화합물번호 296. (2,5-디메톡시-벤질)-(2-피페리딘-1-일-퀴나졸린-4-일)-아민Compound No. 296. (2,5-Dimethoxy-benzyl)-(2-piperidin-1-yl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 7.44(m, 3H), 6.97(m, 2H), 6.79(m, 2H), 5.99(br s, 1H), 4.77(d, J=5.7Hz, 2H), 3.91(br s, 4H), 3.87(s, 3H), 3.75(s, 3H), 1.65(br s, 6H) 1 H NMR (
화합물번호 297. (2,5-디메톡시-벤질)-(2-몰포린-4-일-퀴나졸린-4-일)-아민Compound No. 297. (2,5-Dimethoxy-benzyl)-(2-morpholin-4-yl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 7.48(m, 3H), 7.06(br t, J=7.5Hz, 1H), 6.94(d, J=2.7Hz, 1H), 6.80(m, 2H), 6.05(br s, 1H), 4.76(d, J=5.7Hz, 2H), 3.92(m, 4H), 3.90(s, 3H), 3.79(m, 4H), 3.75(s, 3H) 1 H NMR (
화합물번호 298. (2,5-디메톡시-벤질)-[2-(4-메틸-피페라진-1-일)-퀴나졸린-4-일]-아민
1H NMR(CDCl3, 300 MHz) δ 7.46(m, 3H), 7.06(br t, J=7.8Hz, 1H), 6.95(d, J=3.0Hz, 1H), 6.80(m, 2H), 6.02(br s, 1H), 4.77(d, J=5.7Hz, 2H), 3.97(br t, J=5.8Hz, 4H), 3.86(s, 3H), 3.75(s, 3H), 2.50(br t, J=5.8Hz, 4H), 2.35(s, 3H) 1 H NMR (
화합물번호 299. (3,4-디메톡시-벤질)-(2-피롤리딘-1-일-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 7.49(d, J=3.9Hz, 2H), 7.46(d, J=8.4Hz, 1H), 7.00(m, 3H), 6.84(m, 1H), 5.71(br s, 1H), 4.75(d, J=5.4Hz, 2H), 3.89(s, 3H), 3.86(s, 3H), 3.69(br t, J=6.6Hz, 4H), 1.97(br t, J=6.6Hz, 4H) 1 H NMR (
화합물번호 300. (3,4-디메톡시-벤질)-(2-피페리딘-1-일-퀴나졸린-4-일)-아민Compound No. 300. (3,4-Dimethoxy-benzyl)-(2-piperidin-1-yl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 7.45(m, 3H), 6.99(m, 3H), 6.85(d, J=8.4Hz, 1H) , 5.64(br s, 1H), 4.73(d, J=5.7Hz, 2H), 3.89(m, 10H), 1.65(m, 6H), 1 H NMR (
화합물번호 301. (3,4-디메톡시-벤질)-(2-몰포린-4-일-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 7.52(m, 3H), 7.08(t, J=7.8Hz, 1H), 6.94(m, 2H), 6.85(d, J=8.4Hz, 1H), 5.71(br s, 1H), 4.72(d, J=4.8Hz, 2H), 3.91(m, 4H), 3.89(s, 3H), 3.86(s, 3H), 3.78(m, 4H) 1 H NMR (
화합물번호 302. (3,4-디메톡시-벤질)-[2-(4-메틸-피페라진-1-일)-퀴나졸린-4-일]-아민
1H NMR(CDCl3, 300 MHz) δ 7.49(m, 3H), 7.05(t, J=7.8Hz, 1H), 6.95(m, 2H), 6.84(m, 1H), 5.66(br s, 1H), 4.73(d, J=5.4Hz, 2H), 3.96(br t, J=5.0Hz, 4H), 3.89(s, 3H), 3.86(s, 3H), 2.49(brvt, J=5.0Hz, 4H), 2.35(s, 3H) 1 H NMR (
화합물번호 303. (3,5-디메톡시-벤질)-(2-피롤리딘-1-일-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 7.50(m, 3H), 7.01(m, 1H), 6.56(d, J=1.8Hz, 2H), 6.39(br t, J=2.3Hz, 1H), 5.82(br s, 1H), 4.75(d, J=5.4Hz, 2H), 3.77(s, 6H), 3.67(br t, J=6.6 Hz, 4H), 1.95(br t, J=6.6 Hz, 4H) 1 H NMR (
화합물번호 304. (3,5-디메톡시-벤질)-(2-피페리딘-1-일-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 7.46(m, 3H), 7.02(t, J=8.1Hz, 1H), 6.56(br d, J=2.4Hz, 2H), 6.40(br t, J=1.8Hz, 1H), 5.71(br s, 1H), 4.73(d J=5.4 Hz, 2H), 3.88(m, 4H), 3.78(s, 6H), 1.62(s, 6H) 1 H NMR (
화합물번호 305. (3,5-디메톡시-벤질)-(2-몰포린-4-일-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 7.52(m, 3H), 7.09(br t, J=7.8Hz, 1H), 6.55(br d, J=2.1Hz, 2H), 6.40(br t, J=2.1Hz, 1H), 5.75(br s, 1H), 4.73(d J=5.4 Hz, 2H), 3.91(m, 4H), 3.78(m, 10H) 1 H NMR (
화합물번호 306. (3,5-디메톡시-벤질)-[2-(4-메틸-피페라진-1-일)-퀴나졸린-4-일]-아민
1H NMR(CDCl3, 300 MHz) δ 7.50(m, 3H), 7.06(t, J=7.8Hz, 1H), 6.56(d, J=2.4Hz, 2H), 6.40(br t, J=2.1Hz, 1H), 5.72(br s, 1H), 4.73(d J=5.4 Hz, 2H), 3.94(br t, J=4.2Hz, 4H), 3.78(s, 6H), 2.48(br t, J=5.0Hz, 4H), 2.34(s, 3H) 1 H NMR (
화합물번호 307. 벤조[1,3]디옥솔-5-일메틸-(2-피롤리딘-1-일-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 7.48(br d, J=3.9 Hz, 2H), 7.45(d, J=8.1Hz, 1H), 6.99(quartet, J=4.1 Hz, 1H), 6.92(s, 1H), 6.86(d, J=7.8 Hz, 1H), 6.76(d, J=7.8 Hz, 1H), 5.95(s, 2H), 5.70(br s, 1H), 4.72(d, J=5.7 Hz, 2H), 3.68(br t, J=6.6 Hz, 4H), 1.97(m, 4H) 1 H NMR (
화합물번호 308. 벤조[1,3]디옥솔-5-일메틸-(2-피페리딘-1-일-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 7.48(m, 3H), 7.03(m, 1H), 6.85(m, 3H), 5.95(s, 2H), 5.64(br s, 1H), 4.69(t, J=5.4 Hz, 2H), 3.89(m, 4H), 1.64(m, 6H) 1 H NMR (
화합물번호 309. 벤조[1,3]디옥솔-5-일메틸-(2-몰포린-4-일-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 7.51(m, 3H), 7.07(t, J=7.4 Hz, 1H), 6.89(s, 1H), 6.85(d, J=7.8Hz, 1H), 6.78(d, J=7.8 Hz, 1H), 5.96(s, 2H), 5.69(br s, 1H), 4.70(d, J=5.4 Hz, 2H), 3.89(m, 4H), 3.78(m, 4H) 1 H NMR (
화합물번호 310. 벤조[1,3]디옥솔-5-일메틸-[2-(4-메틸-피페라진-1-일)-퀴나졸린-4-일]-아민
1H NMR(CDCl3, 300 MHz) δ 7.48(m, 3H), 7.05(t, J=8.1Hz, 1H), 6.89(s, 1H), 6.85(d, J=7.8Hz, 1H), 6.78(d, J=7.8 Hz, 1H), 5.96(s, 2H), 5.68(br s, 1H), 4.70(d, J=5.4 Hz, 2H), 3.95(br t, J=4.8 Hz, 4H), 2.48(br t, J=4.8 Hz, 4H), 2.35(s, 3H) 1 H NMR (
화합물번호 311. (2-피롤리딘-1-일-퀴나졸린-4-일)-(3,4,5-트리메톡시-벤질)-아민Compound No. 311. (2-Pyrrolidin-1-yl-quinazolin-4-yl)-(3,4,5-trimethoxy-benzyl) -amine
1H NMR(CDCl3, 300 MHz) δ 7.57(br t, J=7.8 Hz, 2H), 7.48(t, J=7.7Hz, 1H), 7.02(t, J=8.0 Hz, 1H), 6.66(s, 2H), 6.11(br s, 1H), 4.74(d, J=5.4 Hz, 2H), 3.84(s, 9H), 3.71(br t, J=6.2 Hz, 4H), 1.98(br t, J=6.9 Hz, 4H) 1 H NMR (
화합물번호 312. (2-피페리딘-1-일-퀴나졸린-4-일)-(3,4,5-트리메톡시-벤질)-아민Compound No. 312. (2-Piperidin-1-yl-quinazolin-4-yl)-(3,4,5-trimethoxy-benzyl) -amine
1H NMR(CDCl3, 300 MHz) δ 7.50(m, 3H), 7.03(br t, J=8.0 Hz, 1H), 6.65(s, 2H), 5.71(br s, 1H), 4.72(d, J=5.1 Hz, 2H), 3.91(m, 4H), 3.84(s, 9H), 1.65(m, 6H) 1 H NMR (
화합물번호 313. (2-몰포린-4-일-퀴나졸린-4-일)-(3,4,5-트리메톡시-벤질)-아민Compound 313. (2-Morpholin-4-yl-quinazolin-4-yl)-(3,4,5-trimethoxy-benzyl) -amine
1H NMR(CDCl3, 300 MHz) δ 7.53(m, 3H), 7.11(br t, J=8.4 Hz, 1H), 6.63(s, 2H), 5.74(br s, 1H), 4.72(d, J=5.4 Hz, 2H), 3.85(m, 16H) 1 H NMR (
화합물번호 314. [2-(4-메틸-피페라진-1-일)-퀴나졸린-4-일]-(3,4,5-트리메톡시-벤질)-아민Compound number 314. [2- (4-Methyl-piperazin-1-yl) -quinazolin-4-yl]-(3,4,5-trimethoxy-benzyl) -amine
1H NMR(CDCl3, 300 MHz) δ 7.53(m, 3H), 7.06(m, 1H), 6.64(s, 2H), 5.77(br s, 1H), 4.72(d, J=5.1 Hz, 2H), 3.97(br t, J=4.5 Hz, 4H), 3.85(s, 9H), 2.50(br t, J=5.0 Hz, 4H), 2.36(s, 3H) 1 H NMR (
화합물번호 315. (2-피롤리딘-1-일-퀴나졸린-4-일)-(2,4,6-트리메톡시-벤질)-아민Compound 315. (2-Pyrrolidin-1-yl-quinazolin-4-yl)-(2,4,6-trimethoxy-benzyl) -amine
1H NMR(CDCl3, 300 MHz) δ 7.46(m, 2H), 7.38(d, J=8.1 Hz, 1H), 6.98(m, 1H), 6.17(s, 2H), 5.84(br s, 1H), 4.81(d, J=5.1 Hz, 2H), 3.85(s, 6H), 3.83(s, 3H), 3.74(br t, J=6.5 Hz, 4H), 1.98(m, 4H) 1 H NMR (
화합물번호 316. (2-피페리딘-1-일-퀴나졸린-4-일)-(2,4,6-트리메톡시-벤질)-아민Compound 316. (2-Piperidin-1-yl-quinazolin-4-yl)-(2,4,6-trimethoxy-benzyl) -amine
1H NMR(CDCl3, 300 MHz) δ 7.41(m, 3H), 6.98(m, 1H), 6.16(s, 2H), 5.86(br s, 1H), 4.80(d, J=5.1 Hz, 2H), 3.97(m, 4H), 3.85(s, 6H), 3.83(s, 3H), 1.65(m, 6H) 1 H NMR (
화합물번호 317. (2-몰포린-4-일-퀴나졸린-4-일)-(2,4,6-트리메톡시-벤질)-Compound number 317. (2-morpholin-4-yl-quinazolin-4-yl)-(2,4,6-trimethoxy-benzyl)-
아민Amine
1H NMR(CDCl3, 300 MHz) δ 7.47(m, 3H), 7.02(m, 1H), 6.17(s, 2H), 5.93(br s, 1H), 4.79(d, J=5.1 Hz, 2H), 3.99(m, 4H), 3.86(m, 13H) 1 H NMR (
화합물번호 318. [2-(4-메틸-피페라진-1-일)-퀴나졸린-4-일]-(2,4,6-트리메톡시-벤질)-아민Compound number 318. [2- (4-Methyl-piperazin-1-yl) -quinazolin-4-yl]-(2,4,6-trimethoxy-benzyl) -amine
1H NMR(CDCl3, 300 MHz) δ 7.45(m, 3H), 6.98(m, 1H), 6.16(s, 2H), 5.91(br s, 1H), 4.80(d, J=5.1 Hz, 2H), 4.01(br t, J=4.7 Hz, 4H), 3.83(s, 6H), 3.79(s, 3H), 2.52(br t, J=5.0 Hz, 4H), 2.04(s, 3H) 1 H NMR (
화합물번호 319. (2,4-디메톡시-벤질)-(2-에톡시-퀴나졸린-4-일)-아민Compound number 319. (2,4-dimethoxy-benzyl)-(2-ethoxy-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 7.60(m, 2H), 7.52(d, J=8.1 Hz, 1H), 7.23(m, 2H), 6.48(m, 2H), 6.11(br s, 1H), 4.78(d, J=5.4 Hz, 2H), 4.51(quartet, J=7.2 Hz, 2H), 3.88(s, 3H), 3.81(s, 3H), 1.47(t, J=7.2 Hz, 3H) 1 H NMR (
화합물번호 320. 벤조[1,3]디옥솔-5-일메틸-(2-에톡시-퀴나졸린-4-일)-아민Compound number 320. Benzo [1,3] dioxol-5-ylmethyl- (2-ethoxy-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 7.63(m, 3H), 7.24(m, 1H), 6.82(m, 3H), 5.96(s, 2H), 5.79(br s, 1H), 4.75(d, J=5.4 Hz, 2H), 4.50(quartet, J=7.2 Hz, 2H), 1.46(t, J=7.2 Hz, 3H) 1 H NMR (
화합물번호 321. (2-이소프로필-퀴나졸린-4-일)-(2-메톡시-벤질)-아민
1H NMR(CDCl3, 300 MHz) δ 8.01(d, J = 8.1 Hz, 1H), 7.81(d, J = 8.1 Hz, 1H), 7.69(t, J = 7.3 Hz, 1H), 7.43(t, J = 7.4 Hz, 2H), 7.31(m, 1H), 6.93(t, J = 7.0 Hz, 2H), 4.95(d, J = 5.8 Hz, 2H), 3.93(s, 3H), 3,31(m, 1H), 1.41(d, J = 6.8 Hz, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.01 (d, J = 8.1 Hz, 1H), 7.81 (d, J = 8.1 Hz, 1H), 7.69 (t, J = 7.3 Hz, 1H), 7.43 (t , J = 7.4 Hz, 2H), 7.31 (m, 1H), 6.93 (t, J = 7.0 Hz, 2H), 4.95 (d, J = 5.8 Hz, 2H), 3.93 (s, 3H), 3,31 (m, 1H), 1.41 (d, J = 6.8 Hz, 6H)
화합물번호 322. (2,3-디메톡시-벤질)-(2-이소프로필-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 7.97(d, J=8.2 Hz, 1H), 7.82(d, J=8.3 Hz, 1H), 7.69(t, J=7.3 Hz, 1H), 7.41(t, J=7.6 Hz, 1H), 7.03(m, 2H), 6.89(m, 1H), 4.96(d, J=5.8 Hz, 2H), 3.96(s, 3H), 3.89(3, 3H), 3.30(t, J=7.1 Hz, 1H), 1.79(d, J=6.8 Hz, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.97 (d, J = 8.2 Hz, 1H), 7.82 (d, J = 8.3 Hz, 1H), 7.69 (t, J = 7.3 Hz, 1H), 7.41 (t , J = 7.6 Hz, 1H), 7.03 (m, 2H), 6.89 (m, 1H), 4.96 (d, J = 5.8 Hz, 2H), 3.96 (s, 3H), 3.89 (3, 3H), 3.30 (t, J = 7.1 Hz, 1H), 1.79 (d, J = 6.8 Hz, 6H)
화합물번호 323. (3,5-디메톡시-벤질)-(2-이소프로필-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 8.21(d, J=6.3 Hz, 1H), 8.02(d, J=8.4 Hz, 1H), 7.63(t, J=7.7 Hz, 1H), 7.37(t, J=7.5 Hz, 1H), 6.65(d, J=2.1 Hz, 2H), 6.36(d, J=2.0 Hz, 1H), 4.90(d, J=5.5 Hz, 2H), 3.75(s, 6H), 3.34(t, J=7.0 Hz, 1H), 1.38(d, J=6.7 Hz, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.21 (d, J = 6.3 Hz, 1H), 8.02 (d, J = 8.4 Hz, 1H), 7.63 (t, J = 7.7 Hz, 1H), 7.37 (t , J = 7.5 Hz, 1H), 6.65 (d, J = 2.1 Hz, 2H), 6.36 (d, J = 2.0 Hz, 1H), 4.90 (d, J = 5.5 Hz, 2H), 3.75 (s, 6H ), 3.34 (t, J = 7.0 Hz, 1H), 1.38 (d, J = 6.7 Hz, 6H)
화합물번호 324. (3,4-디메톡시-벤질)-(2-이소프로필-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 8.17(d, J=6.2 Hz, 1H), 7.97(d, J=8.5 Hz, 1H), 7.62(t, J=7.7 Hz, 1H), 7.34(t, J=7.5 Hz, 1H), 7.12(s, 1H), 7.05(d, J=8.1 Hz, 1H), 6.82(d, J=8.2 Hz, 1H), 4.90(d, J=5.5 Hz, 2H), 3.86(s, 6H), 3.33(t, J=7.1 Hz, 1H), 1.40(d, J=6.7 Hz, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.17 (d, J = 6.2 Hz, 1H), 7.97 (d, J = 8.5 Hz, 1H), 7.62 (t, J = 7.7 Hz, 1H), 7.34 (t , J = 7.5 Hz, 1H), 7.12 (s, 1H), 7.05 (d, J = 8.1 Hz, 1H), 6.82 (d, J = 8.2 Hz, 1H), 4.90 (d, J = 5.5 Hz, 2H ), 3.86 (s, 6H), 3.33 (t, J = 7.1 Hz, 1H), 1.40 (d, J = 6.7 Hz, 6H)
화합물번호 325. (2-이소프로필-퀴나졸린-4-일)-(3,4,5-트리메톡시-벤질)-아민
1H NMR(CDCl3, 300 MHz) δ 8.22(d, J=6.2 Hz, 1H), 8.00(d, J=8.5 Hz, 1H), 7.64(t, J=7.7 Hz, 1H), 7.36(t, J=7.4 Hz, 1H), 6.79(s, 2H), 4.90(d, J=5.5 Hz, 2H), 3.84(s, 9H), 3.34(t, J=7.2 Hz, 1H), 1.39(d, J=6.7 Hz, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.22 (d, J = 6.2 Hz, 1H), 8.00 (d, J = 8.5 Hz, 1H), 7.64 (t, J = 7.7 Hz, 1H), 7.36 (t , J = 7.4 Hz, 1H), 6.79 (s, 2H), 4.90 (d, J = 5.5 Hz, 2H), 3.84 (s, 9H), 3.34 (t, J = 7.2 Hz, 1H), 1.39 (d , J = 6.7 Hz, 6H)
화합물번호 326. (2,5-디메톡시-벤질)-(2-이소프로필-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 8.06(d, J=8.1 Hz, 1H), 7.86(d, J=8.0 Hz, 1H), 7.70(t, J=7.3 Hz, 1H), 7.43(t, J=7.4 Hz, 1H), 7.01(s, 1H), 6.80(m, 2H), 4.93(d, J=5.6 Hz, 2H), 3.89(s, 3H), 3.75(s, 3H), 3.36(t, J=7.4 Hz, 1H), 1.40(d, J=6.9 Hz, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.06 (d, J = 8.1 Hz, 1H), 7.86 (d, J = 8.0 Hz, 1H), 7.70 (t, J = 7.3 Hz, 1H), 7.43 (t , J = 7.4 Hz, 1H), 7.01 (s, 1H), 6.80 (m, 2H), 4.93 (d, J = 5.6 Hz, 2H), 3.89 (s, 3H), 3.75 (s, 3H), 3.36 (t, J = 7.4 Hz, 1H), 1.40 (d, J = 6.9 Hz, 6H)
화합물번호 327. (2-이소프로필-퀴나졸린-4-일)-(2,4,6-트리메톡시-벤질)-아민
1H NMR(CDCl3, 300 MHz) δ 8.09(d, J=8.0 Hz, 1H), 7.73(d, J=8.1 Hz, 1H), 7.65(t, J=7.2 Hz, 1H), 7.41(t, J=7.3 Hz, 1H), 6.31(br, 1H), 6.18(s, 2H), 4.97(d, J=5.3 Hz, 2H), 3.88(s, 9H), 3.34(t, J=7.3 Hz, 1H), 1.42(d, J=6.5 Hz, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.09 (d, J = 8.0 Hz, 1H), 7.73 (d, J = 8.1 Hz, 1H), 7.65 (t, J = 7.2 Hz, 1H), 7.41 (t , J = 7.3 Hz, 1H), 6.31 (br, 1H), 6.18 (s, 2H), 4.97 (d, J = 5.3 Hz, 2H), 3.88 (s, 9H), 3.34 (t, J = 7.3 Hz , 1H), 1.42 (d, J = 6.5 Hz, 6H)
화합물번호 328. (2-벤질-퀴나졸린-4-일)-(2-메톡시-벤질)-아민
1H NMR(CDCl3, 300 MHz) δ 7.78(d, J=8.1 Hz, 1H), 7.65(m, 1H), 7.58(d, J=8.1 Hz, 1H), 7.37-7.18(m, 6H), 6.87(d, J=8.4 Hz, 1H), 6.83(t, J=7.2 Hz, 1H), 6.21(br, 1H), 4.81(d, J=5.7 Hz, 2H), 4.20(s, 2H), 3.88(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.78 (d, J = 8.1 Hz, 1H), 7.65 (m, 1H), 7.58 (d, J = 8.1 Hz, 1H), 7.37-7.18 (m, 6H) , 6.87 (d, J = 8.4 Hz, 1H), 6.83 (t, J = 7.2 Hz, 1H), 6.21 (br, 1H), 4.81 (d, J = 5.7 Hz, 2H), 4.20 (s, 2H) , 3.88 (s, 3H)
화합물번호 329. (2-벤질-퀴나졸린-4-일)-(2,3-디메톡시-벤질)-아민
1H NMR(CDCl3, 300 MHz) δ 7.78(d, J=8.1 Hz, 1H), 7.67(dd, J 1 =6.7 Hz, J 2 =0.9 Hz, 1H), 7.60(d, J=8.4 Hz, 1H), 7.46(d, J=6.9 Hz, 2H), 7.36-7.17(m, 4H), 6.93(t, J=8.1 Hz, 1H), 6.83(m, 2H), 6.22(br, 1H), 4.83(d, J=5.7 Hz, 2H), 4.20(s, 2H), 3.90(s, 3H), 3.86(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.78 (d, J = 8.1 Hz, 1H), 7.67 (dd, J 1 = 6.7 Hz, J 2 = 0.9 Hz, 1H), 7.60 (d, J = 8.4 Hz , 1H), 7.46 (d, J = 6.9 Hz, 2H), 7.36-7.17 (m, 4H), 6.93 (t, J = 8.1 Hz, 1H), 6.83 (m, 2H), 6.22 (br, 1H) , 4.83 (d, J = 5.7 Hz, 2H), 4.20 (s, 2H), 3.90 (s, 3H), 3.86 (s, 3H)
화합물번호 330. (2-벤질-퀴나졸린-4-일)-(3,5-디메톡시-벤질)-아민
1H NMR(CDCl3, 300 MHz) δ 7.89(t, J=9.0 Hz, 2H), 7.62(t, J=7.7 Hz, 1H), 7.48(d, J=7.1 Hz, 2H), 7.31(m, 4H), 6.55(d, J=1.9 Hz, 2H), 6.37(s, 1H), 4.81(d, J=5.3 Hz, 2H), 4.22(s, 2H), 3.73(s, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.89 (t, J = 9.0 Hz, 2H), 7.62 (t, J = 7.7 Hz, 1H), 7.48 (d, J = 7.1 Hz, 2H), 7.31 (m) , 4H), 6.55 (d, J = 1.9 Hz, 2H), 6.37 (s, 1H), 4.81 (d, J = 5.3 Hz, 2H), 4.22 (s, 2H), 3.73 (s, 6H)
화합물번호 331. (2-벤질-퀴나졸린-4-일)-(3,4-디메톡시-벤질)-아민
1H NMR(CDCl3, 300 MHz) δ 8.11(d, J=6.1 Hz, 1H), 7.91(d, J=8.2 Hz, 1H), 7.52(m, 3H), 7.23(m, 4H), 7.02(s, 1H), 6.92(m, 1H), 6.75(d, J=8.2 Hz, 1H), 4.83(d, J=5.2 Hz, 2H), 4.27(s, 2H), 3.86(s, 3H), 3.69(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.11 (d, J = 6.1 Hz, 1H), 7.91 (d, J = 8.2 Hz, 1H), 7.52 (m, 3H), 7.23 (m, 4H), 7.02 (s, 1H), 6.92 (m, 1H), 6.75 (d, J = 8.2 Hz, 1H), 4.83 (d, J = 5.2 Hz, 2H), 4.27 (s, 2H), 3.86 (s, 3H) , 3.69 (s, 3H)
화합물번호 332. (2-벤질-퀴나졸린-4-일)-(3,4,5-트리메톡시-벤질)-아민
1H NMR(CDCl3, 300 MHz) δ 8.03(d, J=7.6 Hz, 1H), 7.91(d, J=8.4 Hz, 1H), 7.61(t, J=7.7 Hz, 1H), 7.50(d, J=6.8 Hz, 2H), 7.32(t, J=7.6 Hz, 1H), 7.23(m, 3H), 6.66(s, 2H), 4.81(d, J=5.2 Hz, 2H), 4.25(s, 2H), 3.86(s, 9H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.03 (d, J = 7.6 Hz, 1H), 7.91 (d, J = 8.4 Hz, 1H), 7.61 (t, J = 7.7 Hz, 1H), 7.50 (d , J = 6.8 Hz, 2H), 7.32 (t, J = 7.6 Hz, 1H), 7.23 (m, 3H), 6.66 (s, 2H), 4.81 (d, J = 5.2 Hz, 2H), 4.25 (s , 2H), 3.86 (s, 9H)
화합물번호 333. (2-벤질-퀴나졸린-4-일)-(2,4-디메톡시-벤질)-아민
1H NMR(CDCl3, 300 MHz) δ 7.95(d, J=8.1 Hz, 1H), 7.68(m, 2H), 7.54(m, 2H), 7.40-7.24(m, 4H), 7.10(d, J=8.3 Hz, 1H), 6.45(d, J=2.23 Hz, 1H), 6.35(m, 1H), 4.79(d, J=5.5 Hz, 2H), 4.28(s, 2H), 3.86(s, 3H), 3.81(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.95 (d, J = 8.1 Hz, 1H), 7.68 (m, 2H), 7.54 (m, 2H), 7.40-7.24 (m, 4H), 7.10 (d, J = 8.3 Hz, 1H), 6.45 (d, J = 2.23 Hz, 1H), 6.35 (m, 1H), 4.79 (d, J = 5.5 Hz, 2H), 4.28 (s, 2H), 3.86 (s, 3H), 3.81 (s, 3H)
화합물번호 334. (2-벤질-퀴나졸린-4-일)-(2,5-디메톡시-벤질)-아민
1H NMRCDCl3, 300 MHz) δ 8.26(d, J=8.3 Hz, 1H), 8.13(d, J=8.2 Hz, 1H), 7.61(m, 3H), 7.40(t, J=7.7 Hz, 1H), 7.24(m, 4H), 7.79(m, 3H), 4.94(d, J=5.4 Hz, 2H), 4.38(s, 2H), 3.85(s, 3H), 3.68(s, 3H) 1 H NMRCDCl 3 , 300 MHz δ 8.26 (d, J = 8.3 Hz, 1H), 8.13 (d, J = 8.2 Hz, 1H), 7.61 (m, 3H), 7.40 (t, J = 7.7 Hz, 1H ), 7.24 (m, 4H), 7.79 (m, 3H), 4.94 (d, J = 5.4 Hz, 2H), 4.38 (s, 2H), 3.85 (s, 3H), 3.68 (s, 3H)
화합물번호 335. (2-벤질-퀴나졸린-4-일)-(2,4,6-트리메톡시-벤질)-아민
1H NMR(CDCl3, 300 MHz) δ 8.12(d, J=8.1 Hz, 1H), 7.63(m, 4H), 7.35(m, 4H), 6.17(s, 2H), 4.96(d, J=5.4 Hz, 2H), 4.40(s, 2H), 3.85(s, 9H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.12 (d, J = 8.1 Hz, 1H), 7.63 (m, 4H), 7.35 (m, 4H), 6.17 (s, 2H), 4.96 (d, J = 5.4 Hz, 2H), 4.40 (s, 2H), 3.85 (s, 9H)
화합물번호 336. (2-페닐-퀴나졸린-4-일)-(3,4,5-트리메톡시-벤질)-아민
화합물번호 337. (2-페닐-퀴나졸린-4-일)-(2,4,6-트리메톡시-벤질)-아민
1H NMR(CDCl3, 300 MHz) δ 8.76(d, J=5.4 Hz, 2H), 7.69(m, 2H), 7.54(m, 3H), 7.41(t, J=7.6 Hz, 1H), 7.28(s, 1H), 6.19(s, 2H), 5.00(d, 2H, J=5.1 Hz), 3.90(s, 9H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.76 (d, J = 5.4 Hz, 2H), 7.69 (m, 2H), 7.54 (m, 3H), 7.41 (t, J = 7.6 Hz, 1H), 7.28 (s, 1H), 6.19 (s, 2H), 5.00 (d, 2H, J = 5.1 Hz), 3.90 (s, 9H)
화합물번호 338. (2-퓨란-2-일-퀴나졸린-4-일)-(2-메톡시-벤질)-아민
1H NMR(CDCl3, 300 MHz) δ 8.01(d, J=8.4 Hz, 1H), 7.70(m, 3H), 7.48(d, J=6.6 Hz, 2H), 7.39(t, J=7.5 Hz, 1H), 7.29(d, J=7.8 Hz, 1H), 6.95(t, J=7.4 Hz, 2H), 6.60(m, 1H), 6.87(br, 1H), 4.97(d, J=5.3 Hz, 2H), 3.93(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.01 (d, J = 8.4 Hz, 1H), 7.70 (m, 3H), 7.48 (d, J = 6.6 Hz, 2H), 7.39 (t, J = 7.5 Hz , 1H), 7.29 (d, J = 7.8 Hz, 1H), 6.95 (t, J = 7.4 Hz, 2H), 6.60 (m, 1H), 6.87 (br, 1H), 4.97 (d, J = 5.3 Hz , 2H), 3.93 (s, 3H)
화합물번호 339. (2-퓨란-2-일-퀴나졸린-4-일)-(3-메톡시-벤질)-아민
1H NMR(CDCl3, 300 MHz) δ 8.01(d, J=8.4 Hz, 1H), 7.78(d, J=8.1 Hz, 1H), 7.67(m, 2H), 7.42(m, 2H), 7.27(m, 2H), 6.87(d, J=2.0 Hz, 1H), 6.58(m, 1H), 6.50(br, 1H), 4.94(d, J=5.2 Hz, 2H), 3.80(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.01 (d, J = 8.4 Hz, 1H), 7.78 (d, J = 8.1 Hz, 1H), 7.67 (m, 2H), 7.42 (m, 2H), 7.27 (m, 2H), 6.87 (d, J = 2.0 Hz, 1H), 6.58 (m, 1H), 6.50 (br, 1H), 4.94 (d, J = 5.2 Hz, 2H), 3.80 (s, 3H)
화합물번호 340. (2-퓨란-2-일-퀴나졸린-4-일)-(4-메톡시-벤질)-아민
1H NMR(CDCl3, 300 MHz) δ 8.01(d, J=8.3 Hz, 1H), 7.77(d, J=8.1 Hz, 1H), 7.67(t, J=7.2 Hz, 2H), 7.41(m, 4H), 6.90(d, J=8.6 Hz, 2H), 6.59(m, 1H), 6.50(br, 1H), 4.89(d, J=5.5 Hz, 2H), 3.82(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.01 (d, J = 8.3 Hz, 1H), 7.77 (d, J = 8.1 Hz, 1H), 7.67 (t, J = 7.2 Hz, 2H), 7.41 (m) , 4H), 6.90 (d, J = 8.6 Hz, 2H), 6.59 (m, 1H), 6.50 (br, 1H), 4.89 (d, J = 5.5 Hz, 2H), 3.82 (s, 3H)
화합물번호 341. 벤조[1,3]디옥솔-5-일메틸-(2-퓨란-2-일-퀴나졸린-4-일)-아민Compound No. 341.Benzo [1,3] dioxol-5-ylmethyl- (2-furan-2-yl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 7.99(d, J=8.3 Hz, 1H), 7.78(d, J=8.1 Hz, 1H), 7.65(m, 2H), 7.41(t, J=5.6 Hz, 2H), 6.94(t, J=7.6 Hz, 2H), 6.78(d, J=7.9 Hz, 1H), 6.57(m, 1H), 6.41(br, 1H), 5.95(s, 2H), 4.85(d, J=5.4 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.99 (d, J = 8.3 Hz, 1H), 7.78 (d, J = 8.1 Hz, 1H), 7.65 (m, 2H), 7.41 (t, J = 5.6 Hz , 2H), 6.94 (t, J = 7.6 Hz, 2H), 6.78 (d, J = 7.9 Hz, 1H), 6.57 (m, 1H), 6.41 (br, 1H), 5.95 (s, 2H), 4.85 (d, J = 5.4 Hz, 2H)
화합물번호 342. (2,3-디메톡시-벤질)-(2-퓨란-2-일-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 8.02(d, J=8.2 Hz, 1H), 7.71(m, 3H), 7.52(d, J=2.3 Hz, 1H), 7.39(m, 1H), 7.07(t, J=4.9 Hz, 2H), 6.90(m, 1H), 6.67(br, 1H), 6.60(m, 1H), 4.49(d, J=5.5 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.02 (d, J = 8.2 Hz, 1H), 7.71 (m, 3H), 7.52 (d, J = 2.3 Hz, 1H), 7.39 (m, 1H), 7.07 (t, J = 4.9 Hz, 2H), 6.90 (m, 1H), 6.67 (br, 1H), 6.60 (m, 1H), 4.49 (d, J = 5.5 Hz, 2H)
화합물번호 343. (3,5-디메톡시-벤질)-(2-퓨란-2-일-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 8.02(d, J=8.3 Hz, 1H), 7.84(d, J=8.2 Hz, 1H), 7.68(m, 2H), 7.45(d, J=3.1 Hz, 1H), 7.38(m, 1H), 6.65(m, 2H), 6.64(br, 1H), 6.57(m, 1H), 6.40(t, J=2.1 Hz, 1H), 4.90(d, J=5.3 Hz, 2H), 3.77(s, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.02 (d, J = 8.3 Hz, 1H), 7.84 (d, J = 8.2 Hz, 1H), 7.68 (m, 2H), 7.45 (d, J = 3.1 Hz , 1H), 7.38 (m, 1H), 6.65 (m, 2H), 6.64 (br, 1H), 6.57 (m, 1H), 6.40 (t, J = 2.1 Hz, 1H), 4.90 (d, J = 5.3 Hz, 2H), 3.77 (s, 6H)
화합물번호 344. (3,4-디메톡시-벤질)-(2-퓨란-2-일-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 8.00(d, J=8.3 Hz, 1H), 7.79(d, J=8.1 Hz, 1H), 7.66(t, J=2.3 Hz, 2H), 7.47(d, J=3.2 Hz, 1H), 7.36(m, 1H), 7.09(s, 1H), 7.01(m, 1H), 6.86(d, J=8.2 Hz, 1H), 6.59(m, 1H), 6.46(br, 1H), 4.99(d, J=5.3 Hz, 2H), 3.88(s, 3H), 3.85(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.00 (d, J = 8.3 Hz, 1H), 7.79 (d, J = 8.1 Hz, 1H), 7.66 (t, J = 2.3 Hz, 2H), 7.47 (d , J = 3.2 Hz, 1H, 7.36 (m, 1H), 7.09 (s, 1H), 7.01 (m, 1H), 6.86 (d, J = 8.2 Hz, 1H), 6.59 (m, 1H), 6.46 (br, 1H), 4.99 (d, J = 5.3 Hz, 2H), 3.88 (s, 3H), 3.85 (s, 3H)
화합물번호 345. (2-퓨란-2-일-퀴나졸린-4-일)-(3,4,5-트리메톡시-벤질)-아민Compound No. 345. (2-Furan-2-yl-quinazolin-4-yl)-(3,4,5-trimethoxy-benzyl) -amine
1H NMR(CDCl3, 300 MHz) δ 8.01(d, J=8.3 Hz, 1H), 7.86(d, J=8.3 Hz, 1H), 7.65(t, J=6.2 Hz, 2H), 7.54(d, J=3.1 Hz, 1H), 7.34(t, J=7.5 Hz, 1H), 6.80(br, 1H), 6.77(s, 2H), 6.60(m, 1H), 4.99(d, J=5.4 Hz, 2H), 3.87(s, 9H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.01 (d, J = 8.3 Hz, 1H), 7.86 (d, J = 8.3 Hz, 1H), 7.65 (t, J = 6.2 Hz, 2H), 7.54 (d , J = 3.1 Hz, 1H), 7.34 (t, J = 7.5 Hz, 1H), 6.80 (br, 1H), 6.77 (s, 2H), 6.60 (m, 1H), 4.99 (d, J = 5.4 Hz , 2H), 3.87 (s, 9H)
화합물번호 346. (2,4-디메톡시-벤질)-(2-퓨란-2-일-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 8.01(d, J=8.2 Hz, 1H), 7.69(m, 3H),7.51(d, J=4.6 Hz, 1H), 7.38(t, J=7.4 Hz, 2H), 6.60(m, 1H), 6.48(m, 3H), 4.88(d, J=5.4 Hz, 2H), 3.89(s, 3H), 3.81(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.01 (d, J = 8.2 Hz, 1H), 7.69 (m, 3H), 7.51 (d, J = 4.6 Hz, 1H), 7.38 (t, J = 7.4 Hz , 2H), 6.60 (m, 1H), 6.48 (m, 3H), 4.88 (d, J = 5.4 Hz, 2H), 3.89 (s, 3H), 3.81 (s, 3H)
화합물번호 347. (2,5-디메톡시-벤질)-(2-퓨란-2-일-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 8.01(d, J=8.3 Hz, 1H), 7.70(m, 3H), 7.50(d, J=2.9 Hz, 1H), 7.41(d, J=7.3 Hz, 1H), 7.10(d, J=2.8 Hz, 1H), 6.84(m, 2H), 6.58(m, 1H), 4.94(d, J=5.4 Hz, 2H), 3.89(s, 3H), 3.74(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.01 (d, J = 8.3 Hz, 1H), 7.70 (m, 3H), 7.50 (d, J = 2.9 Hz, 1H), 7.41 (d, J = 7.3 Hz , 1H), 7.10 (d, J = 2.8 Hz, 1H), 6.84 (m, 2H), 6.58 (m, 1H), 4.94 (d, J = 5.4 Hz, 2H), 3.89 (s, 3H), 3.74 (s, 3H)
화합물번호 348. (2-퓨란-2-일-퀴나졸린-4-일)-(2,4,6-트리메톡시-벤질)-아민
1H NMR(CDCl3, 300 MHz) δ 8.01(d, J=8.2 Hz, 1H), 7.67(m, 4H), 7.37(t, J=7.5 Hz, 1H), 6.60(m, 1H), 6.21(br, 1H), 6.17(s, 2H), 4.96(d, J=5.4 Hz, 2H), 3.87(s, 9H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.01 (d, J = 8.2 Hz, 1H), 7.67 (m, 4H), 7.37 (t, J = 7.5 Hz, 1H), 6.60 (m, 1H), 6.21 (br, 1H), 6.17 (s, 2H), 4.96 (d, J = 5.4 Hz, 2H), 3.87 (s, 9H)
화합물번호 349. (2-메톡시-벤질)-(2-티오펜-2-일-퀴나졸린-4-일)-아민Compound No. 349. (2-methoxy-benzyl)-(2-thiophen-2-yl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 8.21(d, J=3.3 Hz, 1H), 7.91(d, J=8.3 Hz, 1H), 7.68(m, 2H), 7.52(m, 2H), 7.37(t, J=7.6 Hz, 2H), 7.29(d, J=7.7 Hz, 1H), 7.19(t, J=4.2 Hz, 1H), 6.95(t, J=7.7 Hz, 2H), 6.49(br,1H), 4.98(d, J=5.3 Hz, 2H), 3.95(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.21 (d, J = 3.3 Hz, 1H), 7.91 (d, J = 8.3 Hz, 1H), 7.68 (m, 2H), 7.52 (m, 2H), 7.37 (t, J = 7.6 Hz, 2H), 7.29 (d, J = 7.7 Hz, 1H), 7.19 (t, J = 4.2 Hz, 1H), 6.95 (t, J = 7.7 Hz, 2H), 6.49 (br , 1H), 4.98 (d, J = 5.3 Hz, 2H), 3.95 (s, 3H)
화합물번호 350. (3-메톡시-벤질)-(2-티오펜-2-일-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 8.17(d, J=3.2 Hz, 1H), 7.91(d, J=8.3 Hz, 1H), 7.71(m, 2H), 7.47(m, 1H), 7.37(m, 1H), 7.28(m, 1H), 7.16(m, 1H), 7.06(d, J=7.4 Hz, 2H), 6.84(m, 1H), 6.30(br, 1H), 4.94(d, J=5.5 Hz, 2H), 3.79(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.17 (d, J = 3.2 Hz, 1H), 7.91 (d, J = 8.3 Hz, 1H), 7.71 (m, 2H), 7.47 (m, 1H), 7.37 (m, 1H), 7.28 (m, 1H), 7.16 (m, 1H), 7.06 (d, J = 7.4 Hz, 2H), 6.84 (m, 1H), 6.30 (br, 1H), 4.94 (d, J = 5.5 Hz, 2H), 3.79 (s, 3H)
화합물번호 351. (4-메톡시-벤질)-(2-티오펜-2-일-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 8.17(d, J=3.1 Hz, 1H), 7.90(d, J=8.5 Hz, 1H), 7.70(m, 2H), 7.46(m, 3H), 7.36(m, 1H), 7.17(t, J=4.3 Hz, 1H), 6.91(d, J=8.5 Hz, 2H), 6.23(br, 1H), 4.90(d, J=5.3 Hz, 2H), 3.82(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.17 (d, J = 3.1 Hz, 1H), 7.90 (d, J = 8.5 Hz, 1H), 7.70 (m, 2H), 7.46 (m, 3H), 7.36 (m, 1H), 7.17 (t, J = 4.3 Hz, 1H), 6.91 (d, J = 8.5 Hz, 2H), 6.23 (br, 1H), 4.90 (d, J = 5.3 Hz, 2H), 3.82 (s, 3H)
화합물번호 352. 벤조[1,3]디옥솔-5-일메틸-(2-티오펜-2-일-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 8.10(d, J=3.1 Hz, 1H), 7.88(d, J=8.5 Hz, 1H), 7.69(m, 2H), 7.46(t, J=2.5 Hz, 1H), 7.38(m, 1H), 7.17(m, 1H), 6.96(t, J=7.5 Hz, 2H), 6.80(d, J=7.9 Hz, 1H), 6.11(br, 1H), 5.96(s, 2H), 4.87(d, J=5.3 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.10 (d, J = 3.1 Hz, 1H), 7.88 (d, J = 8.5 Hz, 1H), 7.69 (m, 2H), 7.46 (t, J = 2.5 Hz , 1H), 7.38 (m, 1H), 7.17 (m, 1H), 6.96 (t, J = 7.5 Hz, 2H), 6.80 (d, J = 7.9 Hz, 1H), 6.11 (br, 1H), 5.96 (s, 2H), 4.87 (d, J = 5.3 Hz, 2H)
화합물번호 353. (2,3-디메톡시-벤질)-(2-티오펜-2-일-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 8.21(d, J=3.2 Hz, 1H), 7.91(d, J=8.2 Hz, 1H), 7.69(m, 2H), 7.49(d, J=4.8 Hz, 1H), 7.36(m, 1H), 7.17(m, 2H), 7.04(m, 1H), 6.90(d, J=7.2 Hz, 1H), 6.45(br, 1H), 5.00(d, J=5.4 Hz, 2H), 3.98(s, 3H), 3.90(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.21 (d, J = 3.2 Hz, 1H), 7.91 (d, J = 8.2 Hz, 1H), 7.69 (m, 2H), 7.49 (d, J = 4.8 Hz , 1H), 7.36 (m, 1H), 7.17 (m, 2H), 7.04 (m, 1H), 6.90 (d, J = 7.2 Hz, 1H), 6.45 (br, 1H), 5.00 (d, J = 5.4 Hz, 2H), 3.98 (s, 3H), 3.90 (s, 3H)
화합물번호 354. (3,5-디메톡시-벤질)-(2-티오펜-2-일-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 8.20(d, J=3.3 Hz, 1H), 7.92(d, J=8.4 Hz, 1H), 7.76(d, J=10.9 Hz, 1H), 7.68(t, J=7.7 Hz, 1H), 7.48(d, J=4.9 Hz, 1H), 7.36(t, J=7.6Hz, 1H), 7.16(m, 1H), 6.66(s, 2H), 6.41(s, 1H), 4.90(d, J=5.4 Hz, 2H), 3.78(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.20 (d, J = 3.3 Hz, 1H), 7.92 (d, J = 8.4 Hz, 1H), 7.76 (d, J = 10.9 Hz, 1H), 7.68 (t , J = 7.7 Hz, 1H), 7.48 (d, J = 4.9 Hz, 1H), 7.36 (t, J = 7.6 Hz, 1H), 7.16 (m, 1H), 6.66 (s, 2H), 6.41 (s , 1H), 4.90 (d, J = 5.4 Hz, 2H), 3.78 (s, 3H)
화합물번호 355. (3,4-디메톡시-벤질)-(2-티오펜-2-일-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 8.19(d, J=3.0 Hz, 1H), 7.91(d, J=8.5 Hz, 1H), 7.67(m, 2H), 7.49(t, J=2.5 Hz, 1H), 7.35(m, 1H), 7.17(m, 1H), 7.09(m, 1H), 7.01(m, 1H), 6.85(d, J=8.1 Hz, 1H), 6.38(br, 1H), 4.89(d, J=5.3 Hz, 2H), 3.88(s, 3H), 3.84(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.19 (d, J = 3.0 Hz, 1H), 7.91 (d, J = 8.5 Hz, 1H), 7.67 (m, 2H), 7.49 (t, J = 2.5 Hz , 1H), 7.35 (m, 1H), 7.17 (m, 1H), 7.09 (m, 1H), 7.01 (m, 1H), 6.85 (d, J = 8.1 Hz, 1H), 6.38 (br, 1H) , 4.89 (d, J = 5.3 Hz, 2H), 3.88 (s, 3H), 3.84 (s, 3H)
화합물번호 356. (2-티오펜-2-일-퀴나졸린-4-일)-(3,4,5-트리메톡시-벤질)-아민
1H NMR(CDCl3, 300 MHz) δ 8.19(d, J=3.1 Hz, 1H), 7.91(d, J=8.4 Hz, 1H), 7.79(d, J=8.1 Hz, 1H), 7.68(t, J=7.6 Hz, 1H), 7.48(d, J=5.0 Hz, 1H), 7.36(t, J=7.6 Hz, 1H), 7.17(t, J=4.3 Hz, 1H), 6.75(s, 2H), 6.43(br, 1H), 4.88(d, J=5.4 Hz, 2H), 3.85(s, 9H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.19 (d, J = 3.1 Hz, 1H), 7.91 (d, J = 8.4 Hz, 1H), 7.79 (d, J = 8.1 Hz, 1H), 7.68 (t , J = 7.6 Hz, 1H), 7.48 (d, J = 5.0 Hz, 1H), 7.36 (t, J = 7.6 Hz, 1H), 7.17 (t, J = 4.3 Hz, 1H), 6.75 (s, 2H ), 6.43 (br, 1H), 4.88 (d, J = 5.4 Hz, 2H), 3.85 (s, 9H)
화합물번호 357. (2,4-디메톡시-벤질)-(2-티오펜-2-일-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 8.23(d, J=3.0 Hz, 1H), 7.91(d, J=8.2 Hz, 1H), 7.65(m, 2H), 7.48(t, J=7.6 Hz, 2H), 7.38(d, J=7.9Hz, 1H), 7.19(m, 1H), 6.48(m, 3H), 4.90(d, J=5.4 Hz, 2H), 3.93(s, 3H), 3.80(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.23 (d, J = 3.0 Hz, 1H), 7.91 (d, J = 8.2 Hz, 1H), 7.65 (m, 2H), 7.48 (t, J = 7.6 Hz , 2H), 7.38 (d, J = 7.9 Hz, 1H), 7.19 (m, 1H), 6.48 (m, 3H), 4.90 (d, J = 5.4 Hz, 2H), 3.93 (s, 3H), 3.80 (s, 3H)
화합물번호 358. (2,5-디메톡시-벤질)-(2-티오펜-2-일-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 8.22(d, J=3.1 Hz, 1H), 7.91(d, J=8.5 Hz, 1H), 7.69(m, 2H), 7.49(t, J=3.5 Hz, 1H), 7.37(m, 1H), 7.18(m, 2H), 6.81(t, J=4.8 Hz, 2H), 6.52(br, 1H), 4.95(d, J=5.3 Hz, 2H), 3.90(s, 3H), 3.74(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.22 (d, J = 3.1 Hz, 1H), 7.91 (d, J = 8.5 Hz, 1H), 7.69 (m, 2H), 7.49 (t, J = 3.5 Hz , 1H), 7.37 (m, 1H), 7.18 (m, 2H), 6.81 (t, J = 4.8 Hz, 2H), 6.52 (br, 1H), 4.95 (d, J = 5.3 Hz, 2H), 3.90 (s, 3 H), 3.74 (s, 3 H)
화합물번호 359. (2-티오펜-2-일-퀴나졸린-4-일)-(2,4,6-트리메톡시-벤질)-아민
1H NMR(CDCl3, 300 MHz) δ 8.28(d, J=3.2 Hz, 1H), 7.93(d, J=8.4 Hz, 1H), 7.65(m, 2H), 7.49(d, J=4.8 Hz, 1H), 7.35(t, J=7.6 Hz, 1H), 7.19(t, J=4.3 Hz, 1H), 6.20(br, 1H), 6.18(s, 2H), 5.00(d, J=5.3 Hz, 2H), 3.88(s, 9H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.28 (d, J = 3.2 Hz, 1H), 7.93 (d, J = 8.4 Hz, 1H), 7.65 (m, 2H), 7.49 (d, J = 4.8 Hz , 1H), 7.35 (t, J = 7.6 Hz, 1H), 7.19 (t, J = 4.3 Hz, 1H), 6.20 (br, 1H), 6.18 (s, 2H), 5.00 (d, J = 5.3 Hz , 2H), 3.88 (s, 9H)
화합물번호 360. (2-메톡시-벤질)-[2-(메톡시-페닐-메틸)-퀴나졸린-4-일]-아민Compound No. 360. (2-Methoxy-benzyl)-[2- (methoxy-phenyl-methyl) -quinazolin-4-yl] -amine
1H NMR(CDCl3, 300 MHz) δ 7.90(d, J=8.4 Hz, 1H), 7.68-7.55(m, 4H), 7.38-7.20(m, 6H), 6.85(m, 2H), 6.24(br, 1H), 5.41(s, 1H), 4.84(d, J=6.0 Hz, 2H), 3.87(s, 3H), 3.50(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.90 (d, J = 8.4 Hz, 1H), 7.68-7.55 (m, 4H), 7.38-7.20 (m, 6H), 6.85 (m, 2H), 6.24 ( br, 1H), 5.41 (s, 1H), 4.84 (d, J = 6.0 Hz, 2H), 3.87 (s, 3H), 3.50 (s, 3H)
화합물번호 361. (3-메톡시-벤질)-[2-(메톡시-페닐-메틸)-퀴나졸린-4-일]-아민
1H NMR(CDCl3, 300 MHz) δ 7.95(d, J=8.3 Hz, 1H), 7.75(d, J=8.1 Hz, 1H), 7.64(m, 3H), 7.28(m, 5H), 6.94(s, 2H), 6.83(d, J=8.1 Hz, 1H), 6.59(br, 1H), 5.42(s, 1H), 4.83(d, J=4.9 Hz, 2H), 3.76(s, 3H), 3.49(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.95 (d, J = 8.3 Hz, 1H), 7.75 (d, J = 8.1 Hz, 1H), 7.64 (m, 3H), 7.28 (m, 5H), 6.94 (s, 2H), 6.83 (d, J = 8.1 Hz, 1H), 6.59 (br, 1H), 5.42 (s, 1H), 4.83 (d, J = 4.9 Hz, 2H), 3.76 (s, 3H) , 3.49 (s, 3H)
화합물번호 362. (4-메톡시-벤질)-[2-(메톡시-페닐-메틸)-퀴나졸린-4-일]-아민Compound No. 362. (4-Methoxy-benzyl)-[2- (methoxy-phenyl-methyl) -quinazolin-4-yl] -amine
1H NMR(CDCl3, 300 MHz) δ 7.93(d, J=8.4 Hz, 1H), 7.70-7.57(m, 4H), 7.39-7.22(m, 6H), 6.81(d, J=8.4 Hz, 2H), 5.89(br, 1H), 5.42(s, 1H), 4.76(d, J=5.4 Hz, 2H), 3.79(s, 3H), 3.50(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.93 (d, J = 8.4 Hz, 1H), 7.70-7.57 (m, 4H), 7.39-7.22 (m, 6H), 6.81 (d, J = 8.4 Hz, 2H), 5.89 (br, 1H), 5.42 (s, 1H), 4.76 (d, J = 5.4 Hz, 2H), 3.79 (s, 3H), 3.50 (s, 3H)
화합물번호 363. 벤조[1,3]디옥솔-5-일메틸-[2-(메톡시-페닐-메틸)-퀴나졸린-4-일]-아민Compound No. 363. Benzo [1,3] dioxol-5-ylmethyl- [2- (methoxy-phenyl-methyl) -quinazolin-4-yl] -amine
1H NMR(CDCl3, 300 MHz) δ 7.95(d, J=8.3 Hz, 1H), 7.81(d, J=8.1 Hz, 1H), 7.64(m, 2H), 7.35(m, 5H), 6.83(m, 2H), 6.70(d, J=7.9 Hz, 1H), 5.93(s, 2H), 5.46(s, 1H), 4.76(d, J=5.1 Hz, 2H), 3.51(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.95 (d, J = 8.3 Hz, 1H), 7.81 (d, J = 8.1 Hz, 1H), 7.64 (m, 2H), 7.35 (m, 5H), 6.83 (m, 2H), 6.70 (d, J = 7.9 Hz, 1H), 5.93 (s, 2H), 5.46 (s, 1H), 4.76 (d, J = 5.1 Hz, 2H), 3.51 (s, 3H)
화합물번호 364. (2,3-디메톡시-벤질)-[2-(메톡시-페닐-메틸)-퀴나졸린-4-일]-아민Compound No. 364. (2,3-Dimethoxy-benzyl)-[2- (methoxy-phenyl-methyl) -quinazolin-4-yl] -amine
1H NMR(CDCl3, 300 MHz) δ 8.00(d, J=8.3 Hz, 1H), 7.69(m, 3H), 7.32(m, 5H), 6.89(m, 3H), 5.50(s, 1H), 4.90(d, J=5.2 Hz, 2H), 3.93(s, 3H), 3.88(s, 3H), 3.51(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.00 (d, J = 8.3 Hz, 1H), 7.69 (m, 3H), 7.32 (m, 5H), 6.89 (m, 3H), 5.50 (s, 1H) , 4.90 (d, J = 5.2 Hz, 2H), 3.93 (s, 3H), 3.88 (s, 3H), 3.51 (s, 3H)
화합물번호 365. (3,5-디메톡시-벤질)-[2-(메톡시-페닐-메틸)-퀴나졸린-4-일]-아민Compound No. 365. (3,5-Dimethoxy-benzyl)-[2- (methoxy-phenyl-methyl) -quinazolin-4-yl] -amine
1H NMR(CDCl3, 300 MHz) δ 7.95(d, J=8.3 Hz, 1H), 7.77(d, 1H, J=8.1 Hz), 7.65(m, 3H), 7.31(m, 5H), 6.60(br, 1H), 6.55(s, 2H), 6.39(d, J=2.0 Hz, 1H), 5.44(s, 1H), 4.81(d, J=5.1 Hz, 2H), 3.75(s, 6H), 3.49(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.95 (d, J = 8.3 Hz, 1H), 7.77 (d, 1H, J = 8.1 Hz), 7.65 (m, 3H), 7.31 (m, 5H), 6.60 (br, 1H), 6.55 (s, 2H), 6.39 (d, J = 2.0 Hz, 1H), 5.44 (s, 1H), 4.81 (d, J = 5.1 Hz, 2H), 3.75 (s, 6H) , 3.49 (s, 3H)
화합물번호 366. (3,4-디메톡시-벤질)-[2-(메톡시-페닐-메틸)-퀴나졸린-4-일]-아민
1H NMR(CDCl3, 300 MHz) δ 7.94(d, J=8.4 Hz, 1H), 7.78(d, J=8.1 Hz, 1H), 7.68(d, J=6.9 Hz, 2H), 7.58(t, J=7.6 Hz, 1H), 7.33(m, 5H), 6.96(s, 1H), 6.91(t, J=4.1 Hz, 1H), 5.45(s, 1H), 4.80(d, J=5.2 Hz, 2H), 3.88(s, 3H), 3.80(s, 3H), 3.50(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.94 (d, J = 8.4 Hz, 1H), 7.78 (d, J = 8.1 Hz, 1H), 7.68 (d, J = 6.9 Hz, 2H), 7.58 (t , J = 7.6 Hz, 1H), 7.33 (m, 5H), 6.96 (s, 1H), 6.91 (t, J = 4.1 Hz, 1H), 5.45 (s, 1H), 4.80 (d, J = 5.2 Hz , 2H), 3.88 (s, 3H), 3.80 (s, 3H), 3.50 (s, 3H)
화합물번호 367. [2-(메톡시-페닐-메틸)-퀴나졸린-4-일]-(3,4,5-트리메톡시-벤질)-아민
1H NMR(CDCl3, 300 MHz) δ 7.95(d, J=8.3 Hz, 1H), 7.83(d, J=8.2 Hz, 1H), 7.63(m, 3H), 7.30(m, 5H), 6.75(br, 1H), 6.64(s, 2H), 5.45(s, 1H), 4.80(d, J=5.2 Hz, 2H), 3.78(s, 9H), 3.48(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.95 (d, J = 8.3 Hz, 1H), 7.83 (d, J = 8.2 Hz, 1H), 7.63 (m, 3H), 7.30 (m, 5H), 6.75 (br, 1H), 6.64 (s, 2H), 5.45 (s, 1H), 4.80 (d, J = 5.2 Hz, 2H), 3.78 (s, 9H), 3.48 (s, 3H)
화합물번호 368. (2,4-디메톡시-벤질)-[2-(메톡시-페닐-메틸)-퀴나졸린-4-일]-아민
1H NMR(CDCl3, 300 MHz) δ 7.97(d, J=8.3 Hz, 1H), 7.67(m, 4H), 7.33(m, 5H), 7.18(d, J=8.3 Hz, 1H), 6.48(br, 1H), 6.45(s, 1H), 6.35(m, 1H), 5.50(s, 1H), 4.79(d, J=5.1 Hz, 2H), 8.85(s, 3H), 3.79(s, 3H), 3.52(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.97 (d, J = 8.3 Hz, 1H), 7.67 (m, 4H), 7.33 (m, 5H), 7.18 (d, J = 8.3 Hz, 1H), 6.48 (br, 1H), 6.45 (s, 1H), 6.35 (m, 1H), 5.50 (s, 1H), 4.79 (d, J = 5.1 Hz, 2H), 8.85 (s, 3H), 3.79 (s, 3H), 3.52 (s, 3H)
화합물번호 369. (2,5-디메톡시-벤질)-[2-(메톡시-페닐-메틸)-퀴나졸린-4-일]-아민
1H NMR(CDCl3, 300 MHz) δ 7.96(d, J=8.3 Hz, 1H), 7.66(m, 4H), 7.34(m, 5H), 6.97(s, 1H), 6.80(t, J=3.8 Hz, 1H), 6.54(br, 1H), 5.47(s, 1H), 4.86(d, J=5.0 Hz, 2H), 3.86(s, 3H), 3.72(s, 3H), 3.50(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.96 (d, J = 8.3 Hz, 1H), 7.66 (m, 4H), 7.34 (m, 5H), 6.97 (s, 1H), 6.80 (t, J = 3.8 Hz, 1H), 6.54 (br, 1H), 5.47 (s, 1H), 4.86 (d, J = 5.0 Hz, 2H), 3.86 (s, 3H), 3.72 (s, 3H), 3.50 (s, 3H)
화합물번호 370. [2-(메톡시-페닐-메틸)-퀴나졸린-4-일]-(2,4,6-트리메톡시-벤질)-아민
1H NMR(CDCl3, 300 MHz) δ 7.89(d, J=8.1 Hz, 1H), 7.75(dd, J 1 =8.4 Hz, J 2 =1.2 Hz, 2H), 7.63(td, J 1 =6.9 Hz, J 2 =1.2 Hz, 1H), 7.51(d, J=7.2 Hz, 1H), 7.35-7.21(m, 4H), 6.16(s, 2H), 5.98(br, 1H), 5.43(s, 1H), 4.87(d, J=5.4 Hz, 2H), 3.82(s, 3H), 3.80(s, 6H), 3.52(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.89 (d, J = 8.1 Hz, 1H), 7.75 (dd, J 1 = 8.4 Hz, J 2 = 1.2 Hz, 2H), 7.63 (td, J 1 = 6.9 Hz, J 2 = 1.2 Hz, 1H), 7.51 (d, J = 7.2 Hz, 1H), 7.35-7.21 (m, 4H), 6.16 (s, 2H), 5.98 (br, 1H), 5.43 (s, 1H), 4.87 (d, J = 5.4 Hz, 2H), 3.82 (s, 3H), 3.80 (s, 6H), 3.52 (s, 3H)
화합물번호 371. (2-메톡시-벤질)-[2-(1-페닐-에틸)-퀴나졸린-4-일]-아민
1H NMR(CDCl3, 300 MHz) δ 7.85(d, J=8.6 Hz, 1H), 7.64(m, 2H), 7.56(d, J=7.4 Hz, 2H), 7.30(m, 6H), 6.90(t, J=7.9 Hz, 2H), 6.55(br, 1H), 4.90(d, J=5.4 Hz, 2H), 4.40(d, J=7.0 Hz, 1H), 3.92(s, 3H), 1.79(d, J=7.1 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.85 (d, J = 8.6 Hz, 1H), 7.64 (m, 2H), 7.56 (d, J = 7.4 Hz, 2H), 7.30 (m, 6H), 6.90 (t, J = 7.9 Hz, 2H), 6.55 (br, 1H), 4.90 (d, J = 5.4 Hz, 2H), 4.40 (d, J = 7.0 Hz, 1H), 3.92 (s, 3H), 1.79 (d, J = 7.1 Hz, 3H)
화합물번호 372. (3-메톡시-벤질)-[2-(1-페닐-에틸)-퀴나졸린-4-일]-아민
1H NMR(CDCl3, 300 MHz) δ 7.85(d, J=8.6 Hz, 1H), 7.74(d, J=8.1 Hz, 1H), 7.63(m, 1H), 7.51(d, J=7.2 Hz, 2H), 7.25(m, 5H), 6.97(d, J=7.9 Hz, 2H), 6.86(d, J=2.0 Hz, 1H), 4.88(d, J=5.4 Hz, 2H), 4.36(m, 1H), 3.77(s, 3H), 1.75(d, J=7.1 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.85 (d, J = 8.6 Hz, 1H), 7.74 (d, J = 8.1 Hz, 1H), 7.63 (m, 1H), 7.51 (d, J = 7.2 Hz , 2H), 7.25 (m, 5H), 6.97 (d, J = 7.9 Hz, 2H), 6.86 (d, J = 2.0 Hz, 1H), 4.88 (d, J = 5.4 Hz, 2H), 4.36 (m , 1H), 3.77 (s, 3H), 1.75 (d, J = 7.1 Hz, 3H)
화합물번호 373. (4-메톡시-벤질)-[2-(1-페닐-에틸)-퀴나졸린-4-일]-아민
1H NMR(CDCl3, 300 MHz) δ 7.84(d, J=8.5 Hz, 1H), 7.73(d, J=8.1 Hz, 1H), 7.62(t, J=7.6 Hz, 1H), 7.53(d, J=7.6 Hz, 2H), 7.27(m, 6H), 6.85(d, J=7.6 Hz, 2H), 6.38(br, 1H), 4.81(d, J=5.5 Hz, 2H), 4.40(m, 1H), 3.81(s, 3H), 1.78(d, J=7.3 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.84 (d, J = 8.5 Hz, 1H), 7.73 (d, J = 8.1 Hz, 1H), 7.62 (t, J = 7.6 Hz, 1H), 7.53 (d , J = 7.6 Hz, 2H), 7.27 (m, 6H), 6.85 (d, J = 7.6 Hz, 2H), 6.38 (br, 1H), 4.81 (d, J = 5.5 Hz, 2H), 4.40 (m , 1H), 3.81 (s, 3H), 1.78 (d, J = 7.3 Hz, 3H)
화합물번호 374. 벤조[1,3]디옥솔-5-일메틸-[2-(1-페닐-에틸)-퀴나졸린-4-일]-아민
1H NMR(CDCl3, 300 MHz) δ 7.85(d, J=8.4 Hz, 1H), 7.75(d, J=8.5 Hz, 1H), 7.63(m, 1H), 5.52(d, J=7.5 Hz, 2H), 7.28(m, 4H), 6.85(t, J=6.7 Hz, 2H), 6.73(d, J=7.8 Hz, 1H), 6.49(br, 1H), 5.94(s, 2H), 4.78(d, J=5.4 Hz, 2H), 4.40(m, 1H), 1.78(d, J=7.2 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.85 (d, J = 8.4 Hz, 1H), 7.75 (d, J = 8.5 Hz, 1H), 7.63 (m, 1H), 5.52 (d, J = 7.5 Hz , 2H), 7.28 (m, 4H), 6.85 (t, J = 6.7 Hz, 2H), 6.73 (d, J = 7.8 Hz, 1H), 6.49 (br, 1H), 5.94 (s, 2H), 4.78 (d, J = 5.4 Hz, 2H), 4.40 (m, 1H), 1.78 (d, J = 7.2 Hz, 3H)
화합물번호 375. (2,3-디메톡시-벤질)-[2-(1-페닐-에틸)-퀴나졸린-4-일]-아민
1H NMR(CDCl3, 300 MHz) δ 7.85(d, J=8.0 Hz, 1H), 7.65(m, 2H), 7.55(d, J=7.5 Hz, 2H), 7.28(m, 5H), 6.91(m, 3H), 6.54(br, 1H), 4.91(d, J=5.4 Hz, 2H), 4.41(m, 1H), 3.94(s, 3H), 3.89(s, 3H), 1.78(d, J=7.4 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.85 (d, J = 8.0 Hz, 1H), 7.65 (m, 2H), 7.55 (d, J = 7.5 Hz, 2H), 7.28 (m, 5H), 6.91 (m, 3H), 6.54 (br, 1H), 4.91 (d, J = 5.4 Hz, 2H), 4.41 (m, 1H), 3.94 (s, 3H), 3.89 (s, 3H), 1.78 (d, J = 7.4 Hz, 3H)
화합물번호 376. (3,5-디메톡시-벤질)-[2-(1-페닐-에틸)-퀴나졸린-4-일]-아민
1H NMR(CDCl3, 300 MHz) δ 7.84(d, J=8.3 Hz, 1H), 7.74(d, J=8.1 Hz, 1H), 7.63(m, 1H), 7.52(d, J=7.3 Hz, 2H), 7.24(m, 4H), 6.56(s, 2H), 6.41(s, 1H), 4.48(d, J=5.3 Hz, 2H), 4.38(m, 1H), 3.75(s, 6H), 1.78(d, J=7.1 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.84 (d, J = 8.3 Hz, 1H), 7.74 (d, J = 8.1 Hz, 1H), 7.63 (m, 1H), 7.52 (d, J = 7.3 Hz , 2H), 7.24 (m, 4H), 6.56 (s, 2H), 6.41 (s, 1H), 4.48 (d, J = 5.3 Hz, 2H), 4.38 (m, 1H), 3.75 (s, 6H) , 1.78 (d, J = 7.1 Hz, 3H)
화합물번호 377. (3,4-디메톡시-벤질)-[2-(1-페닐-에틸)-퀴나졸린-4-일]-아민
1H NMR(CDCl3, 300 MHz) δ 7.83(d, J=8.3 Hz, 1H), 7.75(d, J=8.2 Hz, 1H), 7.62(d, J=7.4 Hz, 1H), 7.53(d, J=7.2 Hz, 2H), 7.25(m, 5H), 6.94(d, J=5.6 Hz, 2H), 6.82(d, J=8.6 Hz, 1H), 6.32(br, 1H), 4.84(d, J=5.4 Hz, 2H), 4.38(m, 1H), 3.89(s, 3H), 3.79(s, 3H), 1.78(d, J=7.1 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.83 (d, J = 8.3 Hz, 1H), 7.75 (d, J = 8.2 Hz, 1H), 7.62 (d, J = 7.4 Hz, 1H), 7.53 (d , J = 7.2 Hz, 2H), 7.25 (m, 5H), 6.94 (d, J = 5.6 Hz, 2H), 6.82 (d, J = 8.6 Hz, 1H), 6.32 (br, 1H), 4.84 (d , J = 5.4 Hz, 2H), 4.38 (m, 1H), 3.89 (s, 3H), 3.79 (s, 3H), 1.78 (d, J = 7.1 Hz, 3H)
화합물번호 378. [2-(1-페닐-에틸)-퀴나졸린-4-일]-(3,4,5-트리메톡시-벤질)-아민
1H NMR(CDCl3, 300 MHz) δ 7.82(t, J=9.2 Hz, 2H), 7.54(m, 2H), 7.27(m, 5H), 6.65(s, 2H), 4.86(d, J=5.4 Hz, 2H), 4.40(m, 1H), 3.79(s, 9H), 1.78(d, J=7.1 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.82 (t, J = 9.2 Hz, 2H), 7.54 (m, 2H), 7.27 (m, 5H), 6.65 (s, 2H), 4.86 (d, J = 5.4 Hz, 2H), 4.40 (m, 1H), 3.79 (s, 9H), 1.78 (d, J = 7.1 Hz, 3H)
화합물번호 379. (2,4-디메톡시-벤질)-[2-(1-페닐-에틸)-퀴나졸린-4-일]-아민Compound No. 379. (2,4-Dimethoxy-benzyl)-[2- (1-phenyl-ethyl) -quinazolin-4-yl] -amine
1H NMR(CDCl3, 300 MHz) δ 7.85(d, J=8.4 Hz, 1H), 7.60(m, 4H), 7.32(m, 3H), 7.21(t, J=6.9 Hz, 2H), 6.48(d, J=2.0 Hz, 1H), 6.39(br, 1H), 6.36(d, J=8.1 Hz, 1H), 4.48(d, J=5.3 Hz, 2H), 4.40(m, 1H), 3.88(s, 3H), 3.82(s, 3H), 1,80(d, J=7.1 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.85 (d, J = 8.4 Hz, 1H), 7.60 (m, 4H), 7.32 (m, 3H), 7.21 (t, J = 6.9 Hz, 2H), 6.48 (d, J = 2.0 Hz, 1H), 6.39 (br, 1H), 6.36 (d, J = 8.1 Hz, 1H), 4.48 (d, J = 5.3 Hz, 2H), 4.40 (m, 1H), 3.88 (s, 3H), 3.82 (s, 3H), 1,80 (d, J = 7.1 Hz, 3H)
화합물번호 380. (2,5-디메톡시-벤질)-[2-(1-페닐-에틸)-퀴나졸린-4-일]-아민
1H NMR(CDCl3, 300 MHz) δ 7.83(d, J=8.2 Hz, 1H), 7.63(m, 2H), 7.56(d, J=7.4 Hz, 2H), 7.35(m, 1H), 7.28(m, 2H), 7.19(d, J=7.3 Hz, 1H), 6.98(d, J=2.8 Hz, 1H), 6.82(m, 2H), 6.28(br, 1H), 4.88(d, J=5.4 Hz, 2H), 4.38(m, 2H), 3.88(s, 3H), 3.79(s, 3H), 1.79(d, J=7.1 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.83 (d, J = 8.2 Hz, 1H), 7.63 (m, 2H), 7.56 (d, J = 7.4 Hz, 2H), 7.35 (m, 1H), 7.28 (m, 2H), 7.19 (d, J = 7.3 Hz, 1H), 6.98 (d, J = 2.8 Hz, 1H), 6.82 (m, 2H), 6.28 (br, 1H), 4.88 (d, J = 5.4 Hz, 2H), 4.38 (m, 2H), 3.88 (s, 3H), 3.79 (s, 3H), 1.79 (d, J = 7.1 Hz, 3H)
화합물번호 381. [2-(1-페닐-에틸)-퀴나졸린-4-일]-(2,4,6-트리메톡시-벤질)-아민
1H NMR(CDCl3, 300 MHz) δ 7.76(d, J=8.4 Hz, 1H), 7.64-7.50(m, 4H), 7.31-7.24(m, 3H), 7.16(t, J=7.2 Hz, 1H), 6.17(s, 2H), 6.03(br, 1H), 5.02-4.83(m, 2H), 4.31(q, J=7.2 Hz, 1H), 3.83(s, 9H), 1.80(d, J=7.2 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.76 (d, J = 8.4 Hz, 1H), 7.64-7.50 (m, 4H), 7.31-7.24 (m, 3H), 7.16 (t, J = 7.2 Hz, 1H), 6.17 (s, 2H), 6.03 (br, 1H), 5.02-4.83 (m, 2H), 4.31 (q, J = 7.2 Hz, 1H), 3.83 (s, 9H), 1.80 (d, J = 7.2 Hz, 3H)
화합물번호 382. (2-싸이클로프로필-퀴나졸린-4-일)-(2-메톡시-벤질)-아민Compound No. 382. (2-Cyclopropyl-quinazolin-4-yl)-(2-methoxy-benzyl) -amine
1H NMR(CDCl3, 300 MHz) δ 7.75(d, J=8.0 Hz, 1H), 7.62(m, 2H), 7.35(m, 3H), 6.93(m, 2H), 6.32(br, 1H), 4.81(d, J=5.4 Hz, 2H), 3.98(s, 3H), 2.19(m, 1H), 1.25(m, 2H), 1.01(m, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.75 (d, J = 8.0 Hz, 1H), 7.62 (m, 2H), 7.35 (m, 3H), 6.93 (m, 2H), 6.32 (br, 1H) , 4.81 (d, J = 5.4 Hz, 2H), 3.98 (s, 3H), 2.19 (m, 1H), 1.25 (m, 2H), 1.01 (m, 2H)
화합물번호 383. (2-싸이클로프로필-퀴나졸린-4-일)-(3-메톡시-벤질)-아민
1H NMR(CDCl3, 300 MHz) δ 7.77-7.61(m, 3H), 7.35-7.24(m, 2H), 6.94(m, 2H), 6.84(dd, J 1 =8.4 Hz, J 2 =2.7 Hz, 1H), 5.93(br, 1H), 4.78(d, J=5.7 Hz, 2H), 3.79(s, 3H), 2.17(m, 1H), 1.17(m, 2H), 0.95(m, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.77-7.61 (m, 3H), 7.35-7.24 (m, 2H), 6.94 (m, 2H), 6.84 (dd, J 1 = 8.4 Hz, J 2 = 2.7 Hz, 1H), 5.93 (br, 1H), 4.78 (d, J = 5.7 Hz, 2H), 3.79 (s, 3H), 2.17 (m, 1H), 1.17 (m, 2H), 0.95 (m, 2H )
화합물번호 384. (2-싸이클로프로필-퀴나졸린-4-일)-(4-메톡시-벤질)-아민
1H NMR(CDCl3, 300 MHz) δ 7.78(d, J=7.9 Hz, 1H), 7.70(m, 2H), 7.35(m, 3H), 6.90(d, J=7.8 Hz, 2H), 5.98(br, 1H), 4.74(d, J=5.4 Hz, 2H), 3.82(s, 3H), 2.20(m, 1H), 1.21(m, 2H), 1.01(m, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.78 (d, J = 7.9 Hz, 1H), 7.70 (m, 2H), 7.35 (m, 3H), 6.90 (d, J = 7.8 Hz, 2H), 5.98 (br, 1H), 4.74 (d, J = 5.4 Hz, 2H), 3.82 (s, 3H), 2.20 (m, 1H), 1.21 (m, 2H), 1.01 (m, 2H)
화합물번호 385. 벤조[1,3]디옥솔-5-일메틸-(2-싸이클로프로필-퀴나졸린-4-일)-아민Compound No. 385. Benzo [1,3] dioxol-5-ylmethyl- (2-cyclopropyl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 7.76(d, J=8.0 Hz, 1H), 7.66(m, 2H), 7.43(m, 1H), 6.84(m, 3H), 5.96(s, 2H), 4.71(d, J=5.4 Hz, 2H), 2.19(m, 1H), 1.20(m, 2H), 1.01(m, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.76 (d, J = 8.0 Hz, 1H), 7.66 (m, 2H), 7.43 (m, 1H), 6.84 (m, 3H), 5.96 (s, 2H) , 4.71 (d, J = 5.4 Hz, 2H), 2.19 (m, 1H), 1.20 (m, 2H), 1.01 (m, 2H)
화합물번호 386. (2-싸이클로프로필-퀴나졸린-4-일)-(2,3-디메톡시-벤질)-아민Compound No. 386. (2-Cyclopropyl-quinazolin-4-yl)-(2,3-dimethoxy-benzyl) -amine
1H NMR(CDCl3, 300 MHz) δ 7.74(d, J=7.9 Hz, 1H), 7.64(m, 2H), 7.32(d, J=8.4 Hz, 1H), 6.99(m, 2H), 6.89(m, 1H), 6.32(br, 1H), 4.83(d, J=5.4 Hz, 2H), 3.94(s, 3H), 3.89(s, 3H), 2.18(m, 1H), 1.22(m, 2H), 1.01(m, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.74 (d, J = 7.9 Hz, 1H), 7.64 (m, 2H), 7.32 (d, J = 8.4 Hz, 1H), 6.99 (m, 2H), 6.89 (m, 1H), 6.32 (br, 1H), 4.83 (d, J = 5.4 Hz, 2H), 3.94 (s, 3H), 3.89 (s, 3H), 2.18 (m, 1H), 1.22 (m, 2H), 1.01 (m, 2H)
화합물번호 387. (2-싸이클로프로필-퀴나졸린-4-일)-(3,5-디메톡시-벤질)-아민Compound No. 387. (2-Cyclopropyl-quinazolin-4-yl)-(3,5-dimethoxy-benzyl) -amine
1H NMR(CDCl3, 300 MHz) δ 7.76(d, J=7.8 Hz, 1H), 7.66(m, 2H), 7.35(m, 1H), 6.54(s, 2H), 6.39(s, 1H), 6.23(br, 1H), 4.74(d, J=5.4 Hz, 2H), 3.79(s, 6H), 2.18(m, 1H), 1.19(m, 2H), 0.99(m, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.76 (d, J = 7.8 Hz, 1H), 7.66 (m, 2H), 7.35 (m, 1H), 6.54 (s, 2H), 6.39 (s, 1H) , 6.23 (br, 1H), 4.74 (d, J = 5.4 Hz, 2H), 3.79 (s, 6H), 2.18 (m, 1H), 1.19 (m, 2H), 0.99 (m, 2H)
화합물번호 388. (2-싸이클로프로필-퀴나졸린-4-일)-(3,4-디메톡시-벤질)-아민Compound No. 388. (2-Cyclopropyl-quinazolin-4-yl)-(3,4-dimethoxy-benzyl) -amine
1H NMR(CDCl3, 300 MHz) δ 7.76(d, J=7.8 Hz, 1H), 7.67(t, J=7.4 Hz, 2H), 7.31(t, J=3.8 Hz, 1H), 6.94(d, J=5.0 Hz, 2H), 6.84(t, J=4.3 Hz, 1H), 6.07 (br, 1H), 4.74(d, J=5.4 Hz, 2H), 3.89(s, 3H), 3.87(s, 3H), 2.20(m, 1H), 1.22(m, 2H), 1.00(m, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.76 (d, J = 7.8 Hz, 1H), 7.67 (t, J = 7.4 Hz, 2H), 7.31 (t, J = 3.8 Hz, 1H), 6.94 (d , J = 5.0 Hz, 2H), 6.84 (t, J = 4.3 Hz, 1H), 6.07 (br, 1H), 4.74 (d, J = 5.4 Hz, 2H), 3.89 (s, 3H), 3.87 (s , 3H), 2.20 (m, 1H), 1.22 (m, 2H), 1.00 (m, 2H)
화합물번호 389. (2-싸이클로프로필-퀴나졸린-4-일)-(3,4,5-트리메톡시-벤질)-아민Compound No. 389. (2-Cyclopropyl-quinazolin-4-yl)-(3,4,5-trimethoxy-benzyl) -amine
1H NMR(CDCl3, 300 MHz) δ 7.77-7.64(m, 3H), 7.33(t, J=7.2 Hz, 1H), 6.61(s, 1H), 6.00(br, 1H), 4.72(d, J=5.4 Hz, 2H), 3.84(s, 9H), 2.19(m, 1H), 1.19(m, 2H), 0.98(m, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.77-7.64 (m, 3H), 7.33 (t, J = 7.2 Hz, 1H), 6.61 (s, 1H), 6.00 (br, 1H), 4.72 (d, J = 5.4 Hz, 2H), 3.84 (s, 9H), 2.19 (m, 1H), 1.19 (m, 2H), 0.98 (m, 2H)
화합물번호 390. (2-싸이클로프로필-퀴나졸린-4-일)-(2,4-디메톡시-벤질)-아민
1H NMR(CDCl3, 300 MHz) δ 7.73(d, J=8.3 Hz, 1H), 7.62(m, 2H), 7.32(d, J=9.3 Hz, 2H), 6.48(m, 2H), 6.14(br, 1H), 4.73(d, J=5.4 Hz, 2H), 3.89(s, 3H), 3.81(s, 3H), 2.19(m, 1H), 1.25(m, 2H), 1.01(m, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.73 (d, J = 8.3 Hz, 1H), 7.62 (m, 2H), 7.32 (d, J = 9.3 Hz, 2H), 6.48 (m, 2H), 6.14 (br, 1H), 4.73 (d, J = 5.4 Hz, 2H), 3.89 (s, 3H), 3.81 (s, 3H), 2.19 (m, 1H), 1.25 (m, 2H), 1.01 (m, 2H)
화합물번호 391. (2-싸이클로프로필-퀴나졸린-4-일)-(2,5-디메톡시-벤질)-아민Compound No. 391. (2-Cyclopropyl-quinazolin-4-yl)-(2,5-dimethoxy-benzyl) -amine
1H NMR(CDCl3, 300 MHz) δ 7.74(d, J=8.5 Hz, 1H), 7.63(m, 2H), 7.33(t, J=7.5 Hz, 1H), 6.98(d, J=2.1 Hz, 1H), 6.81(m, 2H), 6.25(br, 1H), 3.88(s, 3H), 3.78(s, 3H), 2.18(m, 1H), 1.25(m, 2H), 1.01(m, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.74 (d, J = 8.5 Hz, 1H), 7.63 (m, 2H), 7.33 (t, J = 7.5 Hz, 1H), 6.98 (d, J = 2.1 Hz , 1H), 6.81 (m, 2H), 6.25 (br, 1H), 3.88 (s, 3H), 3.78 (s, 3H), 2.18 (m, 1H), 1.25 (m, 2H), 1.01 (m, 2H)
화합물번호 392. (2-싸이클로프로필-퀴나졸린-4-일)-(2,4,6-트리메톡시-벤질)-아민Compound No. 392. (2-Cyclopropyl-quinazolin-4-yl)-(2,4,6-trimethoxy-benzyl) -amine
1H NMR(CDCl3, 300 MHz) δ 7.73(d, J=8.3 Hz, 1H), 7.64(m, 1H), 7.53(d, J=6.2 Hz, 1H), 7.29(m, 1H), 2.17(s, 2H), 6.06(br, 1H), 4.82(d, J=5.3 Hz, 2H), 3.87(s, 6H), 3.84(s, 3H), 2.18(m, 1H), 1.30(m, 2H), 1.00(m, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.73 (d, J = 8.3 Hz, 1H), 7.64 (m, 1H), 7.53 (d, J = 6.2 Hz, 1H), 7.29 (m, 1H), 2.17 (s, 2H), 6.06 (br, 1H), 4.82 (d, J = 5.3 Hz, 2H), 3.87 (s, 6H), 3.84 (s, 3H), 2.18 (m, 1H), 1.30 (m, 2H), 1.00 (m, 2H)
화합물번호 393. (2-메톡시-벤질)-(2-프로필-퀴나졸린-4-일)-아민Compound No. 393. (2-Methoxy-benzyl)-(2-propyl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 7.78(d, J=8.2 Hz, 1H), 7.68(m, 2H), 7.44(d, J=7.3 Hz, 1H), 7.38(d, J = 7.0 Hz, 1H), 7.34(m, 1H), 6.95(t, J=7.8 Hz, 2H), 6.24(br, 1H), 4.91(d, J=5.7 Hz, 2H), 3.93(s, 3H), 2.87(t, J=7.7 Hz, 2H), 1.93(m, 2H), 1.04(t, J=7.4 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.78 (d, J = 8.2 Hz, 1H), 7.68 (m, 2H), 7.44 (d, J = 7.3 Hz, 1H), 7.38 (d, J = 7.0 Hz , 1H), 7.34 (m, 1H), 6.95 (t, J = 7.8 Hz, 2H), 6.24 (br, 1H), 4.91 (d, J = 5.7 Hz, 2H), 3.93 (s, 3H), 2.87 (t, J = 7.7 Hz, 2H), 1.93 (m, 2H), 1.04 (t, J = 7.4 Hz, 3H)
화합물번호 394. (3-메톡시-벤질)-(2-프로필-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 7.80(d, J=8.4 Hz, 1H), 7.68(m, 2H), 7.35(m, 2H), 6.99(m, 2H), 6.85(m, 1H), 5.83(br s, 1H), 4.86(d, J=5.1 Hz, 2H), 3.80(s, 3H), 2.86(t, J=7.7 Hz, 2H), 1.90(sixtet, J=7.5 Hz, 2H), 1.02(t, J=7.4 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.80 (d, J = 8.4 Hz, 1H), 7.68 (m, 2H), 7.35 (m, 2H), 6.99 (m, 2H), 6.85 (m, 1H) , 5.83 (br s, 1H), 4.86 (d, J = 5.1 Hz, 2H), 3.80 (s, 3H), 2.86 (t, J = 7.7 Hz, 2H), 1.90 (sixtet, J = 7.5 Hz, 2H ), 1.02 (t, J = 7.4 Hz, 3H)
화합물번호 395. (4-메톡시-벤질)-(2-프로필-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 7.79(d, J=8.4Hz, 1H), 7.65(m, 2H), 7.38(m, 3H), 6.88(d, J=8.4Hz, 2H), 5.81(br s, 1H), 4.80(d, J=5.1 Hz, 2H), 3.81(s, 3H), 2.86(t, J=7.8 Hz, 2H), 1.91(sixtet, J=7.5 Hz, 2H), 1.03(t, J=7.5 Hz, 3H) 1 H NMR (
화합물번호 396. 벤조[1,3]디옥솔-5-일메틸-(2-프로필-퀴나졸린-4-일)-아민Compound No. 396.Benzo [1,3] dioxol-5-ylmethyl- (2-propyl-quinazolin-4-yl) -amine
1H NMR(CDCl3, 300 MHz) δ 7.80(d, J=7.8Hz, 1H), 7.68(m, 2H), 7.37(t, J=7.5 Hz, 1H), 6.89(m, 2H), 6.78(d, J=7.8 Hz, 1H), 5.95(s, 2H), 5.80(br s, 1H), 4.78(d, J=5.4 Hz, 2H), 2.86(t, J=7.8 Hz, 2H), 1.91(sixtet, J=7.5 Hz, 2H), 1.03(t, J=7.5 Hz, 3H) 1 H NMR (
화합물번호 397. (2,3-디메톡시-벤질)-(2-프로필-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 7.76(d, J=8.4Hz, 1H), 7.64(m, 2H), 7.37(t, J=7.2 Hz, 1H), 7.03(d, J=4.8 Hz, 2H), 6.88(t, J=4.8 Hz, 1H), 6.17(br s, 1H), 4.90(d, J=5.7 Hz, 2H), 3.94(s, 3H), 3.89(s, 3H), 2.86(t, J=7.8 Hz, 2H), 1.91(sixtet, J=7.5 Hz, 2H), 1.03(t, J=7.5 Hz, 3H) 1 H NMR (
화합물번호 398. (3,5-디메톡시-벤질)-(2-프로필-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 7.80(d, J=8.1Hz, 1H), 7.70(m, 2H), 7.38(t, J=7.2 Hz, 1H), 6.57(d, J=2.1 Hz, 2H), 6.41(m, 1H), 5.83(br s, 1H), 4.82(d, J=5.4 Hz, 2H), 3.78(s, 6H), 2.86(t, J=7.8 Hz, 2H), 1.91(sixtet, J=7.5 Hz, 2H), 1.03(t, J=7.5 Hz, 3H) 1 H NMR (
화합물번호 399. (3,4-디메톡시-벤질)-(2-프로필-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 7.80(d, J=8.1Hz, 1H), 7.69(m, 2H), 7.37(t, J=7.5 Hz, 1H), 6.97(d, J=7.2 Hz, 2H), 6.85(d, J=8.4 Hz, 1H), 5.81(br s, 1H), 4.81(d, J=5.4 Hz, 2H), 3.88(s, 3H), 3.86(s, 3H), 2.86(t, J=7.8 Hz, 2H), 1.91(sixtet, J=7.5 Hz, 2H), 1.03(t, J=7.5 Hz, 3H) 1 H NMR (
화합물번호 400. (2-프로필-퀴나졸린-4-일)-(3,4,5-트리메톡시-벤질)-아민
1H NMR(CDCl3, 300 MHz) δ 7.81(d, J=8.3 Hz, 3H), 7.71(m, 2H), 4.40(m, 1H), 6.68(s, 2H), 6.07(br, 1H), 4.82(d, J=5.5 Hz, 2H), 3.86(s, 9H), 2.88(t, J=7.7 Hz, 2H), 1.94(m, 2H), 1.03(t, J=7.4 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.81 (d, J = 8.3 Hz, 3H), 7.71 (m, 2H), 4.40 (m, 1H), 6.68 (s, 2H), 6.07 (br, 1H) , 4.82 (d, J = 5.5 Hz, 2H), 3.86 (s, 9H), 2.88 (t, J = 7.7 Hz, 2H), 1.94 (m, 2H), 1.03 (t, J = 7.4 Hz, 2H)
화합물번호 401. (2,4-디메톡시-벤질)-(2-프로필-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 7.78(d, J=8.5 Hz, 1H), 7.64(m, 2H), 7.36(m, 2H), 7.47(m, 2H), 6.14(br, 1H), 4.82(d, J=5.4 Hz, 2H), 3.90(s, 3H), 3.82(s, 3H), 2.87(t, J=7.8 Hz, 2H), 1.96(m, 2H), 1.05(t, J=7.3 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.78 (d, J = 8.5 Hz, 1H), 7.64 (m, 2H), 7.36 (m, 2H), 7.47 (m, 2H), 6.14 (br, 1H) , 4.82 (d, J = 5.4 Hz, 2H), 3.90 (s, 3H), 3.82 (s, 3H), 2.87 (t, J = 7.8 Hz, 2H), 1.96 (m, 2H), 1.05 (t, J = 7.3 Hz, 2H)
화합물번호 402. (2,5-디메톡시-벤질)-(2-프로필-퀴나졸린-4-일)-아민
1H NMR(CDCl3, 300 MHz) δ 7.78(d, J=8.1 Hz, 1H), 7.66(m, 2H), 7.37(m, 1H), 7.05(s, 1H), 6.82(m, 2H), 6.29(br, 1H), 4.87(d, J=5.4 Hz, 2H), 3.88(s, 3H), 3.76(s, 3H), 2.86(t, J=7.6 Hz, 2H), 1.95(m, 2H), 1.05(t, J=7.5 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.78 (d, J = 8.1 Hz, 1H), 7.66 (m, 2H), 7.37 (m, 1H), 7.05 (s, 1H), 6.82 (m, 2H) , 6.29 (br, 1H), 4.87 (d, J = 5.4 Hz, 2H), 3.88 (s, 3H), 3.76 (s, 3H), 2.86 (t, J = 7.6 Hz, 2H), 1.95 (m, 2H), 1.05 (t, J = 7.5 Hz, 2H)
화합물번호 403. (2-프로필-퀴나졸린-4-일)-(2,4,6-트리메톡시-벤질)-아민
1H NMR(CDCl3, 300 MHz) δ 7.76(d, J=8.3 Hz, 1H), 7.60(m, 2H), 7.35(m, 1H), 6.18(s, 2H), 5.98(br, 1H), 4.88(d, J=5.4 Hz, 2H), 3.87(s, 6H), 3.85(3, 3H), 2.88(t, J=7.5 Hz, 2H), 1.98(m, 2H), 1.07(t, J=7.4 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.76 (d, J = 8.3 Hz, 1H), 7.60 (m, 2H), 7.35 (m, 1H), 6.18 (s, 2H), 5.98 (br, 1H) , 4.88 (d, J = 5.4 Hz, 2H), 3.87 (s, 6H), 3.85 (3, 3H), 2.88 (t, J = 7.5 Hz, 2H), 1.98 (m, 2H), 1.07 (t, J = 7.4 Hz, 2H)
화합물번호 404. (2-메톡시-벤질)-퀴나졸린-4-일-아민
1H NMR(CDCl3, 300 MHz) δ 8.74(s, 1H), 7.88(d, J=8.2 Hz, 1H), 7.70(m, 2H), 7.47(m, 2H), 7.32(m, 1H), 6.97(d, J=7.8 Hz, 2H), 6.25(br, 1H), 4.88(d, J=5.5 Hz, 2H), 3.93(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.74 (s, 1H), 7.88 (d, J = 8.2 Hz, 1H), 7.70 (m, 2H), 7.47 (m, 2H), 7.32 (m, 1H) , 6.97 (d, J = 7.8 Hz, 2H), 6.25 (br, 1H), 4.88 (d, J = 5.5 Hz, 2H), 3.93 (s, 3H)
화합물번호 405. (3-메톡시-벤질)-퀴나졸린-4-일-아민
1H NMR(CDCl3, 300 MHz) δ 8.73(s, 1H), 7.86(d, J=8.3 Hz, 1H), 7.73(t, J=9.0 Hz, 2H), 7.47(m, 1H), 7.31(m, 1H), 6.99(t, J=7.4 Hz, 2H), 6.87(d, J=8.1 Hz, 1H), 6.01(br, 1H), 4.87(d, J=5.4 Hz, 2H), 3.82(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.73 (s, 1H), 7.86 (d, J = 8.3 Hz, 1H), 7.73 (t, J = 9.0 Hz, 2H), 7.47 (m, 1H), 7.31 (m, 1H), 6.99 (t, J = 7.4 Hz, 2H), 6.87 (d, J = 8.1 Hz, 1H), 6.01 (br, 1H), 4.87 (d, J = 5.4 Hz, 2H), 3.82 (s, 3H)
화합물번호 406. (4-메톡시-벤질)-퀴나졸린-4-일-아민
1H NMR(CDCl3, 300 MHz) δ 8.71(s, 1H), 7.85(d, J=8.1Hz, 1H), 7.71(m, 2H), 7.45(t, J=7.5 Hz, 1H), 7.34(d, J=8.7 Hz, 2H), 6.90(d, J=8.7 Hz, 1H), 5.88(br s, 1H), 4.80(d, J=5.1 Hz, 2H), 3.82(s, 3H) 1 H NMR (
화합물번호 407. 벤조[1,3]디옥솔-5-일메틸-퀴나졸린-4-일-아민
1H NMR(CDCl3, 300 MHz) δ 8.72(s, 1H), 7.88(d, J=8.4 Hz, 1H), 7.40(m, 2H), 7.48(d, J=7.2 Hz, 1H), 6.90(m, 2H), 6.81(d, J=7.4 Hz, 1H), 5.98(s, 2H), 5.96(br, 1H), 4.78(d, J=5.4 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.72 (s, 1H), 7.88 (d, J = 8.4 Hz, 1H), 7.40 (m, 2H), 7.48 (d, J = 7.2 Hz, 1H), 6.90 (m, 2H), 6.81 (d, J = 7.4 Hz, 1H), 5.98 (s, 2H), 5.96 (br, 1H), 4.78 (d, J = 5.4 Hz, 2H)
화합물번호 408. (2,3-디메톡시-벤질)-퀴나졸린-4-일-아민
1H NMR(CDCl3, 300 MHz) δ 8.70(s, 1H), 7.73(m, 3H), 7.43(m, 1H), 7.04(m, 2H), 6.93(m, 1H), 6.32(br, 1H), 4.89(d, J=5.4 Hz, 2H), 3.95(s, 3H), 3.90(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.70 (s, 1H), 7.73 (m, 3H), 7.43 (m, 1H), 7.04 (m, 2H), 6.93 (m, 1H), 6.32 (br, 1H), 4.89 (d, J = 5.4 Hz, 2H), 3.95 (s, 3H), 3.90 (s, 3H)
화합물번호 409. (3,5-디메톡시-벤질)-퀴나졸린-4-일-아민
1H NMR(CDCl3, 300 MHz) δ 8.71(s, 1H), 7.87(d, J=8.4Hz, 1H), 7.73(m, 2H), 7.47(t, J=7.2 Hz, 1H), 6.40(d, J=2.4 Hz, 2H), 6.41(t, J=2.1 Hz, 1H), 5.93(br s, 1H), 4.81(d, J=5.1 Hz, 2H), 3.79(s, 6H) 1 H NMR (
화합물번호 410. (3,4-디메톡시-벤질)-퀴나졸린-4-일-아민
1H NMR(CDCl3, 300 MHz) δ 8.73(s, 1H), 7.87(d, J=8.2 Hz, 1H), 7.75(t, J=7.4 Hz, 2H), 7.47(t, J=7.6 Hz, 1H), 6.97(d, J=7.8 Hz, 2H), 6.86(d, J=8.0 Hz, 1H), 6.08(br, 1H), 4.81(d, J=5.2 Hz, 2H), 3.89(s, 3H), 3.87(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.73 (s, 1H), 7.87 (d, J = 8.2 Hz, 1H), 7.75 (t, J = 7.4 Hz, 2H), 7.47 (t, J = 7.6 Hz , 1H), 6.97 (d, J = 7.8 Hz, 2H), 6.86 (d, J = 8.0 Hz, 1H), 6.08 (br, 1H), 4.81 (d, J = 5.2 Hz, 2H), 3.89 (s , 3H), 3.87 (s, 3H)
화합물번호 411. 퀴나졸린-4-일-(3,4,5-트리메톡시-벤질)-아민
1H NMR(CDCl3, 300 MHz) δ 8.73(s, 1H), 7.84(m, 1H), 7.78(m, 1H), 7.50(m, 1H), 6.63(d, J=7.8 Hz, 2H), 6.23(br, 1H), 4.80(d, J=5.3 Hz, 2H), 3.85(s, 9H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.73 (s, 1H), 7.84 (m, 1H), 7.78 (m, 1H), 7.50 (m, 1H), 6.63 (d, J = 7.8 Hz, 2H) , 6.23 (br, 1H), 4.80 (d, J = 5.3 Hz, 2H), 3.85 (s, 9H)
화합물번호 412. (2,4-디메톡시-벤질)-퀴나졸린-4-일-아민
1H NMR(CDCl3, 300 MHz) δ 8.70(s, 1H), 7.83(d, J=8.3 Hz, 1H), 7.72(m, 2H), 7.44(t, J=7.6 Hz, 1H), 7.32(d, J=8.2 Hz, 1H), 6.48(m, 2H), 6.26(br, 1H), 4.80(d, J=5.4 Hz, 2H), 3.89(s, 3H), 3.82(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.70 (s, 1H), 7.83 (d, J = 8.3 Hz, 1H), 7.72 (m, 2H), 7.44 (t, J = 7.6 Hz, 1H), 7.32 (d, J = 8.2 Hz, 1H), 6.48 (m, 2H), 6.26 (br, 1H), 4.80 (d, J = 5.4 Hz, 2H), 3.89 (s, 3H), 3.82 (s, 3H)
화합물번호 413. (2,5-디메톡시-벤질)-퀴나졸린-4-일-아민
1H NMR(CDCl3, 300 MHz) δ 8.69(s, 1H), 7.84(d, J=8.4Hz, 1H), 7.69(m, 2H), 7.44(t, J=7.2 Hz, 1H), 6.99(d, J=3.0 Hz, 1H), 6.83(m, 2H), 6.29(br s, 1H), 4.85(d, J=5.4 Hz, 2H), 3.88(s, 3H), 3.76(s, 3H) 1 H NMR (
화합물번호 414. 퀴나졸린-4-일-(2,4,6-트리메톡시-벤질)-아민
1H NMR(CDCl3, 300 MHz) δ 8.72(s, 1H), 7.81(d, J=8.1Hz, 1H), 7.69(t, J=7.5 Hz, 1H), 7.60(d, J=8.1Hz, 1H), 7.40(t, J=7.5 Hz, 1H), 6.19(s, 2H), 6.03(br s, 1H), 4.83(d, J=5.1 Hz, 2H), 3.86(s, 6H), 3.84(s, 3H) 1 H NMR (
화합물번호 415. 4-벤질옥시-2-이소프로필-퀴나졸린Compound number 415. 4-benzyloxy-2-isopropyl-quinazoline
1H NMR(CDCl3, 300 MHz) δ 8.16(d, J=8.1 Hz, 1H), 7.87(s, J=8.4 Hz, 1H), 7.77(m, 1H), 7.54(d, J=7.5 Hz, 2H), 7.49-7.34(m, 4H), 5.66(s, 2H), 3.22(m, 1H), 1.40(d, J=6.9 Hz, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.16 (d, J = 8.1 Hz, 1H), 7.87 (s, J = 8.4 Hz, 1H), 7.77 (m, 1H), 7.54 (d, J = 7.5 Hz , 2H), 7.49-7.34 (m, 4H), 5.66 (s, 2H), 3.22 (m, 1H), 1.40 (d, J = 6.9 Hz, 6H)
화합물번호 416. 4-벤질설파닐-2-이소프로필-퀴나졸린Compound number 416. 4-benzylsulfanyl-2-isopropyl-quinazoline
1H NMR(CDCl3, 300 MHz) δ 8.01(d, J=8.4 Hz, 1H), 7.89(d, J=8.4 Hz, 1H), 7.78(m, 1H), 7.48(m, 3H), 7.35-7.23(m, 3H), 4.67(s, 2H), 3.29(m, 1H), 1.43(d, J=6.9 MHz, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.01 (d, J = 8.4 Hz, 1H), 7.89 (d, J = 8.4 Hz, 1H), 7.78 (m, 1H), 7.48 (m, 3H), 7.35 -7.23 (m, 3H), 4.67 (s, 2H), 3.29 (m, 1H), 1.43 (d, J = 6.9 MHz, 6H)
한편, 본 발명에 따른 상기 화학식 1로 표시되는 화합물은 목적에 따라 여러 형태로 제제화가 가능하다. 다음은 본 발명에 따른 상기 화학식 1로 표시되는 화합물을 활성성분으로 함유시킨 몇몇 제제화 방법을 예시한 것으로 본 발명이 이에 한정되는 것은 아니다.On the other hand, the compound represented by
제조예 1 : 정제의 제조Preparation Example 1 Preparation of Tablet
본 발명의 화합물을 이용하여 다음과 같은 조성으로 경구투여용 정제를 습식 과립법 및 건식과립법을 이용하여 제조하였다.Tablets for oral administration using the compound of the present invention in the following composition were prepared using wet granulation and dry granulation.
[조성][Furtherance]
유효화합물 200 mg, 경질 무수규산 10 mg, 스테아린산 마그네슘 2 mg, 미세결정 셀룰로오즈 50 mg, 전분 글리콜산 나트륨 25 mg, 옥수수 전분 113 mg, 무수에탄올 적량.200 mg of active compound, 10 mg of hard silicic anhydride, 2 mg of magnesium stearate, 50 mg of microcrystalline cellulose, 25 mg of sodium starch glycolate, 113 mg of corn starch, proper amount of ethanol anhydride.
제조예 2 : 연고제의 제조Preparation Example 2 Preparation of Ointment
본 발명의 화합물을 이용하여 다음과 같은 조성으로 연고제를 제조하였다.Using the compound of the present invention was prepared an ointment with the following composition.
[조성][Furtherance]
유효화합물 5 g, 세틸팔미테이트 20 g, 세탄올 40 g, 스테아릴알콜 40 g, 미리스탄이소프로필 80 g, 모노스테아린산 소르비탄 20 g, 폴리솔베이트 60 g, 파라옥시안식향산 프로필 1 g, 파라옥시안식향산 메틸 1 g, 인산 및 정제수 적량Active compound 5 g, cetyl palmitate 20 g, cetanol 40 g, stearyl alcohol 40 g, myristan isopropyl 80 g, monostearic acid sorbitan 20 g, polysorbate 60 g, paraoxybenzoic acid propyl 1 g, para 1 g of methyl oxyanate, phosphoric acid and purified water
제조예 3 : 주사제의 제조Preparation Example 3 Preparation of Injection
본 발명의 화합물을 이용하여 다음과 같은 조성으로 주사제를 제조하였다.Injections were prepared using the compounds of the present invention in the following compositions.
[조성][Furtherance]
유효화합물 100 mg, 만니톨 180 mg, 인산일수소나트륨 25 mg, 주사용 물 2974 mg
실험예 1. 포도당 흡수도 분석Experimental Example 1. Analysis of glucose absorption
근육 세포인 C2C12 세포를 10% 송아지 혈청(bovine calf serum)이 들어있는 DMEM(Dulbecco's modified Eagle's medium) 배지에서 세포 배양하였다. 세포의 밀도가 약 85 ∼ 90% 가량 되면 1% 송아지 혈청 배양액으로 치환한 후 6일간 세포 분화를 유도시켰다. 완전히 분화된 세포를 5 mM의 포도당이 포함된 크렙스 링거 완충액(Krebs Ringer Buffer, KRB)으로 3시간 배양한 후 후보 물질을 10 μM 농도가 되게 첨가하여 30분간 방치한 후 0.2 μCi 2-데옥시글루코스를 첨가하고 20분 동안 방치하였다. KRB 완충액을 제거한 후 차가운 PBS로 세 번 세포를 세척한 후 0.5N NaOH를 사용하여 세포를 용해시키고 방사선 계측기를 이용하여 계수율(cpm)을 측정하였다. Muscle cells C2C12 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) medium containing 10% bovine calf serum. When the cell density was about 85-90%, the cells were replaced with 1% calf serum culture and induced cell differentiation for 6 days. The fully differentiated cells were incubated with Krebs Ringer Buffer (KRB) containing 5 mM glucose for 3 hours, then added to 10 μM of the candidate substance for 30 minutes, and then 0.2 μCi 2-deoxyglucose. Was added and left for 20 minutes. After removing the KRB buffer, the cells were washed three times with cold PBS, and then the cells were lysed using 0.5 N NaOH and counted using a radiometer (cpm).
다음 표 2로부터 확인되는 바와 같이, C2C12 세포에 본 발명에 따른 화학식 1로 표시되는 화합물을 처리하였을 경우 대조군에 비하여 근육 세포주에서 포도당의 흡수가 최대 2.8배까지 증가함을 관찰할 수 있었다.As confirmed from the following Table 2, when the C2C12 cells were treated with the compound represented by
실험예 2. 웨스턴 블롯(Western blot)을 이용한 AMPK 효소의 활성 측정Experimental Example 2 Determination of AMPK Enzyme Activity by Western Blot
C2C12 세포 배양 및 분화는 상기 실험예 1과 동일한 조건에서 수행하며 후보 물질의 처리 조건도 동일하게 실행하였다 (50분 동안 10 μM 처리). 이 후 배양액을 제거하고 세포를 PBS 용액으로 두 번 세척 한 후 lysis 완충액(50 mM 트리스 HCl, pH 7.4, 1 % NP-40, 0.25 % 소듐 데옥시콜레이트, 150 mM NaCl, 1 mM EDTA, 1 mM PMSF, 1 mM 소듐 오르쏘바나데이트, 1 mM NaF, 1 μg/mL 아프로티닌, 1 μg/mL 로이펩틴, 1 μg/mL 펩스타틴)를 사용하여 단백질 추출물을 얻었다. AMPK의 활성도는 AMPK의 기질인 아세틸 CoA 카르복시라제의 세린79 잔기의 인산화 정도와 AMPK 활성화 시 필수적으로 동반되는 알파 서브유닛의 트레오닌172 잔기의 인산화 정도를 웨스턴 블롯(Western blot) 분석을 통하여 간접적으로 측정하였다. 단백질의 일정한 정량을 확인하기 위해서 ERK(Extracellular signal regulated protein kinase)의 양을 웨스턴 블롯(Western blot)으로 확인하였다.C2C12 cell culture and differentiation were carried out under the same conditions as in Experimental Example 1 above, and the treatment conditions of the candidates were also performed (10 μM treatment for 50 minutes). Subsequently, the culture medium was removed and the cells washed twice with PBS solution, followed by lysis buffer (50 mM Tris HCl, pH 7.4, 1% NP-40, 0.25% sodium deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM). Protein extracts were obtained using PMSF, 1 mM sodium orthovanadate, 1 mM NaF, 1 μg / mL aprotinin, 1 μg / mL leupeptin, 1 μg / mL pepstatin). AMPK activity was measured indirectly by Western blot analysis of phosphorylation of serine 79 residues of AMPK substrate, acetyl CoA carboxylase, and threonine172 residues of alpha subunits essential for AMPK activation. It was. In order to confirm the constant quantification of protein, the amount of extracellular signal regulated protein kinase (ERK) was confirmed by Western blot.
다음 표 3은 웨스턴 블롯(Western blot)으로 확인한 결과를 나타낸 것으로, 트레오닌172 잔기의 인산화 정도가 3배 이상 증가한 결과에 대해서는 “strong”으로 표기하였고, 트레오닌172 잔기의 인산화 정도가 1 내지 3배 증가한 결과에 대해서는 “mild”로 표기하였고, 트레오닌172 잔기의 인산화 정도가 1배 미만 증가한 결과에 대해서는 “weak”로 표기하였다.The following Table 3 shows the results confirmed by Western blot. For the result of more than three-fold increase in the degree of phosphorylation of
상기 표 3과 첨부도면 도 1과 도 2a 내지 도 2g로부터 확인할 수 있듯이, 본 발명에 따른 상기 화학식 1로 표시되는 화합물을 근육 세포주에 처리하면 AMPK 효소의 활성이 증가함을 관찰할 수 있었다.As can be seen from Table 3 and the accompanying drawings, Figures 1 and 2a to 2g, the activity of the AMPK enzyme was increased when the compound represented by the formula (1) according to the present invention to the muscle cell line.
실험예 3. 모델동물인 db /db 마우스에서 당뇨/비만 예방 및 치료효과.Experimental Example 3. Prevention and treatment of diabetes / obesity in a model animal db / db mouse.
8∼9주 된 db/db 계통의 수컷 마우스(C57BL/Ks)를 실험에 사용하였다. 0.5% 카르복시메틸셀룰로로스(CMC) 용액의 음성대조군, 0.5% 카르복시메틸셀룰로로스(CMC)에 녹인 양성대조군(Rosiglitazone) 및 시험약물은 매일 오후에 경구 혹은 복강투여 하며, 혈당 측정은 꼬리정맥을 절개하여 3∼4일 간격으로 오후에 일정 시간에 투여 직전에 혈당 측정기로 측정하였다. 동물의 체중과 사료 양은 매일 약물 투여직전에 측정하였다.Male mice of 8-9 weeks old db / db strain (C57BL / Ks) were used for the experiment. Negative control of 0.5% carboxymethylcellulose (CMC) solution, positive control (Rosiglitazone) dissolved in 0.5% carboxymethylcellulose (CMC) and test drug are administered orally or intraperitoneally every afternoon. The incision was measured with a blood glucose meter just before administration at a certain time in the afternoon at intervals of 3 to 4 days. Animal weight and feed volume were measured immediately before daily drug administration.
10일 동안 투여 및 혈당측정과 체중측정이 끝난 후, 혈액을 채취하여 혈청을 분리하여 간기능, 신장기능 및 지질검사를 위한 Biochemical parameter 등을 측정한다.After 10 days of administration, blood glucose measurement and weight measurement, blood is collected and serum is separated to measure liver function, kidney function and biochemical parameters for lipid test.
도 3a 및 3b, 도 4a 및 4b, 도 5a, 5b 및 5c, 그리고 도 6a, 6b 및 6c에서 보듯이, 본 발명에 따른 상기 화학식 1로 표시되는 화합물을 복강 또는 경구 투여를 통하여 실험군과 대조군의 혈당과 체중을 측정하여 분석한 결과, 대조군에 비하여 실험군이 혈당 및 체중이 유의하게 감소하는 것으로 보여 당뇨 및 비만의 예방 및 치료효과를 관찰할 수 있었다.As shown in Figures 3a and 3b, 4a and 4b, 5a, 5b and 5c, and 6a, 6b and 6c, the compound represented by the formula (1) according to the invention through the intraperitoneal or oral administration of the experimental group and the control group As a result of measuring blood sugar and body weight, the experimental group showed a significant decrease in blood sugar and body weight compared to the control group, and thus the prevention and treatment effect of diabetes and obesity was observed.
실험예 3. 모델동물인 ob/ob 마우스에서 당뇨/비만 예방 및 치료효과.Experimental Example 3. Prevention and treatment of diabetes / obesity in ob / ob mice as model animals.
실험예 3-1Experimental Example 3-1
웅성 6주령의 ob/ob 마우스를 Harlan으로부터 공급받아 사료와 물을 자유로이 섭취하도록 하며 SK내 동물실에서 일주일간 순화시켰다. 이후 체중을 측정하여(0 day) 각 그룹의 평균무게가 일정하도록 동물을 분배하였다. 실험군은 대조군(Control), 양성대조군(sibutramine), 각 약물군으로 나누었으며, 투여 용량은 양성대조군 15 mg/kg, 각 약물군은 200 mg/kg/10mL로 약물을 용시 제조하여 인슐린 주사기를 이용하여 복강 투여하였다. 또한 투여는 오후 5시에 매일 1회씩 4주간 투여하였다. 대조군은 0.5% 카르복시메킬셀룰로오스(CMC)만을 kg/10mL로 투여하였다.Male 6-week-old ob / ob mice were fed from Harlan and allowed for free intake of feed and water, followed by a week-long purification in an animal room in SK. The animals were then distributed so that the average weight of each group was constant by weighing (0 day). The experimental group was divided into control group, positive control group, and each drug group, and the dosage was 15 mg / kg positive control group, and 200 mg / kg / 10 mL of each drug group. Administered. In addition, the administration was administered once a day for 4 weeks at 5 pm. The control group was administered with only 0.5% carboxymethyl cellulose (CMC) in kg / 10 mL.
4주간 투여하면서 체중을 측정하였으며, 대조군 그룹의 체중과 약물 투여군 그룹의 체중 차이(g)와, 최초 약물투여한 날(0 day)의 체중으로부터 증가하는 체중의 %를 계산하여 약물이 나타내는 체중증가 억제를 대조군 그룹과 비교함으로써 약효를 평가하였다. 또한 사료 섭취량을 측정하여 사료섭취 억제 효과를 관찰하였다. Body weight was measured during 4 weeks of administration, weight gain of the drug was calculated by calculating the difference in body weight (g) between the control group and the drug group and the percentage of weight gain from the weight of the first day of administration (0 day). Drug efficacy was assessed by comparing inhibition with the control group. In addition, the feed intake was measured to observe the effect of inhibiting feed intake.
실험예 3-2Experimental Example 3-2
실험예 1에서 효과를 보인 약물들에 대해 경구투여를 통한 효과 시험을 실시하였다. 실험군 분배, 투여용량 및 투여기간 등은 실험예 3-1과 동일하며, 단 투여 방법만 존데를 이용하여 강제경구 투여를 실시하였다.Drugs showing the effect in Experimental Example 1 was conducted through the effect test through oral administration. Experimental group distribution, dose and administration period are the same as Experimental Example 3-1, except that only the administration method was forced oral administration using Sonde.
도 7a 및 7b, 도 8a 및 8b, 그리고 도 9에서 보듯이, 본 발명에 따른 상기 화학식 1로 표시되는 화합물을 복강 또는 경구 투여를 통하여 실험군과 대조군의 혈당 또는 체중을 측정하여 분석한 결과, 대조군에 비하여 실험군이 혈당 및 체중이 유의하게 감소하는 것으로 보여 당뇨 및 비만의 예방 및 치료효과를 관찰할 수 있었다.As shown in Figure 7a and 7b, Figure 8a and 8b, and Figure 9, the compound represented by the formula (1) according to the present invention by measuring the blood sugar or body weight of the experimental group and the control group through the abdominal cavity or oral administration, the control group Compared to the experimental group, blood sugar and body weight were significantly decreased, and thus the effect of preventing and treating diabetes and obesity was observed.
상술한 바와 같이, 본 발명에 따른 혈당 저하와 체중 감소 효과가 탁월한 여러 화합물들은 당뇨병 및 비만 치료제로 유용하게 사용할 수 있다.As described above, various compounds excellent in blood sugar lowering and weight loss effects according to the present invention can be usefully used as a therapeutic agent for diabetes and obesity.
Claims (7)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020040117708 | 2004-12-31 | ||
| KR20040117708 | 2004-12-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20060079121A true KR20060079121A (en) | 2006-07-05 |
Family
ID=36615173
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020050134722A KR20060079121A (en) | 2004-12-31 | 2005-12-30 | Quinazoline derivatives for the treatment or prevention of diabetes and obesity |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1844023A1 (en) |
| JP (1) | JP2008526734A (en) |
| KR (1) | KR20060079121A (en) |
| WO (1) | WO2006071095A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101467996B1 (en) * | 2010-04-30 | 2014-12-11 | 전북대학교산학협력단 | The qhinazoline derivatives which are inhibitor of ADP-ribosyl cyclases |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2332527A3 (en) | 2004-10-20 | 2011-11-16 | Resverlogix Corp. | Flavanoids and Isoflavanoids for the prevention and treatment of cardiovascular diseases |
| MX2007010991A (en) | 2005-03-14 | 2007-11-07 | Neurosearch As | Potassium channel modulating agents and their medical use. |
| AU2006275514B2 (en) | 2005-07-29 | 2012-04-05 | Resverlogix Corp. | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
| FR2891829A1 (en) * | 2005-10-12 | 2007-04-13 | Sanofi Aventis Sa | 4-AMINO-QUINAZOLINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF |
| US20090306102A1 (en) * | 2005-12-20 | 2009-12-10 | Eriksen Birgitte L | 2-pyridin-2-yl-quinazoline derivatives as potassium channel modulating agents for the treatment of respiratory diseases |
| PT2118074E (en) | 2007-02-01 | 2014-03-20 | Resverlogix Corp | Compounds for the prevention and treatment of cardiovascular diseases |
| US20090209536A1 (en) * | 2007-06-17 | 2009-08-20 | Kalypsys, Inc. | Aminoquinazoline cannabinoid receptor modulators for treatment of disease |
| WO2009000085A1 (en) * | 2007-06-27 | 2008-12-31 | Painceptor Pharma Corporation | Quinoline and quinazoline derivatives useful as modulators of gated ion channels |
| US8212045B2 (en) | 2007-09-21 | 2012-07-03 | Array Biopharma, Inc. | Pyridin-2-yl-amino-1, 2, 4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus |
| JP5650540B2 (en) * | 2007-12-12 | 2015-01-07 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Carboxamide, sulfonamide, and amine compounds for metabolic disorders |
| KR20100134693A (en) | 2008-04-23 | 2010-12-23 | 교와 핫꼬 기린 가부시키가이샤 | 2-aminoquinazoline derivative |
| CA2711103C (en) | 2008-06-26 | 2016-08-09 | Resverlogix Corp. | Methods of preparing quinazolinone derivatives |
| JP2011527693A (en) * | 2008-07-11 | 2011-11-04 | ミレクシス， インコーポレイテッド | Pharmaceutical compounds as cytotoxic agents and their use |
| CA2747417C (en) | 2009-01-08 | 2017-01-03 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular disease |
| CA3146333A1 (en) | 2009-03-18 | 2010-09-23 | Resverlogix Corp. | Phenyl-quinazolin-4(3h)-one and phenyl-pyrido[2,3-d]pyrimidin-4(3h)-one derivatives and compositions thereof useful as anti-inflammatory agents |
| LT2421533T (en) | 2009-04-22 | 2018-12-27 | Resverlogix Corp. | Novel anti-inflammatory agents |
| PH12012500097A1 (en) * | 2009-07-21 | 2011-01-27 | Shanghai Inst Organic Chem | Potent small molecule inhibitors of autophagy, and methods of use thereof |
| NZ598516A (en) | 2009-09-03 | 2013-02-22 | Bristol Myers Squibb Co | Quinazolines as potassium ion channel inhibitors |
| JP5992049B2 (en) | 2011-11-01 | 2016-09-14 | レスバーロジックス コーポレイション | Oral immediate release formulations for substituted quinazolinones |
| ES2661510T3 (en) | 2011-12-15 | 2018-04-02 | Novartis Ag | Use of inhibitors of PI3K activity or function |
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| WO2014080291A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Biaryl derivatives as bromodomain inhibitors |
| US9073878B2 (en) | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
| AU2013365926B9 (en) | 2012-12-21 | 2019-01-17 | Zenith Epigenetics Ltd. | Novel heterocyclic compounds as bromodomain inhibitors |
| CA2896731A1 (en) * | 2012-12-28 | 2014-07-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof |
| EP3632426A1 (en) | 2013-02-01 | 2020-04-08 | Wellstat Therapeutics Corporation | Amine compounds having anti-inflammatory, antifungal, antiparasitic and anticancer activity |
| CA2905242C (en) | 2013-03-15 | 2016-11-29 | Pfizer Inc. | Indole compounds that activate ampk |
| CN105294682B (en) | 2014-07-26 | 2017-07-07 | 广东东阳光药业有限公司 | Compound of CDK type small molecular inhibitors and application thereof |
| US10087148B2 (en) * | 2014-12-05 | 2018-10-02 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer, National Institute Of Health | Quinazolines as biogenic amine transport modulators |
| EP3226867A4 (en) | 2014-12-05 | 2018-05-09 | Subramaniam Ananthan | Heterocyclic compounds as biogenic amine transport modulators |
| MX2017008520A (en) | 2014-12-24 | 2018-03-01 | Gilead Sciences Inc | Fused pyrimidine compounds for the treatment of hiv. |
| TWI770552B (en) | 2014-12-24 | 2022-07-11 | 美商基利科學股份有限公司 | Quinazoline compounds |
| CN107428693B (en) | 2014-12-24 | 2020-05-29 | 吉利德科学公司 | Isoquinoline compounds for HIV treatment |
| WO2016147053A1 (en) | 2015-03-13 | 2016-09-22 | Resverlogix Corp. | Compositions and therapeutic methods for the treatment of complement-associated diseases |
| CN106045924B (en) * | 2016-07-28 | 2018-08-14 | 黑龙江八一农垦大学 | A kind of synthetic method of aryl substituted quinazoline amine derivative |
| KR20210039368A (en) | 2018-07-26 | 2021-04-09 | 도메인 테라퓨틱스 | Substituted quinazolinone derivatives and their use as positive allosteric modulators of mGluR4 |
| MX2022014505A (en) | 2020-05-19 | 2022-12-13 | Kallyope Inc | Ampk activators. |
| JP2023531726A (en) | 2020-06-26 | 2023-07-25 | キャリーオペ，インク． | AMPK Activator |
| US20230398137A1 (en) * | 2020-10-30 | 2023-12-14 | Resverlogix Corp. | Methods for lowering hba1c level with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor |
| CZ309449B6 (en) * | 2020-12-24 | 2023-01-25 | Ústav experimentální botaniky AV ČR, v. v. i. | Quinazoline derivatives as selective cyclooxygenase-1 inhibitors |
| CN112608302B (en) * | 2020-12-28 | 2022-05-24 | 郑州大学第一附属医院 | Quinazoline derivative for activating target ubiquitination degradation of EGFR protein through low-oxygen reduction and application thereof |
| CN114315802B (en) * | 2021-12-14 | 2023-06-16 | 西安医学院 | Quinazoline nitrogen-containing heterocyclic derivative, preparation method and application |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3340260A (en) * | 1962-12-03 | 1967-09-05 | Ciba Geigy Corp | 4-amino-pyrimidines |
| JPS542325A (en) * | 1977-06-07 | 1979-01-09 | Sankyo Co Ltd | Agricultural and horticultural pesticide |
| IL89027A (en) * | 1988-01-29 | 1993-01-31 | Lilly Co Eli | Quinazoline derivatives, process for their preparation and fungicidal, insecticidal and miticidal compositions containing them |
| PT100905A (en) * | 1991-09-30 | 1994-02-28 | Eisai Co Ltd | BICYCLE HYGIENEOUS HETEROCYCLIC COMPOUNDS CONTAINING BENZENE, CYCLOHEXAN OR PYRIDINE AND PYRIMIDINE, PYRIDINE OR IMIDAZOLE SUBSTITUTES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| JP2657760B2 (en) * | 1992-07-15 | 1997-09-24 | 小野薬品工業株式会社 | 4-aminoquinazoline derivatives and pharmaceuticals containing them |
| GB2295387A (en) * | 1994-11-23 | 1996-05-29 | Glaxo Inc | Quinazoline antagonists of alpha 1c adrenergic receptors |
| US6046206A (en) * | 1995-06-07 | 2000-04-04 | Cell Pathways, Inc. | Method of treating a patient having a precancerous lesions with amide quinazoline derivatives |
| GB9718972D0 (en) * | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| DE19756388A1 (en) * | 1997-12-18 | 1999-06-24 | Hoechst Marion Roussel De Gmbh | New 2-aryl-4-amino-6,7-di:methoxy-quinazoline derivatives useful as guanylate cyclase activators for treating cardiovascular diseases, etc. |
| DE69924500T2 (en) * | 1998-08-21 | 2006-02-09 | Parker Hughes Institute, St. Paul | quinazoline derivatives |
| US6184226B1 (en) * | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
| WO2002062767A1 (en) * | 2001-02-07 | 2002-08-15 | Sumitomo Pharmaceuticals Company, Limited | Novel quinazoline derivatives |
| DE10224462A1 (en) * | 2002-06-03 | 2003-12-11 | Bayer Ag | Use of cGMP stimulating compounds |
| US20070010671A1 (en) * | 2003-03-31 | 2007-01-11 | Yoshinori Sekiguchi | Novel quinazoline derivatives and methods of treatment related to the use thereof |
| CA2520323C (en) * | 2003-04-09 | 2013-07-09 | Exelixis, Inc. | Tie-2 modulators and methods of use |
| AU2004253967B2 (en) * | 2003-07-03 | 2010-02-18 | Cytovia, Inc. | 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis |
-
2005
- 2005-12-30 EP EP05823851A patent/EP1844023A1/en not_active Withdrawn
- 2005-12-30 KR KR1020050134722A patent/KR20060079121A/en not_active Application Discontinuation
- 2005-12-30 WO PCT/KR2005/004664 patent/WO2006071095A1/en active Application Filing
- 2005-12-30 JP JP2007549270A patent/JP2008526734A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101467996B1 (en) * | 2010-04-30 | 2014-12-11 | 전북대학교산학협력단 | The qhinazoline derivatives which are inhibitor of ADP-ribosyl cyclases |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008526734A (en) | 2008-07-24 |
| EP1844023A1 (en) | 2007-10-17 |
| WO2006071095A1 (en) | 2006-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20060079121A (en) | Quinazoline derivatives for the treatment or prevention of diabetes and obesity | |
| DE60131844T2 (en) | 2-AMINO-3- (ALKYL) -PYRIMIDONE DERIVATIVES AS GSK3.BETA. HEMMER | |
| KR100967070B1 (en) | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient | |
| US8653091B2 (en) | Pyrid-2yl fused heterocyclic compounds, and compositions and uses thereof | |
| BG63487B1 (en) | The use of heterocyclic compounds | |
| CN101679365A (en) | As the new pyrrole-2-carboxamides derivatives of glucokinase activators, their manufacture method and pharmaceutical application | |
| MXPA06007715A (en) | (3-oxo-3, 4-dihydro-quinoxalin-2-yl-amino) -benzamide derivatives and related compound as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity. | |
| US20080207614A1 (en) | Quinazoline derivatives for the treatment and prevention of diabetes and obesity | |
| CN102548983A (en) | Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitor | |
| US9708321B2 (en) | Spiro-quinazolinone derivatives and their use as positive allosteric modulators of mGluR4 | |
| WO2007048840A1 (en) | Novel beta-agonists, process for their preparation and their use as medicaments | |
| EP1781620A1 (en) | Novel beta agonists, method for producing the same and their use as drugs | |
| KR100807515B1 (en) | Novel Compounds | |
| KR20030085005A (en) | Antipruritics | |
| EP1340748B1 (en) | Quinazoline derivatives and drugs | |
| KR101676889B1 (en) | Phenylimidazole compounds | |
| DK2303264T3 (en) | METHODS FOR TREATING ALPHA-ADRENERG-MEDIATED CONDITIONS USING IMIDAZOLINE DERIVATIVES | |
| US7368454B2 (en) | (3,4-dihydro-quinazolin-2-yl)-aryl-amines | |
| JPS6157563A (en) | 5-oxypyrimidinone derivative and manufacture | |
| US5681843A (en) | Parabanic acid derivatives | |
| CN114656472A (en) | Pyrazolopyrimidine compound, isomer or salt, and preparation method and application thereof | |
| WO2011023722A1 (en) | Novel quinoxalinone hepcidin antagonists | |
| KR100556559B1 (en) | 2-4-4-4,5-dichloro-2-methylimidazol-1-ylbutyl-1-piperazinyl-5-fluoropyrimidine, preparation and therapeutic use | |
| RU2795572C2 (en) | Compounds and compositions for ire1 inhibition | |
| CN114891003A (en) | Novel dihydropyrimidine compounds, intermediates or salts, and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E601 | Decision to refuse application |